2012 CTRC-AACR SAN ANTONIO BREAST CANCER SYMPOSIUM

PROGRAM SCHEDULE

(AT PRESS TIME)
Refer to **www.sabcs.org** for the most current information.

Room Locations
Exhibit Halls A, B, C & D: Street Level
Ballrooms A & B: Street Level
Bridge Hall: Street Level
Room 206 A-B: Concourse Level

TUESDAY, DECEMBER 4, 2012

8:00 am–7:30 pm
REGISTRATION
Bridge Hall

Pre-registered attendees can obtain materials. Those who have not yet registered may do so.

12:30 pm–2:00 pm
CAREER DEVELOPMENT FORUM: A NETWORKING SESSION FOR YOUNG INVESTIGATORS
Room 206 A–B

Networking and career development opportunities for early career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the SABCS.

Space in the workshop is limited to 200 participants; registrations will be accepted on a first-come, first-served basis and is free of charge.

Discussion topics & mentors*

Balancing Research and Clinical Practice I
Judy E. Garber, Dana-Farber Cancer Institute
Ann H. Partridge, Dana-Farber Cancer Institute

Balancing Research and Clinical Practice II
Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center
Eric P. Winer, Dana-Farber Cancer Institute

Careers in Industry
Steven Shak, Genomic Health, Inc.

Careers in Industry
Mika Derynck, Genentech, Inc.

Careers in Translational Research
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center

Grant Writing - Basic/Translational
Yi Li, Baylor College of Medicine Cancer Center

Grant Writing - Clinical/Translational
Virginia F. Borges, University of Colorado Denver
Matthew J. Ellis, Washington University Siteman Cancer Center

How to Become a Clinical Trialist
John R. Yarnold, The Royal Marsden Hospital
Nancy U. Lin, Dana-Farber Cancer Institute

How to Get the Most Out of Your Fellowship Years
Ian Elliott Krop, Dana-Farber Cancer Institute

How to Get the Most Out of Your Fellowship Years
Rachel Schiff, Baylor College of Medicine

How to Get the Most Out of Your Predoctoral Experience
Rong Li, UT Health Science Center at San Antonio

How to Make the Most Out of Being A Cooperative Group Member
Kathy D. Miller, Indiana University School of Medicine
Hope S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center

Making the Transition From Fellowship to Faculty
Pepper Jo Schedin, University of Colorado Anschutz Medical Campus
Bryan P. Schneider, Indiana University Melvin and Bren Simon Cancer Center

Mentoring and Supervising
Cathrin Brisken, Ecole Polytechnique Fédérale de Lausanne
Jason S. Carroll, Cancer Research UK Cambridge Research Institute

Negotiating a Job Offer or Promotion
Melissa L. Bondy, Baylor College of Medicine Cancer Center

Oral Presentation Skills
Laura J. van 't Veer, UCSF Helen Diller Family Comprehensive Cancer Center
Douglas Yee, Masonic Cancer Center, University of Minnesota

Publication Strategies
Harold J. Burstein, Dana-Farber Cancer Institute

Searching for a Job and Interviewing
Michael T. Lewis, Baylor College of Medicine Cancer Center

Setting Up and Managing a Laboratory
Jeffrey M. Rosen, Baylor College of Medicine

Tenure and Promotion
Suzanne A.W. Fuqua, Baylor College of Medicine Cancer Center
Sharon H. Giordano, The University of Texas MD Anderson Cancer Center

The Path Leading to Clinical Trials
Massimo Cristofanilli, Fox Chase Cancer Center

** Topics and mentors are subject to change*

2:00 pm–7:30 pm
EDUCATIONAL SESSIONS
Ballrooms A & B and Exhibit Hall D

Supported by an educational grant from Susan G. Komen for the Cure®

An update on advances in the technologies available for translational research. Sessions are to provide people with a better understanding of the topics of special current interest they hear using the techniques described. These presentations also provide researchers with a guide to the techniques they should be considering for their studies.

2:00 pm–3:30 pm
The Practical Use of Molecular Profiling
Ballroom A
Moderator: Peter M. Ravdin, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

Molecular profiling for in situ carcinoma of the breast
Lawrence J. Solin, MD, FACR, FASTRO
Albert Einstein Medical Center
Philadelphia, PA

The practical use of molecular profiling: The view of a medical oncologist
Antonio C. Wolff, MD
Johns Hopkins Kimmel Cancer Center
Baltimore, MD

Use of genomic tests in routine practice and clinical research in metastatic breast cancer
Lajos Pusztai, MD, DPhil
Yale Cancer Center
New Haven, CT

Biology of Triple-Negative Breast Cancer
Ballroom B
Moderator: Nicholas Turner, MD
Royal Marsden Hospital
London, UNITED KINGDOM

New vulnerabilities for TNBC – from genetics to therapeutics
Thomas Westbrook, PhD
Baylor College of Medicine
Houston, TX

Triple negative breast cancer: Subtypes, molecular targets, and therapeutic approaches
Jennifer A. Pietenpol, PhD
Vanderbilt University School of Medicine
Nashville, TN

The clonal and mutational evolution of primary triple negative breast cancers
Samuel Aparicio, PhD
University of British Columbia
Vancouver, CANADA

Clinical Trial Designs for New Therapies
Exhibit Hall D
Moderator: Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

Early phase trials - What are they for?
Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

What agents should go into trials?
Angela DeMichele, MD, MSCE
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA

What endpoints should we use?
Clifford A. Hudis, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Randomized clinical trial designs: Still important
Sally Hunsberger, PhD
National Cancer Institute
Rockville, MD

What have we learned?
Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

4:00 pm–5:30 pm

Navigating the Obstacles and Risks of Survivorship
Ballroom A
Moderator: Susan W. Rafte
Pink Ribbons Project
Houston, TX

Emerging sexual pharmacology for the breast cancer survivor
Michael Krychman, MD
The Southern California Center for Sexual Health and Survivorship
Newport Beach, CA

Cognitive changes and breast cancer treatments
Patricia A. Ganz, MD
University of California, Los Angeles
Los Angeles, CA

Risk of second primary breast cancer and other serious late complications issues among survivors of breast cancer
Jonine L. Bernstein, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

Mammary Cell Lineages and Breast Cancer Subtypes
Ballroom B
Moderator: Michael T. Lewis, PhD
Baylor College of Medicine
Houston, TX

Primitive normal human mammary cells – the forerunners of malignant populations
Connie Eaves, PhD
University of British Columbia
Vancouver, CANADA

Deciphering the cellular hierarchy of the mammary gland and its implication for breast cancer
Marielle Ousset, PhD
Université Libre de Bruxelles
Bruxelles, BELGIUM

Understanding human cancer with single cell genetics
Nicholas E. Navin, PhD
UT MD Anderson Cancer Center
Houston, TX

Controversies in the Surgical Management of Breast Cancer
Exhibit Hall D
Moderator: Ismail Jatoi, MD, PhD, FACS
UT Health Science Center San Antonio
San Antonio, TX

Sentinel node biopsy in breast cancer: Before or after neoadjuvant chemotherapy
Eleftherios Mamounas, MD
Aultman Hospital
Canton, OH

Evolving trends in implant breast reconstruction
Andrea L. Pusic, MD, MHS, FRCSC
Memorial Sloan-Kettering Cancer Center
New York, NY

The role of MRI in management of primary breast cancer
Ismail Jatoi, MD, PhD, FACS
UT Health Science Center San Antonio
San Antonio, TX

6:00 pm–7:30 pm

Tumor Dormancy and Late Recurrences
Ballroom A
Moderator: George W. Sledge, Jr, MD
Indiana University Simon Cancer Center
Indianapolis, IN

Mechanisms of breast cancer dormancy and recurrence
Lewis A. Chodosh, MD, PhD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Tumor dormancy from an experimental biologist's perspective
Ann F. Chambers, PhD
London Regional Cancer Program
London, CANADA

Attacking tumor dormancy in the clinic: How do we design the trials?
George W. Sledge, Jr, MD
Indiana University Simon Cancer Center
Indianapolis, IN

Inflammation and Breast Cancer
Ballroom B
Moderator: Charlotte Kuperwasser, PhD
Tufts University School of Medicine
Boston, MA

Mechanism-based insights into prognosis and treatment of breast cancer derived from high resolution multiphoton imaging
John Condeelis, PhD
Albert Einstein College of Medicine
Bronx, NY

Breast cancer stroma: a predictor of clinical outcome and tumour heterogeneity
Morag Park, PhD
McGill University
Montreal, CANADA

Links between inflammation, breast cancer and obesity
Charlotte Kuperwasser, PhD
Tufts University School of Medicine
Boston, MA

Her2-Positive Breast Cancer
Exhibit Hall D
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Adjuvant therapy of HER2 positive breast cancer – the next installment
Karen Gelmon, MD
BC Cancer Agency
Vancouver, CANADA

Advances in HER2+ breast cancer
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Neoadjuvant approach in HER2 over-expressing breast cancer: Therapeutic implications and biomarker discovery
Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

WEDNESDAY, DECEMBER 5, 2012

7:00 am–5:15 pm
REGISTRATION
Bridge Hall

7:00 am–8:30 am
CONTINENTAL BREAKFAST
Exhibit Hall C

7:45 am–8:00 am
WELCOME AND OPENING REMARKS
Exhibit Hall D

8:00 am–8:30 am
PLENARY LECTURE 1
Exhibit Hall D

Hormones and the Breast: Local and Environmental Interactions
Cathrin Brisken, MD, PhD
Ecole Polytechnique Fédérale de Lausanne
Lausanne, SWITZERLAND

8:30 am–11:15 am
GENERAL SESSION 1
Exhibit Hall D

Moderator: Kathy S. Albain, MD, FACP
Loyola University Chicago Stritch School of Medicine
Maywood, IL

8:30 **S1-1. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial**
Metzger O, Giobbie-Hurder A, Mallon E, Viale G, Winer E, Thürlimann B, Gelber RD, Colleoni M, Ejlertsen B, Bonnefoi H, Coates AS, Goldhirsch A, Gusterson B. BIG 1-98 Collaborative Group, International Breast Cancer Study Group.

8:45 **S1-2. ATLAS – 10 v 5 years of adjuvant tamoxifen (TAM) in ER+ disease: Effects on outcome in the first and in the second decade after diagnosis**
Davies C, Pan H, Godwin J, Gray R, Peto R, on Behalf of ATLAS Collaborators Worldwide. University of Oxford, Oxford, United Kingdom; Glasgow Caledonian University, Glasgow, United Kingdom.

9:00 **S1-3. Discussion**
William E. Barlow, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA

9:15 **S1-4. Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg**
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Rukazenkov Y, Martin M. Hospital of Prato, Prato, Italy; Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium; First Faculty of Medicine of Charles University, Prague, Czech Republic; Instituto Nacional del Cáncer, Santiago, Chile; Dnipropetrovsk Municipal Clinical Hospital, Dnipropetrovsk, Ukraine; Republican Clinical Oncological Center, Kazan, Russian Federation; AZ Klina, Brasschaat, Belgium; Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil; Medical Radiological Science Center, Obninsk, Russian Federation; Russian Cancer Research Centre, Moscow, Russian Federation; Kansas City Cancer Center, Kansas City; AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom; Hospital Universitario Gregorio Maranon, Madrid, Spain.

9:30 **S1-5. PIK3CA mutations are linked to PgR expression: A Tamoxifen Exemestane Adjuvant Multinational (TEAM) pathology study**
Sabine VS, Crozier C, Drake C, Piper T, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, Seynaeve C, Rea D, Bartlett JMS. Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Edinburgh Cancer Research Centre, Institute of Genetics & Molecular Medicine, Edinburgh, Scotland, United Kingdom; Leiden University Medical Center, Leiden, Netherlands; University Hospital, Freiburg, Germany; Elblandklinikum, Riesa, Germany; Athens University Medical School, Athens, Greece; St. Augustinus Hospital, Antwerp, Belgium; Erasmus Medical Center-Daniel den Hoed, Rotterdam, United Kingdom; University of Birmingham, Birmingham, United Kingdom.

9:45 **S1-6. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC)**
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Breazna A, Kim ST, Randolph S, Slamon DJ. University of California, Los Angeles, CA; Irish Cooperative Oncology Research Group, Dublin, Ireland; Orszagos Onkologiai Intezet, Budapest, Hungary; Szent Margit Korhaz, Budapest, Hungary; Dnipropetrovsk City Multiple-Discipline Clinical Hospital, Ukraine; Municipal Treatment-and-Prophylactic Institution "Donetsk City Oncological Dispensary", Ukraine; Technical University of Munich, Germany; Comprehensive Blood and Cancer Center, Bakersfield, CA; Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary; University Hospital Mainz, Germany; Lviv State Oncologic Regional Treatment and Diagnostic Center, Ukraine; Comprehensive Cancer Centers of Nevada, Henderson, NV; Kyiv City Clinical Oncology Center, Ukraine; Pfizer Oncology, New York, NY; Pfizer Oncology, San Diego, CA.

10:00 S1-7. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer - First efficacy results from the LEA study
Martin M, Loibl S, von Minckwitz G, Morales S, Crespo C, Anton A, Guerrero A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JA, Gil M, Ramos M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, De la Haba JR, On behalf of GEICAM (Spanish Breast Cancer Research Group), GBG (German Breast Group). Instituto de Investigacion Sanitaria Gregorio Marañon, Madrid, Spain; GBG (German Breast Group), Neu-Isenburg, Germany; University Women´s Hospital Essen, Germany; Medical Practice Berlin, Germany; University Women´s Hospital Muenster, Germany; Klinikum Boeblingen, Germany; H. Arnau Vilanova de Lerida, Spain; Hospital U. Ramon y Cajal, Spain; Hospital Universitario Miguel Servet, Spain; Instituto Valenciano de Oncologia, Spain; Hospital Clinic i Provincial, Spain; Hospital Clinico U. San Carlos, Spain; Instituto Catala d' Oncologia Hospitalet, Spain; GEICAM (Spanish Breast Cancer Research Group), Spain; Hospital U. Reina Sofia, Spain; Centro Oncologico de Galicia, Spain.

10:15 S1-8. Prolactin-humanized mice: an improved animal recipient for therapy response-testing of patient-derived breast cancer xenotransplants
Rui H, Utama FE, Yanac AF, Xia G, Peck AR, Liu C, Rosenberg AL, Wagner K-U, Yang N. Thomas Jefferson University, Philadelphia, PA; Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE.

10:30 S1-9. Comparative performance of breast cancer Index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: A TransATAC Study
Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Erlander MG, Goss PE, Dowsett M. Massachusetts General Hospital, Harvard Medical School, Boston, MA; Centre for Cancer Prevention, Queen Mary University, London, United Kingdom; bioTheranostics Inc., San Diego, CA; Breakthrough Breast Cancer Centre, Royal Marsden Hospital, London, United Kingdom.

10:45 S1-10. Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong J-H, Kim S-R, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers; Aultman Hospital; Graduate School of Public Health, University of Pittsburgh; Genomic Health, Inc.; Allegheny Cancer Center at Allegheny General Hospital; University of Pittsburgh Cancer Institute.

11:00 S1-11. Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)
Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Zujewski JA, Justice R, Loibl S, Wickerham L, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas E, Bergh J, Semiglazov V, Prowell T, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching P, Swain SM, Slaets L, Tang S, Gerber B, Geyer C, Pazdur R, Ditsch N, Rastogi P, Eiermann W, vonMincwitz G. FDA; HELIOS Klinikum Berlin-Buch, Berlin, Germany; NSABP, Pittsburgh, PA; University of Pittsburgh; Institut Bergonié , INSERM U916, and Université Bordeaux Segalen, Bordeaux, France; University of Edinburgh, Edinburgh, Scotland, United Kingdom; San Raffaele Scientific Insitute, Milan, Italy; Fondazione Michelangelo, Milan, Italy; NCI, Bethesda, MD; Lineberger Comprehensive Cancer Center, Chapel Hill, NC; GBG Forschungs GmbH, Germany; Medstar Washington Hospital Center, Washington, DC; St. Gertrauden Hospital, Berlin, Germany; University Women's Hospital, Kiel, Germany; University Womens Hospital, Erlangen, Germany; University Women's Hospital, Rostock, Germany; University Women's Hospital, Munich, Germany; Private Practice, Munich, Germany; Karolinska Institutet and University Hospital, Stockholm, Sweden; EORTC Headquarters, Brussels, Belgium; Memorial Sloan Kettering Cancer Center, NY; NN Petrov Res. Inst. Of Oncology, St.-Petersburg, Russian Federation; Jules Bordet Institute, Brussels, Belgium.

11:15 am–12:00 pm
WILLIAM L. MCGUIRE MEMORIAL LECTURE
Exhibit Hall D

Neoadjuvant Systemic Therapy: Promising Experimental Model, or Improved Standard of Care?
Gabriel N. Hortobagyi, MD
UT MD Anderson Cancer Center
Houston, TX

12:00 pm–1:35 pm
LUNCH

12:30 pm–1:35 pm
CLINICAL SCIENCE FORUM
Treatment on the Edges: Discordance Between Stage and Biology
Ballroom A

Moderator: Kathy S. Albain, MD, FACP
Loyola University Chicago Stritch School of Medicine
Maywood, IL

Bad stage, but good biology
Kathy S. Albain, MD, FACP
Loyola University Chicago Stritch School of Medicine
Maywood, IL

Low stage…but adverse biology
Martine J. Piccart, MD, PhD
Jules Bordet Institute
Brussels, BELGIUM

12:30 pm–1:35 pm
BASIC SCIENCE FORUM
Metastasis – Niches
Ballroom B

Moderator: Yibin Kang, PhD
Princeton University
Princeton, NJ

Cancer stem cells interactions with their niche determine formation of breast cancer metastasis
Joerg Huelsken, PhD
Federal Technical University Lausanne
Lausanne, SWITZERLAND

Tumor-stromal interactions in bone metastasis
Yibin Kang, PhD
Princeton University
Princeton, NJ

1:45 pm–3:15 pm
MINI-SYMPOSIUM 1
The mTOR Pathway: Role in Metabolism and as a Therapeutic Target
Exhibit Hall D

Moderator: Carlos L. Arteaga, MD
Vanderbilt-Ingram Cancer Center
Vanderbilt University
Nashville, TN

Targeting PI3K
Lewis Cantley, PhD
Beth Israel Deaconess Medical Center
Boston, MA

Translating regulation of mTOR and protein synthesis to the clinic for advanced breast cancer
Robert Schneider, PhD
NYU School of Medicine
New York, NY

Clinical development of mTOR inhibitors
Fabrice André, MD, PhD
Gustave Roussy Institute
Villejuif, FRANCE

3:15 pm–4:00 pm

GENERAL SESSION 2
Exhibit Hall D

Moderator: Anthony Lucci, Jr., MD, FACS
UT MD Anderson Cancer Center
Houston, TX

3:15 S2-1. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy - results from the ACOSOG Z1071 trial
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Hunt KK. Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; Magee-Womens Surgical Associates, Pittsburgh, PA; University of Wisconsin-Madison, WI; Columbia University Medical Center, New York, NY; University of Texas Southwestern Medical Center, Dallas, TX; Carolinas Medical Center, Charlotte, NC; University of Washington Medical Center, Seattle, WA; University of North Carolina - Chapel Hill, NC; Allegheny General Hospital, Pittsburgh, PA; Mayo Clinic, Jacksonville, FL; Duke University Medical Center, Durham, NC; The Cancer Institute of New Jersey, New Brunswick, NJ.

3:30 S2-2. Sentinel lymph node biopsy before or after neoadjuvant chemotherapy - final results from the prospective German, multiinstitutional SENTINA-trial
Kuehn T, Bauerfeind IGP, Fehm T, Fleige B, Helms G, Lebeau A, Liedtke C, von Minckwitz G, Nekljudova V, Schrenk P, Staebler A, Untch M. Klinikum Esslingen, Esslingen, Baden Wuerttemberg, Germany; Klinikum Landshut, Landshut, Bayern, Germany; Universitaetsfrauenklinik Tuebingen, Baden Wuerttemberg, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Medical Center, Muenster, Nordrhein-Westfalen, Germany; German Breast Group, Neu- Isenburg, Hessen, Germany; AKH-LFKK, Linz, Austria; University Medical Center, Tuebingen, Baden-Wuerttemberg, Germany.

3:45 S2-3. Disparities in the utilization of axillary sentinel lymph node biopsy among black and white patients with node-negative breast cancer from 2002-2007
Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD. MD Anderson Cancer Center, Houston, TX.

4:00 pm–5:00 pm

SUSAN G. KOMEN FOR THE CURE® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES
Exhibit Hall D

The Basic Science Award is presented to a researcher whose scientific discoveries or novel technologies have added substantively to our understanding of the basic biology of breast cancer and the intrinsic molecular processes that drive the disease, and/or whose work has bridged the gap between basic research and patient care. This year the award is being presented to:

Yosef Yarden, PhD
Department of Biological Regulation
Weizmann Institute of Science
Rehovot, ISRAEL
How Does HER2 Contribute to Breast Cancer Progression?

The Clinical Research Award is presented to a clinical or translational researcher who has advanced the identification of new prevention, detection or treatment approaches for breast cancer and promoted their incorporation into clinical care. This year the award is being presented to:

Hyman B. Muss, MD
Lineberger Comprehensive Cancer Center
The University of North Carolina, Chapel Hill
Chapel Hill, NC
Older Women and Breast Cancer: Challenges and Opportunities

5:00 pm–7:00 pm

POSTER DISCUSSION 1: ENDOCRINE RESISTANCE
Ballroom A

Viewing 5:00 pm
Discussion 5:15 pm

Rachel Schiff, PhD, Chair
Baylor College of Medicine
Houston, TX

Steffi Oesterreich, PhD, Discussant
University of Pittsburgh Cancer Institute
Pittsburgh, PA
and
Suleiman Massarweh, MD, Discussant
University of Kentucky and Markey Cancer Center
Lexington, KY

PD01-01 Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors
Fu X, Kumar V, Shea M, Biswal NC, Nanda S, Chayanam S, Mitchell T, Hergenroeder G, Meerbrey KL, Joshi A, Westbrook TF, Mills GB, Creighton CJ, Hilsenbeck SG, Osborne CK, Schiff R. Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; M.D. Anderson Cancer Center, Houston, TX.

PD01-02 Increased expression of phosphorylated mTOR in metastatic breast tumors compared to primary tumors in patients who received adjuvant endocrine therapy
Hoefnagel LDC, Beelen KJ, Opdam M, Vincent A, Linn SC, vanDiest PJ. University Medical Center, Utrecht, Netherlands; The Netherlands Cancer Institute, Amsterdam, Netherlands.

PD01-03 Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment
Beelen KJ, Opdam M, Severson TM, Koornstra RHT, Vincent A, Wesseling J, Muris JJ, Berns EMJJ, Vermorken JB, vanDiest PJ, Linn SC. The Netherlands Cancer Institute, Amsterdam, Netherlands; Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, Netherlands; Antwerp University Hospital, Edegem, Belgium; University Medical Center, Utrecht, Netherlands.

PD01-04 Deep kinome sequencing identifies a novel D189Y mutation in the Src family kinase LYN as a possible mediator of antiestrogen resistance in ER+ breast cancer
Fox EM, Balko JM, Arteaga CL. Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN.

PD01-05 Analysis of patients with ER-positive breast tumors treated with neoadjuvant aromatase inhibition identifies chemokine receptors as potential modulators of endocrine resistance
Ribas R, Ghazoui Z, Dowsett M, Martin L-A. The Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom.

PD01-06 Inhibition of the Ret receptor tyrosine kinase in combination with endocrine therapy impacts on migration and metastatic potential of estrogen receptor positive breast cancer models
Hynes NE, Gattelli A, Nalvarte I, Roloff T. Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

PD01-07 High throughput sequencing following cross-linked immune-precipitation (HITS-CLIP) of Argonaute protein reveals novel miRNA regulatory pathways of estrogen receptor in breast cancer
Kabos P, Kline E, Brown J, Flory K, Sartorius C, Hesselberth J, Pillai MM. University of Colorado Denver, Aurora, CO.

PD01-08 **Differences in estrogen receptor signaling in non-malignant primary ER-positive breast epithelial cells and breast cancer**
Lim E, He HH, Chi D, Yeung TY, Schnitt S, Liu SX, Garber J, Richardson A, Brown M. Dana-Farber Cancer Institute, Boston, MA; Harvard School of Public Health, Boston, MA; Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA.

5:00 pm–7:00 pm
POSTER DISCUSSION 2: HER2
Ballroom B

Viewing 5:00 pm
Discussion 5:15 pm

Andrea Richardson, MD, PhD, Chair
Dana-Farber Cancer Institute
Boston, MA

Marc Van de Vijver, MD, PhD, Discussant
Academic Medical Center
Amsterdam, NETHERLANDS
and
Antonio C. Wolff, MD, Discussant
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

PD02-01 **Her2 expression measured by AQUA analysis on BCIRG-005 and BCIRG-006 predicts the benefit of Herceptin therapy**
Christiansen J, Barakat N, Murphy D, Rimm DL, Dabbas B, Nerenberg M, Beruti S, Quinaux E, Hall J, Press M, Slamon D. Genoptix Medical Laboratory; Yale University; IDDI; University of Southern California; University of California, Los Angeles.

PD02-02 **The effect of HER2 expression on luminal A breast tumors**
Ellsworth RE, Valente AL, Shriver CD. Henry M. Jackson Foundation, Windber, PA; Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD.

PD02-03 **Added value of HER-2 amplification testing by multiplex ligation-dependent probe amplification (MLPA)**
van Slooten H-J, Kuijpers CC, Moelans CB, Horstman A, Al-Janabi S, Hinrichs JW, van Diest PJ, Jiwa M. Symbiant Pathology Expert Centre, Alkmaar, Netherlands; University Medical Centre Utrecht, Netherlands.

PD02-04 **Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma**
Wang Z, Portier BP, Gruver AM, Bui S, Wang H, Su N, Vo H-T, Ma X-J, Luo Y, Budd GT, Tubbs RR. Cleveland Clinic, Cleveland, OH; Advanced Cell Diagnostics, Hayward, CA.

PD02-05 **Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (D-ISH) in the determination of HER2 status**
Mansfield AS, Sakai Y, Walsh FJ, Wiktor AE, Sukov WR, Dogan A, Jenkins RB. Mayo Clinic, Rochester, MN.

PD02-06 **Concordance between immunohistochemistry and FISH (fluorescence in situ hybridization) & SISH(silver in situ hybridization) for assessment of the HER2**
Lee M-R, Cho S-H, Kim D-C, Lee K-C, Lee J-H, Kwon H-C, Lee H-W, Lee S-e. Dong-A University Medical Center, Busan, Korea.

PD02-07 **Next-generation sequencing of FFPE breast cancers demonstrates high concordance with FISH in calling *HER2* amplifications and commonly detects other clinically relevant genomic alterations**
Lipson D, He J, Yelensky R, Miller V, Sheehan C, Brennan K, Jarosz M, Stephens P, Cronin M, Ross J. Foundation Medicine, Inc, Cambridge, MA; Albany Medical College, Albany, NY.

5:00 pm–7:00 pm
POSTER SESSION 1 & RECEPTION
Exhibit Halls A-B

Detection/Diagnosis: Axillary Staging and Sentinel Nodes

P1-01-01 **Fluorescence mapping with indocyanine green for sentinel lymph node detection in early breast cancer – results of the ICG-10 study**
Benson JR, Loh S-W, Jones LA, Wishart GC. Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom.

P1-01-02 **Withdrawn**

P1-01-03 **Comparison of sentinel lymph node biopsy guided by the multi-modal method of indocyanine green fluorescence, radioisotope and blue dye versus the radioisotope in breast cancer; A randomized phase II trial**
Jung S-Y, Kim S-K, Kim SW, Lee S, Lee J, Shin I-s, Kwon Y, Lee E. National Cancer Center, Goyang, Korea.

P1-01-04 **Tc 99m Tilmanocept and Sulfur Colloid Injection: A comparison of preoperative imaging and intraoperative lymphatic mapping of breast cancer patients – Localization rate and degree of localization**
Cope FO, Metz WL, Hartman RD, Joy MT, Potter BM, Abbruzzese BC, Shuping JL, Blue MS, Christman LA, King DW. Navidea Biopharmaceuticals, Dublin, OH; STATKING Consulting, Inc., Fairfield, OH.

P1-01-05 **The Efficacy of Arm Node Preserving Surgery Using Axillary Reverse Mapping for Preventing Lymphedema in Patients with Breast Cancer: The results from a 2-year follow-up**
Lee J-H, Son G-T, Choi J-E, Kang S-H, Lee S-J, Bae Y-K. Yeungnam University college of medicine, Daegu, Republic of Korea.

P1-01-06 **Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important**
Mittendorf EA, Ballman KV, McCall LM, Hansen N, Lucci A, Gabram S, Urist M, Crow J, Hurd T, Hunt KK, Giuliano AE. The University of Texas MD Anderson Cancer Center; Mayo Clinic; American College of Surgeons Oncology Group; Northwestern University; Emory University; University of Alabama Birmingham; University of Texas Health Science Center San Antonio; Cedars-Sinai Medical Center.

P1-01-07 **The Institut Curie Nomogram including HER2 status predicts additional axillary metastasis in breast cancer patients with a positive sentinel node biopsy: a multicentric validation**
Ngo C, De Rycke Y, Belichard C, Guilhen N, Doridot V, Rouzier R, Coutant C, Hudry D, Fritel X, Fourchotte V, Feron J-G, Pierga J-Y, Salomon A, Alran S. Institut Curie, Paris, France; Poitiers University Hospital, Poitiers, France; Centre de Santé République, Clermont-Ferrand, France; Hopital Tenon, Paris, France; Centre Georges François Leclerc, Dijon, France.

P1-01-08 **A Nomogram for predicting two or less axillary lymph node involvement for breast cancer**
Ahn SK, Kim JS, Kim Mk, Lee JW, Kim T, Kim JY, Moon HG, Han W, Noh D-Y. Seoul National University College of Medicine, Seoul, Korea.

P1-01-09 **Which nomograms may be the best for predicting nonsentinel lymph node metastasis in breast cancer patients: a meta-analysis**
Chen K, Jin L, Zhu L, Shan Q, Su F. Sun Yat-sen Memorial Hopsital, Guangzhou, Guangdong, China.

P1-01-10 **Comparison of sentinel lymph node positivity rates pre and post introduction of OSNA molecular analysis**
Rusby J, Agabiti E, Waheed S, Barry P, Roche N, Allum W, Gui G, MacNeill F, Christaki G, Osin P, Nerurkar A. Royal Marsden NHS Foundation Trust, London, United Kingdom.

P1-01-11 Is OSNA mRNA copy number in sentinel lymph node biopsy predictive of further disease in the axilla?
Rusby JE, Agabiti E, Waheed S, Barry P, Roche N, Allum W, Gui G, MacNeill F, Christaki G, Osin P, Nerurkar A. Royal Marsden NHS Foundation Trust, London, United Kingdom.

P1-01-12 The Performance of the One Step Nucleic Acid Amplification (OSNA) Assay in Breast Cancer Patients with Receiving Preoperative Systemic Therapy
Yagata H, Yamauchi H, Horii R, Osako T, Iwase T, Akiyama F, Kinoshita T, Tsuda H, Tsugawa K, Nakamura S. St. Luke's International Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan; St. Marianna University School of Medicine, Kanagawa, Japan; Showa University School of Medicine, Tokyo, Japan.

P1-01-13 Patterns of definitive axillary management in the era prior to reporting ACOSOG Z0011: comparison between NCCN Centers and hospitals in Michigan
Breslin T, Hwang S, Mamet R, Hughes M, Otteson R, Edge S, Moy B, Rugo H, Wong Y-N, Wilson J, Laronga C, Weeks J, Silver S, Marcom P. University of Michigan, Ann Arbor, MI; Duke University; City of Hope; Dana-Farber/Brigham and Women's Cancer Center; Roswell Park Cancer Institute; University of California San Fransisco; Fox Chase Cancer Center; Ohio State University; Moffitt Cancer Center; Massachusetts General Hospital Cancer Center.

P1-01-14 Effects of axillary lymph node dissection on survival of patients with sentinel lymph node metastasis of breast cancer in the Surveillance, Epidemiology and End Results (SEER) database using a propensity score matching analysis
Bendifallah S, Chereau E, Bezu C, Coutant C, Rouzier R. Tenon, Paris, France; Centre Leclerc, Dijon, France.

P1-01-15 Accuracy of sentinel lymph node in determining the requirement for second axillary surgeries in early breast cancer with retrospective application of the Z0011 criteria
Waters PS, Fennessy PJ, Alazawi D, Sweeney KJ, Kerin MJ. National University of Ireland, Galway, Ireland.

P1-01-16 Intraoperatively-palpable "non-sentinel" nodes: should they be removed?
Crivello ML, Ruth K, Sigurdson ER, Egleston BL, Boraas M, Bleicher RJ. Fox Chase Cancer Center, Philadelphia, PA.

P1-01-17 The impact of triple negativity on lymph node positivity in breast cancer
Weber JJ, Bellin LS, Milbourn DE, Wong J. East Carolina University, Brody School of Medicine, Greenville, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC.

P1-01-18 The results of 55 consecutive cases of intra-operative sentinel node analysis using real time polymerase chain reaction detection of cytokeratin 19 and mammoglobin expression (Metasin) to direct immediate axillary clearance
Nadi K, Sharaiha Y, Sai-Girdhar P, Huws A, Khawaja S, Holt S. Prince Philip Hospital, Llanelli, United Kingdom.

P1-01-19 Prediction of axillary lymph node status in male breast carcinoma
Vaysse C, Sroussi J, Mallon P, Feron J-G, Rivain A-L, Ngo C, Belichard C, Lasry S, Pierga J-Y, Couturaud B, Fitoussi A, Laki F, Fourchotte V, Alran S, Kirova YM, Vincent-Salomon A, Sastre-Garau X, Sigal-Zafrani B, Rouzier R, Reyal F. Institut Curie, Paris, France.

P1-01-20 Clinicopathlogic Analysis of Invasive Breast Carcinoma with Micropapillary Component
Yamanaka T, Suganuma N, Yamanaka A, Kojima I, Nishiyama S, Mukaibashi T, Nakayama H, Matsuura H, Matsuzu K, Chiba A, Inaba M, Rino Y, Yoshida A, Shimizu S, Masuda M. Yokohama City University, Yokohama-City, Kanagawa, Japan; Kanagawa Cancer Center, Yokohama-City, Kanagawa, Japan; Ito Hospital, Tokyo, Japan.

P1-01-21 Sentinel Lymph Node detection after previous breast tumour surgical resection: identification rate and false negative rate through a prospective multi institutional study
Classe J-M, Andrieux N, Tunon de Lara C, Charitansky H, Lecuru F, Houpeau J-L, Faure C, De Blaye P, Houvenaeghel G, Kere D, Marchal F, Raro P, Lefebvre C, Dupré P-F, Rodier J-F. Institut de Cancerologie de l'Ouest, Nantes Saint Herblain, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, Toulouse, France; Centre Hospitalier Georges Pompidou, Paris, France; Centre Oscar Lambret, Lille, France; Centre léon Bérard, Lyon, France; Centre Hospitalier Les Oudairies, La Roche sur Yon, France; Institut Paoli Calmettes, Marseille, France; Institut Jean Godinot, Reims, France; Centre Alexis Vautrin, Nancy, France; Centre Hospitalier Universitaire, Angers, France; Centre Hospitalier Morvan, Brest, France; Centre Paul Strauss, Strasbourg, France.

P1-01-22 The utility of axillary ultrasound and sentinel lymph node biopsy in the management of metaplastic breast carcinoma
Hieken TJ, Fazzio RT, Reynolds C, Jones KN, Ghosh K, Glazebrook KN. Mayo Clinic, Rochester, MN.

P1-01-23 Increased Diagnostic Performance of Sentinel Lymph Node Biopsy Combined with Radiologic-pathologic Factors After Neoadjuvant Chemotherapy in Breast Cancer Patients with Cytologically Proven Node Metastasis at Diagnosis
Park S, Koo JS, Kim MJ, Park JM, Cho JH, Hwang H, Park HS, Kim E-K, Kim SI, Park B-W. Yonsei University College of Medicine, Seoul, Korea.

P1-01-24 Which combinations are helpful to predict axillary lymph node metastasis in T1 breast cancer with ultrasonography and contrast-enhanced MRI and contrast-enhanced ^{18}F-FDG PET-CT?
Hwang SO, Park HY, Jung JH, Kim WW, Lee YH, Lee JJ, Choi HH, Hwangbo SM. Kyungpook National University School of Medicine, Daegu, Korea; Hyosung Hospital, Daegu, Korea.

P1-01-25 Sentinel lymph node biopsy in breast cancer: The approach in day surgery under local anaesthesia for quality-of-life and significant cost reduction
Ricci F, Capuano LG, Saralli E, Di Legge P, Violante A, Polistena A, Scala T, Pacchiarotti A, Cannas P, Cianni R, Fanelli G, Bellardini P, De Masi C. S.M. Goretti Hospital, Latina, Italy; LILT, Latina, Italy.

P1-01-26 Procoagulant biomarkers may direct axillary nodal surgery
Shaker H, Bundred NJ, Glassey E, Kirwan CC. University Hospital of South Manchester, Manchester, United Kingdom; University of Manchester, United Kingdom.

P1-01-27 Novel diagnostic procedure of metastasis to the sentinel lymph node of breast cancer using a semi-dry dot-blot method
Otsubo R, Oikawa M, Shibata K, Hirakawa H, Yano H, Matsumoto M, Hatachi T, Nakao K, Hayashi T, Abe K, Kinoshita N, Nakashima M, Taniguchi H, Omagari T, Itoyanagi N, Nagayasu T. Nagasaki University Hospital, Nagasaki, Japan; The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan; Aiyuukai Memorial Hospital, Chiba, Japan; Nagasaki University Atomic Bomb Disease Institute, Nagasaki, Japan; St. Francis Hospital, Nagasaki, Japan.

P1-01-28 What is the actual impact of micrometastases in sentinel lymph nodes in regards to global survival and disease free survival
Barbosa EM, Araujo Neto JT, Filho EC, Infante KP, Felzener MM, Matielle CR, Modesto MG, Basso R, Goes JCS. Instituto Brasileiro de Controle do Cancer - IBCC, Sao Paulo, Brazil.

P1-01-29 **Intraoperative molecular analysis of sentinel lymph node as a new predictor of axillary status in early breast cancer patients**
Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, Sancho de Salas M, Sansano I, Delgado Sánchez JJ, Pinto W, Gozalbo F, Petit A, Rubio I. Hospital Universitario Vall d'Hebron, Barcelona, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Complejo hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Spain; Hospital Universitario de Salamanca, Salamanca, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario e Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; Instituto Valenciano de Oncología (IVO), Valencia, Spain; Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain.

Detection/Diagnosis: Biopsy Techniques

P1-02-01 **Flat epithelial atypia diagnosed on breast core biopsy: what next?**
Plichta JK, Lapetino S, Rumas N, Rajan P, Godellas C, Perez C. Loyola University Medical Center, Maywood, IL.

P1-02-02 **Receptor discordance in breast cancer recurrence: Is re-biopsy a necessity?**
Fujita T, Sawaki M, Hattori M, Kondo N, Horio A, Ushio A, Gondo N, Hiroji I. Aichi Cancer Center Hospital, Nagoya, Japan.

Tumor Cell and Molecular Biology: Etiology/Carcinogenesis

P1-03-01 **Evidence for the Warburg effect in mammary atypia from high-risk African American women**
Seewaldt V, Hoffman A, Ibarra-Drendall C. Duke University, Durham, NC.

P1-03-02 **'Normal' tissue adjacent to breast cancer is not normal**
Clare SE, Pardo I, Mathieson T, Lillemoe HA, Blosser RJ, Choi M, Sauder CAM, Doxey DK, Badve S, Storniolo AMV, Atale R, Radovich M. Indiana University School of Medicine, Indianapolis, IN; Susan G. Komen for the Cure Tissue Bank at the IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN.

P1-03-03 **Milk deposition in women's mammary duct has been a potential risk factor of breast tumor**
Xu Z, Gu Y, Gong G, Zhang Y. Breast Disease Institution of Jilin Province, Changchun, Jilin, China; Spinal Disease Institution of Jilin Province, Changchun, Jilin, China.

Tumor Cell and Molecular Biology: Oncogenes/Tumor Suppressor Genes

P1-04-01 **Loss of Notch4 reduces mammary tumorigenesis by MYC and activated KRAS**
Rodriguez EM, Bishop JM. G. W. Hooper Research Foundation, University of California, San Francisco, CA.

P1-04-02 **The role of the mTORC1/S6K1 signaling pathway in ER-positive breast cancer**
Holz MK, Unger HA, Sedletcaia A. Stern College for Women of Yeshiva University; Albert Einstein College of Medicine.

P1-04-03 **Knocking down Suppressor of Cytokine Signaling 7 in breast cancer: The role in Insulin-like Growth Factor - I / Phospholipase Cγ-1 signaling**
Sasi W, Ye L, Jiang WG, Mokbel K, Sharma A. St George's Hospital Medical School, University of London, United Kingdom; Cardiff University School of Medicine, Cardiff, Wales, United Kingdom; The London Breast Institute, The Princess Grace Hospital, London, United Kingdom.

P1-04-04 **KSR1 is involved in functional interaction between p53 and BRCA1 and is an independent predictor of overall survival in breast cancer**
Zhang H, Lombardo Y, Filipovic A, Periyasamy M, Coombes RC, Stebbing J, Giamas G. Imperial College London, United Kingdom.

P1-04-05 **Role of the Rb and p53 Tumor Suppressor Pathways in Mammary Tumorigenesis**
Jones RA, Liu JC, Zhe J, Schimmer AA, Eldad Z. University Health Network, Toronto, ON, Canada.

P1-04-06 **Insertional mutagenesis identifies HACE1 as a HER2/Neu Cooperating Breast Cancer Tumor Suppressor Gene**
Goka E, Miller P, Baker K, Stark G, Lippman ME. University of Miami Miller School of Medicine, Miami, FL; Cleveland Clinic, Cleveland, OH; University of Miami, FL.

P1-04-07 **The mRNA Expression of DAP1 in Human Breast Cancer: Correlation with Clinicopathological Parameters**
Wazir U, Jiang WG, Sharma AK, Mokbel K. St Georges' Healthcare NHS Trust, London, United Kingdom; Cardiff University-Peking University Oncology Joint Institute, Cardiff, United Kingdom; The London Breast Institute, The Princess Grace Hospital, London, United Kingdom.

P1-04-08 **Evidence for anti-apoptosis function of GNB1 in human breast cancer**
Wazir U, Kasem A, Sharma AK, Jiang W, Mokbel K. The London Breast Institute, The Princess Grace Hospital, London, United Kingdom; Cardiff University-Peking University Oncology Joint Institute, Cardiff, United Kingdom; St Georges' Healthcare NHS Trust, London, United Kingdom.

P1-04-09 **mTORC1 and Rictor expression in human breast cancer: correlations with clinicopathological parameters and disease outcome**
Wazir U, Kasem A, Sharma AK, Jiang WG, Mokbel K. The London Breast Institute, The Princess Grace Hospital, London, United Kingdom; Cardiff University-Peking University Oncology Joint Institute, Cardiff, United Kingdom; St Georges' Healthcare NHS Trust, London, United Kingdom.

P1-04-10 **PDGFRA signaling in Inflammatory breast cancer**
Joglekar M, van Golen K. University of Delaware, Newark, DE.

P1-04-11 **EZH2 Expands Breast Stem Cells via NOTCH Signaling, Acting to Accelerate Breast Cancer Initiation**
Kleer CG, Li X, Moore HM, Toy KA, Gonzalez ME. University of Michigan, Ann Arbor, MI.

Tumor Cell and Molecular Biology: Tumor Progression, Invasion, and Metastasis

P1-05-01 **Chemokine-mediated nuclear translocation and novel nuclear role for LIM and SH3 Protein-1(LASP-1) in breast cancer**
Raman D, Duvall-Noelle NL, Richmond A. Vanderbilt University Medical Center, Nashville, TN.

P1-05-02 **Epithelial-to-epithelial transition precedes collective breast cancer invasion**
Cheung KJ, Ewald AJ. Johns Hopkins School of Medicine, Baltimore, MD.

P1-05-03 **A requirement for neural precursor cell-expressed developmentally downregulated gene 9 during the initiation of mammary tumorigenesis in MMTV-neu mice**
Serzhanova VA, Little JL, Izumchenko E, Seo S, Kurokawa M, Egleston B, Klein-Szanto AA, Golemis EA. Fox Chase Cancer Center, Philadelphia, PA; Ben Gurion University of the Negev, Beer Sheva, Israel; University of Tokyo, Japan.

P1-05-04 **Expression of Quiescin Sulfhydryl Oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer**
Katchman BA, Ocal T, Hostetter G, Cunliffe HE, Wantanabe A, Lake DF. Arizona State University, Tempe, AZ; Mayo Clinic Arizona, Scottsdale, AZ; Translational Genomic Research Institute, Phoenix, AZ.

P1-05-05 Podocalyxin is a key regulator of breast cancer progression and metastasis
Snyder KA, Hughes MR, Graves M, Roskelly C, McNagny KM. University of British Columbia, Vancouver, BC, Canada.

P1-05-06 A novel mutation in the tyrosine kinase domain of ErbB2: molecular and proteomic investigation of its role in breast cancer invasion
O'Hara J, Kast J. University of British Columbia, Vancouver, BC, Canada.

P1-05-07 Prognostic relevance of Claudin-2 expression in metastatic breast cancer
Hedenfalk I, Kimbung S, Kovacs A, Skoog L, Einbeigi Z, Walz T, Malmberg M, Loman N, Fernö M, Hatschek T, TEX Study Group. Lund University, Lund, Sweden; CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Karolinska University Hospital, Solna, Sweden; Linköping University Hospital, Linköping, Sweden; Helsingborg General Hospital, Helsingborg, Sweden.

P1-05-08 Targeting integrin signaling suppresses invasive recurrence in a three-dimensional model of radiation treated ductal carcinoma in situ
Nam J-M, Ahmed KM, Costes S, Zhang H, Sabe H, Shirato H, Park CC. Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan; Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA; UCSF, San Francisco, CA.

P1-05-09 FH535 inhibited migration and growth of breast cancer cells
Dorchak JA, Iida J, Clancy R, Luo C, Chen Y, Hu H, Mural RJ, Shriver CD. Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD.

P1-05-10 Targeting breast cancer metastasis through disruption of novel PELP1-G9a complex
Mann M, Chakravarty D, Kim CA, Vadlamudi RK. University of Texas Health Science Center at San Antonio, TX; Weill Cornell Medical College, New York, NY.

P1-05-11 Biological characterization of tumor-associated leukocytes in positive and negative lymph node breast cancer patients
ElGhonaimy EA, El-Shinawi M, Abd-El-Tawab R, El Mamlouk T, Sloane BF, Mohamed MM. Faculty of Science, Cairo University, Giza, Cairo, Egypt; Faculty of Medicine, Ain Shams University, Cairo, Egypt; Wayne State University, Detroit, MI.

P1-05-12 Metastatic xenograft models of human estrogen receptor negative breast cancer primary cultures are driven by the recruitment of myeloid-derived suppressor cells
Drews-Elger K, Iorns E, Brinkman JA, Berry DL, Lippman ME, El-Ashry D. Sylvester Comprehensive Cancer Center, Braman Family Breast Cancer Institute, University of Miami, FL; Science Exchange, Palo Alto, CA; Georgetown University Medical Center, Washington, DC.

P1-05-13 CLIC3 is associated with invasive behaviour and poorer prognosis in estrogen receptor-negative breast cancer
Macpherson IR, Dozynkiewicz M, Kalna G, Speirs C, Chaudhary S, Edwards J, Timpson P, Norman J. University of Glasgow, United Kingdom; Beatson Institute for Cancer Research, Glasgow, United Kingdom.

P1-05-14 Multiscale computational modeling of breast cancer invasion: Towards a predictive patient-based tool
Trucu D, Thompson A, Chaplain MAJ. University of Dundee, United Kingdom; Ninewells Hospital, University of Dundee, United Kingdom.

P1-05-15 Identification of a novel Hypoxia Inducible Factor-1 regulated gene involved in breast cancer growth and metastasis
Peacock DL, Schwab LP, Seagroves TN. University of Tennessee Health Science Center, Memphis, TN.

P1-05-16 Sushi Domain Containing 2 (SUSD2): a plasma membrane protein that increases immune evasion in breast tumorigenesis
Watson AP, Davis EM, Egland KA. Sanford Research/USD, Sioux Falls, SD.

P1-05-17 S100A7/RAGE axis enhances breast cancer growth by activating Stat3 signaling
Nasser MW, Wani NA, Qamri Z, Ahirwar D, Powell CA, Ganju RK. The Ohio State University, Columbus, OH.

P1-05-18 Determining the molecular mechanism of the breast cancer-induced brain metastasis and a role of a novel pan-TGF-β inhibitor as a potential therapy for brain metastasis in a mouse xenograft model
De Mukhopadhyay K, Elkahloun AG, Hinck AP, Yoon K, Cornell JE, Shu L, Yang J, Sun L. University of Texas Health Science Center, San Antonio, TX; National Human Genome Research Institute-NIH, Bethesda, MD.

P1-05-19 Modeling Cancer Recurrence and the Therapeutic Effect of Adjuvant Systemic Therapy
Ganesan S, Bhanot G, Boemo M, Lee JH. Cancer Institute of New Jersey- UMDNJ, New Brunswick, NJ; Rutgers University, VPiscataway, NJ.

P1-05-20 Fluorescent Hyaluronan Probes Distinguish Heterogeneous Breast Cancer Cell Subsets and Predict their Invasive Behavior
Veiseh M, Kwon DH, Borowsky AD, Toelg C, Leong H, Lewis J, Turley EA, Bissell MJ. Lawrence Berkeley National Laboratories, Berkeley, CA; University of California Davis, Davis, CA; London Health Sciences Centre-London Regional Cancer Program; University of Western Ontario, London, ON, Canada.

P1-05-21 The role of epsin in promoting Epithelial-Mesenchymal Transition and metastasis by activating NF-kB signaling in breast cancer
Cai X, Brophy ML, Hahn S, McManus J, Chang B, Pasula S, Chen H. Oklahoma Medical Research Foundation, Oklahoma City, OK; University of Oklahoma Health Science Center, Oklahoma City, OK.

P1-05-22 Breast cancer cells that undergo an Epithelial-to-Mesenchymal transition co-opt LPP, a regulator of mesenchymal cell migration and invasion
Ngan E, Northey JJ, Ursini-Siegel J, Siegel PM. McGill University, Montreal, QC, Canada; Lady Davis Institute for Medical Research, Montreal, QC, Canada.

P1-05-23 Blockade of mTORC1 decreases CXCR4-mediated migration and metastasis
Dillenburg Pilla P, Patel V, Dorsam RT, Masedunskas A, Amornphimoltham P, Weigert R, Molinolo AA, Gutkind JS. NIH, Bethesda, MD.

P1-05-24 Pharmacologic reversion of epigenetic silencing of the *PRKD1* promoter blocks breast tumor cell invasion and metastasis
Borges S, Doppler H, Andorfer CA, Perez EA, Sun Z, Anastasiadis PZ, Thompson AE, Geiger XJ, Storz P. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN.

Tumor Cell and Molecular Biology: Angiogenesis

P1-06-01 **Upregulation of metabolism as a potential resistance mechanism to bevacizumab in primary breast cancer**
Mehta S, Hughes NP, Adams RF, Li SP, Han C, Kaur K, Taylor NJ, Padhani AR, Makris A, Buffa FM, Harris AL. Weatherall Institute of Molecular Medicine, Oxford, United Kingdom; Stanford University, Stanford, CA; Oxford University Hospitals NHS Trust, Oxford, United Kingdom; Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom; Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom; Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom.

P1-06-02 **A newly angiogenic biomarker Vasohibin-1 expression in ductal carcinoma in situ of the breast**
Tamaki K, Tamaki N, Kamada Y, Uehara K, Miyashita M, Ishida T, Ohuchi N, Sasano H. Nahanishi Clinic Okinawa, Naha, Okinawa, Japan; Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Tohoku University Hospital, Sendai, Miyagi, Japan.

P1-06-03 **Microvessel density as determined by computerized image analysis of CD34 and CD105 expression correlates with poor outcome in triple-negative breast cancer**
De Brot M, Rocha RM, Soares FA, Gobbi H. Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil; Hospital A.C. Camargo, Sao Paulo, SP, Brazil.

Prognostic and Predictive Factors: Biomarkers - Methods

P1-07-01 **Attainment of extremely high concordance rates between fluorescence in situ hybridization and immunohistochemistry in testing for human epidermal growth factor receptor 2 (HER2) in breast cancer using a normalized scoring system for immunohistochemistry: A four year experience with over 9000 cases**
Gown AM, Goldstein LC, Tse CH, Hwang HC, Kandalaft PL. PhenoPath Laboratories, Seattle, WA.

P1-07-02 **Withdrawn**

P1-07-03 **Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis**
Geretti E, Paragas V, Onsum M, Kudla A, Moulis S, Luus L, Wickham T, McDonagh C, MacBeath G, Hendriks B. Merrimack Pharmaceuticals, Cambridge, MA.

P1-07-04 **Comparison of HER2 expression by immunohistochemistry (IHC) using automated imaging system and fluorescence in situ hybridization (FISH). A retrospective analysis of 2853 cases**
Collins R, Xiang D, Christie A, Leitch M, Euhus D, Rao R, Haley B, Sarode V. University of Texas Southwestern Medical Center, Dallas, TX.

P1-07-05 **Evaluation of tissue processing factors affecting HER2 IHC staining intensity in breast cancer cell lines**
Jensen K, Erickson J, Webster S, Pedersen HC. Dako Denmark, Glostrup, Denmark; Dako North America, Carpinteria, CA.

P1-07-06 **Effect of biospecimen variables on proteomic biomarker assessment in breast cancer**
Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada B, Singh G, Anh-Do K, Garces Z, Mittendorf EA, Babiera G, Wagner J, Bedrosian I, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills G. UT MD Anderson Cancer Center, Houston, TX; Ohio State University, Columbus, OH.

P1-07-07 **Inflammatory gene expression variations in the interval between core needle biopsy and excisional biopsy in early breast cancer**
Jeselsohn RM, Regan MM, Werner L, Fatima A, He HH, Brown M, Iglehart JD, Richardson AL, Come S. Beth Israel Deaconess Medical Center, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA.

P1-07-08 **Effect of sample preservation method and transportation duration on tumor gene expression profiling in breast cancer**
Fumagalli D, Jose V, Salgado R, Majjaj S, Singhal S, Vincent D, Maetens M, Larsimont D, Symmans F, Dinh P, Piccart M, Michiels S, Sotiriou C, Loi S. Institut Jules Bordet, Brussels, Belgium; Breast International Group (BIG), Brussels, Belgium; The University of Texas MD Anderson Cancer Center, Houston, TX.

P1-07-09 **Estrogen receptor positivity: 10% or 1%?**
Yi M, Huo L, Koenig KB, Mittendorf EA, Meric-Bernstam F, Kuerer HM, Bedrosian I, Symmans WF, Hortobagyi GN, Crow JR, Shah RR, Hunt KK. University of Texas MD Anderson Cancer Center, Houston, TX.

P1-07-10 **Comparison of three commercial ER/PR assays on a single clinical outcome series**
Kornaga EN, Klimowicz AC, Konno M, Guggisberg N, Ogilvie T, Cartun RW, Morris DG, Webster MA, Magliocco AM. Alberta Health Services, Calgary, AB, Canada; Calgary Laboratory Services, Calgary, AB, Canada; Hartford Hospital, Hartford, CT; University of Calgary, AB, Canada; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

P1-07-11 **Characterization of progesterone receptor biomarker for predicting antiprogestin activity in human cancers**
Bonneterre J, Bosq J, Lange C, Gilles E. Centre Oscar Lambret, France; Institut Gustave Roussy, France; University of Minnesota; Invivis Pharmaceuticals.

P1-07-12 **Using Natural Language Processing to Identify and Extract HER2 Value from a large EMR system**
Zheng C, Avila C, Haque R. Kaiser Permanente Southern California, Pasadena, CA.

P1-07-13 **Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC CTG MA.14 patients**
Chapman J-AW, Sgroi D, Goss PE, Richardson E, Binns SN, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Pollak MN. NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; Harvard University, Boston, MA; bioTheranostics, Inc., San Diego, CA; Sunnybrook Odette Cancer Centre, University of Toronto, ON, Canada; Jewish General Hospital, McGill University, Montreal, QC, Canada.

P1-07-14 **Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients**
Győrffy B, Lanczky A. Semmelweis University.

P1-07-15 **Revisiting chromosome 17q copy number aberrations in early high-risk breast cancer**
Kotoula V, Bobos M, Eleftheraki AG, Timotheadou E, Razis E, Goussia A, Levva S, Kalogeras KT, Pectasides D, Fountzilas G. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece.

P1-07-16 **Liver derived epithelial cells as source of false positive circulating tumor cells in early breast cancer**
Habets L, Körber W, Frenken B, Danaei M, Kusche M, Peisker U, Kroll T, Pachmann K. Metares.e.V, Aachen, NRW, Germany; Brustzentrum Aachen Kreis Heinsberg, Aachen, NRW, Germany; Medizinische Universitätsklinik Jena, Thueringen, Germany.

P1-07-17 **V Array: A novel tool for constructing virtual tissue microarrays (TMAs), an evaluation of its use in optimizing TMA construction for Ductal Carcinoma in Situ (DCIS)**
Quintayo MA, Starczynski J, Yan FJ, Bartlett JMS, Benko L, Hanna W, Nofech-Mozes S, Rakovitch E. Ontario Institute of Cancer Research, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Leica Microsystems, Buffallo Grove, IL.

P1-07-18 Association between Bone Turnover Markers in patients with breast cancer and bone metastases on treatment with bisphosphonates (ZOMAR study)
Tusquets I, De la Piedra C, Manso L, Crespo C, Gómez P, Calvo L, Ruiz M, Martínez P, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MA, De Juán A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcum A, Chacón JI, Heras L, Barnadas A. Hospital del Mar, Barcelona, Spain; Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain; Hospital 12 de Octubre, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitario Vall d'Hebrón, Barcelona, Spain; Hospital Universitario A Coruña Juan Canalejo, A Coruña, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital de Basurto, Vizcaya, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Virgen Macarena, Sevilla, Spain; H. Universitario Trias y Pujol, Barcelona, Spain; Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain; Hospital Nuestra Señora de Valme, Sevilla, Spain; Hospital Parc Taulí Sabadell, Barcelona, Spain; Hospital Marqués Valdecilla, Santander, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital General de Asturias, Oviedo, Spain; Hospital Costa del Sol, Málaga, Spain; Hospital La Paz, Madrid, Spain; Hospital Palencia Río Carrión, Palencia, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Cruz Roja Hospitalet del Llobregat, Barcelona, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain.

P1-07-19 Mass Spectrometry Based Quantitative Analysis of the HER Family receptors in FFPE Breast Cancer Tissue
Hembrough TA, Scaltriti M, Serra V, Jimenez J, Perez J, Liao W-L, Thyparambil S, Cortes J, Baselga J, Burrows J. OncoPlex Diagnostics, Inc., Rockville, MD; Vall d'Hebron Istitute of Oncology, Barcelona, Spain; Massachusetts General Hospital, Boston, MA.

Epidemiology, Risk, and Prevention: Prevention - Preclinical Studies and Model Systems

P1-08-01 Effects Of An Allosteric AKT Inhibitor (MK2206) Administered With Or Without The Aromatase Inhibitor Vorozole In An ER$^+$ Rat Mammary Cancer Model: Preventive And Therapeutic Effects
Lubet RA, Ellis MJ, Grubbs CJ. National Cancer Institutes, Bethesda, MD; University of Washington at Saint Louis, MO; University of Alabama at Birmingham, AL.

P1-08-02 Gene expression changes in methylnitrosourea (MNU)-induced ER$^+$ mammary cancers following short-term treatment of rats with SERMs (Tamoxifen and Arzoxifene)
Lubet R, Vedell P, Grubbs C, Bernard P, You M. National Cancer Institute, Bethesda, MD; Medical School of Wisconsin, Milwaukee, WI; Hunstman Cancer Center, Salt Lake City, UT; University of Alabama at Birmingham, AL.

Epidemiology, Risk, and Prevention: Prevention - Clinical Trials

P1-09-01 Long-term effect of tamoxifen use on the risk of contralateral breast cancer
Mellemkjær L, Steding-Jessen M, Frederiksen K, Andersson M, Olsen JH. Danish Cancer Society Research Center, Copenhagen, Denmark; Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

P1-09-02 Pilot study of a 1-year intervention of high-dose vitamin D in women at high risk for breast cancer
Sivasubramanian PS, Hershman DL, Maurer M, Kalinsky K, Feldman S, Brafman L, Refice S, Kranwinkle G, Crew KD. Columbia University, New York, NY.

P1-09-03 Chemoprevention in patients with newly diagnosed breast cancers
Refinetti AP, Chun J, Schnabel F, Guth A, Axelrod D. NYU Langone Medical Center, New York, NY.

P1-09-04 Down-regulation of trefoil protein 1(TFF1) in normal breast tissue of postmenopausal women at increased risk for breast cancer on exemestane
Gatti-Mays M, Kallakury BVS, Makariou E, Venzon D, Permaul E, Isaacs C, Cohen P, Warren R, Gallagher A, Eng-Wong J. Georgetown University Hospital, Washington, DC; National Cancer Institute, National Institutes of Health, Bethesda, MD; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.

P1-09-05 The RAZOR trial: a phase II prevention trial of screening plus goserilin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer
Motion J, Ashcroft L, Dowsett M, Cuzick J, Hickman J, Evans G, Eccles D, Eeles R, Greenhalgh R, Affen J, Bundred S, Boggis C, Sergeant J, Fallowfield L, Adams J, Howell A. University Hospital South Manchester, Manchester, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Royal Marsden Hospital, London, United Kingdom; Queen Mary, University of London, United Kingdom; Princess Anne Hospital, Southampton, United Kingdom; The Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom; University of Sussex - (SHORE-C), Brighton, United Kingdom; University of Manchester, United Kingdom; Manchester Royal Infirmary, Manchester, United Kingdom.

P1-09-06 Biological Effects of Green Tea Capsule Supplementation in Pre-surgery Breast Cancer Patients
Yu S, Spicer D, Hawes D, Wu A. University of Southern California, Los Angeles, CA.

P1-09-07 Topical 4-OHT trial in women with DCIS of the breast: Vreport of plasma and breast tissue concentration of tamoxifen metabolites
Lee O, Chatterton RT, Muzzio M, Page K, Jovanovic B, Helenowski I, Dunn B, Heckman-Stoddard B, Foster K, Shklovskaya J, Skripkauskas S, Bergan R, Khan SA. Northwestern University, Chicago, IL; IIT Research Institute, Chicago, IL; National Cancer Institute, Bethesda, MD.

Epidemiology, Risk, and Prevention: Prevention - Nutritional Studies

P1-10-01 Curcumin suppresses MMP-9 expression via inhibition of PKCα/MAPKs and NF-κB/AP-1 activation in MCF-7 cells
Kim SK, Kim YW, Youn HJ, Jung SH. Chonbuk National University Medical School, Jeonju, Jeollabukdo, Republic of Korea.

P1-10-02 Comparative Preventive Efficacy of Select Chinese Herbs in Breast Carcinoma Derived Isogenic Cells with Modulated Estrogen Receptor Functions
Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow HL, Wong GYC. Palindrome Liaisons, Montvale, NJ; American Foundation for Chinese Medicine, New York, NY; Skin of Color Research Institute, Leroy T. Canoles Jr. Cancer Research Center, Hampton University, Eastern Virginia Medical School, Hampton, VA; David & Alice Jurist Institute for Research, Hackensack University Medical Center, Hackensack, NJ; David & Alice Jurist Institute for Research, Hackensack, NJ; American Foundation for Chinese Medicine, Beth Israel Medical Center, New York, NY.

Epidemiology, Risk, and Prevention: Prevention - Behavioral Interventions

P1-11-01 Physical Activity Reduces the Risk of Breast Cancer
Hardefeldt PJ, Edirimanne S, Eslick GD. University of Sydney, NSW, Australia; Nepean Hospital, University of Sydney, Penrith, NSW, Australia.

Treatment: Chemotherapy - Advanced Disease

P1-12-01 Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095)
Sato N, Yamamoto D, Rai Y, Iwase H, Saito M, Iwata H, Masuda N, Oura S, Watanabe J, Kuroi K. Niigata Cancer Center Hospital, Niigata, Japan; Kansai Medical University Hirakata Hospital, Hirakata, Osaka, Japan; Sagara Hospital, Kagoshima, Japan; Kumamoto University Hospital, Kumamoto, Japan; Juntendo University Hospital, Bunkyo, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Wakayama Medical University, Wakayama, Wakayama, Japan; Shizuoka Cancer Center, Nagaizumi-cho, Suntou-gun, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan.

P1-12-02 Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer
Vahdat L, Schwartzberg L, Glück S, Rege J, Liao J, Cox D, O'Shaughnessy J. Weill Cornell Medical College, New York, NY; The West Clinic, Memphis, TN; Sylvester Comprehensive Cancer Center, Miami, FL; Eisai Inc, Woodcliff Lake, NJ; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.

P1-12-03 Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study
Ambros T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Mani A, Kronish L, Mahtani RL, Vogel CL. University of Miami, FL; Mount Sinai Medical Center, Miami Beach, FL; Memorial Hospital West, Pembroke Pines, FL; SUNY Downstate, Brooklyn, NY.

P1-12-04 Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer
Lo SS, Guo R, Czaplicki KL, Robinson PA, Gaynor E, Barhamand FB, Schulz WC, Kash JJ, Horvath LE, Bayer RA, Petrowsky C, De la Torre R, Park JH, Albain KS. Loyola University Medical Center, Maywood, IL; Hematology Oncology Consultants Ltd., Naperville, IL; Swedish Americal Regional Cancer Center, Rockford, IL; Edward Cancer Center, Naperville, IL; Central Dupage Cancer Center, Winfield, IL; CDPG Oncology at Delnor, Delnor, IL.

P1-12-05 First-line chemotherapy with pegylated liposomal doxorubicin versus capecitabine in elderly patients with metastatic breast cancer: results of the phase III OMEGA study of the Dutch Breast Cancer Trialists' Group (BOOG)
Smorenburg CH, Seynaeve C, Wymenga MANM, Maartense E, de Graaf H, de Jongh FE, Braun HJ, Los M, Schrama JG, Portielje JEA, Hamaker M, van Tinteren H, de Groot SM, van Leeuwen-Stok EAE, Nortier HWR. Medical Center Alkmaar, Alkmaar, Netherlands; Erasmus Medical Center-Daniel den Hoed Cancer Center, Rotterdam, Netherlands; Medisch Spectrum Twente, Enschede, Netherlands; Reinier de Graaf Hospital, Delft, Netherlands; Medical Center Leeuwarden, Leeuwarden, Netherlands; Ikazia Hospital, Rotterdam, Netherlands; Vlietland Hospital, Schiedam, Netherlands; St. Antonius Hospital, Nieuwegein, Netherlands; Spaarne Hospital, Hoofddorp, Netherlands; Haga Hospital, The Hague, Netherlands; Diaconessehuis, Utrecht, Netherlands; Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, Netherlands; Comprehensive Cancer Centre the Netherlands, Amsterdam, Netherlands; Dutch Breast Cancer Trialists' Group BOOG, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands.

P1-12-06 N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)
Moreno-Aspitia A, Rowland, Jr. KM, Allred JB, Liu H, Stella PJ, Gross HM, Soori GS, Karlin NJ, Perez EA. Mayo Clinic, Jacksonville, FL; Carle Foundation - Carle Cancer Center, Urbana, IL; Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Hematology & Oncology of Dayton, Inc., Dayton, OH; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Mayo Clinic, Scottsdale, AZ.

P1-12-07 A Retrospective Analysis of *nab*-Paclitaxel as First-Line Therapy for Metastatic Breast Cancer Patients with Poor Prognostic Factors
O'Shaughnessy J, Gradishar W, Bhar P, Iglesias J. Baylor Sammons Cancer Center, Texas Oncology and US Oncology, Dallas, TX; Maggie Daley Center for Women's Cancer Care, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, IL; Celgene Corporation, Durham, NC; Celgene Corporation, Mississauga, ON, Canada.

P1-12-08 Withdrawn

Treatment: Chemotherapy - Adjuvant

P1-13-01 A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis
Burnell MJ, Shepherd L, Gelmon K, Bramwell V, Walley B, Vandenberg E, Chalchal H, Pritchard K, Whelan T, Albain K, Perez E, Rugo H, O'Brien P, Chapman J, Levine M. NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; British Columbia Cancer Agency (BCCA), Vancouver, BC, Canada; University of Calgary, AB, Canada; Saint John Regional Hospital, Saint John, NB, Canada; London Regional Cancer Centre, London, ON, Canada; Sunnybrook Cancer Centre, Toronto, ON, Canada; Juravinski Cancer Centre, Hamilton Health Sciences Centre, Hamilton, ON, Canada; Loyola University Medical Center, Maywood, IL; Mayo Clinic Jacksonville, FL; University of California, San Francisco, CA; McMaster University, Hamilton, ON, Canada; Allan Blair Cancer Centre, Regina, SK, Canada.

P1-13-02 Withdrawn

P1-13-03 Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse
Bliss JM, Ellis P, Kilburn L, Bartlett J, Bloomfield D, Cameron D, Canney P, Coleman RE, Dowsett M, Earl H, Verril M, Wardley A, Yarnold J, Ahern R, Atkins N, Fletcher M, McLinden M, Barrett-Lee P. Institute of Cancer Research, Sutton, Surrey, United Kingdom; Guy's Hospital, Kings Health Partners AHSC, London, United Kingdom; Velindre NHS Trust Cancer Centre, Cardiff, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh, United Kingdom; The Christie Hospital, Manchester, United Kingdom; Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom; Brighton & Sussex University Hospitals, Brighton, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom; ICR and Royal Marsden NHS Trust, London, United Kingdom; University of Cambridge, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom; Weston Park Hospital, Sheffield, United Kingdom; NHS National Services Scotland, Edinburgh, United Kingdom.

P1-13-04 Optimal duration of adjuvant chemotherapy for high risk node negative breast cancer patients: 6-year results of the prospective randomized phase III trial PACS 05
Kerbrat P, Coudert B, Asselain B, Levy C, Lortholary A, Marre A, Delva R, Rios M, Viens P, Brain E, Serin D, Edel M, Mauriac L, Campone M, Mouret-Reynier M-A, Bachelot T, Foucher-Goudier M-J, Roca L, Martin A-L, Roche H. Centre Eugene Marquis, Rennes, France; Centre Georges François Leclerc, Dijon, France; Institut Curie, Paris, France; Centre Francois Baclesse, Caen, France; Centre Catherine de Sienne, Nantes, France; Centre Hospitalier, Rodez, France; ICO Centre Paul Papin, Angers, France; Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France; Institut Paoli Calmettes, Marseille, France; Institut Curie, Saint Cloud, France; Institut Sainte-Catherine, Avignon, France; Centre Hospitalier Emile Muller, Mulhouse, France; Institut Bergonié, Bordeaux, France; ICO Centre René Gauducheau, Saint Herblain, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Léon Berard, Lyon, France; Centre Hospitalier Bretagne-Sud, Lorient, France; Centre Val d'Aurelle, Montpellier, France; R&D Unicancer, Paris, France; Institut Claudius Regaud, Toulouse, France.

P1-13-05 The association between timing in adjuvant chemotherapy administration and overall survival for women with breast cancer within the National Comprehensive Cancer Network (NCCN)
Vandergrift JL, Breslin TM, Niland JC, Edge SB, Wolff AC, Marcom PK, Rugo HS, Moy B, Wilson JL, Ottesen RA, Weeks JC, Wong Y-N. National Comprehensive Cancer Network, Fort Washington, PA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; City of Hope Comprehensive Cancer Center, Duarte, CA; Dana-Farber/Brigham Women's Cancer Center, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Duke Cancer Institute, Durham, NC; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; The Ohio State University Comprehensive Cancer Center and James Cancer Hospital and Solove Research Institute, Columbus, OH; Massachusetts General Hospital Cancer Center, Boston, MA; Fox Chase Cancer Center, Philadelphia, PA.

P1-13-06 Withdrawn

P1-13-07 Association between Delayed Initiation of Adjuvant Chemotherapy and Survival in Breast Cancer: A Single-Institution Study and a Systematic Review and Meta-analysis
Yu K-D, Fan L, Yang C, Shao Z-M. Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, China.

P1-13-08 Chemotherapy for Breast Cancer Causes Sustained Alteration in Number and Type of B Lymphocytes
Verma R, Smalle N, McCurtin RE, Horgan K, Carter CRD, Hughes TA. Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom; St James's University Hospital, Leeds, West Yorkshire, United Kingdom; University of Leeds, West Yorkshire, United Kingdom.

P1-13-09 A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer
Mavroudis D, Malamos N, Boukovinas I, Kakolyris S, Kourousis C, Athanasiadis A, Ziras N, Makrantonakis P, Polyzos A, Christophylakis C, Georgoulias V. Hellenic Oncology Research Group (HORG), Athens, Greece.

P1-13-10 Efficacy, toxicity and quality of life in older patients with early-stage breast cancer treated with oral Tegafur-uracil or classical CMF (cyclophosphamide, methotrexate, and fluorouracil): an exploratory analysis of National Surgical Adjuvant Study for Breast Cancer (N-SAS BC) 01 Trial
Hara F, Watanabe T, Shimozuma K, Ohashi Y. NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; Hamamatsu Oncology Center, Hamamatsu, Shizuoka, Japan; College of Life Sciences, Ritsumeikan University, Kusatsu, Shiga, Japan; School of Public Health, University of Tokyo, Bunkyo-ku, Tokyo, Japan.

P1-13-11 Adjuvant treatment of early-stage breast cancer with eribulin mesylate following dose-dense doxorubicin and cyclophosphamide: preliminary results from a phase 2, single-arm feasibility study
Traina TA, Hudis C, Fornier M, Lake D, Lehman R, Berkowitz AP, Rege J, Liao J, Cox D, Seidman AD. Memorial Sloan-Kettering Cancer Center, New York, NY; Eisai Inc, Woodcliff Lake, NJ.

P1-13-12 Withdrawn

P1-13-13 First planned efficacy analysis of the NNBC 3-Europe trial: Addition of docetaxel to anthracycline containing adjuvant chemotherapy in high risk node-negative breast cancer patients
Thomssen C, Kantelhardt EJ, Meisner C, Vetter M, Schmidt M, Martin P-M, Veyret C, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jaenicke F, von Minckwitz G, Harbeck N, On Behalf of the NNBC 3-Europe Study Group. Martin-Luther University Halle-Wittenberg, Halle an der Saale, Germany; Eberhard-Karls-University Tuebingen, Tuebingen, Germany; Johannes Gutenberg-Universität Mainz, Mainz, Germany; Medical Faculty Marseille, Marseille, France; Henri Becquerel Center, Rouen, France; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Fürth, Fürth, Germany; Technical University Munich, München, Germany; St. Vincenz-Hospital, Paderborn, Germany; St. Josefs-Hospital, Wiesbaden, Germany; Katholisches Klinikum, Mainz, Germany; Radbourd University Nijmegen, Nijmegen, Netherlands; University Hamburg, Hamburg, Germany; German Breast Group, Neu-Isenburg, Germany; Ludwig-Maximilian-University, Munich, Germany.

Treatment: Neoadjuvant Chemotherapy

P1-14-01 Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro
von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Blohmer J-U, Costa S-D, Jackisch C, Paepke S, Schneeweiss A, Kuemmel S, Denkert C, Mehta K, Untch M. German Breast Group, Neu-Isenburg; Louisenkrankenhaus Düsseldorf; University Erlangen; University Duesseldorf; Bethanien-Kankenhaus Frankfurt; Klinikum Landshut; Eilenriedeklinik Duesseldorf; University Kiel; University Rostock; Roteskreuzklinikum Muenchen; Sankt Gertrauden Berlin; University Magdeburg; Klinikum Offenbach; Frauenklinik München; University Heidelberg; Kliniken Essen Mitte; Charite Berlin; Helios Kliniken Berlin.

P1-14-02 Preoperative docetaxel (T) with or without capecitabine (X) following epirubicin, 5-fluorouracil and cyclophosphamide (FEC) in patients with operable breast cancer (OOTR N003): Results of comparative study and predictive marker analysis
Toi M, Ohno S, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Murakami S, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Chow LWC. Organisation for Oncology and Translational Research (OOTR), Kyoto, Japan.

P1-14-03 Overall survival results of a multicenter randomized phase II study in locally advanced breast cancer patients treated with or without neoadjuvant Trastuzumab for HER2 positive tumor (Remagus 02 trial)
Giacchetti S, Pierga J-Y, Asselain B, Delaloge S, Brain E, Espié M, Mathieu M-C, Bertheau p, de Cremoux P, Tembo O, Marty M. Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France.

P1-14-04 **Long- term outcome after neoadjuvant radiochemotherapy in locally advanced non-inflammatory breast cancer and predictive factors for a pathologic complete remission; results of a multi-variate analysis**
Matuschek C, Boelke E, Roth S, Bojar H, Audretsch W, Janni JW, Nestle-Kraemling C, Sauer R, Speer V, Budach W. Heinrich Heine University, Düsseldorf, Germany; European Institute for Molecular Oncology, Düsseldorf, Germany; Marien Hospital, Düsseldorf, Germany; Krankenhaus Gerresheim, Düsseldorf; University of Erlangen, Germany.

P1-14-05 **Phase I/II Trial of primary chemotherapy with non-pegylated liposomal doxorubicin, paclitaxel and lapatinib in patients with HER2-positive, early stage breast cancer**
Aktas B, Kümmel S, Krocker J, Elling D, Lantzsch T, Bischoff J, Fersis N, Böhme M, Belau AK, Lampe D, Schmid P. University Hospital of Essen, Germany; Kliniken Essen Mitte, Essen, Germany; Sana Klinikum Lichtenberg, Berlin, Germany; St. Barbara Krabkenhaus, Halle, Germany; University Hospital of Magdeburg, Germany; Klinikum Chemnitz, Germany; Klinik St. Marienstift, Magdeburg, Germany; University Hospital of Greifswald, Germany; Asklepios Klinik Weißenfels, Weißenfels, Germany; University of Sussex, United Kingdom.

P1-14-06 **Significance of examining biomarkers of residual tumors after neoadjuvant chemotherapy using trastuzumab in combination with anthracycline and taxane in patients with primary HER2-positive breast cancer**
Kurozumi S, Takei H, Inoue K, Matsumoto H, Hayashi Y, Ninomiya J, Kubo K, Tsuboi M, Nagai S, Ookubo F, Oba H, Kurosumi M, Horiguchi J, Takeyoshi I. Saitama Cancer Center, Saitama, Japan; Gunma University Graduate School of Medicine, Gunma, Japan.

P1-14-07 **Neoadjuvant chemotherapy and pathologic complete response in relation to the clinical response, results from a phase III study (INTENS) of the Dutch Breast Cancer Trialists' Group (BOOG)**
Tjan-Heijnen VCG, Vriens BE, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, van Laarhoven HW, van Spronsen DJ, Borm GF. Maastricht University Medical Centre, Maastricht, Netherlands; Comprehensive Cancer Centre, Nijmegen, Netherlands; Atrium Medical Centre, Heerlen, Netherlands; Jeroen Bosch Hospital, 's Hertogenbosch, Netherlands; Catharina Hospital, Eindhoven, Netherlands; Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; Canisius-Wilhelmina Hospital, Nijmegen, Netherlands.

P1-14-08 **A prospective multicenter randomized phase II neo-adjuvant study of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) followed by docetaxel, cyclophosphamide and trastuzumab (TCH) versus TCH followed by FEC versus TCH alone, in patients (pts) with operable HER2 positive breast cancer: JBCRG-10 study**
Masuda N, Sato N, Higaki K, Kashiwaba M, Matsunami N, Takano T, Yamamura J, Kaneko K, Takahashi M, Ohno S, Fujisawa T, Tsuyuki S, Miyoshi Y, Ohtani S, Yamamoto Y, Bando H, Onoda T, Kawabata H, Morita S, Ueno T, Toi M. NHO Osaka National Hospital, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Hiroshima City Hospital, Hiroshima, Japan; Iwate Medical University, Morioka, Japan; Osaka Rosai Hospital, Sakai, Japan; Toranomon Hospital, Tokyo, Japan; Hokkaido Cancer Center, Sapporo, Japan; National Kyushu Cancer Center, Fukuoka, Japan; Gunma Prefectural Cancer Center, Ohta, Japan; Osaka Red Cross Hospital, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kumamoto University Hospital, Kumamoto, Japan; University of Tsukuba, Faculty of Medicine, Tsukuba, Japan; Yokohama Asahi Central General Hospital, Yokohama, Japan; Yokohama City University Graduate School of Medicine and Medical Center, Yokohama, Japan; Kyoto University, Kyoto, Japan.

P1-14-09 **Immunohistochemical classification of intrinsic subtypes as a predictive biomarker of pathological complete response in breast cancer patients treated with preoperative chemotherapy**
Nagayama A, Jinno H, Takahashi M, Hayashida T, Hirose S, Kitagawa Y. School of Medicine, Keio University, Shinjuku, Tokyo, Japan.

P1-14-10 **Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)**
Fernandez M, Calvo I, Martinez N, Herrero M, Quijano Y, Duran H, Garcia-Aranda M, Suarez A, Lopez-Rios F, Perez D, Perea S, Hidalgo M, Garcia-Estevez L. Centro Integral Oncológico Clara Campal, Madrid, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital Costa del Sol, Marbella, Spain.

P1-14-11 **Assessing Prognosis and Therapy Response in Primary Systemic Therapy of Breast Cancer with Magnetic Resonance Spectroscopy**
Bolan PJ, Wey A, Eberly LE, Nelson MT, Haddad TC, Yee D, Garwood M. University of Minnesota, Minneapolis, MN; Masonic Cancer Center, University of Minnesota, Minneapolis, MN.

P1-14-12 **Response to neoadjuvant chemotherapy and prognosis of primary breast cancer according to intrinsic subtype**
Kochi M, Ito M, Ohtani S, Higaki K. Hiroshima City Hospital, Hiroshima, Japan.

P1-14-13 **Increased Pathologic Complete Response Rate and Reduced Tumour RNA Levels Upon Treatment of Locally Advanced Breast Cancer with Neoadjuvant Concurrent Chemotherapy and Radiation**
Brackstone M, Chambers A, Guo B, Vandenberg T, Potvin K, Perea F, Parissenti A. London Health Sciences Centre, London, ON, Canada; Health Sciences North, Sudbury, ON, Canada; RNA Diagnostics, Inc., Sudbury, ON, Canada.

P1-14-14 **Neoadjuvant Sunitinib (S) Administered with Weekly Paclitaxel (P)/Carboplatin(C) in Patients (Pts) with Locally Advanced Triple-Negative Breast Cancer (TNBC): Preliminary Results from a Phase I/II Trial of the Sarah Cannon Research Institute**
Yardley DA, Barton J, Hendricks C, Webb C, Priego V, Nimeh N, Gravenor D, Shastry M, Chirwa T, Burris HA. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Baptist Hospital East, Louisville, KY; Center for Cancer and Blood Disorders, Bethesda, MD; Cancer Center of Southwest Oklahoma Research, Lawton, OK; Family Cancer Center Foundation, Inc., Memphis, TN.

P1-14-15 **Recent experience of neoadjuvant chemotherapy according to breast cancer subtype: experience from a large United Kindgom teaching hospital**
Rattay T, Kaushik M, Ahmed S, Shokuhi S. University Hospitals of Leicester, United Kingdom.

P1-14-16 **Young age: predicts poor response rate after neoadjuvant chemotherapy in endocrine-responsive breast cancer**
Kim MK, Noh D-Y, Han W, Moon H-G, Ahn S-K, Kim JS, Kim T, Kim JY, Lee JW. Seoul National University Hospital, Seoul, Korea.

P1-14-17 **Study of breast cancer shrinkage modes after neoadjuvant chemotherapy with whole-mount serial sections and three-dimensional pathological and MRI reconstruction**
Wang Y-S, Zhang Z-P, Liu G, Mu D-B, Sun X-Y. Shandong Cancer Hospital & Institute, Jinan, Shandong, China.

P1-14-18 **Overall survival results of a multicenter randomized phase II study in locally advanced breast cancer patients treated with or without celecoxib for HER2 negative tumor (Remagus 02 trial)**
Giacchetti S, Pierga J-Y, Delaloge S, Asselain B, Brain E, Guinebretière JM, Che-Lehman J, Mathieu M-C, Sigal B, Marty M. Hôpital Saint Louis, Assitance Publique-Hôpitaux, Paris, France; Institut Curie, Paris, France; Institut Gustave Roussy, Villejuif, France; Institut Curie-Saint Cloud, Saint Cloud, France.

P1-14-19 **Breast-Conserving Surgery after Neoadjuvant Chemotherapy Is Oncologically Safe for Stage III Breast Cancer Patients**
Shin H-C, Han W, Moon H-G, Im S-A, Park S-J, Noh D-Y. Chung-Ang University Hospital, Seoul, Republic of Korea; Seoul National University Hospital, Seoul, Republic of Korea.

P1-14-20 **Withdrawn**

P1-14-21 **High antitumoral activity of neoadjuvant chemotherapy (NCT) with weekly paclitaxel + capecitabine and trastuzumab in patients with locally advanced HER2+ breast cancer (HER2+ LABC): Preliminary results**
Augereau P, Raro P, Verriele V, Delva R, Abadie-Lacourtoisie S, Ceban T, Paillocher N, Valo I, Maillart P, Soulie P. ICO Paul Papin, Angers, France.

Treatment: Toxicities - Management

P1-15-01 **Patterns of granulocyte colony stimulating factor (G-CSF) use in elderly breast cancer (BC) patients receiving myelosuppressive chemotherapy**
Blaes AH, Chia V, Solid C, Page J, Barron RL, Choi MR, Arneson TJ. University of Minnesota, Minneapolis, MN; Amgen, Inc., Thousand Oaks, CA; Minneapolis Medical Research Foundation, Minneapolis, MN.

P1-15-02 **Febrile neutropenia (FN) risk assessment and granulocyte colony-stimulating factor (G-CSF) guideline adherence in patients with breast cancer – results from a German prospective multicentre observational study (PROTECT)**
Steffens C-C, Eschenburg H, Kurbacher C, Goehler T, Schmidt M, Eustermann H, Schaffrik M, Otremba B. MVZ für Hämatologie/Onkologie, Klinik Dr. Hancken; Praxis für Hämatologie und internistische Onkologie, Güstrow; Praxis für Gynäkologie und gynäkologische Onkologie, Medizinisches Zentrum Bonn; Praxis für Hämatologie und internistische Onkologie, Dresden; Gynäkologische Onkologie, Universitätsfrauenklinik Mainz; WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld; Amgen GmbH, München; Onkologische Praxis Oldenburg/Delmenhorst.

P1-15-03 **Withdrawn**

P1-15-04 **The relationship of relative dose intensity and supportive care to febrile neutropenia rates in patients with early stage breast cancer receiving chemotherapy: a prospective cohort study of chemotherapy-associated toxicity**
Culakova E, Poniewierski MS, Wogu AF, Kuderer NM, Crawford J, Dale DC, Lyman GH. Duke University, Durham, NC; University of Washington, Seattle, WA.

P1-15-05 **GSTP1 polymorphism is associated with chemotherapy induced neuropathy**
Miltenburg NC, Opdam M, Winter M, van Geer M, Oosterkamp HM, Boogerd W, Linn SC. The Netherlands Cancer Institute, Amsterdam, Netherlands.

P1-15-06 **The impact of musculoskeletal toxicity on adherence to endocrine therapy in women with early stage breast cancer– observations in a non-trial setting**
Dent SF, Campbell MM, Crawley FL, Clemons MJ. The Ottawa Hospital Regional Cancer Center, Ottawa, ON, Canada.

P1-15-07 **Ixabepilone-associated peripheral neuropathy in metastatic breast cancer patients and its effects on the ultrastructure of neurons**
Jain S, Carlson K, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MV, Schneider S, Ramnarain A, Carey B, Ward M, Lane M, Strickland S, Vahdat L. Weill Cornell Medical College; Rockefeller University.

P1-15-08 **Higher toxicity of docetaxel for obese women with early breast cancer: lean body mass is a significant predictor of chemotherapy dose intensity reduction**
Gouerant S, Clatot F, Modzlewski R, Chaker M, Rigal O, Veyret C, Leheurteur M. Henri Becquerel Center, Rouen, France; Rouen University Hospital, Rouen, France.

P1-15-09 **Multi-Institutional Evaluation of Bioimpedance Spectroscopy (BIS) in the Early Detection of Breast Cancer Related Lymphedema**
Vicini F, Arthur D, Shah C, Anglin BV, Curcio L, Laidley AL, Beitsch P, Whitworth P, Lyden M. Michigan Healthcare Professionals/21st Century Oncology; Virginia Commonwealth University; Beaumont Health System; The Medical Center of Plano; Advanced Breast Care Specialists of Orange County; Texas Breast Specialists; Dallas Surgical Group; Nashville Breast Center; Biostat Inc.

P1-15-10 **Chemotherapy-Induced Neutropenia in Breast Cancer Patients Receiving Sequential Anthracycline and Taxane Chemotherapy: An Institutional Experience**
Staudigl C, Seifert M, Tea M-K, Pfeiler G, Fink-Retter A, Fritzer N, Singer CF. Medical University of Vienna, Austria; Alps-Adria University Klagenfurt, Klagenfurt, Austria.

P1-15-11 **The Kampo medicine Goshajinkigan prevents docetaxel-related peripheral neuropathy in breast cancer patients**
Abe H, Mori T, Kawai Y, Itoi N, Tomida K, Cho H, Kubota Y, Umeda T, Tani T. Shiga University of Medical Science Hospital, Otsu, Shiga, Japan; Shiga University of Medical Science, Otsu, Shiga, Japan.

P1-15-12 **Single Nucleotide Polymorphism (SNP) Bayesian networks (BNs) Predict Risk of Chemotherapy-Induced Side Effects in Patients with Breast Cancer Receiving Dose Dense (DD) Doxorubicin/Cyclophosphamide Plus Paclitaxel (AC+T)**
Schwartzberg LS, Sonis ST, Walker MS, Weidner SM, Alterovitz G. The West Clinic, Memphis, TN; Brigham and Women's Hospital, Boston, MA; ACORN CRO, Memphis, TN; Inform Genomics, Boston, MA; Harvard Medical School, Boston, MA.

Ongoing Trials 1: Her2

OT1-1-01 **A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab for node-positive breast cancer**
Hirano A, Hattori A, Kamimura M, Ogura K, Kim N, Setoguchi Y, Okubo F, Inoue H, Jibiki N, Miyamoto R, Kinoshita J, Kimura K, Fujibayashi M, Shimizu T. Tokyo Women's Medical University, Medical Center East, Tokyo, Japan; Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan.

OT1-1-02 **A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE)**
Bachelot T, Ciruelos E, Peretz-Yablonski T, Schneeweiss A, Puglisi F, Mitchell L, Dünne A, Miles D. Centre Leon Bérard, Lyon, France; Hospital Universitario 12 Octubre, Madrid, Spain; Hadassah- Hebrew University Medical Center, Jerusalem, Israel; National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; University Hospital of Udine, Italy; F. Hoffmann-La Roche, Basel, Switzerland; Mount Vernon Cancer Centre, Mount Vernon Hospital, Middlesex, United Kingdom.

OT1-1-03 **PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer**
Earl HM, Cameron DA, Miles D, Wardley AM, Ogburn ERM, Vallier A-L, Loi S, Higgins HB, Hiller L, Dunn JA. University of Cambridge, Cambridge, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom; Edinburgh University, Edinburgh, United Kingdom; Mount Vernon Cancer Centre, Middlesex, United Kingdom; The Christie Hospital, Manchester, United Kingdom; Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom; Cambridge Cancer Trials Centre, Cambridge.

OT1-1-04 **ALTERNATIVE: safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (AI) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer**
Johnston S, Wroblewski S, Huang Y, Harvey C, Nagi F, Franklin N, Gradishar W. Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Stockley Park, United Kingdom; Northwestern University, Chicago, IL.

OT1-1-05 **A Phase I pharmacokinetics trial comparing PF-05280014 and trastuzumab in healthy volunteers (REFLECTIONS B327-01)**
Ricart AD, Zacharchuk C, Reich SD, Meng X, Barker KB, Taylor CT, Hansson AG. Pfizer Inc., San Diego, CA; Pfizer Inc., Cambridge, MA; Pfizer Inc., New Haven, CT.

OT1-1-06 **A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer**
Crown JP, Moulton B, O'Donovan N. St Vincent's University Hospital, Elm Park, Dublin, Ireland; ICORG (All Ireland Cooperative Oncology Research Group), Dublin 4, Ireland; National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland.

OT1-1-07 **Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)**
Lin N, Danso MA, David AK, Muscato J, Rayson D, Houck, III WA, Ellis C, DeSilvio M, Garofalo A, Nagarwala Y, Winer E. Dana-Farber Cancer Institute, Boston, MA; Virginia Oncology Associates, Norfolk, VA; Augusta Oncology Associates, Augusta, GA; Missouri Cancer Associates, Columbia, MO; QEII Health Sciences Centre, Halifax, NS, Canada; Virginia Cancer Specialists, PC, Winchester, VA; GlaxoSmithKline Oncology, Collegeville, PA.

OT1-1-08 **Clinical outcomes among ErbB2+ MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study)**
Abulkhair O, Uslu R, Sezgin C, Büyükberber S, Darwish T, Isikdogan A, Gumus M, Dane F, Sevinc A, Halawani H, Uncu D, Marrero N, Tobler J, Soares C, Landis S, Moraes E, Gidekel R, Santillana S, Nunez P, Cagnolati S, Rodriguez JG. Ege University Medical Faculty, Izmir, Turkey; Gazi University Medical Faculty, Ankara, Turkey; King Abdulaziz Medical City National Guard Health Affairs, Riyadh, Saudi Arabia; King Abdullah Medical City - Oncology Centre, Jeddah, Saudi Arabia; Dicle University Medical Faculty, Diyarbakir, Turkey; Kartal Training and Research Hospital, Istanbul, Turkey; Marmara University Training and Research Hospital, Istanbul, Turkey; Gaziantep University Medical Faculty, Gaziantep, Turkey; King Fahad Specialist Hospital, Dammam, Saudi Arabia; Numune Training and Research Hospital, Ankara, Turkey; Instituto Docente de Urología, Valencia, Venezuela; GlaxoSmithKline, Rio de Janeiro, Brazil; GlaxoSmithKline, Buenos Aires, Argentina; GlaxoSmithKline, Stockley Park, United Kingdom; Hospital Oncológico Padre Machado, Caracas, Venezuela; Centro Oncologico-FIDES-La Plata, Buenos Aires, Argentina.

OT1-1-09 **Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer**
Gavilá J, Llombart A, Guerrero A, Ruiz A, Guillem V. Fundación Instituto Valenciano de Oncología, Valencia, Spain; Hospital Arnau de Vilanova, Valencia, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain.

OT1-1-10 **DETECT III - A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus lapatinib in patients with initially HER2-negative metastatic breast cancer but with HER2-positive circulating tumor cells**
Melcher CA, Janni JW, Schneeweiss A, Fasching PA, Hagenbeck CD, Aktas B, Pantel K, Solomayer EF, Ortmann U, Jaeger BAS, Mueller V, Rack BK, Fehm TN. University Hospital Duesseldorf, Germany; National Center for Tumor Diseases, Heidelberg, Germany; University Hospital Erlangen; University Hospital Essen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospital Homburg, Germany; Ludwig-Maximilians-University Munich, Munich, Germany; University Hospital Hamburg-Eppendorf, Germany; University Hospital Tuebingen, Germany.

OT1-1-11 **TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases**
Freedman RA, Gelman RS, Wefel JS, Krop IE, Melisko ME, Ly A, Agar NYR, Connolly RM, Blackwell KL, Nabell LM, Ingle JN, Van Poznak CH, Puhalla SL, Niravath PA, Ryabin N, Wolff AC, Winer EP, Lin N. Dana-Farber Cancer Institute, Boston, MA; The University of Texas MD Anderson Cancer Center, Houston, TX; University of California, San Francisco, CA; Brigham and Women's Hospital, Boston, MA; Johns Hopkins University, Baltimore, MD; Duke University, Durham, NC; University of Alabama, Birmingham, AL; Mayo Clinic, Rochester, MN; University of Michigan, Ann Arbor, MI; Univerity of Pittsburgh, Pittsburgh, PA; Baylor, Houston, TX,

OT1-1-12 **NSABP FB-7 Trial: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel and Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer**
Lu J, Jacobs SA, Buyse ME, Paik S, Wolmark N. State University of New York at Stony Brook, Stony Brook, NY; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA.

OT1-1-13 **Dual blockade with Afatinib and Trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70**
Hanusch C, Schneeweiss A, Untch M, Paepke S, Kuemmel S, Jackisch C, Huober J, Hilfrich J, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Loibl S, Nekljudova V, von Minckwitz G. Rotkreuzklinikum Muenchen; University Heidelberg; Helios Klinik Berlin; Frauenklinik Muenchen; Kliniken Essen Mitte; Klinikum offenbach; University Duesseldorf; Eilenriedeklinik Düsseldorf; University Rostock; University Kiel; Charite Berlin; University Magdeburg; Sankt Gertrauden Berlin; German Breast Group, Neu-Isenburg.

OT1-1-14 **Open-label, Phase II trial of afatinib, with or without vinorelbine, for the treatment of HER2-overexpressing inflammatory breast cancer (IBC)***
Swanton C, Cromer J, On behalf of the 1200.89 trial group. CR-UK London Research Institute, London, United Kingdom; Boehringer Ingelheim, North Ryde, Australia.

OT1-1-15 **LUX-Breast 3: Randomized Phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy***
Joensuu H, Ould-Kaci M, On behalf of the 1200.67 trial group. Helsinki University Central Hospital, Helsinki, Finland; Boehringer Ingelheim, Paris, France.

OT1-1-16 **LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment***
Xu B, Im S-A, Huang C-S, Im Y-H, Ro J, Zhang Q, Arora R, Mehta A, Jung K, Yeh D-C, Lee S, Jassem J, Wojtukiewicz M, Chen S-C, Lahogue A, Uttenreuther-Fischer M, Hurvitz S-A, Harbeck N, Piccart-Gebhart M, On behalf of the LUX-Breast 1 study group. Chinese Academy of Medical Sciences, Beijing, China; Seoul National University Hospital, Seoul, Korea; National Taiwan University Hospital, Taipei, Taiwan; Samsung Medical Center, Seoul, Korea; National Cancer Center, Goyang, Korea; Third Affiliated Hospital of Harbin Medical University, Heilongjiang Province, China; Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, Amravati, India; Central India Cancer Research Institute, Nagpur, India; Asan Medical Center, Seoul, Korea; Taichung Veterans General Hospital, Taichung, Taiwan; Severance Hospital, Seoul, Korea; Medical University, Gdansk, Poland; Medical University, Bialystok, Poland; Chang Gung Memorial Hospital - Linkou Branch, Taoyuan County, Taiwan; SCS Boehringer-Ingelheim Comm.V, Brussels, Belgium; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; UCLA, Los Angeles, CA; University of Munich, Munich, Germany; Institut Jules Bordet, Brussels, Belgium.

OT1-1-17 **LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib***
Hickish T, Mehta A, Jain M, Huang C-S, Kovalenko N, Udovitsa D, Pemberton K, Uttenreuther-Fischer M, Tseng L-M, On behalf of the LUX-Breast 2 study group. Bournemouth Hospital, Bournemouth University, Dorset, United Kingdom; Central India Cancer Research Institute, Maharashtra, India; Ruby Hall Clinic, Maharashtra, India; National Taiwan University Hospital, Taipei, Taiwan; Regional Clinical Oncology Dispensary, Stavropol, Russian Federation; GUZ Oncological Dispesary #2, Sochi, Russian Federation; Boehringer Ingelheim Limited, Bracknell, United Kingdom; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Taipei Veterans General Hospital, National Yang Ming University, Taipei, Taiwan.

Ongoing Trials 1: Radiation Therapy

OT1-2-01 **NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx)**
Cobleigh MA, Anderson SJ, Julian TB, Siziopikou KP, Arthur DW, Rabinovitch R, Zheng P, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Rush University Medical Center, Chicago, IL; University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; Northwestern University Feinberg School of Medicine, Chicago, IL; Virginia Commonwealth University, Richmond, VA; University of Colorado, Aurora, CO; Aultman Hospital, Canton, OH.

OT1-2-02 **SHARE. A French multicenter phase III trial comparing accelerated partial irradiation (APBI) versus standard or hypofractionated whole breast irradiation in low risk of local recurrence breast cancer**
Belkacemi Y, Bourgier C, Kramar A, Lemonier J, Auzac G, Dumas I, Lacornerie T, Mijonnet S, Mege J-P, Lartigau E. APHP; GH Henry Mondor and UPEC, Paris, Créteil, France; Institut Gustave Roussy, Villejuif, France; Oscar Lambret Center, Lille, France; UNICANCER, Paris, France.

7:30 pm–9:30 pm
OPEN SATELLITE EVENT PRESENTED BY RESEARCH TO PRACTICE
Marriott Rivercenter

ONE YEAR LATER: The Practical Application of Research Advances in the Management of Early and Advanced Breast cancer

Website: **http://www.researchtopractice.com/Meetings/SA2012**

THURSDAY, DECEMBER 6, 2012

6:45 am–5:15 pm
REGISTRATION
Bridge Hall

7:00 am–9:00 am
POSTER DISCUSSION 3: METFORMIN/STATINS
Ballroom A

Viewing 7:00 am
Discussion 7:45 am

Adrian Lee, PhD, Chair
University of Pittsburgh Cancer Institute
Pittsburgh, PA

Michael Pollak, MD, Discussant
McGill University
Montreal, CANADA
and
Vered Stearns, MD, Discussant
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, MD

PD03-01 **Effect of metformin on apoptosis in a presurgical trial in non-diabetic patients with breast cancer**
Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Guerrieri-Gonzaga A, Dell'Orto P, Gentilini OD, Vingiani A, Pagani G, Puccio A, Bonanni B. European Institute of Oncology (EIO), Milan; Ospaedali Galliera, Genova; University of Milan.

PD03-02 **Evidence for the anti-cancer action of metformin mediated via tumor AMPK, Akt and Ki67, in a preoperative window of opportunity trial**
Hadad SM, Dowling RJO, Chang MC, Done SJ, Purdie CA, Jordan LB, Dewar J, Goodwin PJ, Stambolic V, Thompson AM. University of Sheffield, United Kingdom; University Health Network, Toronto, Canada; Mount Sinai Hospital, Toronto, Canada; University of Dundee, United Kingdom; Princess Margaret Hospital and Mount Sinai Hospital, Toronto, Canada.

PD03-03 **Pre-surgical trial of metformin in overweight and obese, multi-ethnic patients with newly diagnosed breast cancer**
Kalinsky K, Crew KD, Refice S, Wang A, Feldman SM, Taback B, Hibshoosh H, Maurer M, Hershman DL. Columbia University Medical Center, New York, NY.

PD03-04 **Discovery of metformin derivatives with potent antitumor activity in triple-negative breast cancer**
Márquez-Garbán DC, Deng G, Anderson N, Aivazyan L, Kazmi N, Hamilton N, Jung ME, Pietras RJ. UCLA, Los Angeles, CA.

PD03-05 **Analysis of tumour cell signaling in response to neoadjuvant metformin in women with early stage breast cancer**
Dowling RJO, Niraula S, Chang MC, Done SJ, Ennis M, Hood N, McCready DR, Leong W, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V. Ontario Cancer Institute, University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Mt. Sinai Hospital, Toronto, ON, Canada; Campbell Family Institute for Breast Cancer Research and Laboratory Medicine Program, University Health Network, Toronto, ON; Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada; Applied Statistician, Markham, ON, Canada.

PD03-06 **Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with post-mastectomy radiation**
Lacerda L, Reddy J, Liu D, Larson R, Masuda H, Brewer T, Debeb B, Xu W, Hortobagyi GN, Buchholz TA, Ueno NT, Woodward WA. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX.

PD03-07 **Statin-induced decrease in proliferation depends on HMG-CoA reductase expression in breast cancer**
Bjarnadottir O, Romero Q, Bendahl P-O, Rydén L, Rose C, Loman N, Uhlén M, Jirström K, Grabau D, Borgquist S. Clinical Sciences, Lund University, Lund, Sweden; School of Biotechnology, KTH - Royal Institute of Technology, Stockholm, Sweden.

PD03-08 **Statin use and improved survival outcome in primary inflammatory breast cancer: retrospective cohort study**
Brewer TM, Masuda H, Iwamoto T, Liu P, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. The University of Texas M.D. Anderson Cancer Center, Houston, TX; Eastern Virginia Medical School, Norfolk, VA; Okayama University Hospital, Okayama, Japan.

PD03-09 **Statins and breast cancer risk: A follow-up analysis of the Women's Health Initiative Cohort**
Desai P, Jay A, Wu C, Cauley JA, Manson J, Peters U, Agalliu I, Abdul-Hussein M, Bock C, Budrys N, Chlebowski R, Cote M, Lane D, Luo J, Martin L, Park H, Petrucelli N, Rosenberg CA, Thomas F, Wactawski-Wende J, Simon MS. Providence Hospital Medical Center, Southfield, MI; Wayne State University, Detroit, MI; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pittsburgh, PA; Harvard School of Medicine, Boston, MA; Albert Einstein College of Medicine, Bronx, NY; Lakeland Regional Medical Center, MI; Karmanos Cancer Institute, Wayne State University, Detroit, MI; University of Texas Health Science Center San Antonio, TX; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Stony Brook University Medical Center, Stony Brook, NY; West Virginia University, Morgantown, WV; George Washington University, Washington, DC; University of California, Irvine, CA; NorthShore University Health System, Evanston, IL; University of Tennessee Health Science Center, Memphis, TN; University at Buffalo, NY.

7:00 am–9:00 am
POSTER DISCUSSION 4: LOCAL THERAPY DECISION MAKING AND DCIS
Ballroom B

Viewing 7:00 am
Discussion 7:45 am

Richard Crownover, MD, PhD, Chair
UT Health Science Center
San Antonio, TX

John Benson, MD, PHD, MA, DM, FRCS, Discussant
Addenbrooke's Hospital
Cambridge, UNITED KINGDOM
and
I-Tien Yeh, MD, Discussant
Virginia Hospital Center
Arlington, VA

PD04-01 **Intra-operative ultrasound in breast-conserving surgery for palpable breast cancer significantly improves both surgical accuracy and cosmetic outcome while saving costs**
Haloua M, Krekel N, Coupe V, van den Tol P, Meijer S. VU Medical Center, Amsterdam, Nederland, Netherlands; Alkmaar Medical Center, Alkmaar, Noord-Holland, Netherlands.

PD04-02 **Accelerated hypofractionated versus conventional whole breast radiotherapy for localised left-sided breast cancer: the effect on long-term cardiac morbidity**
Chan EK, Woods R, Virani S, Speers C, Wai ES, Nichol A, McBride ML, Tyldesley S. British Columbia Cancer Agency, Vancouver Centre; Vancouver General Hospital; British Columbia Cancer Agency, Vancouver Island Centre; British Columbia Cancer Agency.

PD04-03 **Is breast conservation therapy an option for young women with operable breast cancer? Local recurrence rates in young women following surgery: a single centre experience**
Lewis CR, Smith R, Matthews A, Choo E, Lee C. Prince of Wales Cancer Centre (POWCC), Randwick, NSW, Australia; Prince of Wales Hospital, Randwick, NSW, Australia; NHMRC Clinical Trials Unit, University of Sydney, NSW, Australia.

PD04-04 **What is influencing breast conservation rates in the United States? Data from the National Accreditation Program of Breast Centers**
Chagpar AB, Kaufman CS, Connolly J, Burgin C, Granville T, Winchester D. Yale University School of Medicine, New Haven, CT; Bellingham Breast Center; Beth Israel Deaconess, Boston, MA; National Accreditation Center for Breast Centers; Pat Nolan Center for Breast Health, Glenview, IL.

PD04-05 **Molecular predictors for type of recurrence following conservative treatment for DCIS**
Sakr RA, Andrade VP, Chandarlapaty S, Giovanni C, Giri D, Heguy A, De Brot M, Olvera N, Muhsen S, Koslow S, Van Zee KJ, Morrow M, Rosen N, King TA. Memorial Sloan-Kettering Cancer Center, New York.

PD04-06 **Molecular phenotypes of DCIS predict invasive and DCIS recurrence**
Williams KE, Barnes NLP, Cheema K, Dimopoulos N, Bundred NJ, Landberg G. The University of Manchester, Manchester, Greater Manchester, United Kingdom.

PD04-07 **The Ki-67 labeling index predicts the risk of recurrence of DIN patients treated with radiotherapy following breast conserving surgery**
Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore L, Del Castillo A, Viale G, Bonanni B. European Institute of Oncology, Milan, Italy; European Institute of Oncology, Milan; University of Milan, School of Medicine.

PD04-08 **Cell cycle algorithm correlates with grade of DCIS and p53 status, allows elimination of 'intermediate grade' disease and gives clinically meaningful information**
Sainsbury R, Loddo M, Proctor I, Stoeber K, Williams G, Thorat M, Cuzick J. University College London, United Kingdom; Wolfson Institute of Preventative Medicine, Queen Mary College, London, United Kingdom.

7:00 am–9:00 am
POSTER SESSION 2 & CONTINENTAL BREAKFAST
Exhibit Halls A-B

P2-01-01 **Establishment and validation of circulating tumor cell-based prognostic nomograms in 497 first-line metastatic breast cancer patients**
Giordano A, Reuben JM, Egleston BL, Hajage D, Hortobagyi GN, Cristofanilli M, Pierga J-Y, Bidard F-C. The University of Texas MD Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA; Institut Curie, Paris, France.

P2-01-02 Circulating Tumor Cells (CTC) may Express HER2/neu in Patients With Early HER2/neu Negative Breast Cancer – Results of the German SUCCESS C Trial
Jaeger BAS, Rack BK, Andergassen U, Neugebauer JK, Melcher CA, Scholz C, Hagenbeck C, Schueller K, Lorenz R, Decker T, Heinrich G, Fehm T, Schneeweiss A, Lichtenegger W, Beckmann MW, Pantel K, Sommer HL, Friese K, Janni W. Klinikum der Ludwig-Maximilians-Universitaet, Munich, Germany; Heinrich Heine University, Duesseldorf, Germany; Stat-up Statistische Beratung und Dienstleistung, Munich, Germany; Gemeinschaftspraxis Dr. Lorenz/Hecker/Wesche, Braunschweig, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Praxis Dr. Heinrich, Fuerstenwalde, Germany; Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany; National Center for Tumor Disease and Department of Gynecology and Obstetrics, University Hospital Heidelberg, Germany; Charité Medical University, Berlin, Germany; Universitaet Erlangen, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

P2-01-03 Truncated HER2 receptor in circulating tumor cells (CTCs) of early and metastatic breast cancer patients
Kallergi G, Nasias D, Papadaki M, Mavroudis D, Georgoulias V, Agelaki S. University of Crete, Heraklion, Crete, Greece; University General Hospital of Heraklion, Crete, Greece.

P2-01-04 Long term independent prognostic impact of circulating tumor cells detected before neoadjuvant chemotherapy in non-metastatic breast cancer: 70 months analysis of the REMAGUS02 study
Bidard F-C, Delaloge S, Giacchetti S, Brain E, de Cremoux P, Vincent-Salomon A, Marty M, Pierga J-Y. Institut Curie, France; Institut Gustave Roussy, France; Hopital Saint Louis, France.

P2-01-05 Parallel DNA and RNA profiling of EpCAM-positive cells in blood of metastatic breast cancer (MBC) patients confirm their malignant nature
Magbanua MJM, Hauranieh L, Sosa EV, Pendyala P, Scott JH, Rugo HS, Park JW. University of California, San Francisco, CA.

P2-01-06 Association between Circulating Tumor Cells and Bone Turnover Markers in patients with breast cancer and bone metastases on treatment with bisphosphonates (ZOMAR study)
Manso L, Barnadas A, Tusquets I, Crespo C, Gómez P, Calvo L, Ruiz M, Martínez P, Perelló A, Antón A, Codes M, Margelí M, Murias A, Salvador J, Seguí MA, De Juán A, Gavilá J, Luque M, Pérez D, Zamora P, Arizcum A, Chacón JI, Heras L, De la Piedra C. Hospital 12 de Octubre, Madrid, Spain; Hospital Santa Creu i Sant Pau, Barcelona, Spain; Hospital del Mar, Barcelona, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitario Vall d'Hebrón, Barcelona, Spain; Hospital Universitario A Coruña Juan Canalejo, A Coruña, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Basurto, Vizcaya, Spain; Hospital Son Dureta, Palma de Mallorca, Spain; Hospital Miguel Servet, Zaragoza, Spain; Hospital Virgen Macarena, Sevilla, Spain; Hospital Universitario Trias y Pujol, Barcelona, Spain; Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain; Hospital Nuestra Señora de Valme, Sevilla, Spain; Hospital Parc Taulí Sabadell, Barcelona, Spain; Hospital Marqués Valdecilla, Santander, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Hospital General de Asturias, Oviedo, Spain; Hospital Costa del Sol, Málaga, Spain; Hospital La Paz, Madrid, Spain; Hospital Palencia Río Carrión, Palencia, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital Cruz Roja Hospitalet del Llobregat, Barcelona, Spain; Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain

P2-01-07 Effect of first-line chemotherapy in the expression of stemness and epithelial-to-mesenchymal transition markers in circulating tumor cells of patients with metastatic breast cancer
Papadaki MA, Kallergi G, Mavroudis D, Georgoulias V, Theodoropoulos PA, Agelaki S. University of Crete, Heraklion, Crete, Greece; University General Hospital of Heraklion, Crete, Greece.

P2-01-08 Different numbers and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
Peeters DJ, van Dam P-J, Wuyts H, Van den Eynden GG, Jeuris K, Prové A, Rutten A, Peeters M, Pauwels P, Van Laere SJ, Hauspy J, van Dam PA, Vermeulen PB, Dirix LY. GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium.

P2-01-09 Tumor cell emboli in the lung and transcriptional profiles of circulating tumor cells derived from different vascular compartments in patients with metastatic breast cancer
Peeters DJ, Van den Eynden GG, Rutten A, Onstenk W, Sieuwerts AM, De Laere B, van Dam PA, Peeters M, Pauwels P, Van Laere SJ, Vermeulen PB, Dirix LY. GZA Hospitals Sint-Augustinus, Antwerp, Belgium; University of Antwerp, Belgium; Erasmus University Medical Center and Cancer Genomics Center, Rotterdam, South Holland, Netherlands; Catholic University of Leuven, Leuven, Vlaams-Brabant, Belgium.

P2-01-10 Immunocytochemistry staining for estrogen and progesterone receptor in circulating tumor cells: Concordance between primary and metastatic tumors
Bischoff FZ, Pham T, Wong KL, Villarin E, Xu X, Kalinsky K, Mayer JA. Biocept, Inc., San Diego, CA; Columbia University Medical Center, New York, NY.

P2-01-11 Detection and characterization of circulating and disseminated tumour cells in blood and bone marrow of breast cancer patients by two different biochemical methods
Andergassen U, Rack BJ, Zebisch M, Kölbl AC, Schindlbeck C, Neugebauer J, Liesche F, Hiller Ral, Friese K, Jeschke U. Ludwig - Maximilians-University, Munich, Germany; Klinikum Traunstein, Traunstein, Germany.

P2-01-12 Circulating tumor cells and Epithelial Mesenchymal Transition in primary breast cancer patients
Mego M, Karaba M, Minarik G, Benca J, Sedlackova T, Manasova D, Sieberova G, Gronesova P, Pechan J, Mardiak J, Reuben JM. Faculty of Medicine, Comenius University, Bratislava, Slovakia (Slovak Republic); National Cancer Institute, Bratislava, Slovakia (Slovak Republic); Cancer Research Institute, Bratislava, Slovakia (Slovak Republic); University of Texas, MD Anderson Cancer Center, Houston, TX.

P2-01-13 Prognostic value of Circulating Tumor Cells count at progressive disease after first line chemotherapy metastatic breast patients in a large prospective multicenter trial including serum tumor markers (IC 2006-04 study)
Pierga J-Y, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Asselain B, Cottu PH, Dieras V, Bidard F-C. Institut Curie, Paris; Centre Léon Bérard, Lyon; Institut Gustave Roussy, Villejuif; Institut de Cancérologie de L'Ouest.

P2-01-14 Circulating tumor cells in breast cancer exhibit dynamic changes in epithelial and mesenchymal cell composition
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S. Massachusetts General Hospital, Harvard Medical School; Howard Hughes Medical Institute.

Detection/Diagnosis: Circulating Markers

P2-02-01 **Accurate identification of metastatic breast cancer using methylated gene markers in circulating free DNA in peripheral blood**
Sukumar S, Fackler MJ, Lopez-Bujanda Z, Teo WW, Jeter S, Umbricht C, Visvanathan K, Wolff AC. Johns Hopkins University School of Medicine, Baltimore, MD.

P2-02-02 **Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients in neoadjuvant setting**
Koh YW, Lee HJ, Ahn J-H, Lee JW, Gong G. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Bundang-Gu, Kyeonggi-Do, Korea.

P2-02-03 **The Collagen Receptor Endo180: A Metastatic Plasma Marker in Breast Cancer Modulated by Bisphosphonate Treatment**
Sturge J, Caley MP, Purshouse K, Fonseca A-V, Rodriguez-Teja M, Kogianni G, Waxman J, Palmieri C. Imperial College London, United Kingdom; The University of Hull, Hull, United Kingdom.

P2-02-04 **The interaction between menopausal status and zoledronic acid can differentially affect serum levels of the TGFβ superfamily**
Wilson C, Winter MC, Holen I, Freeman JV, Evans AC, Coleman RE. University of Sheffield, United Kingdom; Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom.

Detection/Diagnosis: Micrometastases

P2-03-01 **Identification of cancer stem cells (CD44+CD24-/lo) in bone marrow as a prognostic factor in early breast cancer patients**
Giordano A, Gao H, Cohen EN, Anfossi S, Hess KR, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Ueno NT, Lucci A, Reuben JM. The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center; Fox Chase Cancer Center.

Tumor Cell and Molecular Biology: Animal Models

P2-04-01 **Development of mouse breast cancer models based on induced cancer stem cells (iCSC)**
Takamoto Y, Onishi N, Kai K, Saya H. Institute for Advanced Medical Research (IAMR), School of Medicine, Keio university, Shinjyuku-ku, Tokyo, Japan; The University of Texas MD Anderson Cancer Center, Houston, TX.

P2-04-02 **Identification of genes associated with breast cancer micrometastatic disease in bone marrow using a human-in-mouse xenograft system**
Aft R, Li S, Mudalagiriyappa C, Dasgupta N, Watson M, Fleming T, Ellis M, Pillai S. Washington University, St. Louis, MO.

P2-04-03 **A robust transgenic mouse model to study male breast cancer**
Krause S, Lurvey HL, Tobin H, Ingber DE. Boston's Children's Hospital, Boston, MA; Wyss Institute of Biologically Inspired Engineering, Boston, MA.

P2-04-04 **Prolactin cooperates with loss of p53 to promote mammary tumorigenesis**
O'Leary KA, Sullivan R, Rugowski DE, Schuler LA. University of Wisconsin, Madison, WI.

P2-04-05 **Prolonged targeted overexpression of Aurora-A in mammary epithelium promotes mammary adenocarcinoma with genomic instability**
Treekitkarnmongkol W, Katayama H, Sen S. University of Texas M.D. Anderson Cancer Center, Houston, TX.

P2-04-06 **Transgenic expression of a breast-cancer specific GATA3 mutant leads to mammary hyperplasia**
Kenny PA, Chandiramani N. Albert Einstein College of Medicine, Bronx, NY.

P2-04-07 **Modeling orthotopic and metastatic progression of mammary tumors to evaluate the efficacy of TGF-β inhibitors in a pre-clinical setting**
Biswas T, Yang J, Zhao L, Sun L. UTHSCSA, San Antonio, TX; UCSD, CA.

P2-04-08 **Targeted Expression of the Human Chaperone BAG3 to the Murine Mammary Gland Dysregulates Mammary Gland Development and Differentiation By Unrestricted Expansion of Luminal Cells**
Virador VM, Casagrange G, Raafat A, Callahan R, Kohn E. National Cancer Institute, Bethesda, MD.

Tumor Cell and Molecular Biology: Biomarkers

P2-05-01 **Gene expression changes associated with response to neoadjuvant chemotherapy are observed early in treatment: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)**
Wolf DM, Yau C, Magbanua M, Boudreau A, Davis S, Haqq C, Park J, I-SPY TRIAL-1 Investigators, Esserman L, van't Veer L. University of California, San Francisco, CA; I-SPY 1 TRIAL Institutions.

P2-05-02 **Clinical significance of microRNA regulator Lin28 expression in patient with early breast cancer**
Park S, Shin YK, Song BJ, Chae BJ, Jung SS, Choi Y-L. Seoul St. Mary's Hospital, Catholic University School of Medicine, Seoul, Korea; Seoul National University College of Pharmacy, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

P2-05-03 **Mouse double minute 2 nuclear expression as a prognostic marker in patients with breast cancer**
Park HS, Park S, Koo JS, Cho JH, Park JM, Kim S-I, Park B-W. Yonsei University College of Medicine, Seodaemoon-gu, Seoul, Korea.

P2-05-04 **Differential potency of TORC1/C2 (INK/MLN-128) and pan-PI3K (GDC0941) inhibitors on breast cancer polysome composition and phosphoprotein response biomarkers**
Wilson-Edell KA, Yevtushenko M, Hanson I, Rogers AN, Scott GK, Benz CC. Buck Institute for Research on Aging, Novato, CA.

P2-05-05 **Circulating HER2 extracellular domain (ECD) predicts a poor prognosis for metastatic breast cancer patients**
Wang X-j, Shao X-Y, Xu X-H, Chen Z-H, Wang S, Cai J-F, Huang J, Huang P, Lou C-J, Ling Z-Q, Han MX. Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Hangzhou Polar Gene Company, Hangzhou, Zhejiang, China.

P2-05-06 **Quantitative measurement of HER2 expression in breast cancers: comparison with "real world" HER2 testing in a multi-center Collaborative Biomarker Study (CBS) and correlation with clinicopathological features**
Yardley DA, Kaufman PA, Adams JW, Krekow L, Savin M, Lawler WE, Zrada S, Starr A, Einhorn H, Schwartzberg LS, Huang W, Weidler J, Lie Y, Paquet A, Haddad M, Anderson S, Brigino M, Bosserman L. Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology PLLC, Nashville, TN; Dartmouth Hitchcock Medical Center, Lebanon, NH; Arlington Cancer Center, Arlington, TX; Texas Oncology Bedford, Bedford, TX; Texas Oncology at Medical City Dallas 2, Dallas, TX; St. Jude Heritage Medical Group, Fullerton, CA; The Center for Cancer and Hematologic Disease, Cherry Hill, NJ; Monroe Medical Associates, Harvey, IL; Swedish American Regional Cancer Center, Rockford, IL; The West Clinic, Memphis, TN; Monogram Biosciences, Inc., So. San Francisco, CA; Center for Molecular Biology and Pathology, Laboratory Corporation of America, Inc., Research Triangle Park, NC; Wilshire Oncology Medical Group, Rancho Cucamonga, CA.

P2-05-07 **Comparison of hormone receptor and HER-2 expression in primary breast cancers and sentinel lymph node metastases**
Rokutanda N, Horiguchi J, Takata D, Nagaoka R, Sato A, Tokiniwa H, Tozuka K, Uchida S, Takeyoshi I. Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

P2-05-08 **Determination of HER2 amplification by dual-color in situ hybridization before and after neoadjuvant chemotherapy**
Niikura N, Kumaki N, Iwamoto T, Tsuda B, Okamura T, Yuki S, Suzuki Y, Tokuda Y. Tokai University School of Medicine, Isehara, Kanagawa, Japan; Okayama University Hospital, Okayama, Japan.

P2-05-09 **Identification and validation of a miRNA signature associated with breast cancer progression**
Waters PS, Dwyer RM, Kerin MJ. National University of Ireland, Galway, Ireland.

P2-05-10 **^{64}Cu-DOTA-trastuzumab positron emission tomography imaging of HER2 in women with advanced breast cancer**
Mortimer JE, Conti P, Shan T, Carroll M, Kofi P, Colcher D, Raubitschek AA, Bading JR, Miles J. City of Hope Cancer Center/Beckman Research Institute, Duarte, CA; USC, Los Angeles, CA.

P2-05-11 **Proteomic identification and in-silico verification of subtype-specific signatures in breast cancer**
Pavlou MP, Dimitromanolakis A, Diamandis EP. University of Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada.

P2-05-12 **Effects of de-escalated bisphosphonate therapy on bone turnover or metastasis markers and their correlation with risk of skeletal related events – A biomarker analysis in conjunction with the REFORM study**
Addison CL, Zhao H, Mazzarello S, Mallick R, Amir E, Tannock I, Clemons M. Ottawa Hospital Research Institute, Ottawa, ON, Canada; Princess Margaret Hospital, Toronto, ON, Canada; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.

P2-05-13 **Correlation of conventional versus experimental biomarkers of bone turnover and metastasis behaviour with skeletal related events – A biomarker analysis in conjunction with the TRIUMPH study**
Addison CL, Kuchuk I, Bouganim N, Zhao H, Mazzarello S, Vandermeer L, Mallick R, Goss GD, Clemons M. Ottawa Hospital Research Institute, Ottawa, ON, Canada; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; McGill University Health Centre, Montreal, QC, Canada.

P2-05-14 **Clinical significance of Lysyl oxidase-like 2 (LOXL 2) in breast cancer**
Ahn SG, Lee HM, Hwang SH, Lee SA, Jeong J, Lee H-E. Gangnam Severance Hospital, Yonsei University Medical College, Seoul, Republic of Korea.

P2-05-15 **Assessment of Notch Signaling Pathway Components as Biomarkers for Triple Negative Breast Cancer: Comparison of Triple Negative Breast Cancer Cell Lines and Human Breast Cancer Samples**
Zlobin A, Olsauskas-Kuprys R, Hodge S, O'Toole M, Ersahin C, Osipo C. Loyola University Chicago, Cardinal Bernardin Cancer Center, Maywood, IL.

P2-05-16 **Expression of β-III tubulin, foxo 3 protein and deoxythymidine kinase in breast cancer patients receiving neoadjuvant chemotherapy**
Chow LWC, Loo WTY, Yip AYS, Ong EYY, Ng W-K. UNIMED Medical Institute, Hong Kong; Organisation for Oncology and Translational Research, Hong Kong; Central Hospital, Hong Kong.

P2-05-17 **Correlation between cyclin D1, estrogen and progesterone receptors in invasive breast cancer after short-term treatment with tamoxifen or anastrozole**
Millen EC, Mattar A, Logullo AF, Nonogaki S, Soares FA, Gebrim LH. Federal University of Sao Paulo, Sao Paulo, SP, Brazil; Perola Byington Hospital, Sao Paulo, SP, Brazil; Federal University of Sao Paulo, Sao Paulo, SP; Arnaldo Vieira de Carvalho, Sao Paulo, SP, Brazil.

P2-05-18 **Withdrawn**

P2-05-19 **Pathway-based analysis of breast cancer**
Song D, Cui M, Fan Z, Yang Y, Xue L, Zhang DY, Ye F. The First Hospital of Jilin University, Changchun, Jilin, China; The Mount Sinai Medical Center, New York, NY; Nanfang Hospital Southern Medical University, Guangzhou, China.

P2-05-20 **Validation and comparison of CS-IHC4 score with a nomogram based on Ki67 index, Adjuvant! Online, and St. Gallen risk stratification to predict recurrence in early Hormone Receptor (HR)-positive breast cancers**
Park YH, Im S-A, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh D-Y, Yang JH, Ahn JS, Im Y-H. Samsung Medical Center; Seoul National University College of Medicine.

P2-05-21 **Molecular subtypes of invasive breast cancers show differential expression of the proliferation marker Aurora Kinase A (AURKA)**
Kovatich AJ, Luo C, Chen Y, Hooke JA, Kvecher L, Rui H, Shriver CD, Mural RJ, Hu H. Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA.

P2-05-22 **Preferential Activation of BP1 and c-Myc in Breast Cancer of African American Women Compared with Caucasian American Women**
Berg PE, Ghimbovschi S, Grizzle WE, Nguyen TH. George Washington University Medical Center, Washington, DC; Children's National Medical Center, Washington, DC; University of Alabama at Birmingham, AL.

Tumor Cell and Molecular Biology: Genomics

P2-06-01 **Breast-to-breast metastasis can cause hormone-receptor positive / triple negative bilateral synchronous tumors**
Schwab RB, Bao L, Pu M, Crain B, Dai Y, Nazareth LV, Matsui H, Wallace AM, Hasteh F, Harismendy O, Frazer KA, Parker BA, Messer K. University of California, San Diego, La Jolla, CA; Rady Children's Hospital, Division of Genome Information Sciences, University of California, San Diego, La Jolla, CA.

P2-06-02 **Genomic evolution from primary breast cancers to distant metastases**
Hoefnagel LDC, Moelans CB, van der Groep P, van der Wall E, van Diest PJ. University Medical Center Utrecht, Netherlands.

P2-06-03 **Specific Transcriptional Response of Four Blockers of Estrogen Receptors on Estrogen-Modulated Genes in ZR-75-1 Breast Cancer Xenografts**
Calvo E, Luu-The V, Martel C, Labrie F. Laval University Hospital Research Center (CRCHUL), Quebec City, QC, Canada; Laval University, Quebec City, QC, Canada; EndoCeutics Inc., Quebec City, QC, Canada.

P2-06-04 **Impact of genomic testing on chemotherapy utilization**
Riley L, Nakijima H, Balinger K, Anderson D. St. Luke's University Health Network, Bethlehem, PA.

P2-06-05 **Single-cell RNA sequencing of paclitaxel-treated breast cancer cell lines to find individual cell response**
Vaske CJ, Lee W, Benz SC, Sanborn JZ, Emerson BM, Pourmand N, Lopez Diaz F. Five3 Genomics, LLC, Santa Cruz, CA; University of California, Santa Cruz, CA; Salk Institute, La Jolla, CA.

P2-06-06 **Integrating multiple molecular profiles with pathways to learn sub-type specific interactions with PARADIGM**
Sedgewick AJ, Vaske CJ, Benz SC. Five3 Genomics, Santa Cruz, CA; University of Pittsburgh, PA.

P2-06-07 **Exome sequencing identifies somatic mutations in basal-like breast cancer before and after neoadjuvant chemotherapy**
Jiang Y-Z, Yu K-D, Shao Z-M. Shanghai Cancer Center, Shanghai, Shanghai, China.

Tumor Cell and Molecular Biology: Genetics - Germline Changes

P2-07-01 **BRCA1 regulates RHAMM function in breast cancer**
Fleisch MC, Yang Y, Mei Q, Sadat F, Brandi L, Iwaniuk KM, Honisch E, Maxwell CA, Niederacher D. Heinrich Heine University, Duesseldorf, Germany; University of British Columbia, Vancouver, BC, Canada.

P6-07-31 **Assessing germline Homologous Recombination pathway deficiency in BRCA1 mutation carriers using Single Cell Network Profiling**
Rosen DB, Leung LY, Louie B, Evensen E, Fields SZ, Cesano A, Shapira I, Hawtin RE. Nodality Inc, South San Francisco, CA; Monter Cancer Center, North Shore Long Island Jewish Medical School, Lake Success, NY.

Tumor Cell and Molecular Biology: Genetics - Somatic Changes

P2-08-01 **PIK3CA mutations associate with decreased Ki67 in early stage breast cancer (BC) and better outcomes in patients even among those with low Ki67 tumors**
Datko FM, Patil S, Kalinsky K, Asher M, Wen YH, Hedvat C, Moynahan ME. Memorial Sloan-Kettering Cancer Center; Columbia University Medical Center.

P2-08-02 **The large scale structure of the HER-2/neu amplicon in breast cancer**
Pauletti G, Anderson L, Rong H-M, Yu J, Slamon DJ. David Geffen School of Medicine, University of California, Los Angeles, CA.

P2-08-03 **Phosphatidylinositol-3-kinase mutations are common in lobular neoplasia**
Troxell ML, Ang D, Warrick A, Beadling C, Corless CL. Oregon Health & Science University, Portland, OR.

P2-08-04 ***HER2* gene status change after taxane based chemotherapy: be aware of mis-interpretation of polyploidization! Impact for patient management**
Valent A, Penault-Llorca F, Cayre A, Kroemer G. Institut Gustave Roussy, Villejuif, France; Centre Jean Perrin, Clermont-Ferrand, France.

Tumor Cell and Molecular Biology: Epigenetics

P2-09-01 **Reactivation of epigenetically silenced retinoic acid receptor-beta for therapy of breast cancer- from molecular mechanism to potential clinical applications**
Ordentlich P, Nguyen N, Jin K, Sadik H, Han L, Sukumar S. Syndax Pharmaceuticals; Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine.

P2-09-02 **Epigenetic Regulation of histone variants - a role in hormone therapy resistant breast cancer?**
Nayak SR, Oesterreich S, Pathiraja T. Magee Women's Research Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.

P2-09-03 **Identifying a landscape of DNA methylation-driven genes in breast cancer using MethylMix**
Gevaert O, Plevritis S. Stanford University.

P2-09-04 **DNA methylation landscapes in ER-negative breast cancer**
Worsham MJ, Chen KM, Chitale D, Divine G. Henry Ford Health System, Detroit, MI.

P2-09-05 **Screening of significantly hypermethylated genes in breast cancer using MIRA-based microarray and identifying their expression levels**
Lian Z-q, Wang Q, Li W-p, Zhang A-q, Wu L. Breast Disease Center, Guangdong Women and Children Hospital of Guangzhou Medical College.

P2-09-06 **The structure design and biological activities of inhibitory peptides, which block the interactions among polycomb repressive complex 2**
LI KK, Luo L, Kong X, Li L, Luo C. Rui Jin Hospital Affiliated with the Shanghai JiaoTong University School of Medicine, Shanghai, China; Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Prognostic and Predictive Factors: Prognostic Factors - Clinical

P2-10-01 **PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy**
Liu MC, Pitcher BN, Mardis ER, Davies SR, Snider JE, Vickery T, Reed JP, DeSchryver K, Singh B, Friedman PN, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, Winer EP, Hudis CA, Perou CM, Ellis MJ, Barry WT. Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC; Duke University Medical Center, Durham, NC; Washington University, St. Louis, MO; Washington University School of Medicine, St. Louis, MO; New York University Medical Center, New York, NY; University of Chicago, IL; Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL; Mayo Clinic, Jacksonville, FL; The Angeles Clinic and Research Institute, Santa Monica, CA; Hofstra North Shore-LIJ School of Medicine, ProHEALTH Care Associates, Lake Success, NY; Memorial Sloan-Kettering Cancer Center, New York, NY; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC; Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.

P2-10-02 **Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study**
Gnant M, Filipits M, Mlineritsch B, Dubsky P, Jakesz R, Kwasny W, Fitzal F, Rudas M, Knauer M, Singer C, Greil R, Ferree S, Storhoff J, Cowens JW, Schaper C, Liu S, Nielsen T, On behalf of the ABCSG. Medical University of Vienna, Austria; Medizinische Universität Salzburg, Austria; A.ö. KH Wr. Neustadt, Wr. Neustadt, Austria; Hospital of the Sisters of Mercy, Linz, Austria; Nanostring Technologies, Seattle, WA; Vancouver Hospital, Vancouver, BC, Canada; MyRAQA Inc, Redwood Shores, CA; Vancouver Coastal Health, Vancouver, BC, Canada.

P2-10-03 **A cross-platform comparison of genomic signatures and OncotypeDx score to discover potential prognostic/predictive genes and pathways**
Kuderer NM, Barry WT, Geradts J, Ginsburg GS, Lyman GH, Datto M, Liotcheva V, Isner P, Veldman T, Agarwal P, Hwang S, Ready N, Marcom PK. Duke University Medical Center, Durham, NC.

P2-10-04 **The Mammostrat Test Is an Effective Tool To Stratify Patient Samples Previously Characterized as Intermediate by the Oncotype Dx Test**
Bloom KJ, Kyshtoobayeva A, Hilaire L, Gutekunst K. Clarient Diagnostic Services, Aliso Viejo, CA.

P2-10-05 **Continuous association of a 200-gene prognostic risk score with probability of neoadjuvant chemotherapy response and translation from fresh frozen to FFPE tissue for clinical use**
van Laar R, DiPaola J, Carbaugh H, Murphy T, DiRamio A, Flinchum R, Brown N, Albino T. Signal Genetics, New York, NY.

P2-10-06 **Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast cancer stem cells are associated with intrinsic chemoresistance and worse survival**
Landis MD, Yau C, Neumeister V, Rimm DL, I-SPY 1 TRIAL Investigators, Esserman L, Chang JC. The Methodist Hospital, Houston, TX; University of California, San Francisco, CA; Yale University School of Medicine, New Haven, CT.

P2-10-07 **Stem cell marker aldehyde dehydrogenase 1 in stromal cells strongly correlates with prognosis in breast cancer**
Sjöström M, Hartman L, Holmdahl J, Grabau D, Malmström P, Fernö M, Niméus-Malmström E. Lund University, Lund, Sweden.

P2-10-08 **Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial**
Gluz O, Kreipe HH, Kates RE, Christgen M, Liedtke C, Shak S, Clemens M, Salem M, Liedtke B, Aktas B, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N. West German Study Group, Moenchengladbach, NRW, Germany; Ev. Bethesda Hospital, Moenchengladbach, NRW, Germany; Medizinische Hochschule Hannover, Niedersachsen, Germany; University of Muenster, Muenster, Germany; Genomic Health, Inc., Germany; Clinics Mutterhaus, Trier, Germany; University of Cologne, Germany; Ev. Hospital, Bergisch Gladbach, Germany; University of Essen, Germany; Clinics Südstadt, Rostock, Germany; Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Clinics Deggendorf, Deggendorf, Germany; University of Halle, Germany; University of Munich, Munich, Bavaria, Germany.

P2-10-09 **The incidence of false negative of HER2/Neu status in primary breast cancer in the era of standardized testing: a Canadian prospective study**
Hanna W, Barnes PJ, Chang MC, Gilks B, Magliocco A, Rees H, Robertson S, SenGupta SK, Nofech-Mozes S. Sunnybrook Health Sciences Centre; Capital Health District Authority; Mount Sinai Hospital; Vancouver General Hospital; Tom Baker Cancer Centre; Saskatoon City Hospital; Ottawa General Hospital; Kingston General Hospital.

P2-10-10 **Clinical implications of molecular heterogeneity in highly proliferative, ER-positive, HER2-negative breast cancer**
Bianchini G, Pusztai L, Kelly CM, Iwamoto T, Callari M, Symmans WF, Gianni L. Ospedale San Raffaele, Milan, Italy; MD Anderson Cancer Center, Houston, TX; Mater Misericordiae University Hospital, Dublin, Ireland; Okayama University Hospital, Okayama, Japan; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

P2-10-11 **Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM/9906 trial**
Martin M, Brase JC, Ruiz-Borrego M, Krappmann K, Munarriz B, Fisch K, Ruiz A, Weber KE, Crespo C, Petry C, Rodriguez CA, Kronenwett R, Calvo L, Alba E, Carrasco E, Casas M, Caballero R, Rodriguez-Lescure A. Hospital General Universitario Gregorio Marañon, Madrid, Spain; Sividon Diagnostics GmbH, Cologne, Germany; Hospital Universitario Virgen del Rocio, Sevilla, Spain; Hospital Universitario La Fe, Valencia, Spain; Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario Ramon y Cajal, Madrid, Spain; Hospital Clinico Universitario de Salamanca, Salamanca, Spain; Complejo Hospitalario Universitario A Coruña, Coruña, Spain; Hospital Universitario Virgen de la Victoria, Malaga, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Hospital General Universitario de Elche, Alicante, Spain.

P2-10-12 **How well predict the 2011 St Gallen early breast cancer surrogate phenotypes metastatic survival?**
Vanderstichele A, Brouckaert O, Tuyls S, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Weltens C, Peeters S, Moerman P, Floris G, Paridaens R, Wildiers H, Vergote I, Christiaens M-R, Van Calster B, Neven P. University Hospitals, Leuven, Belgium.

P2-10-13 **CD4 positive tumor-infiltrating lymphocytes are associated with improved prognosis in node-negative breast cancer**
Schmidt M, van de Sandt L, Boehm D, Sicking I, Battista M, Lebrecht A, Solbach C, Koelbl H, Gehrmann M, Rahnenführer J, Hengstler JG. University Hospital, Mainz, Germany; Technical University, Dortmund, Germany; Bayer, Leverkusen, Germany; Leibniz Research Centre for Working Environment and Human Factors (IfADo), Dortmund, Germany.

P2-10-14 **Triple Negative Breast Cancer: prognosis of triple-negative breast cancers and non-triple-negative breast cancers in a large registry of certified breast units**
Kern P, Rezai M. Breast Unit Düsseldorf Louis Hospital, Düsseldorf, Northrhine-Westfalia, Germany.

P2-10-15 **Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study**
Sgroi DC, Sestak I, Zhang Y, Erlander MG, Schnabel CA, Goss PE, Cuzick J, Dowsett M. Massachusetts General Hospital and Harvard Medical School, Boston, MA; Queen Mary University, London, United Kingdom; bioTheranostics Inc, San Diego, CA; Royal Marsden Hospital, London, United Kingdom.

P2-10-16 **Quantitative HER3 protein expression and PIK3CA mutation status in matched samples from primary and metastatic breast cancer tissues and correlation with time to recurrence**
Sperinde J, Lara J, Michaelson R, Sun X, Conte P, Guarneri V, Barbieri E, Ali S, Leitzel K, Weidler J, Lie Y, Cook J, Haddad M, Paquet A, Winslow J, Howitt J, Hurley L, Eisenberg M, Petropoulos C, Huang W, Lipton A. Monogram Biosciences/Integrated Oncology/LabCorp, South San Francisco, CA; Saint Barnabas Medical Center, Livingston, NJ; University of Modena, Modena, Italy; Penn State/Hershey Medical Center, Hershey, PA; Lebanon VA Medical Center, Lebanon, PA; Laboratory Corporation of America, Research Triangle Park, NC.

P2-10-17 **SET index predicts response to endocrine therapy rather than prognosis independently of other genomic signatures in a blinded validation study**
Karn T, Hatzis C, Symmans F, Pusztai L, Ruckhäberle E, Schmidt M, Müller V, Hanker L, Heinrich T, Holtrich U, Kaufmann M, Rody A. Goethe-University; Nuvera Biosciences; The University of Texas MD Anderson Cancer Center; Gutenberg-University Mainz; University Hospital Hamburg-Eppendorf; Saarland-University, Homburg.

P2-10-18 **Cell Cycle Profiling – risk score (C2P-RS) based on the specific activity of CDK1 and CDK2 predicts relapse in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy**
Kim SJ, Masuda N, Tsukamoto F, Inaji H, Akiyama F, Sonoo H, Kurebayashi J, Yoshidome K, Tsujimoto M, Takei H, Masuda S, Nakamura S, Noguchi S. Graduate School of Medicine, Osaka University, Suita, Osaka, Japan; National Hospital Organization Osaka National Hospital, Osaka, Japan; Osaka Koseinenkin Hospital, Osaka, Japan; Osaka Medical Center for Cancer & Cardiovascular Diseases, Osaka, Japan; The Cancer Institute of Japan Foundation for Cancer Research, Tokyo, Japan; Kawasaki Medical School, Kurashiki, Okayama, Japan; Osaka Police Hospital, Osaka, Japan; Saitama Cancer Center, Kita-Adachi, Saitama, Japan; Nihon University School of Medicine, Tokyo, Japan; Showa University School of Medicine, Tokyo, Japan.

P2-10-19 **Are the mitotic factors Mitotic Activity Index (MAI) and Phosphohistone 3 (PPH3) stronger prognostic proliferation factors than Ki67 in node-negative breast cancer?**
Klintman M, Strand C, Gudlaugsson E, Janssen E, Skaland I, Malmström P, Baak J, Fernö M. Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden; Stavanger University Hospital, Stavanger, Norway; Stavanger University Hospital and the Gade Institute, University of Bergen, Stavanger, Norway.

P2-10-20 A tumor DNA complexity index is an independent predictor of survival in a dataset of 1950 breast cancers; a METABRIC group study
Vollan HKM, Rueda OM, Børresen-Dale A-L, Aparicio S, Caldas C. Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, Norway; Oslo University Hospital, Oslo, Norway; Cambridge Research Institute, Cambridge, United Kingdom; University of Cambridge, United Kingdom; University of British Colombia, Vancouver, BC, Canada; British Colombia Cancer Research Center, Vancouver, BC, Canada; Cambridge Experimental Cancer Medicine Centre, Cambridge, United Kingdom; Addenbrooke's Hospital, Cambridge University Hospital, Cambridge, United Kingdom.

P2-10-21 Prognostic value of estrogen receptor status in women with synchronous or metachronous breast cancers
Huo D. University of Chicago, IL.

P2-10-22 Phosphorylation of Steroid Receptor Coactivator 3 (SRC3) at Ser543 is a novel independent prognostic marker in breast cancer
Palmieri C, Gojis O, Rudraraju B, Abdel-Fatah TMA, Moore D, Shaw J, Green A, Ellis IO, Coombes RC, Ali S. Imperial College London, United Kingdom; Nottingham University City Hospital, Nottingham, United Kingdom; University of Leicester, United Kingdom; Nottingham University Hospitals, City Hospital Campus, Nottingham, United Kingdom.

P2-10-23 Lymphovascular Invasion (LVI) and Overall Survival in Node-negative and Node-positive Breast Cancer Patients: A Meta-analysis
Sahebjam S, Diaz-Padilla I, Ocana A, Seruga B, Amir E. Princess Margaret Hospital; Institute of Oncology Ljubljana.

P2-10-24 Independent validation of Recurrence Online using 1,638 breast cancer microarray samples
Györffy B, Weltz B, Benke Z, Timar J, Sztupinszki Z, Schaefer R. Hungarian Academy of Sciences; Semmelweis University; Charité.

P2-10-25 Prognostic value of relative change in tumor marker CA 27.29 in early stage breast cancer – The SUCCESS trial
Hepp P, Tesch H, Forstbauer H, Rezai M, Beck T, Schrader I, Kleine-Tebbe A, Hucke J, Finas D, Soeling U, Zahm D-M, Weiss E, Beckmann MW, Janni W, Rack B. University Düsseldorf; Praxis Prof. Tesch Frankfurt; Gemeinschaftspraxis Dr. Forstbauer & Dr. Ziske Troisdorf; Luisenkrankenhaus Düsseldorf; Städtisches Klinikum Rosenheim; Henriettenstiftung Krankenhaus Hannover; DRK Kliniken Berlin Köpenick; Bethesda Krankenhaus Wuppertal; Universitätsklinikum Schleswig-Holstein, Campus Lübeck; Gemeinschaftspraxis Siehl & Söling; SRH Wald-Klinikum Gera; Klinikum Sindelfingen-Böblingen; Universitätsfrauenklinik Erlangen; Universitätsfrauenklinik Munich.

P2-10-26 Association between circulating tumor cells and molecular breast cancer subtypes
Gang N, Haibo W, Funian L, Chen L, Xiaoyi L, Xingang W, Zhidong L. Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong, China.

P2-10-27 No Discordant Receptor Status Results among 50 Paired Breast and Axillary Metastasis Core Biopsies when Pre-analytic Variation is Controlled
Miller DV, Rosenthall RE, Avent JM, Carter CC, Hansen J, Hammond MEH. Intermountain Healthcare, Salt Lake City, UT.

P2-10-28 The Prognostic Index, KiGE, Combining Proliferation, Histological Grade and Estrogen Receptor Status Challenges Gene Profiling –
A Study in 1,854 Chemo-Naïve Women with N0/N1 Primary Breast Cancer
Strand C, Bak M, Borgquist S, Chebil G, Falck A-K, Fjällskog M-L, Grabau D, Hedenfalk I, Jirström K, Klintman M, Malmtröm P, Olsson H, Rydén L, Stål O, Bendahl P-O, Fernö M. Lund University, Division of Oncology, Skåne University Hospital, Lund, Sweden; Odense University Hospital, Odense, Denmark; Mammography, Bergaliden, Helsingborg, Sweden; Helsingborg Hospital, Helsingborg, Sweden; Uppsala University Hospital, Uppsala, Sweden; Lund University, Skåne University Hospital, Lund, Sweden; Lund University, Division of Pathology, Lund, Sweden; Skåne University Hospital, Lund, Sweden; Linköping University, County Council of Östergötland, Linköping, Sweden; Lund University, Division of Surgery, Skåne University Hospital, Lund, Sweden.

P2-10-29 Time dependent breast cancer metastasis prediction using novel biological imaging, clinico-pathological and genomic data combined with Bayesian modeling to reduce over-fitting and improve on inter-cohort reproducibility
Sheeba I, Kelleher M, Lawler K, Festy F, Barber P, Shamill E, Gargi P, Weitsman G, Barrett J, Fruhwirth G, Huang L, Tullis I, Woodman N, Pinder S, Ofo E, Fernandes L, Beutler M, Ameer-Beg S, Holmberg L, Purushotham A, Fraternali F, Condeelis J, Hanby A, Gillett C, Ellis P, Vojnovic B, Coolen A, Ng T. Kings College London, Guy's Medical School Campus, London, England, United Kingdom; King's College London, Strand Campus, London, England, United Kingdom; Guy's and St Thomas Foundation Trust, London, England, United Kingdom; Gray Institute for Radiation Oncology & Biology, University of Oxford, England, United Kingdom; Leeds Institute of Molecular Medicine, Leeds, England, United Kingdom.

P2-10-30 Expression of lipid metabolism genes in contralateral unaffected breast associated with estrogen receptor status of breast cancer
Wang J, Scholtens D, Holko M, Ivancic D, Lee O, Hu H, Chatterton RT, Khan SA. Northwestern university, Chicago, IL.

P2-10-31 Correlation of quantitative p95HER2 and total HER2 levels with clinical outcomes in a combined analysis of two cohorts of trastuzumab-treated metastatic breast cancer patients
Duchnowska R, Sperinde J, Leitzel K, Szostakiewicz B, Paquet A, Ali SM, Jankowski T, Haddad M, Fuchs E-M, Arlukowicz-Czartoryska B, Winslow J, Singer C, Wysocki PJ, Lie Y, Horvat R, Foszczynska-Kloda M, Petropoulos C, Radecka B, Litwiniuk M, Debska S, Weidler J, Huang W, Biernat W, Köstler WJ, Jassem J, Lipton A. Military Institute of Medicine, Warsaw, Poland; Monogram Biosciences/Integrated Oncology/LabCorp, South San Francisco, CA; Penn State/Hershey Medical Center, Hershey, PA; Medical University of Gdansk, Poland; Lublin Oncology Center, Lublin, Poland; Medical University of Vienna, Austria; Bialystok Oncology Center, Bialystok, Poland; Greater Poland Cancer Center, Poznan, Poland; West Pomeranian Oncology Center, Szczecin, Poland; Opole Oncology Center, Opole, Poland; Poznan University of Medical Sciences, Poznan, Poland; Regional Cancer Center, Lódz, Poland.

P2-10-32 Sialyl Lewis^x and inflammatory mediators in breast cancer patients: biological correlations and prognostic value
Lee B-N, Arun BK, Cohen EN, Tin S, Gutierrez-Barrera AM, Miura T, Kiyokawa I, Alvarez RH, Valero V, Ueno NT, Cristofanilli M, Reuben JM. University of Texas MD Anderson Cancer Center, Houston, TX; Nitto Boseki Co., Ltd, Tokyo, Japan; Fox Chase Cancer Center, Philadelphia, PA.

P2-10-33 Mitotic Component of Grade Can Distinguish Breast Cancer Patients at Greatest Risk of Local Relapse
Done SJ, Miller NA, Wei Shi W, Pintilie M, McCready DR, Liu F-F, Fyles A. University Health Network, Toronto, ON, Canada; Princess Margaret Hospital, University Health Network, Toronto, ON, Canada; University of Toronto, ON, Canada.

P2-10-34 **Development and validation of ClinicoMolecular Triad Classification (CMTC), a platform for breast cancer (BC) prognostic and predictive gene signature portfolios**
Leong WL, Wang D-Y, Done S, McCready D. University Health Network, Toronto, ON, Canada.

P2-10-35 **The grade of accompanying DCIS in IDC as important prognostic factor**
Kim JY, Moon H-G, Han WS, Noh DY. Seoul National University Hospital, Breast Cancer Center, Seoul, Korea.

P2-10-36 **Analysis of biomarker expression and biological subtype in primary tumour, corresponding lymph node and distant metastasis with 5-year follow-up**
Falck A-K, Ferno M, Bendahl P-O, Chebil G, Olsson H, Rydén L. Clinical Sciences, Lund, Sweden.

P2-10-37 **Long-term prognosis of early breast cancer in a population-based cohort with a known *BRCA1/2* mutation status**
Nilsson MP, Werner Hartman L, Idvall I, Kristoffersson U, Olsson H, Johansson O, Borg Å, Loman N. Clinical Sciences, Lund University, Sweden; Lund University, Sweden; Landspitali University Hospital, Reykjavik, Iceland.

P2-10-38 **Prognostic factors uPA/PAI-1: measurement in core needle biopsies**
Vetter M, Landstorfer B, Lantzsch T, Buchmann J, Große R, Ruschke K, Holzhausen H-J, Thomssen C, Kantelhardt E-J. Martin-Luther University Halle-Wittenberg, Halle/Saale, Germany; St. Elisabeth & St. Barbara Hospital, Halle/Saale, Germany; Martha-Maria Hospital, Halle/Saale, Germany.

P2-10-39 **Does E-cadherin or N-cadherin or epithelial-mesenchymal transition have a probability of clinical implication of the prognostic marker in invasive ductal carcinoma?**
Lee J, Yang G, Paik SS, Chung MS. Hanyang University Medical Center, Seoul, Republic of Korea.

P2-10-40 **Correlation between expression of the prognostic marker Progranulin (GP88) with Oncotype Dx Recurrence Score in estrogen receptor positive breast tumors**
Serrero G, Koka M, Goicochea L, Tkaczuk KR, Fernandez KL, Logan LS, Tuttle K, Yue B, Ioffe OB. A&G Pharmaceutical Inc, Columbia, MD; University of Maryland Greenebaum Cancer Center, Baltimore, MD; Franklin Square Hospital, Baltimore, MD; Mercy Hospital, Baltimore, MD.

P2-10-41 **The prediction of invasion in ductal carcinoma in situ: developing prediction model and validation**
Lee SK, Kim M, Nam SJ, Lee JE, Yang J-H. Samsung Medical Center, Sungkyunkwan University School of Medicine; Konkuk University Medical Center.

P2-10-42 **Gene expression profiling to predict the risk of locoregional recurrence in breast cancer**
Drukker CA, Nijenhuis MV, Elias SG, Wesseling J, Russell NS, de Snoo F, van 't Veer LJ, Beitsch PD, Rutgers EJT. Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands; Agendia Inc., Amsterdam, Netherlands; University of California San Francisco, San Francisco; Dallas Surgical Group, Dallas.

P2-10-43 **The combination of immunohistochemistry for predicting *TP53* mutation is useful prognostic marker in breast cancer**
Watanabe G, Ishida T, Takahasi S, Ishioka C, Watanabe M, Ohuchi N. Tohoku Univ., Sendai, Miyagi, Japan.

Psychosocial, Quality of Life, and Educational Aspects: Survivorship Research

P2-11-01 **Effects of chemotherapy on the ovary: What you didn't know**
Barton DL, Thompson SL, Senn-Reeves JN, Satele DV, Frost M. Mayo Clinic, Rochester, MN.

P2-11-02 **Perception and practice of reproductive specialists towards fertility preservation of young breast cancer patients**
Shimizu C, Kato T, Tamura N, Asada Y, Hiroko B, Mizota Y, Yamamoto S, Fujiwara Y. National Cancer Center Hospital, Tokyo, Japan; Asada Lady's Clinic, Nagoya, Aichi, Japan; University of Tsukuba, Ibaragi, Japan; National Cancer Center, Tokyo, Japan.

P2-11-03 **Randomized, single blind trial comparing limited and intensive survivorship interventions following adjuvant therapy in a multiethnic cohort of breast cancer survivors**
Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brooks-Brafman L, Fuentes D, Tsai W-Y, Crew KD. Columbia Univeristy Medical Center, New York, NY; Mailman School of Public Health, New York, NY.

P2-11-04 **Chemotherapy Induces Neuroinflammation and Cognitive Deficits in Female Mice**
Jarrett BL, Lustberg MB, Hinzey A, Stuller KA, Shapiro CL, DeVries C. The Ohio State University Wexner Medical Center, Columbus, OH; The Ohio State University Comprehensive Cancer Center, Columbus, OH.

P2-11-05 **Work status and financial stability during treatment for early breast cancer: a pilot study of an ethnically diverse sample**
Eberle CE, Min S-H, Jung S, Ramirez J, Patil S, Gany F, Blinder VS. Memorial Sloan-Kettering Cancer Center, New York, NY.

P2-11-06 **Mortality among offspring of women diagnosed with breast cancer; a population based study**
Verkooijen HM, Ang X, Liu J, Czene K, Salim A, Hartman M. University Medical Center Utrecht, Netherlands; National University of Singapore, Singapore; Karolinska Institute, Stockholm, Sweden; National University Hospital, Singapore, Singapore.

P2-11-07 **Endothelial progenitor cells as novel markers of anthracycline induced cardiac injury**
Lustberg MB, Ruppert AS, Carothers S, Bingman A, McCarthy B, Raman S, Das M, Kanji S, Lu J, Das H, Cinar-Akakin H, Gurcan MN, Berger MJ, Wesolowski R, Olson EM, Ramaswamy B, Mrozek E, Layman RM, Binkley P, Shapiro CL. The OSU Breast Program at Stefanie Spielman Comprehensive Breast Center; OSU.

P2-11-08 **Feasibility of Enrollment into a Survivorship Care Plan Study at Initial Diagnosis**
Bulloch KJ, Irwin M, Chagpar A, Sanft T. Yale University, New Haven, CT.

P2-11-09 **Weight Change and Risk of Incident Diabetes after Breast Cancer**
Erickson KD, Patterson RE, Natarajan L, Lindsay SP, Heath D, Caan BJ. Moores UC San Diego Cancer Center, University of California, San Diego, La Jolla, CA; San Diego State University, San Diego, CA; Kaiser Permanente Northern California, Oakland, CA.

P2-11-10 **Prospective memory impairment in early breast cancer survivors: Finally homing in on the real deficit?**
Verma S, Collins B, Song X, Bedard M, Paquet L. The Ottawa Hospital Regional Cancer Centre; The Ottawa Hospital; Carleton University.

P2-11-11 **Patient Reported Outcomes after Breast Cancer Surgery and Adjuvant Therapy from a German Breast Cancer Centre**
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R. Institute for Health Care Research in Oncology, Koblenz, Germany; Catholic Clinical Centre Koblenz-Montabaur, Koblenz, Germany; Oncology Group Practice Koblenz, Germany.

P2-11-12 **Proactive approach to risk reduction and early detection of breast cancer related lymphedema**
Fu MR, Guth A, Kleinman R, Cartwright F, Haber J, Axelrod D. New York University, New York, NY; NYU Cancer Center, New York, NY.

P2-11-13 **The Effect of Positive Axillary Lymph Nodes on Symptoms, Physical Impairments, and Function**
Kesarwala AH, Pfalzer LA, O'Meara WP, Stout NL. National Cancer Institute, Bethesda, MD; University of Michigan - Flint, MI; Lahey Clinic, Burlington, MA; Walter Reed National Military Medical Center, Bethesda, MD.

P2-11-14 **Symptoms, Physical Impairments, and Function in Breast Cancer Patients with Negative Axillary Lymph Nodes**
Kesarwala AH, Pfalzer LA, O'Meara WP, Stout NL. National Cancer Institute, Bethesda, MD; University of Michigan - Flint, MI; Lahey Clinic, Burlington, MA; Walter Reed National Military Medical Center, Bethesda, MD.

P2-11-15 **Development of a web-based survey tool to assess change in breast cancer (BrCa) survivor knowledge after receipt of cancer treatment summary and survivorship care plan (SCP)**
Custer JL, Rocque GB, Wisinski KB, Jones NR, Donohue S, Koehn TM, Champeny TL, Terhaar AR, Chen KB, Peck KA, Tun MT, Wiegmann DA, Sesto ME, Tevaarwerk AJ. University of Wisconsin, Madison, WI.

P2-11-16 **Cardiac Morbidity After Adjuvant Chemotherapy (CT) for Early Breast Cancer in the Community Setting**
Patt D, Espirito J, Turnwald B, Denduluri N, Wang Y, Lina A, Hoverman R, Neubauer M, Bosserman L, Busby L, Brooks B, Cartwright T, Sitarik M, Schnadig I, Winter W, Garey J, Ginsburg-Arlen A, Bergstrom K, Beveridge R. Pathways Task Force, US Oncology Network, McKesson Specialty Health, Austin, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Arlington, VA; US Oncology Network, McKesson Specialty Health, The Woodlands, TX; Kansas City Cancer Center, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Overland Park, KS; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Rancho Cucamonga, CA; Rocky Mountain Cancer Centers, Pathways Task Force, US Oncology Network, McKesson Specialty Health, Boulder, CO; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Dallas, TX; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Ocala, FL; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Tualatin, OR; Pathways Task Force, US Oncology Network, McKesson Specialty Health, Portland, OR.

P2-11-17 **Pilot Study to Evaluate a Home-based Exercise and Weight Loss Intervention on Cardiopulmonary Fitness and Markers of Breast Cancer Risk in Postmenopausal Breast Cancer Survivors**
Burnett D, Klemp JR, Porter C, Schmitz KJ, Fabian CJ, Kluding P. University of Kansas Medical Center, Kansas City, KS; University of Kansas Hospital, Kansas City, KS; University of Pennsylvania, Philadelphia, PA.

Psychosocial, Quality of Life, and Educational Aspects: Quality of Life - Supportive Care

P2-12-01 **Prospective Evaluation of Joint Symptoms in Postmenopausal Women Initiating Aromatase Inhibitors for Early Stage Breast Cancer**
Crew KD, Chehayeb Makarem D, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brafman L, Fuentes D, Hershman DL. Columbia University Medical Center, New York, NY.

P2-12-02 **Withdrawn**

P2-12-03 **A pilot study evaluating the benefits and feasibility of an exercise program for breast cancer patients receiving adjuvant chemotherapy**
Petrella TM, Laredo S, Oh P, Marzolini S, Warner E, Dent R, Verma S, Eisen A, Pritchard K, Trudeau M, Zhang L, Bjarnason G. Odette Cancer Centre, Toronto, ON, Canada; Women's College Hospital, Toronto, ON, Canada; Toronto Rehabilitation Institute, Toronto, ON, Canada; Macrostat Inc, Toronto, ON, Canada.

P2-12-04 **Music Therapy Reduces Radiotherapy-Induced Fatigue in Patients with Breast or Gynecological Cancer: A Randomized Trial**
Freitas NMA, Silva TRMA, Freitas-Junior R, Paula Junior W, Silva DJ, Machado GDP, Ribeiro MKA, Carneiro JP. Araujo Jorge Hospital/ACCG, Goiania, Goias, Brazil; Federal University of Goias, Goiania, Goias, Brazil; Instituto Integrado de Neurociencias/IINEURO, Goiania, Goias, Brazil.

P2-12-05 **Limited Absorption of Low Dose 10 µg Intravaginal 17-β Estradiol (Vagifem®) in Postmenopausal Women with Breast Cancer on Aromatase Inhibitors**
Goldfarb SB, Dickler M, Dnistrian A, Patil S, Dunn L, Chang K, Berkowitz A, Tucker N, Carter J, Barakat R, Hudis C, Castiel M. Memorial Sloan-Kettering Cancer Center, New York, NY.

P2-12-06 **Ultra-low dose vaginal estriol and Lactobacillus acidophilus (Gynoflor®) in early breast cancer survivors on aromatase inhibitors: Pharmacokinetic, efficacy and safety results from a phase I study**
Neven P, Donders G, Mögele M, Lintermans A, Bellen G, Ortmann O, Buchholz S. University Hospital Gasthuisberg Leuven, Belgium; Femicare vzw, Clinical Research for Women, Tienen, Belgium; Universitätsklinikum Regensburg, Germany.

P2-12-07 **A review of clinical endpoints and use of quality-of-life outcomes in phase III metastatic breast cancer clinical trials**
Tatla R, Landaverde D, Victor C, Miles D, Verma S. University of Toronto, ON, Canada; Sunnybrook Odette Cancer Center, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, ON, Canada; Mount Vernon Cancer Centre, United Kingdom.

P2-12-08 **Sorafenib for treatment of breast-cancer related lymphedema**
Zambetti M, Guidetti A, Carlo-Stella C, De Benedictis E, Tessari A, Balzarini A, Caraceni A, Gianni L, Gianni AM. IRCCS Ospedale San Raffaele, Milan, Italy; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy; Humanitas Cancer Center, IRCCS Istituto Clinico Humanitas, Rozzano, Italy.

P2-12-09 **A randomized controlled trial of support group intervention after breast cancer treatment: Results on sick leave, health care utilization and health economy**
Granstam Björneklett H, Rosenblad A, Lindemalm C, Ojutkangas M-L, Letocha H, Strang P, Bergkvist L. Centre for Clinical Research, Västerås, Västmanland, Sweden; Cancer Center Karolinska, Karolinska, Stockhoöm, Sweden; Karolinska Institutet, Stockholm, Sweden.

P2-12-10 **Psycho-spiritual therapy for improving the quality of life and spiritual well-being of women with breast cancer**
Loghmani A, Jafari N, Zamani A, Farajzadegan Z, Bahrami F, Emami H. Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran; University of Isfahan, Islamic Republic of Iran.

P2-12-11 **Use of the DigniCap™ System To Prevent Hair Loss in Women Receiving Chemotherapy (CTX) for Stage I Breast Cancer (BC)**
Rugo HS, Serrurier KM, Melisko M, Glencer A, Hwang J, D'Agostino, Jr. R, Hutchens S, Esserman LJ, Melin S. University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, CA; Wake Forest Baptist Health Medical Center, Winston-Salem, NC.

P2-12-12 **Efficacy and safety of scalp cooling (SC) treatment for alopecia prevention in women receiving chemotherapy (CTX) for breast cancer (BC)**
Serrurier KM, Melisko ME, Glencer A, Esserman LJ, Rugo HS. UCSF Helen Diller Comprehensive Cancer Center.

P2-12-13 **Results of randomised controlled phase II study (KBCSG02 trial) of the efficiency of palonosetron, aprepitant, and dexamethasone for day 1 with or without dexamethasone on days 2 and 3**
Kosaka Y, Sengoku N, Kikuchi M, Nishimiya H, Enomoto T, Kuranami M, Watanabe M. Kitasato University School of Medicine, Sagamihara, Japan.

P2-12-14 Use of the MD Anderson Symptom Inventory To Screen for Depression in Breast Cancer
Kvale EA, Azuero CB, Azuero A, Fisch M, Ritchie C. Birmingham VA Medical Center, Birmingham, AL; University of Alabama at Birmingham, AL; University of Alabama, Tuscaloosa, AL; MD Anderson Cancer Center, Houston, TX; University of California, San Francisco, CA.

P2-12-15 Understanding the complex non face-to-face interventions delivered by the clinical nurse specialists in metastatic breast cancer
Warren M, Mackie D, Leary A. Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; Royal Marsden NHS Foundation Trust, London, United Kingdom; Independent Healthcare Consultant and Research Analyst.

Treatment: Endocrine Therapy - Adjuvant

P2-13-01 Impact of Body Mass Index (BMI) on the efficacy of aromatase inhibitors to suppress estradiol serum levels in postmenopausal patients with early breast cancer: a prospective proof of principle
Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P. Medical University of Vienna, Austria; Applied Cancer Research – Institution for Translational Research Vienna (ACR-ITR VIEnna)/CEADDP, Austria; Universityhospital of Giessen and Marburg GmbH, Germany.

P2-13-02 Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27
Higgins MJ, Chapman J-AW, Ingle JN, Sledge G, Budd GT, Ellis MJ, Pritchard KI, Clemons M, Badovinac Crnjevic T, Han L, Gelmon K, Rabaglio M, Elliott C, Shepherd LE, Goss PE. Massachusetts General Hospital, Boston, MA; NCIC Clinical Trials Group, Queen's University, Kingston, ON, Canada; Mayo Clinic, Rochester, MN; Ottawa Hospital and Faculty of Medicine, University of Ottawa, ON, Canada; Vancouver Centre, BCCA, Vancouver, BC, Canada; Sunnybrook Odette Cancer Centre, Toronto, ON, Cayman Islands; Indiana University, Indianapolis, IN; Cleveland Clinic, Cleveland, OH; Washington University in St. Louis, MO; University Hospital Berne, Switzerland.

P2-13-03 Prevalence of non-metastatic breast cancer patients treated with aromatase inhibitors in the United States
Liede A, Hernandez RK, Pirolli M, Quigley J, Quach D. Amgen Inc., Thousand Oaks, CA; IMS Health, Plymouth Meeting, PA.

P2-13-04 Superior efficacy of anastrozole to tamoxifen as adjuvant therapy for postmenopausal patients with hormone-responsive breast cancer. Efficacy results of long-term follow-up data from N-SAS BC 03 trial
Imoto S, Osumi S, Aogi K, Hozumi Y, Mukai H, Iwata H, Yokota I, Yamaguchi T, Ohashi Y, Watanabe T, Takatsuka Y, Aihara T. School of Medicine, Kyorin University, Tokyo, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan; Jichi Medical University, Tochigi, Japan; National Cancer Center Hospital East, Chiba, Japan; Aichi Cancer Center Hospital, Aichi, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Miyagi, Japan; Hamamatsu Oncology Center, Shizuoka, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan.

P2-13-05 A pilot prospective study of adherence to aromatase inhibitor adjuvant therapy in patients with stage 1-3 breast carcinoma
Heiss B, Thompson J, Nightingale G, Tait N, Kesmodel S, Bellavance E, Chumsri S, Bao T, Goloubeva O, Feigenberg S, Tkaczuk K. Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD; Thomas Jefferson University, Philadelphia, PA.

P2-13-06 Effect of letrozole on bone and joints in collagen-induced arthritis in mice
Lintermans A, Verhaeghe J, Van Bree R, Vanderschueren D, Vanderhaegen J, Braem K, Lories R, Neven P. University Hospitals Leuven, KU Leuven, Belgium; KU Leuven, Leuven, Belgium; University Hospitals Leuven, Belgium.

P2-13-07 Long-term follow-up data of the side effect profile of anastrozole compared with tamoxifen in Japanese women: findings from N-SAS BC03 trial
Iwata H, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Yokota I, Yamaguchi T, Ohashi Y, Watanabe T, Takatsuka Y, Aihara T. Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; Jichi Medical University, Tochigi, Japan; School of Medicine, Kyorin University, Tokyo, Japan; National Cancer Center Hospital East, Chiba, Japan; School of Public Health, University of Tokyo, Tokyo, Japan; Tohoku University School of Medicine, Sendai, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan; Kansai Rosai Hospital, Hyogo, Japan; Aihara Hospital, Osaka, Japan.

P2-13-08 Comparison of Compliance to Anti Estrogen Therapy in Patients with Early Breast Cancer followed at Tertiary Centers versus Through Family Physicians and Primary Surgeons: A Practice Review
Alkhayyat SS, Younus J, Mirza FN, Stitt L. The Scarborough Hospital, Scarborough, ON, Canada; The University of Western Ontario, London, ON, Canada; Harvard University, Cambridge, MA.

P2-13-09 Pharmacological impact of endoxifen in a laboratory simulation of tamoxifen therapy in postmenopausal breast cancer patients
Maximov PY, McDaniel RE, Bhatta P, Brauch H, Jordan VC. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.

P2-13-10 Prospective randomized and multicentric evaluation of cognition in menopausal breast cancer patients receiving adjuvant hormonotherapy: a phase III study (Preliminary results)
Vanlemmens L, Delbeuck X, Servent V, Mailliez A, Vanlemmens L, Lefeuvre-Plesse C, Kerbrat P, Petit T, Fournier C, Vendel Y, Clisant S, Bonneterre J, Pasquier F, Le Rhun E. Centre Mémoire de Ressource et de Recherche - CHRU Lille, Lille, France; Centre Oscar Lambret, Université Lille Nord de France, Lille, France; Centre Eugène Marquis, Rennes, France; Centre Paul Strauss, Strasbourg, France; Centre Oscar Lambret, Lille, France; CHRU, Lille, France.

Treatment: Endocrine Therapy - Advanced Disease

P2-14-01 Fulvestrant vs exemestane for treatment of metastatic breast cancer in patients with acquired resistance to non-steroidal aromatase inhibitors – a meta-analysis of EFECT and SoFEA (CRUKE/03/021 & CRUK/09/007)
Johnston SRD, Chia S, Kilburn LS, Gradishar WJ, Cameron D, Dodwell D, Ellis P, Howell A, Im Y-H, Coombes G, Piccart M, Dowsett M, Bliss J, On behalf of the SoFEA and EFECT Investigators. The Royal Marsden Hospital NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Christie Hospital NHS Trust, Manchester, United Kingdom; Edinburgh Cancer Research Centre, University of Edinburgh and NHS Lothian, Edinburgh, United Kingdom; Leeds Teaching Hospitals NHS Trust, St. James's University Hospital, Leeds, United Kingdom; Guy's and St Thomas's NHS Foundation Trust, London, United Kingdom; Samsung Medical Center, Seoul, Korea; Jules Bordet Institute, Brussels, Belgium; The Royal Marsden NHS Foundation Trust, London, United Kingdom.

P2-14-02 **Preclinical Evaluation of Enzalutamide in Breast Cancer Models**
Cochrane DR, Bernales S, Jacobsen BM, D'Amato NC, Guerrero J, Gómez F, Protter AA, Elias AD, Richer JK. University of Colorado Anschutz Medical Campus, Aurora, CO; Medivation Inc., San Francisco, CA; Fundación Ciencia & Vida, Santiago, Chile.

P2-14-03 **"Ethinylestradiol" is beneficial for postmenopausal advanced breast cancer patients heavily pre-treated with endocrine agents**
Iwase H, Yamamoto Y, Murakami K-I, Yamamoto-Ibusuki M, Tomita S, Omoto Y. Kumamoto University, Kumamoto, Japan.

P2-14-04 **A Phase Ib Dose Escalation Trial of RO4929097 (A γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer**
Means-Powell JA, Minton SE, Mayer IA, Abramson VG, Ismail-Khan R, Arteaga CL, Ayers DA, Sanders MS, Lush RM, Miele L. Vanderbilt-Ingram Cancer Center, Nashville, TN; Moffit Cancer Center, Tampa, FL; University of Mississippi Health Care Cancer Institute, Jackson, MS.

P2-14-05 **A phase II study of combined fulvestrant and RAD001 (everolimus) in metastatic estrogen receptor (ER) positive breast cancer after aromatase inhibitor (AI) failure**
Croley JJ, Black EP, Romond E, Chambers M, Waynick S, Slone S, Waynick C, Stevens M, Weiss HL, Massarweh SA. University of Kentucky and Markey Cancer Center, Lexington, KY.

P2-14-06 **A phase II trial of low dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to an aromatase inhibitor**
Howell SJ, Seif MW, Armstrong AC, Cope J, Wilson G, Welch RS, Misra V, Ryder D, Blowers E, Palmieri C, Wardley AM. University of Manchester, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; Imperial College, London, United Kingdom.

P2-14-07 **Evaluation of Aromatase Inhibitor failure and total healthcare expenditures among post-menopausal women with metastatic ER+/HER2- breast cancer in the US**
Namjoshi M, Landsman-Blumberg P, Thomson E, Chu BC. Novartis Pharmaceuticals Corporation, East Hanover, NJ; Thomson Reuters, Washington, DC.

P2-14-08 **The Pilot Trial of Intermittent Exemestane Therapy for Metastatic Breast Cancer**
Luu T, Frankel PH, Somlo G, Wong C, Leong L, Mortimer JE, Hurria A, Koczywas M, Chao J, Chow W, Chung C, Chen S. City of Hope, Duarte, CA; Angeles Clinic & Research Institute, Santa Monica, CA.

Treatment: Patient Resources

P2-15-01 **An efficient resource to accelerate research into the cause and prevention of breast cancer: the Love/Avon Army of Women**
Love SM. Dr. Susan Love Research Foundation, Santa Monica, CA.

P2-15-02 **The Efficacy of Recruitment and Retention Strategies for Research Subjects in an Early Phase Investigator-Initiated Breast Cancer Trial**
Reichow J, Higgins D, Parker S, Childs J, Disis ML, Salazar LG. University of Washington, Seattle, WA.

Treatment: Tissue and Data Banks

P2-16-01 **Prospective Breast Cancer Quality Evaluation Application Developed for Native Android Tablet and Web Browser for Improving Mutltidisciplinary Breast Cancer Care**
Grobmyer SR, Raum N, Sposato V. University of Florida, Gainesville, FL; University of Florida, Gaineville, FL.

P2-16-02 **A web-based data management system for a multicenter international breast cancer oriented blood, tissue, and data biobank**
Margossian AL, Saadjian H, Mira A, Contreras A, Rimawi MF, Margossian ML, Scheurer M, Osborne K, Gutierrez C. Breast Center, Buenos Aires, Argentina; Dan Duncan Cancer Center/Smith Breast Center, Baylor College of Medicine, Houston, TX.

P2-16-03 **Creation of a 'state-of-the-art' breast cancer data and biobank in Argentina**
Margossian AL, Gutierrez C, Saadjian H, May M, Ohanessian R, Bacigalupo S, Baravalle S, Margossian J, Osborne KC, Scheurer ME. Breast Center, Buenos Aires, Argentina; Dan Duncan Cancer Center/Smith Breast Center, Baylor College of Medicine, Houston, TX.

P2-16-04 **Attitudes of metastatic breast cancer patients towards research biopsies**
Seah DS, Scott SM, Najita J, Openshaw T, Krag KJ, Frank E, Sohl J, Stadler ZK, Garrett M, Winer EP, Come S, Lin NU. Dana-Farber Cancer Institute, Boston, MA; Beth Isreal Deaconness Medical Center, Boston, MA; Cancer Care of Maine, Brewer, ME; Mass General North Shore Cancer Center, Danvers, MA; Memorial Sloan-Kettering Cancer Center, New York, NY.

9:00 am–9:30 am
PLENARY LECTURE 2
Exhibit Hall D

Estrogen Receptor Cistrome: Implications for Breast Cancer
Jason S. Carroll, PhD
Cancer Research UK, University of Cambridge
Cambridge, UNITED KINGDOM

9:30 am–11:30 am
GENERAL SESSION 3
Exhibit Hall D

Moderator: Sandra M. Swain, MD
Washington Hospital Center
Washington, DC

9:30 **S3-1. Neoadjuvant chemotherapy in the very young 35 years of age or younger**
Loibl S, Jackisch C, Gade S, Untch M, Paepke S, Kuemmel S, Schneeweiss A, Jackisch C, Huober J, Hilfrich J, Hanusch C, Gerber B, Eidtmann H, Denkert C, Costa S-D, Blohmer J-U, Nekljudova V, Mehta K, von Minckwitz G. German Breast Group, Neu-Isenburg; Klinikum Offenbach; Helios Kliniken Berlin; University Muenchen; Kliniken Essen Mitte; University Heidelberg; Uni Duesseldorf; Eilenriedeklinik Duesseldorf; Rotkreuzklinikum Muenchen; University Rostock; University Kiel; Charite Berlin; University Magdeburg; Sankt Gertrauden Berlin.

9:45 **S3-2. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: The CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)**
Aebi S, Gelber S, Lang I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas EP, Geyer Jr. CE, Maibach R, Gelber RD, Wolmark N, Wapnir I. International Breast Cancer Study Group, Bern, Switzerland; National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; Breast International Group, Brussels, Belgium.

10:00 S3-3. The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)
Cameron D, Barrett-Lee P, Canney P, Banerji J, Bartlett J, Bloomfield D, Bowden S, Brunt M, Earl H, Ellis P, Fletcher M, Morden JP, Robinson A, Sergenson N, Stein R, Velikova G, Verrill M, Wardley A, Coleman R, Bliss JM. Edinburgh Cancer Research Centre, University of Edinburgh, United Kingdom; Velindre NHS Trust Cancer Centre, Cardiff, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; The Institute of Cancer Research, Sutton, United Kingdom; Ontario Institute for Cancer Research, Toronto, Canada; Brighton & Sussex University Hospitals, Brighton, United Kingdom; University of Birmingham, United Kingdom; University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom; University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom; Guys Hospital & King College, London, United Kingdom; Leeds Institute of Molecular Medicine, Leeds, United Kingdom; Southend University Hospital, Southend, United Kingdom; Information Services Division NHS National Services Scotland, Edinburgh, United Kingdom; UCL Hospitals, London, United Kingdom; Northern Centre For Cancer Care, Newcastle upon Tyne, United Kingdom; The Christie Hospital, Manchester, United Kingdom; Weston Park Hospital, Sheffield, United Kingdom.

10:15 S3-4. Ten year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C)) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with ≥ 4 positive lymph nodes
Moebus V, Schneeweiss A, du Bois A, Lueck H-J, Eustermann H, Kuhn W, Kurbacher C, Nitz U, Kreienberg R, Jackisch C, Huober J, Thomssen C, Untch M. Klinikum Frankfurt Höchst, Frankfurt, Germany; University of Heidelberg, Germany; Klinikum Essen Mitte, Essen, Germany; Gynäkologisch-Onkologische Praxis, Hannover, Germany; WiSP Research Institute, Langenfeld, Germany; University of Bonn, Germany; Medizinisches Zentrum Bonn-Friedensplatz, Bonn, Germany; Ev. Krankenhaus Bethesda, Mönchengladbach, Germany; University of Ulm, Germany; Klinikum Offenbach, Offenbach, Germany; University of Duesseldorf, Germany; University of Halle, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany.

10:30 S3-5. Myelodysplatic syndrome and/or acute myelogenous leukemia (MDS and/or AML) after a breast cancer diagnosis: the National Comprehensive Cancer Network (NCCN) experience
Karp JE, Blackford A, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Hughes ME, Weeks JC, Wolff AC. Johns Hopkins Kimmel Cancer Center; University of California San Francisco; Massachusetts General Hospital; Fox Chase Cancer Center; Washington University School of Medicine; University of Utah School of Medicine; Dana Farber Cancer Institute.

10:45 S3-6. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease
Balko JM, Wang K, Sanders ME, Kuba MG, Pinto JA, Doimi F, Gomez H, Palmer G, Cronin MT, Miller VA, Yelensky R, Stephens PJ, Arteaga CL. Vanderbilt University, Nashville, TN; Foundation Medicine, Cambridge, MA; Oncosalud, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.

11:00 S3-7. Treatment with histone deacetylase inhibitors creates 'BRCAness' and sensitizes human triple negative breast cancer cells to PARP inhibitors and cisplatin
Bhalla KN, Rao R, Sharma P, Das Gupta S, Chauhan L, Stecklein S, Fiskus S. University of Kansas Cancer Center, Kansas City, KS.

11:15 S3-8. Identification of novel synthetic-lethal targets for MYC-driven triple-negative breast cancer
Goga A, Samson S, Horiuchi D. UCSF, San Francisco, CA.

11:30 am–12:00 pm
AACR OUTSTANDING INVESTIGATOR AWARD FOR BREAST CANCER RESEARCH, FUNDED BY SUSAN G. KOMEN FOR THE CURE ®
Exhibit Hall D

Breast Tumor Evolution: Drivers and Clinical Relevance
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

12:00 pm–1:35 pm
LUNCH

12:30 pm–1:35 pm
CASE DISCUSSION 1
Ballroom A

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists:

Elisabeth Burgess
Breast Cancer Aotearoa Coalition
Auckland, NEW ZEALAND

Michael Gnant, MD
Medical University of Vienna
Vienna, AUSTRIA

Minetta Liu, MD
Mayo Clinic
Rochester, MN

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Richard Zellars, MD
Johns Hopkins University School of Medicine
Baltimore, MD

12:30 pm–1:35 pm
BASIC SCIENCE FORUM
Ballroom B

Epigenetics in Breast Cancer
Moderator: Nancy E. Davidson, MD
University of Pittsburgh Cancer Institute,
Pittsburgh, PA

Estrogen-mediated epigenetic gene silencing in luminal cancers
Tim Hui-Ming Huang, PhD
UT Health Science Center San Antonio
San Antonio, TX

Translational implications of epigenetic gene regulation
Stephen B. Baylin, MD
Johns Hopkins University School of Medicine
Baltimore, MD

1:45 pm–3:15 pm
MINI-SYMPOSIUM 2
Exhibit Hall D

Breast Density: Mechanisms and Clinical Implications
Moderator: Melissa Bondy, PhD
Baylor College of Medicine
Houston, TX

Genetics and epidemiology
Celine M. Vachon, PhD
Mayo Clinic College of Medicine
Rochester, MN

Clinical
Norman Boyd, MD, DSC
Ontario Cancer Institute
Toronto, CANADA

Biological basis of breast density and cancer risk
Thea D. Tlsty, PhD
University of California, San Francisco
San Francisco, CA

3:15 pm–5:00 pm
GENERAL SESSION 4
Exhibit Hall D

Moderator: Matthew Goetz, MD
Mayo Clinic College of Medicine
Rochester, MN

3:15 **S4-1. The UK START (Standardisation of Breast Radiotherapy) Trials: 10-Year follow-up results**
Haviland JS, Agrawal R, Aird E, Barrett J, Barrett-Lee P, Brown J, Dewar J, Dobbs J, Hopwood P, Hoskin P, Lawton P, Magee B, Mills J, Morgan D, Owen R, Simmons S, Sydenham M, Venables K, Bliss JM, Yarnold JR, on behalf of the START Trialists. The Institute of Cancer Research, Sutton, United Kingdom; Shrewsbury and Telford Hospital NHS Trust, United Kingdom; Mount Vernon Hospital, Northwood, United Kingdom; Royal Berkshire NHS Foundation Trust, Reading, United Kingdom; Velindre Hospital NHS Trust, Cardiff, United Kingdom; previously University of Bristol, now Eli Lilly & Company, United Kingdom; formerly Ninewells Hospital, Dundee, United Kingdom; formerly Guys and St Thomas' NHS Trust, London, United Kingdom; Nottingham City Hospital, United Kingdom; formerly The Christie NHS Foundation Trust, Manchester, United Kingdom; formerly Nottingham University Hospital NHS Trust, United Kingdom; formerly Cheltenham General Hospital, United Kingdom; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.

3:30 **S4-2. Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial- updated analysis of local recurrence and first analysis of survival**
Vaidya JS, Wenz F, Bulsara M, Joseph D, Tobias JS, Keshtgar M, Flyger H, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sutterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg H, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M. University College London, London, United Kingdom; University Medical Centre Mannheim, University of Heidelberg, Heidelberg, Germany; University of Notre Dame, Fremantle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; University College Hospital, London, United Kingdom; Royal Free Hospital, London, United Kingdom; University of Copenhagen, Copenhagen, Denmark; Centro di Riferimento Oncologia, Aviano, Italy; University of California, San Francisco, CA; University of Western Australia, Perth, WA, Australia; Red Cross Hospital, Munich, Germany; Ninewells Hospital, Dundee, United Kingdom; Technical University of Munich, Munich, Germany; University College London Hospitals, London, United Kingdom; National Cancer Research Institute and Independent Cancer Patient's, Voice, United Kingdom; Moffit Cancer Centre , Tampa, FL.

3:45 **S4-3. The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients**
Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, Dietze O, Weber KE, Petry C, Kronenwett R, Rudas M, Knauer M, Gnant M, Filipits M. Medical University Vienna, Austria; Sividon Diagnostics GmbH, Cologne, Germany; Paracelsus Private Medical University, Salzburg, Austria; Sisters of Charity Hospital, Linz, Austria.

4:00 **S4-4. Independent validation of Genomic Grade in the BIG 1-98 study**
Sotiriou C, Ignatiadis M, Desmedt C, Azim Jr. HA, Veys I, Larsimont D, Lyng M, Viale G, Leyland-Jones B, Ditzel H, Giobbie-Hurder A, Regan M, Piccart M, Michiels S. Universite Libre de Bruxelles; Institut Jules Bordet; University of Southern Denmark; University of Milan; Edith Sanford Research; Harvard Medical School.

4:15 **S4-5. Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial**
Denkert C. Blohmer JU, Müller BM, Eidtmann H, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Prinzler J, Rüdiger T, Budczies J, Erbstößer E, Loibl S, von Minckwitz G. Charite University Hospital, Berlin, Germany; Sankt Gertrauden Krankenhaus, Berlin, Germany; Christian-Albrechts Universität zu Kiel, Kiel, Germany; Rotkreuzklinikum, München, Germany; Universitätsfrauenklinik Rostock, Germany; Bethanien Krankenhaus, Frankfurt, Germany; Eilenriede Klinik, Hannover, Germany; University of Düsseldorf, Germany; Universitäts Frauenklinik, Tübingen, Germany; Kliniken Essen Mitte, Essen, Germany; Klinikum Offenbach, Offenbach, Germany; Klinikum Karlsruhe, Karlsruhe, Germany; Klinikum St. Salvator, Halberstadt, Germany; German Breast Group, Neu-Isenburg, Germany.

4:30 **S4-6. An international Ki67 reproducibility study**
Nielsen TO, Polley M-YC, Leung SCY, Mastropasqua MG, Zabaglo LA, Bartlett JMS, Viale G, McShane LM, Hayes DF, Dowsett M, on behalf of the International Ki67 in Breast Cancer Working Group of the BIG-NABCG collaboration. University of British Columbia, Vancouver, BC, Canada; National Cancer Institute, Bethesda, MD; European Institute of Oncology, Milan, Italy; The Institute of Cancer Research, London, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Royal Marsden Hospital, London, United Kingdom; Breast International Group-North American Breast Cancer Group Collaboration.

4:45 **S4-7. Discussion**
W. Fraser Symmans, MD, MD Anderson Cancer Center, Houston, TX

5:00 pm–7:00 pm
POSTER DISCUSSION 5: CLINICAL SEQUENCING
Ballroom A

Viewing 5:00 pm
Discussion 5:15 pm

Charles Perou, PhD, Chair
University of North Carolina
Chapel Hill, NC

Katherine Hoadley, PhD, Discussant
University of North Carolina
Chapel Hill, NC
and
Christine Desmedt, PhD, Discussant
Jules Bordet Institute
Bruxelles, BELGIUM

PD05-01 **Next generation genomic sequencing (NGS) identifies molecular targets in inflammatory breast cancer (IBC)**
Cristofanilli M, Alpaugh KR, Ross J, Binghman C, Wu H, Stephens P, Lipson D, Palmer G. Fox Chase Cancer Center, Philadelphia, PA; Foundation Medicine, Cambridge, MA.

PD05-02 **Novel mutations in lobular carcinoma in situ (LCIS) as uncovered by targeted parallel sequencing**
De Brot M, Andrade VP, Morrogh M, Berger MF, Won HH, Koslow Mautner S, Qin L-X, Giri DD, Olvera N, Sakr RA, King TA. Memorial Sloan-Kettering Cancer Center, New York, NY.

PD05-03 **What is the appropriate sample (s) on which to perform sequencing for mutational analysis to guide the selection of targeted therapy?**
Alpaugh RK, Bingham C, Fittipaldi P, Banzi M, Palmer G, Cristofanilli M. Fox Chase Cancer Center, Philadelphia, PA; Silicon Biosystems, Spa, Bologna, Italy; Foundation Medicine, Cambridge, MA.

PD05-04 **Targeted resequencing in oncogenetics : developing a new approach for molecular diagnostics**
Sevenet N, Lafon D, Dupiot-Chiron J, Hubert C, Jones N, Debled M, Tunon de Lara C, Longy M, Bonnet F. Institut Bergonie, Bordeaux, France; Centre de Génomique Foncionnelle de Bordeaux, Bordeaux, France; Institut Bergonie & Universite Bordeaux Segalen, Bordeaux, France.

PD05-05 **RNA-seq identifies unique transcriptomic changes after brief exposure to preoperative nab-paclitaxel (N), bevacizumab (B) or trastuzumab (T) and reveals down-regulation of TGF-β signaling associated with response to bevacizumab**
Varadan V, Kamalakaran S, Janevski A, Banerjee N, Lezon-Geyda K, Miskimen K, Bossuyt V, Abu-Khalaf M, Sikov W, Dimitrova N, Harris LN. Philips Research North America, Briarcliff Manor, NY; Yale University School of Medicine, New Haven, CT; Yale Comprehensive Cancer Center, New Haven, CT; Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, CT; Warren Alpert Medical School of Brown University, New Haven, CT; Seidman Cancer Center, Cleveland, OH.

PD05-06 **Next-generation RNA-sequencing of triple negative breast cancer compared to donated microdissected normal epithelium and adjacent normal tissues**
Radovich M, Atale R, Clare SE, Sledge GW, Schneider BP. Indiana University School of Medicine, Indianapolis, IN.

PD05-07 **Detection of fusion transcripts among 100 breast cancer samples by next generation sequencing**
Kim J, Han W, Moon H-G, Ahn SK, In Y-H, Kim S, Lee H-S, Lee JW, Kim JY, Kim T, Kim MK, Noh D-Y. Seoul National University Hospital, Seoul, Korea; Cancer Research institute, Seoul National University, Seoul, Korea; i-Pharm (Information Center for Bio-pharmacological Network) IBBI (Integrated Bioscience and Biotechnology Institute) Advanced Institute of Convergence Technology, Seoul National University, Seoul, Korea; Seoul National University, Seoul, Korea; Macrogen Inc., Seoul, Korea.

PD05-08 **Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification**
Ng CKY, Gauthier A, Mackay A, Lambros MBK, Rodrigues DN, Arnoud L, Lacroix-Triki M, Penault-Llorca F, Baranzelli MC, Sastre-Garau X, Lord CJ, Zvelebil M, Mitsopoulos C, Ashworth A, Natrajan R, Weigelt B, Delattre O, Cottu P, Reis-Filho JS, Vincent-Salomon A. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France.

PD05-09 **Whole-genome progression of breast cancer from early neoplasia to invasive carcinoma**
West RB, Kashef-Haghighi D, Newburger D, Weng Z, Brunner A, Salari R, Guo X, Troxell M, Zhu S, Varma S, Sidow A, Batzoglou S. Stanford University, Stanford, CA; Oregon Health & Science University, Portland, OR.

5:00 pm–7:00 pm
POSTER DISCUSSION 6: KI67
Ballroom B

Viewing 5:00 pm
Discussion 5:15 pm

Peter Ravdin, MD, Chair
UT Health Science Center
San Antonio, TX

Rinat Yerushalmi, MD, Discussant
Davidoff Center
Petach Tikva, ISRAEL
and
Allen M. Gown, MD, Discussant
PhenoPath Labs PLLC
Seattle, WA

PD06-01 **Automated computational Ki67 scoring in the GeparTrio breast cancer study cohort**
Klauschen F, Wienert S, Blohmer J-U, Mueller BM, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, Fehm T, Barinoff J, Jackisch C, Erbstoesser E, Loibl S, Denkert C, von Minckwitz G. Charite Universitaetsmedizin Berlin, Berlin, Germany; Sankt Getrauden Hospital, Berlin, Germany; University of Munich, Munich, Germany; Klinikum Suedstadt Rostock, Rostock, Germany; Onkologisches Zentrum am Bethanien-Kankenhaus, Frankfurt, Germany; Ellenriede Hospital, Hannover, Germany; University Duesseldorf, Germany; University of Tuebingen, Germany; Kliniken Essen Mitte, Essen, Germany; Kliniken Offenbach, Offenbach, Germany; Salvator Hospital, Germany; German Breast Group, Neu-Isenburg, Germany.

PD06-02 **Standardized assessment of Ki-67 using virtual slides and automated analyzer for breast cancer patients: Comparison of automated and central/local pathology assessment**
Mizuno Y, Yamada J, Abe H, Natori T, Sato K. Tokyo-West Tokushukai Hospital, Tokyo, Japan; SRL, Inc., Tokyo, Japan.

PD06-03 **Development of a highly reproducible clinical test for Ki67 using AQUA technology**
Murphy DA, Pacia E, Beruti S, Lamoureux J, Dabbas B, Diver J, Christiansen J. Genoptix Medical Laboratory, Carlsbad, CA.

PD06-04 **St. Gallen 2011 clinicopathological subtyping of breast cancer: impact of different proliferation assessment methods**
Focke CM, Gläser D, Finsterbusch K, Decker T. Bonhoeffer Medical Center, Neubrandenburg, Germany.

PD06-05 **St. Gallen 2011 clinico-pathological subtypes of breast cancer: concordance of core biopsies and related surgical specimens**
Decker T, Focke CM. Bonhoeffer Medical Center, Neubrandenburg, Germany.

PD06-06 **Relationship between molecular subtype and change in Ki-67 in the placebo arms of window of opportunity trials**
Pruneri G, Gandini S, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Lazzeroni M, Puntoni M, Toesca A, Caldarella P, Johansson H, Bonanni B, DeCensi A. European Institute of Oncology, Milan, Italy; Galliera Hospital, Genoa, Italy; University of Milan, School of Medicine, Milan, Italy.

PD06-07 **Evaluation of an optimal cut-off point for the Ki-67 index as a prognostic factor in primary breast cancer**
Tashima R, Nishimur R. Kumamoto Municipal Hospital, Kumamoto, Japan.

PD06-08 **Strong prognostic concordance between Ki67 and binary, but not multi-level gene expression signatures**
Tobin NP, Lindström LS, Carlson JW, Bergh J, Wennmalm K. Karolinska Institutet and University Hospital, Stockholm, Sweden.

5:00 pm–7:00 pm
POSTER SESSION 3 & RECEPTION
Exhibit Halls A–B

Detection/Diagnosis: Breast Imaging - Mammography

P3-01-01 **Insulin, Insulin-like Growth Factor-1 and cycling estrogen predict premenopausal mammographic density**
Frydenberg H, Flote VG, Iversen A, Finstad SE, Furberg A-S, Fagerland M, Wist EA, Schlichting E, Ellison PT, McTiernan A, Ursin G, Thune I. Oslo University Hospital, Oslo, Norway; University of Tromsø, Norway; Harvard University, Cambridge, MA; Fred Hutchinson Cancer Research Center, Seattle, WA; The Norwegian Cancer Registry, Oslo, Norway.

P3-01-02 **Correlation of Mammographic breast density and tumor characteristics in Korean breast cancer patients**
Cho JY, Ahn SH, Lee JW, Yu JH, Koh BS, Kim HJ, Lee JW, Son BH, Gong G-y, Kim HH. College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea.

P3-01-03 **Breast density profile in a prospective large breast cancer screening program in South Brazil**
Caleffi M, Zignani J, Clarissa A, Ademar BJ, Ribeiro R, Dakir DF. Núcleo Mama Porto Alegre, Hospital Moinhos de Vento, Porto Alegre, RS, Brazil.

P3-01-04 **Surgical management of mammographic microcalcification is improved by full field digital mammography (FFDM)**
Bundred SM, Zhou J, Hurley E, Wilson M, Morris J, Bundred NJ. University Hospital of South Manchester; University of Manchester.

P3-01-05 **The Role of Mammographic Calcification in the Neo-adjuvant Therapy of Breast Cancer Imaging Evaluation**
Li JJ, Chen CM, Di GH, Wu J, Lu JS, Shao Z-M. Shanghai Cancer Center and Cancer Institute, Shanghai, China.

P3-01-06 **Ultrasound as single mode of imaging may miss significant pathology in symptomatic women aged 35-39**
Baker EL, Masudi T, Waterworth A. Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, West Yorkshire, United Kingdom.

P3-01-07 **Estimated risk of radiation-induced breast cancer from mammographic screening**
Freitas-Junior R, Correa RS, Peixoto J-E, Ferreira RS, Tanaka RMN. Federal University of Goias, Goiania, Goias, Brazil; Comissão Nacional de Energia Nuclear, Goiania, Goias, Brazil; National Cancer Institute of Brazil, Rio de Janeiro, RJ, Brazil; Superintendência de Vigilância em Saúde do Estado de Goias, Goiania, Goias, Brazil.

P3-01-08 **Mammographic density and estrogen receptor α gene polymorphism in Javanese ethnic women**
Choridah L, Aryandono T, Faisal A, Sadewa AH, Purnomosari D. Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, DIY, Indonesia; Faculty of Medicine, Universitas Gadjah Mada.

Detection/Diagnosis: Screening

P3-02-01 **Mammographic Screening: Good Prognosis Tumor Biology in Screen-detected Breast Cancers**
Drukker CA, Schmidt MK, Rutgers EJT, Cardoso F, Kerlikowske K, Esserman LJ, Slaets L, Bogaerts J, van't Veer LJ. Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Champalimaud Cancer Centre, Lisbon, Portugal; University of California, San Francisco; EORTC, Brussels, Belgium; Agendia NV, Amsterdam, Netherlands.

P3-02-02 **Use of contrast-enhanced computed tomography in clinical staging of asymptomatic breast cancer patients to detect asymptomatic distant metastases**
Tanaka S, Sato N, Fujioka H, Takahashi Y, Kimura K, Iwamoto M, Uchiyama K. Osaka Medical College, Takatsuki City, Osaka, Japan.

P3-02-03 **Increased risk of breast cancer in women with false-positive screening test: can it be entirely explained by misclassification?**
von Euler-Chelpin M, Kuchiki M, Vejborg I. University of Copenhagen, Denmark; University Hospital Copenhagen, Denmark.

P3-02-04 **Screen detected HER2 positive breast cancer within the West of London Breast Screening population:Incidence, Management and Outcome**
O'Cathail S, White A, Brindley JH, Hadjiminas D, Xynos Y, Cleator S, Hogben K, Palmieri C. Imperial College Healthcare NHS Trust, London, United Kingdom.

P3-02-05 **Subtypes of screen-detected invasive breast cancer and symptomatic invasive breast cancer and their impact on survival**
Kobayashi N, Hikichi M, Miyajima S, Utsumi T. Fujita Health University, Toyoake, Aichi, Japan.

P3-02-06 **Survival impact of early detection of recurrence after surgery in early breast cancer patients**
Hojo T, Tamura K, Masuda N, Inoue K, Kinoshita T, Fujisawa T, Hara F, Saji S, Asaga S, Anan K, Yamamoto N, Wada N, Takahashi M, Nakagami K, Kuroi K, Iwata H. National Cancer Center Hospital, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Saitama Cancer Center, Saitama, Japan; Gunma Prefectural Cancer Center, Gunma, Japan; Shikoku Cancer Center, Shikoku, Japan; Kyoto University Graduate School of Medicine, Kyoto, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Japan; Chiba Cancer Center, Chiba, Japan; National Cancer Center Hospital East, Chiba, Japan; Hokkaido Cancer Center, Hokkaido, Japan; Shizuoka General Hospital, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.

P3-02-07 **Rates of Cancer Detection and Abnormal Results among Clients Recruited for Mammography through Outreach and Education Supported by the Avon Breast Health Outreach Program**
Hurlbert M, Rose J, Opdyke KM, Gates-Ferris K. Cicatelli Associates Inc. (CAI), New York, NY; Avon Foundation for Women, New York, NY.

P3-02-08 **Is repetition of the contralateral mammogram of patients referred from breast cancer screening for unilateral findings necessary?**
Castro C, Schipper R-J, van Roozendaal L, van Goethem M, Lobbes M, Smidt M. Maastricht University Medical Center, Maastricht, Netherlands; Antwerp University Hospital, Antwerp, Belgium.

P3-02-09 **Cost-effectiveness of screening with additional MRI for women with familial risk for breast cancer without a genetic predisposition**
Saadatmand S, Heijnsdijk EA, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Obdeijn I-M, de Koning HJ, Tilanus-Linthorst MM. Erasmus Medical Center, Rotterdam, Netherlands; The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; University Medical Center Groningen, Netherlands; Leiden University Medical Center, Leiden, Netherlands; Erasmus Medical Center, Netherlands.

P3-02-10 **Implementation and uptake of a provincial, population-based, organized breast screening program for high risk women in Ontario: The Ontario breast screening program (OBSP) high risk program**
Eisen A, Carroll J, Chiarelli AM, Horgan M, Meschino W, Rabeneck L, Shumak R, Warner E. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; University of Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; Cancer Care Ontario, Toronto, ON, Canada; North York General Hospital, Toronto, ON, Canada.

P3-02-11 **Screening Magnetic Resonance Imaging (MRI) of the breast in women at increased lifetime risk for breast cancer: A retrospective single institution study**
Ehsani S, Strigel R, Pettke E, Wilke L, Szalkucki L, Tevaarwerk AJ, Wisinski KB. University of Wisconsin Carbone Cancer Center, Madison, WI.

P3-02-12 **The Cost of Mammography Screening in the United States by Screening Policy**
Thorsen CM, Eklund M, Ozanne EM, Esserman LJ. University of California, San Francisco, CA; Karolinska Institute, Stockholm, Sweden.

P3-02-13 **Analysis of infrastructure for mammography screening in the State of Goias, Brazil, 2010**
Freitas-Junior R, Correa RS, Peixoto J-E, Rodrigues DCN, Rahal RMS. Federal University of Goias, Goiania, Goias, Brazil; Comissão Nacional de Energia Nuclear, Goiania, Goias, Brazil; National Cancer Institute of Brazil, Rio de Janeiro, RJ, Brazil.

P3-02-14 **Integrated program for breast cancer control: Partial presentation of the results obtained in the first 24 months of operation**
Blanco EC, Borges MM, Pinotti M, Gennari MB, Ribeiro IM, Nascimento CCP, Santos LFG, Sahium RC. Oswaldo Cruz Alemão Hospital, São Paulo, Brazil.

Detection/Diagnosis: Radiology - Tumor Monitoring

P3-03-01 **3D mapping of total choline in human breast cancer using high-speed MR spectroscopic imaging at 3T: initial experience during neoadjuvant therapy**
Posse S, Zhang T, Royce M, Dayao Z, Lopez S, Sillerud L, Casey L, Eberhardt S, Lomo L, Rajput A, Russell J, Lee S-j, Bolan P. University of New Mexico School of Medicine and UNM Cancer Center, Albuquerque, NM; New Mexico Cancer Center, Albuquerque, NM; University of Minnesota, Minneapolis, MN.

P3-03-02 **The metastatic rate of IMLN, when IMLN metastasis is suspected with PET CT**
Lee J-H, Son G-T, Choi J-E, Kang S-H, Lee S-J. Yeungnam University College of Medicine, Daegu, Republic of Korea.

P3-03-03 **A tri-modality imaging assessment algorithm to evaluate neoadjuvant therapy response in patients with operable breast cancer**
Umphrey H, Bernreuter W, Bland K, Carpenter J, Falkson C, Forero A, Keene K, Krontiras H, Meredith R, Urist M, De Los Santos J. University of Alabama at Birmingham, AL.

Tumor Cell and Molecular Biology: Molecular Profiles

P3-04-01 **Protein pathway activation mapping of the I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with triple negative tumors**
Wulfkuhle JD, Wolf D, Gallagher RI, Yau C, Calvert V, Espina V, Illi J, Wu Q, Boe M, Yan Y, I-SPY TRIAL-1 Investigators, Liotta LA, van't Veer L, Esserman L, Petricoin EF. George Mason University, Manassas, VA; University of California, San Francisco, CA; Genentech, South San Francisco, CA.

P3-04-02 **Protein pathway activation mapping of I-SPY 1 biopsy specimens identifies new network focused drug targets for patients with HR+/HER2- tumors**
Wulfkuhle JD, Yau C, Gallagher RI, Wolf D, Calvert V, Espina V, Illi J, Wu Q, Boe M, Yan Y, I-SPY TRIAL-1 Investigators, Liotta LA, van't Veer L, Esserman L, Petricoin EF. George Mason University, Manassas, VA; University of California, San Francisco, CA; Genentech, South San Francisco, CA.

P3-04-03 **A seven-gene profile predicting benefit of postmastectomy radiotherapy independently of nodal status in high risk breast cancer**
Tramm T, Mohammed H, Myhre S, Alsner J, Børresen-Dale A-L, Sørlie T, Frigessi A, Overgaard J. Aarhus University Hospital, Aarhus, Denmark; Oslo University Hospital, Radiumhospitalet, Oslo, Norway; University Oslo, Norway.

P3-04-04 **Identification of a 'BRCAness' signature in triple negative breast cancer by Comparative Genomic Hybridization**
Toffoli S, Bar I, Abdulsater F, Delrée P, Hilbert P, Cavallin F, Moreau F, Clark J, Lacroix-Triki M, Campone M, Martin A-L, Roché H, Machiels J-P, Carrasco J, Canon J-L. Institute of Pathology and Genetics, Gosselies, Belgium; MDxHealth, Liège, Belgium; Institut Claudius Regaud, Toulouse, France; Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain - Nantes, France; UNICANCER, Paris, France; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Grand Hôpital de Charleroi (GHdC), Charleroi, Belgium.

P3-04-05 **Kinomic and phospho-proteomic analysis of breast cancer stem-like cells**
Leth-Larsen R, Christensen AG, Ehmsen S, Moeller M, Palmisano G, Larsen MR, Ditzel HJ. University of Southern Denmark, Odense, Denmark; Odense University Hospital, Odense, Denmark.

P3-04-06 **Higher gene expression of CSPG4 in the basal-like subtype of invasive breast cancer and its negative association with lymph node metastasis**
Luo C, Iida J, Chen Y, Dorchak J, Kovatich AJ, Mural RJ, Hu H, Shriver CD. Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA.

P3-04-07 **Comparison of breast tumors with HER2 amplification and polysomy 17**
Field LA, Deyarmin B, Ellsworth RE, Shriver CD. Windber Research Institute, Windber, PA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD.

P3-04-08 **Expression of hormone-responsive genes in benign breast tissue varies with menstrual cycle phase and menopausal status**
Hu H, Wang J, Lee O, Shidfar A, Iyer S, Ivancic D, Chatterton RT, Stearns V, Sukumar S, Khan SA. Northwestern University, Chicago, IL; Johns Hopkins University School of Medicine.

P3-04-09 **Withdrawn**

P3-04-10 **Comparison between RNA-Seq and Affymetrix gene expression data**
Fumagalli D, Haibe-Kains B, Michiels S, Brown DN, Gacquer D, Majjaj S, Salgado R, Larsimont D, Detour V, Piccart M, Sotiriou C, Desmedt C. Institut Jules Bordet, Brussels, Belgium; Institut de Recherches Cliniques de Montréal, Montréal, QC, Canada; Université Libre de Bruxelles, Campus Erasme, Brussels, Belgium.

P3-04-11 **Systemic treatment decision making for patients with stage I and II, hormone receptor positive, her2/neu negative breast cancer**
Zhu X, Graham N, Paquet L, Dent S, Song X. University of Ottawa, ON, Canada; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; Carleton University, Ottawa, ON, Canada.

P3-04-12 **BreastMark: An integrated approach to mining publically available Transcriptomic Datasets relating to Breast Cancer Outcome**
Madden S, Gaule P, Clarke C, Aherne ST, O'Donovan N, Clynes M, Crown J, Gallagher WM. Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland; University College Dublin, Dublin 9, Ireland.

Tumor Cell and Molecular Biology: Tumor Heterogeneity/Molecular Subclassification

P3-05-01 **Molecular subtyping improves stratification of patients into diagnostically more meaningful risk groups**
Cristofanilli M, Turk M, Kaul K, Weaver J, Wesseling J, Stork-Sloots L, de Snoo F, Yao K. Fox Chase Cancer Center; NorthShore University HealthSystem; Netherlands Cancer Institute; Agendia NV.

P3-05-02 **Pathological assessment of discordant cases for molecular (BluePrint and MammaPrint) versus clinical subtypes for breast cancer among 621 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial**
Viale G, Slaets L, de Snoo F, van't Veer L, Rutgers E, Piccart M, Bogaerts J, van den Akker J, Stork-Sloots L, Engelen K, Russo L, Dell'Orto P, Cardoso F. European Institute of Oncology; European Organisation for Research and Treatment of Cancer; Agendia NV; Netherlands Cancer Institute; Jules Bordet Institute; Champalimaud Cancer Center.

P3-05-03 **Characterization of PIK3CA mutations in lobular breast cancer**
Desmedt C, Metzger O, Fumagalli D, Brown D, Singhal S, Vincent D, Adnet P-Y, Smeets D, Bertucci F, Galant C, Salgado R, Veys I, Saini K, Pruneri G, Krop I, Winer E, Michiels S, Piccart M, Lambrechts D, Larsimont D, Viale G, Sotiriou C. Institut Jules Bordet, Brussels, Belgium; Dana-Farber Cancer Institute, Boston; Vesalius Research Centre, VIB, Leuven, Belgium; Institut Paoli Calmettes, Marseille, France; Université Catholique de Louvain, Brussels, Belgium; European Institute of Oncology, University of Milan, Milan, Italy.

P3-05-04 **Intra-tumor heterogeneity as a predictor of therapy response in HER2 positive breast cancer**
Rye IH, Helland Å, Sætersdal A, Naume B, Almendro V, Polyak K, Børessen-Dale A-L, Russnes HG. Institute for Cancer Research, Oslo, Norway; Oslo University Hospital, Oslo, Norway; University of Oslo, Oslo, Norway; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Hospital Clínic, Barcelona, Spain.

P3-05-05 **HER2 Expression and Gene copy analysis by Immunofluorescence and Fluorescence in situ Hybridization, on a Single formalin-fixed paraffin-embedded tissue section**
Ha T, Seppo A, Ginty F, Kenny K, Henderson D, Kyshtoobayeva A, Gerdes M, Larriera A, Liu X, Corwin A, Zingelewicz S, Lazare M, Jun N, Kyshtoobayeva A, Chow C, Al-Kofahi Y, Hollman D, Bloom K. GE Global Research, Niskayuna, NY; Clarient Diagnostics Services, Aliso Viejo, CA.

P3-05-06 **Automated analysis of Her2 FISH using combined Immunofluorescence and FISH signals**
Seppo A, Al-Kofahi Y, Padfield D, Ha T, Jun N, Kyshtoobayeva A, Kaanumalle L, Corwin A, Henderson D, Kamath V, McCulloch C, Hollman D, Bloom KJ. GE Global Research, Niskayuna, NY; Clarient Diagnostics Services, Aliso Viejo, CA.

P3-05-07 **Poor prognosis early breast cancer: pathological characteristics of the Unicancer-PACS08 trial including patients treated with docetaxel or ixabepilone in adjuvant setting**
Lacroix-Triki M, Delrée P, Filleron T, Penault-Llorca F, Bor C, Mery E, Maisongrosse V, Génin P, Jacquemier J, Reyre J, Caveriviere P, Quintyn-Ranty M-L, Escourrou G, Mesleard C, Lemonnier J, Martin A-L, Campone M. Institut Claudius Regaud, Toulouse, France; Institut de Pathologie et de Génétique, Gosselies, Belgium; Centre Jean Perrin, Clermont-Ferrand, France; Centre Francois Baclesse, Caen, France; Centre Alexis Vautrin, Vandoeuvre les Nancy, France; Institut Paoli Calmettes, Marseille, France; Laboratoire Anatomie et de Cytologie des Feuillants, Toulouse, France; CHU Rangueil, Toulouse, France; R&D Unicancer, Paris, France; ICO Centre René Gauducheau, Saint Herblain, France.

P3-05-08 **Analysis of the expression of claudin-3, -4, -7 and E-cadherin in breast cancer: are they surrogates for the claudin-low subtype?**
Tokes A-M, Szasz AM, Kovács AK, Juhasz E, Nemeth Z, Baranyai Z, Madaras L, Kulka J. Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary.

P3-05-09 **The role of TGF-beta receptor type 3 in breast cancer progression**
Jovanovic B, Ashby WJ, Zijlstra A, Pietenpol JA, Moses HL. Vanderbilt University, Nashville, TN.

Prognostic and Predictive Factors: Response Predictions - Biomarkers and Other Factors

P3-06-01 **Hotspot mutations in PIK3CA are predictive for treatment outcome on aromatase inhibitors but not for tamoxifen**
Ramirez Ardila DE, Helmijr JC, Lurkin I, Look M, Ruigrok-Ritstier K, Simon I, Van Laere S, Sweep F, Span P, Linn S, Foekens J, Sleijfer S, Berns EMJJ, Jansen MPHM. Erasmus MC - Daniel den Hoed, Rotterdam, Zuid Holland, Netherlands; Agendia BV, Amsterdam, Netherlands; Antwerp University/Oncology Centre, GZA Hospitals St-Augustinus, Antwerp, Belgium; Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands.

P3-06-02 **Genetic polymorphisms from genome-wide association study associated with the metabolic and cell proliferation pathways affect the time to distant metastases of hormone receptor-positive and Her2-negative early breast cancer**
Huang C-S, Kuo S-H, Yang S-Y, Lien H-C, Lin C-H, Lu Y-S, Cheng A-L, Chang K-J. National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; College of Public Health, National Taiwan University, Taipei, Taiwan.

P3-06-03 **Association between PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients**
Jørgensen CLT, Nielsen TO, Bjerre KD, Liu S, Wallden B, Balslev E, Nielsen DL, Ejlertsen B. Herlev University Hospital, Herlev, Denmark; Danish Breast Cancer Cooperative Group, Copenhagen, Denmark; University of British Columbia, Vancouver, BC, Canada; NanoString Technologies, Seattle, WA.

P3-06-04 **Role of pMAPkinase, pAKT, p27 & IGF-IR as predictive markers of response to trastuzumab in patients with HER2-positive invasive breast cancer treated with neoadjuvant chemotherapy ± trastuzumab in the REMAGUS02 trial**
Mathieu MC, Goubar A, Sigal B, Bertheau P, Guinebretière JM, André F, Pierga JY, Delaloge S, Giacchetti S, Brain E, Marty M. Institut Gustave Roussy - INSERM U981, Villejuif, France; Institut Curie, Paris, France; Hopital Saint-Louis, Paris, France.

P3-06-05 **Expression of SPARC in human breast cancer and its predictive value in the GeparTrio neoadjuvant trial**
Untch M, Prinzler J, Fasching P, Müller BM, Gade S, Meinhold-Heerlein I, Huober J, Karn T, Liedtke C, Loibl S, Müller V, Rack B, Schem C, Darb-Esfahani S, von Minckwitz G, Denkert C. Helios Klinikum Berlin-Buch, Germany; Charité Universitätsmedizin Berlin, Germany; Universitätsklinikum Erlangen, Germany; German Breast Group, Germany; Universitätsklinikum Aachen, Germany; Universitätsklinikum Düsseldorf, Germany; Universitätsklinikum Frankfurt am Main, Germany; Universitätsklinikum Münster, Germany; Universitätsklinikum Hamburg-Eppendorf, Germany; Universitätsklinikum München; Universitätsklinikum Schleswig-Holstein, Germany.

P3-06-06 **Lactate dehydrogenase B in breast cancer contributes to glycolytic phenotype and predicts response to neoadjuvant chemotherapy**
Dennison JB, Molina JR, Mitra S, Gonzalez-Angulo AM, Brown RE, Mills GB. MD Anderson Cancer Center, Houston, TX; University of Texas Health Science Center, Houston, TX.

P3-06-07 **Ki67 as a Predictive Marker of Response to Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer (ESBC): A Systematic Review and Evidence Summary**
Lyman GH, Culakova E, Poniewierski MS, Wogu AF, Barry W, Ginsburg GS, Marcom PK, Ready N, Abernethy A, Geradts J, Hwang S, Kuderer NM. Duke University.

P3-06-08 Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer
Marme F, Schneeweiss A, Aigner J, Eidt S, Altevogt P, Sinn P, Wirtz RM. National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathologie at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany.

P3-06-09 Test of association between Ki67 index of early breast cancer and local relapse after adjuvant hypofractionated radiotherapy
Rodrigues DN, Somaiah N, Daley F, Davies S, Rakha E, A'Hern R, Haviland J, Sydenham M, Owen R, Reis-Filho J, Yarnold JR. Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; Institute of Cancer Research, Sutton, Surrey, United Kingdom; University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Cheltenham General Hospital, Cheltenham, United Kingdom.

P3-06-10 Pretreatment Vitamin D Levels and Response to Neoadjuvant Chemotherapy in the I-SPY 1 TRIAL
Clark AS, Chen J, Kapoor S, Esserman LJ, DeMichele A, I-SPY TRIAL-1 Investigators. Abramson Cancer Center, Philadelphia, PA; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA; Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; UCSF/Mount Zion Medical Center, San Francisco, CA; I-SPY1 TRIAL Investigators.

P3-06-11 Response and long-term outcomes after neo-adjuvant chemotherapy: Pooled dataset of patients stratified by molecular subtyping using MammaPrint and BluePrint
Glück S, Peeters J, Stork-Sloots L, Somlo G, van't Veer L, de Snoo F. University of Miami, Sylvester Comprehensive Cancer Center; Agendia NV; City of Hope; University of California, San Francisco.

P3-06-12 Effect of TOP2A and cMYC gene copy number on outcome in a Phase II trial of adjuvant TC (Docetaxel/Cyclophosphamide) plus trastuzumab (HER TC) in HER2-positive early stage breast cancer
Jones S, Collea R, Paul D, Sedlacek S, Favret A, Gore I, Lindquist DL, Holmes FA, Allison MAK, Steinberg MS, Stokoe C, Portillo RM, Crockett M, Wang Y, Lina A, Robert NJ, O'Shaughnessy J. US Oncology Research, McKesson Specialty Health, The Woodlands, TX; Texas Oncology, Baylor-Sammons Cancer Center, Dallas, TX; New York Oncology Hematology, Albany, NY; Rocky Mountain Cancer Center, Denver, CO; Virginia Cancer Specialists, Fairfax, VA; Birmingham Hematology and Oncology, Birmingham, AL; Arizona Oncology Associates, Sedona, AZ; Texas Oncology-Texas Memorial City, Houston, TX; Comprehensive Cancer Center, Henderson, NV; Virginia Oncology Associates, Virginia Beach, VA; Texas Oncology - Plano East, Plano, TX; Texas Oncology - El Paso West, El Paso, TX.

P3-06-13 Expression of Phosphorylated Activating Transcription factor 2 (ATF2) is associated with sensitivity to endocrine therapy in breast cancer
Palmieri C, Rudraraju B, Abdel-Fatah TMA, Moore DA, Shaw J, Green A, Ellis IO, Coombes RC, Simak A. Imperial College London, United Kingdom; Nottingham University City Hospital, Nottingham, United Kingdom; University of Leicester, United Kingdom.

P3-06-14 Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple Negative Breast Cancer
Yu K-D, Zhu R, Zhan M, Shao Z-M, Yang W, Symmans WF, Rodriguez AA, Makris A, Wong ST, Chang JC. Shanghai Cancer Center and Cancer Institute of Fudan University, Shanghai, China; The Methodist Hospital, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Mount Vernon Cancer Centre, United Kingdom; The Methodist Hospital Research Institute, Houston, TX.

P3-06-15 Baseline CD4/CD8 tumor infiltrating lymphocytes (TIL) ratio predicts pathologic response to neoadjuvant chemotherapy (NC) in breast cancer
García-Martínez E, Luengo Gil G, Chaves Benito A, García García T, Vicente Conesa AM, Zafra Poves M, García Garre E, Vicente García V, Ayala de la Peña F. University Hospital Morales Meseguer, Murcia, Spain; Centro de Hemodonación Regional, Murcia, Spain.

P3-06-16 Predictive biomarker of pathologic complete response to neoadjuvant chemotherapy in triple negative breast cancer
Kim T, Han W, Moon H-G, Noh D-Y. Seoul National University College of Medicine, Seoul, Korea.

P3-06-17 Withdrawn

P3-06-18 Increase of serum androgen and its metabolites in postmenopausal primary breast cancer patients with disease progression during neo-adjuvant exemestane treatment; JFMC 34-0601 TR
Takada M, Saji S, Honma N, Masuda N, Yamamoto Y, Kuroi K, Yamashita H, Ohno S, Aogi K, Ueno T, Toi M. Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan; Osaka National Hospital, Osaka, Japan; Kumamoto University Hospital, Kumamoto, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Hokkaido University, Sapporo, Japan; National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan; National Hospital Organization Shikoku Cancer Center, Ehime, Japan.

P3-06-19 Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer
Aigner J, Schneeweiss A, Marme F, Eidt S, Altevogt P, Sinn P, Wirtz R. National Center for Tumor Diseases, University-Hospital Heidelberg, Germany; Institut of Pathology at the St.-Elisabeth-Hospital, Cologne, Germany; German Cancer Research Center, Heidelberg, Germany; University of Heidelberg, Germany; STRATIFYER MolecularPathology GmbH, Cologne, Germany.

P3-06-20 Is it possible to predict the efficacy of a combination of Panitumumab plus FEC 100 followed by docetaxel (T) for patients with triple negative breast cancer (TNBC)? Final biomarker results from a phase II neoadjuvant trial
Nabholtz J-M, Dauplat M-M, Abrial C, Weber B, Mouret-Reynier M-A, Gligorov J, Tredan O, Vanlemmens L, Petit T, Guiu S, Jouannaud C, Tubiana-Mathieu N, Kwiatkowski F, Cayre A, Uhrhammer N, Privat M, Desrichard A, Chollet P, Chalabi N, Penault-Llorca F. Centre Jean Perrin, Clermont-Ferrand, France; Centre Alexis Vautrin, Vandoeuvre les Nancy, France; Hôpital Tenon, Paris, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Centre Paul Strauss, Strasbourg, France; Centre Georges François Leclerc, Dijon, France; Institut Jean Godinot, Reims, France; CHU Dupuytren, Limoges, France.

P3-06-21 Unique Molecular Subtypes of Triple Negative Breast Carcinomas by Routine IHC: Implications for Treatment and Prognosis
Ashfaq R, Wright B, Russell K, Voss A. Caris Life Sciences, Phoenix, AZ.

P3-06-22 Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
Jinno H, Sato T, Hayashida T, Takahashi M, Hirose S, Kitagawa Y. Keio University School of Medicine, Shinjuku, Tokyo, Japan.

P3-06-23 Predicting response to neoadjuvant letrozole
Larionov A, Turnbull A, Sims A, Renshaw L, Kay C, Harrison D, Dixon JM. University of Edinburgh, Scotland, United Kingdom.

P3-06-24 Early activation of IFN/STAT signaling in tumor cells of patient-derived triple negative breast cancer xenografts predicts tumor sensitivity to chemotherapy
Legrier M-E, Yvonnet V, Beurdeley A, Stephant G, Le Ven E, Banis S, Lassalle M, Deas O, Cairo S, Judde J-G. Xentech, Evry, Ile de France, France.

P3-06-25 **PTEN mRNA positivity using *in situ* measurements is associated with better outcome in Tamoxifen treated breast cancer patients**
Schalper KA, Li K, Rimm DL. Yale School of Medicine, New Haven, CT.

P3-06-26 **Serum anti-p53 antibody titers predict pathological response to preoperative chemotherapy in women with HER2 positive or triple negative breast cancer**
Yoshiyama T, Nakamura Y, Igawa A, Saruwatari A, Shigechi T, Ueda N, Kuba S, Ishida M, Nishimura S, Nishiyama K, Ohno S. National Kyushu Cancer Center, Fukuoka, Japan.

P3-06-27 **Dynamic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer**
Carp SA, Wanyo CM, Specht M, Schapira L, Moy B, Finkelstein DM, Boas DA, Isakoff SJ. Massachusetts General Hospital, Charlestown, MA; Massachusetts General Hospital, Boston, MA.

P3-06-28 **Use of the MiCK drug-induced apoptosis assay improves clinical outcomes in recurrent breast cancer (BRCA)**
Bosserman L, Rogers K, Davidson D, Whitworth P, Karimi M, Upadhyaya G, Rutledge J, Hallquist A, Perree M, Presant C. Wilshire Oncology Medical Group-US Oncology; Nashville Oncology Associates; Tennessee Plateau Oncology; Nashville Breast Center; Data Vision; DiaTech Life Sciences.

P3-06-29 **Change of circulating tumor cells before and after neoadjuvant chemotherapy in patients with primary breast cancer**
Horiguchi J, Takata D, Rokutanda N, Nagaoka R, Tokiniwa H, Tozuka K, Sato A, Kikuchi M, Oyama T, Takeyoshi I. Gunma University Hospital, Maebashi, Gunma, Japan.

P3-06-30 **Predictors of Pathologic Complete Response to Chemotherapy and Antiangiotherapy in Breast Cancer**
Makhoul I, Griffin RJ, Dhakal I, Raj V, Hennings L, Kadlubar SA. University of Arkansas for Medical Sciences, Little Rock, AR.

P3-06-31 **Etirinotecan pegol in patients with metastatic breast cancer (mBC): Modeling CA27.29 response and its correlation with tumor response**
Chia YL, Hoch U, Hannah A, Eldon MA. Nektar Therapeutics, San Francisco, CA.

P3-06-32 **Topoisomerase 1 gene copy aberration is a frequent finding in clinical breast cancer samples**
Stenvang J, Smid M, Nielsen S, Balslev E, Timmermans M, Rømer M, Nygaard S, Christensen I, Nielsen D, Foekens J, Brünner N, Martens J. University of Copenhagen, Denmark; Erasmus University Medical Center/Daniel den Hoed Cancer Center, Rotterdam, Netherlands; Herlev University Hospital, Copenhagen, Denmark; Copenhagen Biocenter, Rigshospitalet, Copenhagen, Denmark.

P3-06-33 **Effect of trastuzumab-based therapy on serum activin A levels in metastatic breast cancer**
Zubritsky LM, Ali SM, Leitzel K, Koestler W, Fuchs E-M, Costa L, Knight R, Laadem A, Sherman ML, Lipton A. Penn State Hershey Medical Center, Hershey, PA; Lebanon VA Medical Center, Lebanon, PA; Medical University of Vienna, Austria; Santa Maria Hospital, Lisbon, Portugal; Celgene Corp., Summit, NJ; Acceleron Pharma, Cambridge, MA.

P3-06-34 **Plasma (p) VEGF-A and VEGFR-2 biomarker (BM) results from the BEATRICE phase III trial of bevacizumab (BEV) in triple-negative early breast cancer (BC)**
Carmeliet P, Pallaud C, Deurloo RJ, Bubuteishvili-Pacaud L, Henschel V, Dent R, Bell R, Mackey J, Scherer SJ, Cameron D. Vesalius Research Center, Leuven, Belgium; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Genentech, Inc., South San Francisco; University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, United Kingdom; Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada; National Cancer Center, Singapore, Singapore; Andrew Love Cancer Centre, Geelong, Australia; Cross Center Institute, Edmonton, Canada.

P3-06-35 **Topoisomerase 1 gene copy aberrations in 52 human breast cancer cell lines and association to gene expression**
Stenvang J, Smid M, Nielsen S, Timmermans M, Rømer M, Nielsen D, Foekens J, Brünner N, Martens J. University of Copenhagen, Denmark; Erasmus University Medical Center/Daniel den Hoed Cancer Center, Rotterdam, Netherlands; Herlev University Hospital, Copenhagen, Denmark.

Epidemiology, Risk, and Prevention: Epidemiology - Population Studies

P3-07-01 **Withdrawn**

P3-07-02 **Time-trends in survival in young women with breast cancer in a SEER population-based study**
Ademuyiwa FO, Groman A, Hong C-C, Kumar S, Levine EG, Miller A, Ambrosone CB. Roswell Park Cancer Institute.

P3-07-03 **The impact of Carcinoma *in situ* of the breast and family history on risk of subsequent breast cancer events and mortality-a population based study from Sweden**
Sackey H, Hui M, Czene K, Edgren G, Frisell J, Hartman M. Karolinska Institutet, Stockholm, Sweden; Saw Swee Hock School of Public Health, National University of Singapore, Singapore; Harvard School of Public Health, Boston; National University Hospital, Singapore.

P3-07-04 **Cigarette smoking and postmenopausal breast cancer risk: results from the NIH-AARP Diet and Health Study**
Nyante SJ, Gierach GL, Dallal CM, Park Y, Hollenbeck AR, Brinton LA. National Cancer Institute, Rockville, MD; AARP, Washington, DC.

P3-07-05 **Bisphosphonate use after primary breast cancer and risk of contralateral breast cancer using pharmacy data**
Kwan M, Habel L, Song J, Weltzien E, Chung J, Sun Y, Fletcher S, Haque R. Division of Research, Kaiser Permanente Northern California; Kaiser Permanente Southern California; Harvard Medical School.

P3-07-06 **Initial treatment and survival among elderly breast cancer patients with positive estrogen receptor status by progesterone receptor status and stage: an analysis of US national registry data 2000-2009**
Lang K, Huang H, Namjoshi M, Federico V, Menzin J. Boston Health Economics, Waltham, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

P3-07-07 **Incidence and survival among breast cancer patients in the United States by race and stage diagnosis: an analysis of national registry data 2000-2009**
Lang K, Huang H, Namjoshi M, Federico V, Menzin J. Boston Health Economics, Waltham, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

P3-07-08 **Recent trends in the characteristics of patients with distant stage breast cancer in the United States Surveillance, Epidemiology and End Stage Disease (SEER) program**
Li J, Dalvi T, Pawaskar M, Tsai K, Caspard H, Fryzek J. Medimmune, Gaithersburg, MD; Epistat Institute, Gaithersburg, MD.

P3-07-09 **Prevalence and effects of off-label use of chemotherapeutic agents in elderly breast cancer patients: estimates from Surveillance, Epidemiology and End Results-Medicare data**
Eaton AA, Sima CS, Panageas KS. Memorial Sloan-Kettering Cancer Center, New York, NY.

P3-07-10 **Effect of lifestyle and single nucleotide polymorphisms on breast cancer risk: A case-control study in Japanese women**
Mizoo T, Taira N, Nishiyama K, Nogami T, Iwamoto T, Motoki T, Shien T, Matuoka J, Doihara H, Ishihara S, Kawai N, Kawasaki K, Ishibe Y, Ogasawara Y. Okayama Medical University, Okayama, Japan; Okayama Saiseikai General Hospital, Okayama, Japan; Okayama Rousai Hospital, Okayama, Japan; Kagawa Prefectural Cancer Detection Center, Takamatsu, Kagawa, Japan; Mizushima Kyodo Hospital, Kurashiki, Okayama, Japan; Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, Japan.

P3-07-11 **Retrospective database review of outcomes in invasive lobular carcinoma and invasive ductal carcinoma of the breast**
Shih Y-C, Dillon P. University of Virginia, Charlottesville, VA.

P3-07-12 **Risk Factors for Breast Cancer in Women Served in Odete Valadares Maternity, Belo Horizonte-MG**
Sediyama CMNO, Peluzio MCG, Abranches MV. Universidade Federal de Viçosa, Viçosa, MG, Brazil.

P3-07-13 **Importance of socioeconomic status in relation to breast cancer risk and prognostic factors in Argentina**
Croce MV, Demichelis SO, Cermignani L, Zwenger A, Segal-Eiras A, Giacomi N. Faculty of Medical Sciences, UNLP, La Plata, Buenos Aires, Argentina.

P3-07-14 **Initial treatment and survival among elderly breast cancer patients in the United States by estrogen receptor status and cancer stage at diagnosis: an analysis of national registry data 2000-2009**
Lang K, Huang H, Namjoshi M, Federico V, Menzin J. Boston Health Economics, Waltham, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

Epidemiology, Risk, and Prevention: Epidemiology - Genetic and Molecular

P3-08-01 **The prospective risk of ovarian cancer in 1433 women in a breast cancer family history clinic: no increased risk in families testing negative for *BRCA1* and *BRCA2***
Evans DGR, Ingham SL, Sahin S, Buchan I, Warwick J, O'Hara C, Moran A, Howell A. St Mary's Hospital, Manchester, United Kingdom; Wythenshawe Hospital, Manchester, United Kingdom; The University of Manchester, Manchester, United Kingdom; Imperial College London, United Kingdom; North West Cancer Intelligence Service, NHS Foundation Trust, Manchester, United Kingdom; Christie Hospital, Manchester, United Kingdom.

P3-08-02 **Common variants at 10p14 and 1p11.2 display heterogeneity in breast cancer associations by E-cadherin tumor tissue expression in two independent datasets**
Horne HN, Sherman ME, Garcia-Closas M, Pharoah PD, Blows FM, Yang XR, Lissowska J, Brinton LA, Chanock SJ, Figueroa JD. National Cancer Institute, Rockville, MD; The Institute of Cancer Research, Sutton, Surrey, United Kingdom; University of Cambridge, United Kingdom; M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

P3-08-03 **Urinary levels of prostaglandin E_2 metabolite and postmenopausal breast cancer**
Kim S, Taylor JA, Sandler DP. Georgia Health Sciences University, Augusta, GA; National Institute of Environmental Health Sciences, Research Triangle Park, NC.

P3-08-04 **Impact of CYP3A variation on estrone levels and breast cancer risk**
Ross GM, Johnson N, Orr N, Walker K, Gibson L, Folkerd E, Haynes B, Palles C, Coupland B, Shoemaker M, Jones M, Broderick P, Sawyer E, Kerin M, Tomlinson I, Zvelebil M, Chilcott-Burns S, Tomczyk K, Simpson G, Williamson J, Hillier S, Houlston R, Swerdlow A, Ashworth A, Dowsett M, Peto J, dos Santos I, Fletcher O. Royal Marsden Hospital, London, United Kingdom; Breakthrough Breast Cancer, Institute of Cancer Research, London, United Kingdom; London School of Hygiene and Tropical Medicine, United Kingdom; Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom; Biomedical Research Centre, Guys, United Kingdom; Edinburgh University, United Kingdom; University Hospital, Galway, Ireland.

P3-08-05 **Copy number variation and risk of chemotherapy-related infection**
Abraham JE, Rueda OM, Chin S-F, Guo Q, Harrington P, Earl HM, Pharoah PD, Caldas C. Strangeway's Research Laboratory, University of Cambridge, Cambridgeshire, United Kingdom; University of Cambridge NHS Foundation Hospitals, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, Cambridgeshire, United Kingdom.

P3-08-06 **Triple Negative Breast Cancer and BRCA Status: Implications for Genetic Counseling**
Haque R, Alvarado M, Ahmed SA, Shi JM, Chung JWL, Avila CC, Zheng CX, Tiller GE. Kaiser Permanente Southern California, Pasadena, CA.

P3-08-07 **HER2 positive breast carcinomas: trend in evolution between 1998 and 2008 and relationship with clinico-pathological characteristics in a population based study**
Beltjens F, Bertaut A, Pigeonnat S, Pouget N, Guiu S, Poillot M-L, Charon-Barra C, Coudert B, Dabakuyo S, Fumoleau P, Arveux P, Arnould L. Centre GF Leclerc, Dijon, France.

P3-08-08 **Vitamin D status at breast cancer diagnosis: correlation with patient and tumor characteristics**
Berger N, Klein P, Boolbol SK, Gillego A, Estabrook A, Malamud S, Chadha M, Boachie-Adjei K, Shao T. Lutheran Medical Center, Brooklyn, NY; Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; St. Luke's-Roosevelt Hospital center, Continuum Cancer Centers of New York, New York, NY.

P3-08-09 **Clinical and Pathological Characteristics of Breast Cancer in Women with Neurofibromatosis Type 1**
Yap Y-S, Wong J, Chan M, Yong W-S, Ong K-W, Lo S-K, Ngeow J, Tan B, Madhukumar P, Tan M-H, Ang P, Teh B-T, Tan P-H, Lee AS-G. National Cancer Centre Singapore; Singapore General Hospital.

Epidemiology, Risk, and Prevention: Ethnic/Racial Aspects

P3-09-01 **Odds of the triple negative subtype and survival of stages 1-3 breast cancer: Variation by race/ethnicity**
Parise C, Caggiano V. Sutter Institute for Medical Research, Sacramento, CA.

P3-09-02 **The HER2 –positive subtypes by stage and race/ethnicity**
Caggiano V, Parise C. Sutter Institute for Medical Research, Sacramento, CA.

P3-09-03 **Breast cancer subtype distribution among HapMap classified ethnic groups**
Luo C, Chen Y, Shriver CD, Hu H, Mural RJ. Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD.

P3-09-04 **The associations between body mass index and breast cancer intrinsic subtypes in Japanese women**
Kimura K, Tanaka S, Iwamoto M, Uchiyama K. Osaka Medical College, Takatsuki City, Osaka, Japan.

P3-09-05 **The role of breast size in detection of breast cancer in asian women**
Lee S, Sandhu H, Zheng Y. Holy Name Medical Center.

Treatment: Inflammatory Breast Cancer

P3-10-01 **Epidemiological risk factors and normal breast tissue markers in inflammatory breast cancer**
Atkinson RL, Sexton KR, Ueno NT, El-Zein R, Brewster AM, Krishnamurthy SA, Woodward WA. University of Texas MD Anderson Cancer Center, Houston, TX; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.

P3-10-02 **Modulation of mRNA and miRNAs by the novel histone deacetylase inhibitor, CG-1521 disrupts cytokinesis in SUM149PT inflammatory breast cancer cells**
Chatterjee N, Tenniswood MPR. University at Albany, Rensselaer, NY.

P3-10-03 ***Bartonella henselae*** **Infection Detected in Patients with Inflammatory Breast Cancer**
Fernandez SV, Aburto L, Maggi R, Breitschwerdt EB, Cristofanilli M. Fox Chase Cancer Center, Philadelphia, PA; North Caroline State University, Raleigh, NC.

P3-10-04 **Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase**
Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL. The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium; Delaware State University, Dover, DE.

P3-10-05 **Response to neoadjuvant systemic therapy (NST) in inflammatory breast cancer (IBC) according to estrogen receptor (ER) and HER2 expression**
Masuda H, Iwamoto T, Brewer T, Hsu L, Kai K, Woodward WA, Reuben JM, Valero V, Alvarez RH, Willey J, Hortobagyi GN, Ueno NT. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX; Okayama University Hospital, Okayama, Japan.

P3-10-06 **Patterns of failure in patients with inflammatory breast cancer: the case for aggressive local/regional treatment**
Warren LE, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.

P3-10-07 **Lymph node status and survival in inflammatory breast cancer**
Sieffert MR, Pedersen RC, Tereffe W, Cui H, Woods RR, Viscusi RK, LeBeau-Grasso L, Lang JE. University of Arizona College of Medicine, Tucson, AZ; University of Texas MD Anderson Cancer Center, Houston, TX; University of Arizona Cancer Center, Tucson, AZ; University of Arizona Health Sciences Center, Tucson, AZ; University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

P3-10-08 **A new in vitro method of growing and studying inflammatory breast cancer emboli**
Lehman HL, Daasner EJ, Vermeulen PB, Dirix LY, Van Laere S, van Golen KL. The University of Delaware, Newark, DE; Sint Augustine Hospital, Antwerp, Belgium; Catholic University, Leuven, Belgium.

P3-10-09 **Peptide-based molecular targeting of inflammatory breast cancer**
Eckhardt BL, Miao RY, Cao Y, Driessen WH, Krishnamurthy S, Arap W, Ueno N, Anderson RL, Pasqualini R. The University of Texas at MD Anderson Cancer Center, Houston, TX; Stanford University School of Medicine; Trescowthick Research Laboratories, Peter MacCallum Cancer Center; The University of Texas at MD Anderson Cancer Center.

P3-10-10 **Status of anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma**
Krishnamurthy S, Woodward W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Ueno NT. MD Anderson Cancer Center, Houston, TX; LabCorp, Durham, NC; Link Genomics, Toyoka, Japan

Treatment: Male Breast Cancer

P3-11-01 **Matched-pair analysis of patients with male and female breast cancer**
Kim M, Lee SK, Choi M-Y, Kim S, Kim J, Jung SP, Bae SY, Kil WH, Lee JE, Nam SJ. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

P3-11-02 **Male breast cancer: A comparison between *BRCA* mutation carriers and non-carriers in Hong Kong, Southern China**
Kwong A, Chau WW, Wong CHN, Law FBF, Ng EKO, Suen DTK, Kurian AW, West DW, Ford JM, Ma ESK. University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong; Stanford University School of Medicine, Stanford, CA; Hong Kong Sanitorium & Hospital, Happy Valley, Hong Kong.

P3-11-03 **Treatment outcomes for early stage male breast cancer: a single centre retrospective case-control study**
Kwong A, Visram H, Graham N, Balchin K, Petrcich W, Dent S. The Ottawa Hospital, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada.

P3-11-04 **Male breast cancer: Overall survival in a single institution**
Bello MA, Bergmann A, Costa CRA, Pinto RR, Millen EC, Thuler LCS, Bender PFM. Brazilian National Cancer Institute, Rio de Janeiro, Brazil.

Treatment: Brain Metastases

P3-12-01 **Serum biomarkers identification using quantitative proteomics in patients (pts) with untreated brain metastases from HER2-positive breast cancer receiving capecitabine (C) and lapatinib (L) (UNICANCER LANDsCAPE trial)**
Gonçalves A, Camoin L, Ben Younès I, Romieu G, Campone M, Diéras V, Cropet C, Mahier Aït-Oukhatar C, Dalenc F, Le Rhun E, Labbe-Devilliers C, Borg J-P, Bachelot T. Institut Paoli Calmettes, Marseille, France; Université de la Méditerranée, Marseille, France; Centre Val d'Aurelle, Montpellier, France; Institut de Cancérologie de l'Ouest, Nantes, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Unicancer, Paris, France; Institut Claudius Regaud, Toulouse, France; Centre Oscar Lambret, Lille, France.

P3-12-02 **The impact of estrogen receptor status on treatment outcomes following gamma knife radiosurgery for brain metastases of primary breast cancer**
Cupelo EC, Aridgides PD, Bogart JA, Hahn SS, Shapiro AJ. SUNY Upstate Medical University, Syracuse, NY.

P3-12-03 **Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases**
Kodack DP, Chung E, Yamashita H, Incio J, Peters A, Song Y, Ager E, Huang Y, Farrar C, Lussiez A, Goel S, Snuderl M, Kamoun W, Hiddingh L, Tannous BA, Fukumura D, Engelman JA, Jain RK. Massachusetts General Hospital, Boston, MA.

P3-12-04 **A phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer**
Lin NU, Schwartzberg LS, Kesari S, Yardley DA, Verma S, Anders CK, Shih T, Shen Y, Miller K. UC San Diego, La Jolla, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Dana-Farber Cancer Institute, Boston, MA; The West Clinic, Memphis, TN; Geron, Menlo Park, CA; University of North Carolina at Chapel Hill, NC; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC., Nashville, TN.

P3-12-05 **Clinical features and outcomes of leptomeningeal metastasis in patients with breast cancer: a single center experience**
Jo J-C, Kang MJ, Ahn J-H, Jung KH, Kim JE, Gong G, Kim HH, Ahn SD, Kim SS, Son BH, Ahn SH, Kim S-B. Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

P3-12-06 **Clinicopathological Analysis of Breast Cancer Patients with Brain Metastases**
Ushio A, Sawaki M, Fujita T, Hattori M, Kondo N, Horio A, Gondou N, Iwata H. Aichi Cancer Center, Japan.

P3-12-07 **Voyagers and their aids: The role of interactions between tumor and endothelial cells in brain metastasis**
Shah KN, Faridi JS. University of the Pacific, Stockton, CA.

P3-12-08 **Incidence, predictive factors and outcome of brain metastases (BM) in a single institution cohort of breast cancer patients**
Perelló A, Alarcon J, Garcias C, Duran J, Colom B, Clemente G, Avella A, Canet R, Torrecabota J, Rifa J. Hospital Universitari Son Espases, Palma, Balearic Islands, Spain.

P3-12-09 **The risk of brain metastases according to expression of selected immunohistochemical markers in primary breast cancers**
Sosinska-Mielcarek K, Winczura P, Duchnowska R, Badzio A, Majewska H, Lakomy J, Peksa R, Pieczynska B, Radecka B, Debska S, Zok J, Rogowski W, Strzelecka M, Kulma-Kreft M, Blaszczyk P, Litwiniuk M, Jesien-Lewandowicz E, Rutkowski T, Jaworska-Jankowska M, Adamowicz K, Foszczynska-Kloda M, Biernat W, Jassem J. Regional Oncology Center, Gdansk, Poland; Medical University of Gdansk, Poland; Military Institute of Medicine, Warsaw, Poland; Regional Oncology Center in Opole, Opole, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; PCK Marine Hospital, Gdynia, Poland; Oncology Center in Bydgoszcz, Poland; Medical University of Poznan, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Wroclaw, Poland; Pomeranian Oncology Center, Szczecin, Poland.

P3-12-10 **Age, breast cancer subtype approximation and the risk of the development of brain metastasis in breast cancer patients**
Hung M-H, Liu C-Y, Chao T-C, Wang Y-L, Tsai Y-F, King K-L, Chiu J-H, Shiau C-Y, Shyr Y-M, Tzeng C-H, Tseng L-M. Taipei Veterans General Hospital, Taipei, Taiwan; National Yang-Ming University, Taipei, Taiwan.

P3-12-11 **Clinical outcome in patients with surgically resected brain metastases from breast cancer: prognostic considerations regarding molecular status and established prognostic classification systems**
Tabouret E, Metellus P, Tallet A, Figarella-Branger D, Charaffe-Jauffret E, Viens P, Gonçalves A. Institut Paoli Calmettes, Marseille, France; APHM, Marseille, France; Insitut Paoli-Calmettes, Marseille, France.

P3-12-12 **Chemotherapy and targeted therapy after whole-brain radiotherapy may improve survival in RPA class II/III patients with brain metastases from breast cancer**
Zhang Q, Chen J, Cai G, Yang Z, Chen J. Fudan University Shanghai Cancer Center, Shanghai, China.

Treatment: Bone Metastases

P3-13-01 **Prospective study of treatment pattern, effectiveness, and safety of zoledronic acid (ZOL) therapy beyond 24 months: subgroup analysis of patients (pts) with metastatic bone disease (MBD) from breast cancer (BC)**
Van den Wyngaert T, Delforge M, Doyen C, Duck L, Wouters K, Delabaye I, Wouters C, Wildiers H. Antwerp University Hospital; University Hospitals Leuven; C.H.U. Mont – Godinne; Clinique St-Pierre; Novartis Pharmaceuticals.

P3-13-02 **Safety and Efficacy of Zoledronic Acid Beyond 24 Months in Breast Cancer Patients**
Suzuki Y, Saito Y, Ogiya R, Oshitanai R, Terao M, Terada M, Morioka T, Tsuda B, Niikura N, Okamura T, Tokuda Y. Tokai University School of Medicine, Isehara, Kanagawa, Japan.

P3-13-03 **Molecular factors associated with bone metastases in breast cancer patients**
Winczura P, Sosinska-Mielcarek K, Duchnowska R, Badzio A, Lakomy J, Majewska H, Peksa R, Pieczynska B, Radecka B, Debska S, Zok J, Rogowski W, Strzelecka M, Kulma-Kreft M, Blaszczyk P, Litwiniuk M, Jesien-Lewandowicz E, Rutkowski T, Jaworska-Jankowska M, Adamowicz K, Foszczynska-Kloda M, Biernat W, Jassem J. Medical University of Gdansk, Poland; Regional Oncology Center, Gdansk, Poland; Regional Oncology Center, Opole, Poland; Military Institute of Medicine, Warsaw, Poland; Medical University of Lódz, Poland; Warmia and Masuria Oncology Center, Olsztyn, Poland; Maritime Hospital, Gdynia, Poland; Oncology Center, Bydgoszcz, Poland; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland; Regional Hospital in Wroclaw, Poland; West Pomeranian Oncology Center, Szczecin, Poland.

P3-13-04 **Skeletal related Events and Bone Metastasis Patients with Breast Cancer in Japan. A Retrospective Study**
Yamashiro H, Takada M, Imai S, Yamauch A, Tsuyuki S, Inamoto T, Matsutani Y, Sakata S, Wada Y, Okamura R, Harada T, Tanaka F, Moriguchi Y, Kato H, Higashide S, Kan N, Yoshibayashi H, Suwa H, Okino T, Nakayama I, Ichinose Y, Yamagami K, Hashimoto T, Nakatani E, Nagata Y, Kudo Y, Toi M. National Hospital Organization KURE Medical Center, Kure, Hiroshima, Japan; Graduate School of Medicine, Kyoto University, Kyoto, Japan; Kurashiki Central Hospital, Kurashiki, Okayama, Japan; Kitano Hospital (The Tazuke Kofukai Medical Research Institute), Osaka, Japan; Osaka Red Cross Hospital, Osaka, Japan; Tenri Hospital, Tenri, Nara, Japan; National Hospital Organization Kyoto Medical Center, Kyoto, Japan; National Hospital Organization Himeji Medical Center, Himeji, Hyogo, Japan; Yamatotakada Municipal Hospital, Yamatotakada, Nara, Japan; Osaka Saiseikai Noe Hospital, Osaka, Japan; Fukui Red Cross Hospital, Fukui, Japan; Kyoto City Hospital, Kyoto, Japan; Nagahama City Hospital, Nagahama, Shiga, Japan; Kan Norimichi Clinic, Kyoto, Japan; Japanese Red Cross Society Wakayama Medical Center, Wakayama, Wakayama, Japan; Hyogo Prefectural Tsukaguchi Hospital, Amagasaki, Hyogo, Japan; Kouga Public Hospital, Kouga, Shiga, Japan; Kyoto Min-iren Chuo Hospital, Kyoto, Japan; Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan; Shinko Hospital, Kobe, Hyogo, Japan; Hashimoto Clinic, Kobe, Hyogo, Japan; Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Hyogo, Japan; Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.

P3-13-05 **Evaluating efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal related events. TRIUMPH: A pragmatic multicentre trial**
Bouganim N, Vandermeer L, Kuchuk I, Dent S, Hopkins S, Song X, Robbins D, Spencer P, Mazzarello S, Hilton JF, Amir E, Dranitsaris G, Addison C, Mallick R, Clemons MJ. McGill University Health Center, Montreal, QC, Canada; Ottawa Hospital Cancer Center, Ottawa, ON, Canada; Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Health Economics and Biostatistics Consultant, Toronto, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON.

P3-13-06 **Osteocytic Connexin 43 Hemichannels in Prevention of Bone Metastasis**
Zhou JZ, Jiang JX. University of Texas Health Science Center, San Antonio, TX.

Treatment: DCIS/LCIS

P3-14-01 **Molecular definition of the transition of ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC)**
Colavito S, Stepansky A, Madan A, Harris LN, Hicks J, Bossuyt V, Rimm D, Lannin D, Stern DF. Yale University, New Haven, CT; Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; Case Western Reserve University, Cleveland, OH.

P3-14-02 Withdrawn

P3-14-03 Differences in pathological and biological factors between DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC)
MacGrogan G, Baranzelli MC, Picquenot JM, Penault-Llorca F, Mathieu MC, Tas P, Fermeaux V, Mery E, Sagan C, Blanc-Fournier C, Brabencova E, Arnould L, Jacquemier J, Ettore F, Velasco V, Gonzalves B, Brouste V, Tunon de Lara C. Institut Bergonié, Bordeaux, France; Centre Oscar Lambret, Lille, France; Centre Henri Becquerel, Rouen, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Gustave Roussy, Villejuif, France; Centre Eugène Marquis, Rennes, France; CHU de Limoges, Limoges, France; Institut Claudius Regaud, Toulouse, France; Centre René Gauducheau, Saint Herblain, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Centre Georges François Leclerc, Dijon, France; Institut Paoli Calmettes, Marseille, France; Centre Antoigne Lacassagne, Nice, France.

P3-14-04 Symptomatic DCIS is a risk factor for invasion and should be managed accordingly
Dimopoulos N, Williams K, Kirwan CC, Johnson R, Howe M, Bundred NJ. University Hospital of South Manchester.

P3-14-05 Recurrence in Patients Diagnosed with Ductal Carcinoma In Situ: Predictors and Prognostic Significance
Sue GR, Killelea B, Horowitz NR, Lannin DR, Chagpar AB. Yale University School of Medicine, New Haven, CT.

P3-14-06 The Utility of Margin Index To Predict Residual DCIS Following Breast Conserving Surgery
Aneja S, Lannin DR, Killelea B, Horowitz NR, Chagpar AB. Yale University School of Medicine, New Haven, CT.

Ongoing Trials 2: Surgery/Nodes

OT2-1-01 Feasibility of sentinel node detection after neoadjuvant chemotherapy for patient with proved axillary lymph node involvement: the French prospective multiinstitutional GANEA 2 ongoing trial
Classe J-M, Bordes V, Gimbergues P, Tunon de Lara C, Faure C, Belichard C, Houpeau J-L, Raro P, Dupré P-F, Houvenaeghel G, Barranger E, Marchal F, Deblay P, Rouanet P, Lefebvre C, Bourcier C, Alran S. Institut de Cancerologie de l'Ouest, Nantes Saint Herblain, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Bergonié, Bordeaux, France; Centre Leon Berard, Lyon, France; Centre Huguenin, Saint Cloud, France; Centre Oscar Lambret, Lille, France; Centre Hospitalier Universitaire Morvan, Brest, France; Paoli Calmettes, Marseille, France; CHU Lariboisière, Paris, France; Centre Alexis Vautrin, Nancy, France; Centre <Hospitalier Les Oudairies, La Roche sur Yon, France; Centre Val d'Aurelle, Montpellier, France; Centre Hospitalier Universitaire, Angers, France; Institut Curie, Paris, France.

OT2-1-02 Clinical node negative breast cancer patients undergoing breast conserving therapy: follow-up versus sentinel lymph node biopsy
van Roozendaal LM, Smidt ML, de Wilt HHW, van Dalen T, Strobbe LJA, van der Hage J, Tjan-Heijnen VCG, Linn SC, Serroyen JL. Maastricht University Medical Center, Maastricht, Netherlands; Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; Diakonessen Hospital Utrecht, Utrecht, Netherlands; Canisius-Wilhelmina Hospital, Nijmegen, Netherlands; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Maastricht University, Maastricht, Netherlands.

OT2-1-03 The Z11 design for breast cancer patients undergoing a mastectomy
van Roozendaal LM, Smidt ML, de Wilt HHW, van Dalen T, Strobbe LJA, van der Hage J, Tjan-Heijnen VCG, Linn SC, Serroyen JL. Maastricht University Medical Center, Maastricht, Netherlands; Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; Diakonessen Hospital Utrecht, Utrecht, Netherlands; Canisius-Wilhelmina Hospital, Nijmegen, Netherlands; Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Maastricht University, Maastricht, Netherlands.

OT2-1-04 Intraoperative assessment of tumor margins with a new optical imaging technology: A multi-center, randomized, blinded clinical trial
Jacobs LK, Carney PS, Cittadine AJ, McCormick DT, Somera AL, Darga DA, Putney JL, Adie SG, Ray P, Cradock KA, Tafra L, Gabrielson EW, Boppart SA. The Johns Hopkins University School of Medicine, Baltimore, MD; University of Illinois, Urbana, IL; Diagnostic Photonics, Inc, Chicago, IL; Carle Foundation Hospital, Urbana, IL; AdvancedMEMS, San Francisco, CA; Anne Arundel Medical Center, Annapolis, MD.

Ongoing Trials 2: Endocrine Therapy

OT2-2-01 SOFT and TEXT: Trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor-positive early breast cancer
Zickl L, Francis P, Fleming G, Pagani O, Walley B, Price KN, Gelber RD, Regan MM. International Breast Cancer Study Group, North American Breast Cancer Group.

OT2-2-02 Prospective multicentre study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial
Lintermans A, Dieudonné A-S, Blomme C, Lambrechts D, Wildiers H, Christiaens M-R, Timmerman D, Van Calster B, Decloedt J, Berteloot P, Joerger M, Zaman K, Dezentjé V, Neven P. University Hospitals Leuven, Belgium; Vesalius Research Center and VIB, Catholic University Leuven, Leuven, Belgium; AZ Sint-Blasius, Dendermonde, Belgium; AZ Sint-Maarten, Duffel, Belgium; Cantonal Hospital, Sint-Gallen, Switzerland; University Hospital CHUV, Lausanne, Switzerland; Leiden University Medical Center, Leiden, Netherlands.

OT2-2-03 Dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine-resistant HER2–/HR+ breast cancer: a phase II study
Andre F, Greil R, Denduluri N, Barrios C, Campone M, Cortes J, Neven P, Reddick C, Squires M, Zhang Y, Yovine A, Blackwell K. Institut Gustave Roussy, Villejuif, France; Medizinische Universitätsklinik Salzburg mit Hämatologie, Salzburg, Austria; Virginia Cancer Specialists, US Oncology, Arlington, VA; Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre, Brazil; Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain, France; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Hospital Gasthuisberg, Leuven, Belgium; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland; Duke University Medical Center, Durham, NC.

OT2-2-04 A phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk, hormone receptor-(HR) positive and HER2-negative breast cancer: SWOG/NSABP S1207
Chavez-Mac Gregor M, Barlow WE, Gonzalez-Angulo AM, Rastogi P, Mamounas EP, Ganz PA, Schott AF, Paik S, Lew DL, Bandos H, Hortobagyi GN. The University of Texas MD Anderson Cancer Center, Houston, TX; SWOG Statistical Center, Seattle, WA; NSABP/Four Allegheny Center, Pittsburgh, PA; Aultman Cancer Center, Canton, OH; UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; University of Michigan, Ann Arbor, MI; NSABP Division of Pathology, Pittsburgh, PA; NSABP Biostatistical Center, Graduate School of Public Health, University of Pittsburgh, PA.

OT2-2-05 A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (GBG-54 MALE)
Linder M, von Minckwitz G, Kamischke A, Rudlowski C, Eggemann H, Nekljudova V, Loibl S. German Breast Group, Neu-Isenburg; Kinderwunschzentrum Münster, Germany; Universitätsfrauenklinik Bonn; Universitätsfrauenklinik Magdeburg.

Ongoing Trials 2: Targeted Agents

OT2-3-01 Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC)
Schott AF, Wicha M, Cristofanilli M, Ruffini P, McCanna S, Reuben JM, Goldstein LJ. University of Michigan, Ann Arbor, MI; Fox Chase Cancer Center, Philadelphia, PA; Dompé s.p.a., Milano, Italy; MD Anderson Cancer Center, Houston, TX.

OT2-3-02 Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data
Canon JL, Bergh J, Saura C, Oliveira M, Houk B, Millham R, Barton J, Dowsett M, Giorgetti C. Grand Hopital de Charleroi, Charleroi, Belgium; Karolinska Institutet and University Hospital, Stockholm, Sweden; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Pfizer Oncology, La Jolla; Pfizer Oncology, Groton; Pfizer Biotechnology Unit & Oncology Clinical Research, San Diego; Royal Marsden Hospital, London, United Kingdom; Pfizer Oncology, Milan, Italy.

OT2-3-03 Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase 3 clinical trial
Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Ke C, Maniar T, Coleman RE. Massachusetts General Hospital, Boston, MA; PUCRS School of Medicine, Porto Alegre, Brazil; Breast Cancer Research Centre, Perth, WA, Australia; Aichi Cancer Center, Nagoya, Chikusa-ku, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc., Thousand Oaks, CA; CR-UK/YCR Sheffield Cancer Research Centre, Sheffield, United Kingdom.

OT2-3-04 A pilot phase II study to evaluate the impact of denosumab on disseminated tumor cells (DTC) in patients with early stage breast cancer (ESBC)
Li J, Rugo HS. University of California, San Francisco, CA.

OT2-3-05 AVASTEM: a phase II randomized trial evaluating anti-cancer stem cell activity of pre-operative bevacizumab and chemotherapy in breast cancer
Gonçalves A, Pierga J-Y, Brain E, Tarpin C, Cure H, Esterni B, Boyer-Chammard A, Bertucci F, Jalaguier A, Houvenaeghel G, Viens P, Charaffe-Jauffret E, Extra J-M. Institut Paoli Calmettes, Marseille, France; Institut Curie-Centre René Huguenin, Paris, France; Institut Jean Godinot, Reims, France.

OT2-3-06 A phase II, non-randomized, multicenter, exploratory trial of single agent BKM120 in patients with triple-negative metastatic breast cancer
Saura C, Lin N, Ciruelos E, Maurer M, Lluch A, Gavilé J, Winer E, Baselga J, Rodón J. Vall d'Hebron University Hospital, Barcelona, Spain; Dana-Farber Cancer Institute, Boston, MA; Hospital 12 de Octubre, Madrid, Spain; Columbia University Medical Center, New York; Hospital Clínico de Valencia, Valencia, Spain; Instituto Valenciano de Oncología, Valencia, Spain; Massachusetts General Hospital, Boston; SOLTI Breast Cancer Research Group, Barcelona, Spain.

OT2-3-07 A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with *BRCA1* or *BRACA2* mutation and metastatic breast cancer
Isakoff SJ, Pulhalla S, Shepherd SP, Falotico N, Kaufman B, Friedlander M, Robson M, Domchek S, Garber J, McKeegan E, Chyla B, Qian J, Giranda VL. Massachusetts General Hospital, Boston, MA; University of Pittsburgh, PA; Abbott, Abbott Park, IL, Virgin Islands, British; Sheba Medical Center, Israel; Prince of Wales Hospital, Sydney, Australia; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Pennsylvania, Philadelphia, PA; Dana Farber Cancer Institute, Boston, MA.

OT2-3-08 Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer, treated with aromatase inhibitor, and progressed on or after mTOR inhibitor-based treatment – BELLE-3
Di Leo A, Germa C, Weber D, Di Tomaso E, Dharan B, Massacesi C, Hirawat S. Sandro Pitigliani Hospital of Prato, Prato, Italy; Novartis Oncology, Paris, France; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

OT2-3-09 Phase III randomized study of the oral pan-PI3K inhibitor BKM120 with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer resistant to aromatase inhibitor – BELLE-2
Baselga J, Campone M, Cortes J, Iwata H, de Laurentiis M, Jonat W, Di Tomaso E, Hachemi S, Goteti S, Germa C, Massacesi C, Arteaga C. Massachusetts General Hospital, Boston, MA; Centre René Gauducheau, Nantes, France; Vall d'Hebron Institute Oncology, Barcelona, Spain; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Università degli Studi di Napoli Federico II, Naples, Italy; Christian-Albrechts-Universität zu Kiel, Kiel, Germany; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA; Novartis Oncology, Paris, France; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Vanderbilt-Ingram Cancer Center, Nashville, TN.

OT2-3-10 Phase II study of panitumumab, nab-paclitaxel, and carboplatin for patients with primary inflammatory breast cancer (IBC) without HER2 overexpression
Willey JS, Alvarez RH, Valero V, Lara JM, Parker CA, Hortobagyi GN, Ueno NT. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of TX, MD Anderson Cancer Center, Houston, TX.

OT2-3-11 Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer
Mayer EL, Miller K, O'Shaughnessy J, Dickler M, Vogel C, Leyland-Jones B, Steelman L, Robinson M, Kuriyama N, Agarwal S. Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Baylor-Charles A. Sammons Cancer Center, Texas Oncology and US Oncology, Dallas, TX; Memorial Sloan-Kettering Cancer Center, New York, NY; Sylvester Comprehensive Cancer Center, Miami, FL; Sanford Research/USD, Sioux Falls, SD; AVEO Oncology, Cambridge, MA.

7:30 pm–10:00 pm
OPEN SATELLITE EVENT presented by Clinical Care Options
Marriott Rivercenter

HER2-Positive Breast Cancer: Applying the Latest Developments to Clinical Practice

WEBSITE: **http://clinicaloptions.com/HER2Positive**

7:30 pm–10:00 pm

OPEN SATELLITE EVENT presented by Clinical Care Options
Marriott Rivercenter

Practical Answers to Your Clinical Challenges: Optimal Use of Bone-Modifying Agents in Breast Cancer

WEBSITE: **http://clinicaloptions.com/BoneHealthBreastCancer**

FRIDAY, DECEMBER 7, 2012

6:45 am–5:15 pm

REGISTRATION
Bridge Hall

7:00 am–9:00 am

POSTER DISCUSSION 7: NEOADJUVANT ENDOCRINE THERAPY & BISPHOSPHONATES
Ballroom A

Viewing 7:00 am
Discussion 7:45 am

Ruth O'Regan, MD, Chair and Discussant
Emory University School of Medicine
Atlanta, GA
and
Ingrid Mayer, MD, MSCI, Discussant
Vanderbilt University Medical Center
Nashville, TN

PD07-01 **Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%**
Ellis MJ, Suman V, McCall L, Luo R, Hoog J, Brink A, Watson M, Ma C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther M, Dayao Z, Leitch M, Ota D, Olson J, Hunt K, Allred C. Siteman Cancer Center, Washington University, St Louis, MO; Mayo Clinic; Duke University; Doctor's Hospital of Laredo; Nashville Breast Center; MD Anderson Cancer Center; St. Elizabeth Med Ctr Southwest; Univ of New Mexico; UT Southwestern; University of Maryland Medical Center.

PD07-02 **Anticancer activity of letrozole plus zoledronic acid as neoadjuvant therapy for postmenopausal patients with breast cancer: FEMZONE trial results**
Fasching PA, Jud SM, Hauschild M, Kümmel S, Schütte M, Warm M, Hanf V, Muth M, Baier M, Schulz-Wendtland R, Beckmann MW, Lux MP. Erlangen University Hospital, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany; Frauenklinik Rheinfelden, Rheinfelden, Germany; Frauenklinik, Klinikum Essen-Mitte, Essen, Germany; Essen University Hospital, Essen, Germany; Cologne University Hospital, Cologne, Germany; Kliniken der Stadt Köln Holweide, Cologne, Germany; Klinikum Fuerth, Fuerth, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Erlangen University Hospital, Friedrich Alexander University of Erlangen–Nuremberg, Erlangen, Germany.

PD07-03 **Increased pathologic complete response rate after a long term neoadjuvant letrozole treatment in postmenopausal estrogen and/or progesterone receptor-positive breast cancer**
Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Generali D, Berruti A, Bottini A. A.O. Istituti Ospitalieri di Cremona, Cremona, Italy; A.O.U. San Luigi Gonzaga di Orbassano, Orbassano, TO, Italy.

PD07-04 **A randomized phase II neoadjuvant trial evaluating anastrozole and fulvestrant efficiency for post-menopausal ER-positive, HER2-negative breast cancer patients: first results of the UNICANCER CARMINA 02 French trial**
Lerebours F, Bourgier C, Alran S, Mouret-Reynier M-A, Venat Bouvet L, Kerbrat P, Salmon R, Mijonnet S, Becette V, Trassard M, Spyratos F, Lebas N, Martin A-L, Lemonnier J, Mouret-Fourme E. Institut Curie, Saint Cloud, France; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Centre Jean Perrin, Clermont-Ferrand, France; CHU, Limoges, France; Centre Eugene Marquis, Rennes, France; R&D Unicancer, Paris, France.

PD07-05 **A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer**
Hasegawa Y, Kohno N, Horiguchi J, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Akazawa K. Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; Tokyo Medical University Hospital, Tokyo, Japan; Gunma University Hospital, Maebashi, Gunma, Japan; Toranomon Hospital, Tokyo, Japan; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; Osaka University Hospital, Suita, Osaka, Japan; Naga Municipal Hospital, Kinokawa, Wakayama, Japan; Konan Hospital, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, Osaka, Japan; Shinko Hospital, Kobe, Hyogo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan.

PD07-06 **NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)**
van de Ven S, Liefers G-j, Putter H, van Warmerdam LJ, Kessels LW, Dercksen W, Pepels MJ, Maartense E, van Laarhoven HWM, Vriens B, Smit VTHBM, Wasser MNJM, Meershoek-Klein Kranenbarg EM, van Leeuwen-Stok E, van de Velde CJH, Nortier JWR, Kroep JR. Leiden University Medical Center (LUMC), Leiden, Netherlands; Catharina Hospital, Eindhoven, Netherlands; Deventer Hospital, Deventer, Netherlands.

PD07-07 **Prediction of antiproliferative response to lapatinib by HER3 in an exploratory analysis of HER2-non-amplified (HER2-) breast cancer in the MAPLE presurgical study (CRUK E/06/039)**
Dowsett M, Leary A, Evans A, A'Hern R, Bliss J, Sahoo R, Detre S, Hills M, Haynes B, Harper-Wynne C, Bundred N, Coombes G, Smith IE, Johnston S. Royal Marsden Hospital, London, United Kingdom; Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset, United Kingdom; Institute of Cancer Research, London, United Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom; University Hospital of South Manchester NHS Trust, Manchester, United Kingdom.

PD07-08 **Zoledronic acid specifically inhibits development of bone metastases in the post-menopausal setting – evidence from an in vivo breast cancer model**
Holen I, Wang N, Reeves KJ, Fowles AM, Croucher PI, Eaton CL, Ottewell PD. University of Sheffield, United Kingdom.

PD07-09 **Zoledronate versus ibandronate comparative evaluation (ZICE) trial - first results of a UK NCRI 1,405 patient phase III trial comparing oral ibandronate versus intravenous zoledronate in the treatment of breast cancer patients with bone metastases**
Barrett-Lee PJ, Casbard A, Abraham J, Grieve R, Wheatley D, Simmons P, Coleman R, Hood K, Griffiths G, Murray N. Velindre NHS Trust, Cardiff, Wales, United Kingdom; Cardiff University School of Medicine, Cardiff, Wales, United Kingdom; University Hospital, Coventry, England, United Kingdom; Royal Cornwall Hospital, Truro, England, United Kingdom; University Hospital, Southampton, England, United Kingdom; Weston Park Hospital, Sheffield, England, United Kingdom; Royal Adelaide Hospital, Adelaid, South Australia, Australia.

7:00 am–9:00 am
POSTER DISCUSSION 8: DISPARITIES
Ballroom B

Viewing 7:00 am
Discussion 7:45 am

Patricia Ganz, MD, Chair
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA

Dawn Hershman, MD, Discussant
Columbia University Medical Center
New York, NY
and
Amelie Ramirez, DRPH, MPH, DO, Discussant
UT Health Science Center
San Antonio, TX

PD08-01 **Utilization of Oncotype DX in an inner-city population: Race or place?**
Guth AA, Fineberg S, Fei K, Franco R, Bickell N. NYU School of Medicine, New York, NY; Montefiore Medical Center, Bronx, NY; Mount Sinai School of Medicine, New York, NY.

PD08-02 **Disparities in the utilization of reconstruction after mastectomy: The California Teachers Study**
Kruper L, Xu XX, Bernstein L, Henderson K. City of Hope Cancer Center, Duarte, CA.

PD08-03 **Barriers to breast reconstructive surgery in an underprivileged community: Does income really matter?**
Zelek LH, Festa A, Barbeau E, Morere J-F. Assistance Publique Hôpitaux de Paris, CHU Avicenne, Bobigny, France; Oncologie 93, Bobigny, France.

PD08-04 **Factors which affect surgical management in an underinsured, county hospital population**
Komenaka IK, Olsen L, Klemens AE, Hsu C-H, Nodora J, Martinez ME, Thompson PA, Bouton M. Maricopa Medical Center, Phoenix, AZ; University of Arizona, Tucson, AZ; Moores Cancer Center, University of California, San Diego, CA.

PD08-05 **Spanning the continuum to assess, serve and navigate Latinas with breast cancer: A tale of six projects**
Ramirez AG, Holden AE, Gallion K, SanMiguel SA, Munoz E, Penedo FJ, Perez-Stable EJ, Talavera GG, Carrillo JE, Fernandez ME. University of Texas Health Science Center at San Antonio, TX; Redes en Accion: The National Latino Cancer Research Network, The University of Texas Health Science Center at San Antonio, San Antonio, TX.

PD08-06 **Significant clinical impact of recurrent *BRCA1* and *BRCA2 (BRCA)* mutations in Mexico**
Villarreal-Garza C, Herrera LA, Herzog J, Port D, Mohar A, Perez-Plasencia C, Clague J, Alvarez RMa, Santibanez M, Blazer KR, Weitzel JN. Instituto Nacional de Cancerologia, Mexico City, Mexico DF, Mexico; Instituto Nacional de Cancerologia – Instituto de Investigaciones Biomedicas, UNAM, Mexico City, Mexico DF, Mexico; City of Hope, Duarte, CA.

7:00 am–9:00 am
POSTER SESSION 4 & CONTINENTAL BREAKFAST
Exhibit Halls A–B

Detection/Diagnosis: Breast Imaging - MRI

P4-01-01 **Integrating dynamic magnetic resonance imaging and gene expression profiling reveals novel therapeutic targets in locally advanced breast cancer**
Hughes NP, Mehta S, Winchester L, Han C, Buffa FM, Adams RF, Harris AL. Stanford University, Stanford, CA; University of Oxford, United Kingdom; Churchill Hospital, Oxford, United Kingdom.

P4-01-02 **Association of DCE-MRI texture features with molecular phenotypes and neoadjuvant therapy response in breast cancer**
Banerjee N, Maity S, Varadan V, Janevski A, Kamalakaran S, Sikov W, Abu-Khalaf M, Bossuyt V, Lannin D, Harris L, Cornfeld D, Dimitrova N. Philips Research North America; Yale Comprehensive Cancer Center; Warren Alpert Medical School of Brown University; Yale-New Haven Hospital; Yale Breast Cancer Program; Seidman Cancer Center.

P4-01-03 **Quantitative DCE-MRI to predict the response of primary breast cancer to neoadjuvant therapy**
Li X, Arlinghaus LR, Chakravarthy AB, Abramson RG, Abramson VG, Farley J, Ayers GD, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders ME, Yankeelov TE. Vanderbilt University.

P4-01-04 **MRI enhancement in stromal tissue surrounding breast tumors: Association with RFS following neoadjuvant chemotherapy**
Jones EF, Sinha SP, Newitt D, Klifa C, Kornak J, Park CC, Hylton NM. University of California, San Francisco, CA.

P4-01-05 **Utility of Preoperative Routine MRI and PET/CT in Breast Cancer Staging vs. Surgical Staging**
Higaki K, Kochi M, Ito M, Otani S. Hiroshima City Hospital, Hiroshima, Japan.

P4-01-06 **Evaluation of 3D T2-weighted Breast MRI**
Moran CJ, Hargreaves BA, Saranathan M, Daniel BL. Stanford University, Stanford, CA.

P4-01-07 **The Relationship of Breast Density in Mammography and Magnetic Resonance (MR) Imaging in a High Risk Population**
Chun J, Refinetti AP, Schnabel F, Leite AP, Price A, Billig J, Schwartz S, Moy L. NYU Langone Medical Center, New York, NY.

P4-01-08 **Effect of bilateral salpingo-oophorectomy on breast MRI fibroglandular volume and background parenchymal enhancement for BRCA 1/2 mutation carriers**
DeLeo, III MJ, Domchek S, Kontos D, Conant E, Weinstein S. Hospital of the University of Pennsylvania, Philadelphia, PA.

P4-01-09 **Screening breast magnetic resonance imaging (MRI) in early-stage breast cancer survivors**
Dowton AA, Meyer ME, Ruddy KJ, Yeh ED, Partridge AH. Dana-Farber Cancer Institute, Boston, MA; Brigham & Women's Hospital, Boston, MA.

P4-01-10 **High-resolution diffusion weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3 Tesla**
Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Joe BN, Hylton NM. University of California, San Francisco, CA; Siemens Medical Solutions, USA, Inc, San Francisco, CA; Siemens Medical Solutions, Erlangen, Germany.

P4-01-11 **Clinical Findings and Outcomes from MRI Staging of Breast Cancer in a Diverse Population**
Raghavendra A, Ji L, Ricker C, Tang S, Church TD, Larsen L, Sheth P, Sposto R, Sener S, Tripathy D. University of Southern California Keck School of Medicine, Los Angeles, CA; Los Angeles County and University of Southern California (LAC+USC) Healthcare Network, Los Angeles, CA; USC Norris Comprehensive Cancer Center, Los Angeles, CA.

P4-01-12 **Compliance with Recommended Follow-Up after MRI-Guided Core Needle Biopsy of Suspicious Breast Lesions: A Retrospective Study**
Thompson MO, Lipson JA, Daniel BL, Harrigal CL, Mullarkey PJ, Ikeda DM. Stanford University School of Medicine, Stanford, CA.

P4-01-13 **Practice patterns of MRI utilization for breast cancer treatment within the University of California system as part of the Athena initiative**
Tokin CA, Ojeda H, Mayadev JS, Hylton NM, Fowble BL, Rugo HS, Hwang S, Hurvitz S, Wells C, Blair SL. University of California, San Diego; University of California, Davis; University of California, San Francisco; Duke University; University of California, Los Angeles.

P4-01-14 **Can MRI predict the response to neoadjuvant chemotherapy in breast cancer accurately?**
Fatayer H, Kim B, Dall B, Sharma N, Manuel D, Shabaan A, Perren T, Velikova G, Horgan K, Lansdown M. Leeds General Infirmary; St James's University Hospital.

P4-01-15 **Impact of Preoperative MRI on the Surgical Treatment of Breast Cancer: A SEER-Medicare Analysis**
Thorsen CM, Weiss JE, Kerlikowske K, Ozanne EM, Buist DS, Hubbard RA, Tosteson AN, Henderson LM, Virnig BA, Goodrich ME, Onega TL. University of California, San Francisco, CA; Dartmouth Medical School, Lebanon, NH; University of Washington, Seattle, WA; University of North Carolina, Chapel Hill, NC; University of Minnesota, Minneapolis, MN.

P4-01-16 **Withdrawn**

P4-01-17 **Ductolobular breast carcinoma and the role of preoperative magnetic resonance imaging**
Postma EL, El Sharouni MA, Verkooijen HM, Witkamp AJ, van den Bosch MA, van Hillegersberg R, van Diest PJ. UMC Utrecht, Utrecht, Utrecht, Netherlands.

Detection/Diagnosis: Molecular, Functional, and Novel Imaging

P4-02-01 **18F-FDG PET/CT for the assessment of locoregional lymph node involvement and radiotherapy indication in stage II-III breast cancer treated with neoadjuvant chemotherapy**
Koolen BB, Valdés Olmos RA, Vogel WV, Vrancken Peeters M-JTFD, Rodenhuis S, Rutgers EJT, Elkhuizen PHM. Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.

P4-02-02 **Comparison of 18F-FDG PET-CT and 11C-MET PET-CT for assessment of response to neoadjuvant chemotherapy in locally advanced breast carcinoma**
Dinesh A, Ramteke VK, Chander J, Tripathi M, Mahajan S. Maulana Azad Medical College, New Delhi, Delhi, India; Institute of Nuclear Medicine & Allied Sciences, New Delhi, Delhi, India.

P4-02-03 **FDG PET/CT for early monitoring of response to neoadjuvant chemotherapy in breast cancer patients**
Andrade W, Soares F, Lima E, Maciel MdS, Toledo C, Iyeyasu H, Cruz M, Fanelli M. A. C. Camargo Cancer Hospital, São Paulo, SP, Brazil.

P4-02-04 **Tissue oxyhemoglobin dynamics measured with functional optical imaging immediately after starting chemotherapy correlates with markers of cellular proliferation and inflammation in a rat breast tumor model**
Ueda S, Roblyer D, Cerussi A, Saeki T, Tromberg B. Beckman Laser Institute, University of California, Irvine, Irvine, CA; Saitama Medical University, Hidaka, Saitama, Japan.

P4-02-05 **A novel 64Cu-liposomal PET agent (MM-DX-929) predicts response to liposomal chemotherapeutics in preclinical breast cancer models**
Lee H, Zheng J, Gaddy D, Kirpotin D, Dunne M, Drummond D, Allen C, Jaffray D, Hendriks B, Wickham T. Merrimack Pharmaceuticals, Boston, MA; Princess Margaret Hospital, University Health Network, Toronto, ON, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, ON, Canada.

P4-02-06 **Molecular imaging with trastuzumab and pertuzumab of HER2-positive breast cancer in mice: a step towards personalized medicine**
Collin B, Oudot A, Vrigneaud J-M, Moreau M, Raguin O, Duchamp O, Tizon X, Denat F, Varoqueaux N, Brunotte F, Fumoleau P. Centre Georges François Leclerc, Dijon, France; Institut de Chimie Moléculaire de l'université de Bourgogne, Dijon, France; Oncodesign, Dijon, France; Roche France, Boulogne Billancourt, France.

P4-02-07 **Early Optical Tomography Changes Predict Breast Cancer Response to Neoadjuvant Chemotherapy**
Lim EA, Gunther JE, Flexman M, Kim HK, Hibshoosh H, Kalinsky K, Crew K, Maurer M, Taback B, Feldman S, Brown M, Refice S, Alvarez-Cid M, Hielscher A, Hershman DL. Columbia University Medical Center, New York, NY; Columbia University, New York, NY; Herbert Irving Comprehensive Cancer Center, New York, NY; Mailman School of Public Health, New York, NY.

P4-02-08 **Quantitative Characterization of 3D Vasculature Spatial Patterns Within Tumor Microenvironment of Breast Cancer Stem Cells**
Zhan M, Li F, Zhu Y, Ma J, Landua J, Wei W, Vadakkan T, Zhang M, Dickinson M, Lewis M, Rosen J, Wong S. NCI Center for Modeling Cancer Development, The Methodist Hospital, Houston, TX; Baylor College of Medicine, Houston, TX.

P4-02-09 **Molecular Breast Imaging: the sensitivity of breast-specific gamma imaging (BSGI) as a diagnostic adjunct to mammography and ultrasound in a triple assessment protocol**
Weigert JM, Kieper DA, Stern LH, Böhm-Vélez M. Mandell and Blau MDs PC, New Britain, CT; Hampton University, Hampton, VA; Thomas Jefferson University, Methodist Division, Philadelphia, PA; Weinstein Imaging Associates, Pittsburgh, PA.

P4-02-10 **Molecular Breast Imaging: A multicenter clinical registry to compare breast-specific gamma imaging (BSGI) and breast MRI in the detection of breast carcinoma**
Weigert JM, Kieper DA, Stern LH, Böhm-Vélez M. Hampton University, Hampton, VA; Thomas Jefferson University, Methodist Division, Philadelphia, PA; Mandell and Blau MDs PC, New Britain, CT; Weinstein Imaging Associates, Pittsburgh, PA.

Detection/Diagnosis: Breast Imaging - Other Methods

P4-03-01 **Distance of breast cancer from the skin influence axillary nodal metastasis**
Kim EJ, Chae BJ, Song BJ, Kwak HY, Chang EY, Kim SH, Jung SS. Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

P4-03-02 **Automatic BI-RADS Diagnosis of Breast Lesions by CAD(computer-aid diagnosis)**
Kuo W-H, Chuang S-C, Yang S-H, Chen C-N, Chen A, Chang K-J. National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Graduate Institute of Industrial Engineering, National Taiwan University, Taipei, Taiwan.

P4-03-03 **Feasibility study of a new volume navigation system-guided breast biopsy method for incidental enhancing lesions detected by breast contrast-enhanced magnetic resonance imaging**
Takahashi M, Jinno H, Hayashida T, Nemoto M, Tanimoto A, Kitagawa Y. Keio University School of Medicine, Tokyo, Japan.

P4-03-04 **The potential use of Optical Coherence Tomography for intraoperative breast tumour margin width estimation**
Wilson BC, Akens MK, Niu CJ. University Health Network, Ontario Cancer Institute, Toronto, ON, Canada; Tornado Medical System, Toronto, ON, Canada.

P4-03-05 **The Clinical Trial of New Optical Mammography**
Ogura H, Yoshimoto K, Nasu H, Hosokawa Y, Matsunuma R, Ide Y, Yamaki E, Yamashita D, Suzuki T, Oda M, Ueda Y, Yamashita Y, Sakahara H. Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan.

P4-03-06 **Non-invasive classification of microcalcifications by the use of X-ray phase contrast mammography as a novel tool in breast diagnostics**
Hauser N, Wang Z, Kubik-Huch RA, Singer G, Trippel M, Roessl E, Hohl MK, Stampanoni M. Interdisciplinary Breast Center Kantonsspital Baden, Baden, Switzerland; Paul Scherrer Institut, Villigen, Switzerland; Kantonsspital Baden, Baden, Switzerland; Philips Research Laboratories, Hamburg, Germany.

P4-03-07 **Angiogenic effect of bevacizumab and paclitaxel in metastatic breast cancer: evaluation by contrast-enhanced ultrasonography using Sonazoid®**
Ito T, Mizuno H, Iiboshi Y, Yamamura N, Fujii H, Hitora T, Fujii R, Ohashi T, Nakagawa T, Izukura M. Rinku General Medical Center, Izumisano, Osaka, Japan.

P4-03-08 **A new real-time image fusion technique, a coordinated sonography and MRI using magnetic position tracking system, improves the sonographic identification of enhancing lesions in breast MRI**
Nakano S, Fujii K, Yoshida M, Kousaka J, Mouri Y, Fukutomi T, Ishiguchi T. Aichi Medical University, Nakakute, Aichi, Japan.

P4-03-09 **A comparison of MRI, PET-CT, and ultrasonography for evaluation of tumor response to neoadjuvant chemo-therapy in patients with locally advanced breast cancer**
Boothe DL, Stessin A, Nagar H, Hayes MK. Weill Cornell Medical College, New York, NY.

P4-03-10 **Sonographic-pathological correlation in contrast-enhanced ultrasonography in the diagnosis of breast cancers**
Kato K, Miyamoto Y, Kamio M, Nogi H, Imawari Y, Mimoto R, Toriumi Y, Nakata N, Takeyama H, Uchida K. The Jikei University School of Medicine, Tokyo, Japan.

P4-03-11 **SUVmax of FDG-PET/CT Is Associated with Chemotherapy Response Assay Test Results and Prognostic Factors in Breast Cancer Patients**
Lee A, Chang J, Bang B, Lee J, Han D, Min S, Yun C, Kim BS, Lim W, Paik N, Moon B-I. Ewha Womans University Hospital, Seoul, Republic of Korea.

P4-03-12 **Diagnostic value and clinical significance of integrin αvβ3 in breast mass**
Xu Z, Song Y, Sun L, Sun G, Ma Q, Gao S, Wang K. China-Japan Union Hospital of JiLin University, JiLin Province Breast Diseases Institute, Changchun, Jilin, China; China-Japan Union Hospital of JiLin University, Changchun, Jilin, China.

Tumor Cell and Molecular Biology: Immunology and Preclinical Immunotherapy

P4-04-01 **Combination of intratumoral CpG with systemic anti-OX40 and anti-CTLA4 mAbs eradicates established triple negative breast tumors in mice**
Li J, Tandon V, Levy R, Esserman L, Campbell M. University of California, San Francisco, CA; Stanford University, Stanford, CA.

P4-04-02 **Tumor-initiated peripheral myeloid cell expansion is reversed by radiation therapy**
Gough MJ, Savage T, Bahjat KS, Redmond W, Bambina S, Kasiewicz M, Cottam B, Newell P, Crittenden MR. Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR; Providence Cancer Center, Portland, OR; The Oregon Clinic, Portland, OR.

P4-04-03 **Monocytic immature myeloid cells permit tumor immune evasion during postpartum involution**
Schedin P, Martinson H, Callihan E, Jindal S, Borges V. University of Colorado, Aurora, CO.

P4-04-04 **Immunohistochemical analysis of Cancer Testis antigens and Topoisomerase 2-alpha expression in triple negative breast carcinomas: a retrospective study**
Juretic A, Mrklic I, Spagnoli GC, Pogorelic Z, Tomic S. Zagreb University Hospital Centre, Zagreb, Croatia; Split University Hospital Centre, Split, Croatia; University of Basel, Switzerland.

P4-04-05 ***Listeria monocytogenes*-based bivalent *Lm*-LLO immunotherapy for the treatment of HER2/neu positive and triple negative breast cancer and its impact on immunosuppression**
Wallecha A, Ramos K, Malinina I, Singh R. Advaxis Inc, Princeton, NJ.

P4-04-06 **Young women's breast cancer is characterized by increased immune suppression through circulating myeloid derived supressor cells**
Borges VF, Ramirez O, Borakove M, Manthey E, Diamond JR, Elias AD, Finlayson C, Kounalakis N, Jordan K. University of Colorado Denver, Aurora, CO; University of Colorado Cancer Center, Aurora, CO.

P4-04-07 **Tartrate-resistant Acid Phosphatase (TRAcP)-Expressed Tumor-Associated Macrophages Promote Breast Cancer Progression**
Dai M-S, Wu C-C, Chang P-Y, Ho C-L, Hsieh Y-F, Lo K-Y, Kao W-Y, Chao T-Y, Yu J-C. Tri-Service General Hospital, Taipei, Taiwan; Taipei Medical University, Taipei, Taiwan.

P4-04-08 **A Potential non-viral vector to transfect dendritic cell and thereby MHC-Class I antigen presentation might be a potential use in carcinoma**
Shaheen S, Akita H, Souichirou I, Miura N, Harashima H. Hokkaido University, Sapporo, Hokkaido, Japan.

Tumor Cell and Molecular Biology: Gene Therapy

P4-05-01 **Oncolytic Herpes Simplex Virus Vector G47Δ Effectively Targets Breast Cancer Stem Cells**
Liu R, Zeng W, Hu P, Wu J, Li J, Wang J, Lei L. The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; The Sichuan Province Cancer Hospital, Chengdu, Sichuan, China.

Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets

P4-06-01 **JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting**
Overmoyer BA, Almendro V, Shu S, Peluffo G, Park SY, Nakhlis F, Bellon JR, Yeh ED, Jacene HA, Hirshfield-Bartek J, Polyak K. Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Seoul National University, Seoul, Korea.

P4-06-02 **Identification of novel G-protein coupled receptor targets in HER2-positive breast cancer**
Yadav P, Bhat RR, Chayanam S, Christiny PI, Nanda S, Hu H, Creighton C, Osborne CK, Schiff R, Trivedi MV. University of Houston, TX; Lester & Sue Smith Breast Center, Dan Duncan Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX.

P4-06-03 **Zinc Finger Nuclease Genome Engineering Reveals Multiple Functions of Secretory Leukocyte Peptidase Inhibitor in Regulating Pleuripotency of Cancer Stem Cells in Inflammatory Breast Cancer**
Robertson FM, Hibbs S, Boley KM, Chu K, Ye Z, Wright MC, Liu H, Luo AZ, Cristofanilli M, Wemhoff G. The University of Texas MD Anderson Cancer Center, Houston, TX; Sigma-Aldrich, St. Louis, MO; Fox Chase Cancer Center, Philadelphia, PA.

P4-06-04 **Gamma-secretase inhibitors suppress the activation of NFκB and the expression of TNFα, IL-6 and IL-8 in triple negative breast cancer cells**
Gu J-W, King J, Makey KL, Chinchar E, Gibson J, Miele L. University of Mississippi Medical Center, Jackson, MS.

P4-06-05 **NF-κB Upregulates β1-integrin via Increased Transcriptional Activity in Three-dimensional Culture: a Mechanism by which Malignant Breast Cells Acquire Radioresistance**
Ahmed KM, Zhang H, Park CC. Lawrence Berkeley National Laboratory, Berkeley, CA; University of California, San Francisco, CA.

P4-06-06 **RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate chemosensitivity in breast cancer**
Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, Shay JW. University of Texas Southwestern, Dallas, TX.

P4-06-07 **Moved to Poster Session 6, Saturday, December 8 7:00 AM - 8:30 AM**

P4-06-08 **Clinical utility of functional analysis of FGFR kinase family for selecting patients who may benefit from FGFR inhibitors**
Hoe N, Zhou J, Kuy C, Jin K, Srikrishnan R, Soundararajan A, Ma Y, Liu X, Singh S. Prometheus Labs, San Diego, CA.

P4-06-09 **Cell surface receptor CDCP1 as a potential marker of triple negative breast cancers progression**
Campiglio M, Sasso M, Bianchi F, De Cecco L, Turdo F, Triulzi T, Orlandi R, Morelli D, Aiello P, Ghirelli C, Agresti R, Tagliabue E. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Fondazione IRCCS Istituto Nazionale dei Tumori.

P4-06-10 **Epigenetic silencing of glutamine synthetase (Glul) defines glutamine depletion therapy**
Cavicchioli F, Shia A, O'Leary K, Haley V, Crook TR, Thompson AM, Lackner M, Lo Nigro C, Schmid P. Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom; Ninewells Hospital, University of Dundee, United Kingdom; Genentech, Inc., San Francisco; S. Croce General Hospital, Cuneo, Italy.

P4-06-11 **Expression of genes spanning a breast cancer susceptibility locus on 6q25.1 is modulated by epigenetic modification**
Dunbier AK, White J, Van Huffel S. University of Otago, Dunedin, Otago, New Zealand.

P4-06-12 **Monoclonal antibodies against nicastrin for the treatment of breast cancer: *in vitro* and *in vivo* characterisation and function**
Filipovic A, Lombardo Y, Deonarain M, Giamas G, Cordingley H, Tralau-Stewart C, Coombes RC. Imperial College London, United Kingdom.

P4-06-13 **Effects of Statin on triple-negative breast cancer (TNBC) with Ets-1 overexpression**
Lee S, Jung HH, Park YH, Ahn JS, Im Y-H. Samsung Medical Center.

P4-06-14 **CD146-suppresses breast tumor invasion via a novel transcription target TIMPv**
Shanmuganathan S, AbdElmageed Z, Fernando A, Gaur R, Ramkumar A, Bhat S, Gupta I, Muzumdar S, Hakkim L., Ouhtit A. Sultan Qaboos University, Al-Khod, Seeb, Oman.

P4-06-15 **Mifepristone modifies the tumor microenvironment increasing the therapeutic efficiency of low doses of Doxorubicin liposomes or paclitaxel-albumin nanoparticles in a murine model of breast cancer**
Sequeira GR, Vanzulli SI, Lamb CA, Rojas PA, Lanari C. Instituto de Biología y Medicina Experimental, Ciudad Autónoma de Buenos Aires, Argentina; Academia Nacional de Medicina, Ciudad Autónoma de Buenos Aires, Argentina.

P4-06-16 **TGF-β2, A Novel Target of CD44-Promoted Breast Cancer Invasion**
Gupta I, Madani S, Abdraboh M, Al Riyami H, Muzumdar S, AbdElmageed Z, Shanmuganathan S, Bhat S, Ramkumar A, Hakkim L, Ouhtit A. College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Al Khuwd, Oman.

P4-06-17 **Antitumor activity of the novel mithramycin analog EC8042 in triple negative breast cancer**
Pandiella A, Montero JC, Cuenca D, Re-Louhau F, Nuñez LE, Moris F, Ocana A. Salamanca Cancer Research Center, Salamanca, Spain; Translational Research Unit, Albacete University Hospital, Albacete, Spain; Entrechem SL, Oviedo, Spain.

P4-06-18 **Targeting basal-like breast cancer through downstream effectors of oncogene cooperation**
McMurray HR, Walters EA, Heyer DM, Candelaria PV, Wang S, Grose VA, Llop JR, Zhang Y. University of Rochester Medical Center, Rochester, NY.

P4-06-19 **Astemizole and calcitriol: A novel targeted therapeutic strategy for breast cancer**
García J, García R, Villanueva O, Santos N, Barrera D, Avila E, Ordaz D, Halhali A, Camacho J, Larrea F, Díaz L. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF, Mexico; Centro de Investigación y de Estudios Avanzados del I.P.N., México, DF, Mexico.

Tumor Cell and Molecular Biology: New Drugs and Mechanisms

P4-07-01 **The Class I Selective PI3K Inhibitor GDC-0941 Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing the Rate of Apoptosis**
Wallin JJ, Guan J, Prior WW, Lee LB, Ross L, Belmont LD, Koeppen H, Belvin M, Sampath D, Friedman LS. Genentech, Inc., South San Francisco, CA.

P4-07-02 **Withdrawn**

P4-07-03 **Rapamycin and Dalotuzumab in combination inhibit parental and endocrine resistant breast cancer cells**
Beckwith H, Fettig-Anderson L, Yueh N, Douglas Y. University of Minnesota, Minneapolis, MN.

P4-07-04 **Methioninase cell-cycle synchronization potentiates chemotherapy for breast cancer**
Yano S, Li S, Han Q, Tan Y, Fujiwara T, Hoffman RM. AntiCancer Inc., San Diego, CA; Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan; University of California, San Diego, CA.

P4-07-05 **MEDI3379, an antibody against HER3, is active in HER2-driven human breast tumor models**
Xiao Z, Rothstein R, Carrasco R, Wetzel L, Kinneer K, Chen H, Tice D, Hollingsworth R, Steiner P. MedImmune, LLC, Gaithersburg, MD.

Tumor Cell and Molecular Biology: Drug Resistance

P4-08-01 **PI3K/mTOR inhibition overcomes *in vitro* and *in vivo* trastuzumab resistance independent of feedback activation of pAKT**
O'Brien NA, McDonald K, Tong L, Von Euw E, Conklin D, Kalous O, Di Tomaso E, Schnell C, Linnartz R, Hurvitz SA, Finn RS, Hirawat S, Slamon DJ. UCLA, Los Angeles, CA; Novartis Pharmaceuticals, Cambridge, MA; Novartis Pharmaceuticals, Basel, Switzerland.

P4-08-02 **Reactivation of oncogenic signaling through mTOR inhibitors-induced feedback adaptations**
Rodrik-Outmezguine V, Chandarlapaty S, Poulikakos P, Scaltriti M, Baselga J, Rosen N. MSKCC, New York, NY; MGH, Charlestown, MA.

P4-08-03 **The impact of the heregulin-HER receptor signaling axis on response to HER tyrosine kinase inhibitors**
Gwin WR, Liu L, Zhao S, Xia W, Spector NL. Duke University, Durham, NC.

P4-08-04 **Abcc10 status affects proliferation, metastases and tumor sensitivity**
Domanitskaya N, Paulose C, Jacobs J, Foster K, Hopper-Borge E. Fox Chase Cancer Center, Philadelphia, PA.

P4-08-05 **Basement membrane localized tumor cells are protected from HER2-targeted therapy in vivo**
Zoeller JJ, Bronson RT, Gilmer TM, Selfors LM, Lu Y, Apple SK, Press MF, Hurvitz SA, Slamon DJ, Mills GB, Brugge JS. Harvard Medical School, Boston, MA; GlaxoSmithKline, Research Triangle Park, NC; UT MD Anderson Cancer Center, Houston, TX; University of California, Los Angeles, CA; University of Southern California, Los Angeles, CA.

P4-08-06 **Notch-dependent Regulation of Novel Genes Associated with Trastuzumab Resistance**
Osipo C, Baumgartner A, Zlobin A, O'Toole M. Loyola University Chicago, Maywood, IL.

P4-08-07 **Novel insight into the tumor "flare" phenomenon and lapatinib resistance**
Piede JA, Zhao S, Liu L, Lyerly HK, Osada T, Wang T, Xia W, Spector N. Duke University Medical Center, Durham, NC.

P4-08-08 **HOXC10, a homeobox protein overexpressed in breast cancer, modulates the response to chemotherapy treatment**
Sadik H, Nguyen N, Panday H, Kumar R, Pandita T, Sukumar S. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; UT Southwestern Medical Center, Dallas, TX.

P4-08-09 **Targeting Thyroid Receptor β in Estrogen Receptor Negative Breast Cancer**
Gu G, Covington K, Rechoum Y, O'Malley B, Mangelsdorf D, Minna J, Webb P, Fuqua S. Baylor College of Medicine, Houston, TX; UT Southwestern Medical Center; The Methodist Hospital Research Institute.

P4-08-10 **Systematic expression analysis of the genes related to drug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines**
Tang J, Li W, Zhong S, Xu J, Zhao J. Jiangsu Cancer Hospital, Nanjing, Jiangsu, China; Jiangsu Cancer Hospital, Nanjing, Jiangsu, China.

Prognostic and Predictive Factors: Prognostic Factors - Preclinical

P4-09-01 **Retrospective evaluation of precision of gene-expression-based signatures of prognosis and tumor biology in replicate surgical biospecimens from patients with breast cancer**
Barry WT, Marcom PK, Geradts J, Datto MB. Duke University Medical Center, Durham, NC.

P4-09-02 **A robust signature of long-term clinical outcome in breast cancer**
Boudreau A, Elias SG, Yau C, Wolf DM, van't Veer LJ. University of California, San Francisco; Netherlands Cancer Institute.

P4-09-03 **Withdrawn**

P4-09-04 **Gene expression profile that predict outcome of Tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study**
Lyng MB, Lænkholm A-V, Tan Q, Vach W, Gravgaard KH, Knoop A, Ditzel HJ. University of Southern Denmark, Odense, Denmark; Slagelse Hospital, Slagelse, Denmark; Odense University Hospital, Odense, Denmark; University Medical Center Freiburg, Germany.

P4-09-05 **Microarray anlyses of breast cancers identify CH25H, a cholesterol gene, as a potential marker and target for late metastatic reccurences**
Saghatchian M, Mittempergher L, Michiels S, Wolf D, Canisius SV, Dessen P, Delaloge S, Lazar V, Benz SC, Roepman P, Glas AM, Tursz T, Bernards R, van't Veer LJ. The Netherlands Cancer Institute, Amsterdam, Netherlands; Institut Jules Bordet, Brussels, Belgium; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco; Institut Gustave Roussy, Villejuif, France; University of California, Santa Cruz; Agendia, Amsterdam, Netherlands.

P4-09-06 **miR-187 is an independent prognostic factor in lymph node-positive breast cancer patients**
O'Connor DP, Mulrane L, Brennan DJ, Madden S, Gremel G, McGee SF, McNally S, Martin FM, Crown JP, Jirstrom K, Higgins DG, Gallagher W. UCD Conway Institute, Dublin, Ireland; Molecular Therapeutics for Cancer Ireland, Dublin City University, Dublin, Ireland; St Vincent's University Hospital, Dublin, Ireland; Lund University, Lund, Sweden.

P4-09-07 **ING1 Expression Measured by AQUA can be an Independent Prognostic Marker in Breast Cancer**
Thakur S, Klimowicz A, Pohorelic B, Dean M, Konno M, Bose P, Magliocco A, Riabowol K. University of Calgary, AB, Canada; Tom Baker Cancer Center, Calgary, AB, Canada.

P4-09-08 **HOXB9, a gene promoting tumor angiogenesis and proliferation, is significantly associated with poor clincal outcomes in ER-positive breast cancer patients**
Seki H, Hayashida T, Jinno H, Takahashi M, Suzuki K, Kaneda M, Hara H, Osaku M, Asanuma F, Yamada Y, Mukai M, Kitagawa Y. Kitasato University Kitasato Institute Hospital, Tokyo, Japan; Keio University School of Medicine, Tokyo, Japan; Keio University School of Medicine, Japan.

P4-09-09 **Circulating HER2 extracellular domain (ECD) levels are associated with progression-free survival in metastatic breast cancer patients**
Wang X-j, Shao X-Y, Chen Z-H, Ye W-w, Qin J, Zhang Y-m, Zheng Y-b, Yu X-y, Lei L, Ling Z-Q, Feng J-g, Han MX. Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Hangzhou Polar Gene Company, Hangzhou, Zhejiang, China.

P4-09-10 **Prospective Analysis of Fatty Acid Synthase (FASN) in Breast Cancer Tissue of Early-Stage Breast Cancer Patients**
Puig T, Blancafort A, Casoliva G, Oliveras G, Casas M, Buxo M, Saiz E, Viñas G, Dorca J, Porta R. University of Girona and Girona Biomedical Research Institute (IDIBGi), Girona, Spain; Assistència Sanitària Institute, Girona, Spain; Catalan Institute of Oncology, Girona, Spain; Dr. Josep Trueta Hospital, Girona, Spain; Dr. Josep Trueta Hospital and Girona Biomedical Research Institute (IDIBGi), Girona, Spain; Health Inequalities Research Group - Employment Conditions Knowledge Network (GREDS-EMCONET), Universitat Pompeu Fabra, Barcelona, Spain; Dr. Josep Trueta Hospitaland Girona Biomedical Research Institute (IDIBGi), Girona, Spain.

P4-09-11 **Fatty Acid Synthase (FASN) expression in Triple-Negative Breast Cancer**
Viñas G, Oliveras G, Perez-Bueno F, Giro A, Blancafort A, Puig-Vives M, Marcos-Gragera R, Dorca J, Brunet J, Puig T. Catalan Institute of Oncology and Girona Biomedical Research Institute (IDIBGi), Girona, Spain; University of Girona and Biomedical Research Institute (IDIBGi), Girona, Spain; Dr. Josep Trueta Hospital and Catalan Institute of Health (ICS), Girona, Spain; Catalan Institute of Oncology, Girona, Spain; University of Girona, Spain.

P4-09-12 **TIMP-4 – Prognostic Marker and Treatment Target for Triple-Negative Breast Cancers**
Wallon UM, Sabol JL, Gilman PB, Zemba-Palko V, DuHadaway JB, Ciocca RM, Ali ZA, Carp NZ, Choy NS, Wojciechowski BS, Prendergast GC. Lankenau Medical Center, Wynnewood, PA.

Epidemiology, Risk, and Prevention: Familial Breast Cancer - Molecular Genetics

P4-10-01 **Edgetic perturbation of BRCT-mediated interactions caused by the BRCA1 H1686Q sequence variant**
De Nicolo A, Pathania S, Parisini E, Joukov V. Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Italian Institute of Technology, Milan, Italy.

P4-10-02 Targeted resequencing of BRCA1 and BRCA2 in inherited breast cancer
Wong MW, Li S, Wilkins M, Avery-Kiejda KA, Bowden NA, Scott RJ. University of Newcastle, NSW, Australia; University of New South Wales, Sydney, NSW, Australia; Hunter Area Pathology Service (HAPS), Newcastle, NSW, Australia.

Epidemiology, Risk, and Prevention: Familial Breast Cancer - Genetic Testing

P4-11-01 Rapid genetic counseling and testing in newly diagnosed breast cancer patients, findings from an RCT
Wevers MR, Ausems MG, Bleiker EM, Rutgers EJ, Witkamp AJ, Hahn DE, Brouwer T, Kuenen MA, van der Sanden-Melis J, van der Luijt RB, Hogervorst FB, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Huisman JJ, Bouma WH, Rijna H, Vente JP, Valdimarsdottir H, Verhoef S, Aaronson NK. Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; University Medical Center, Utrecht, Netherlands; Diakonessen Hospital, Utrecht, Netherlands; St. Antonius Hospital, Nieuwegein, Netherlands; Meander Medical Center, Amersfoort, Netherlands; Rivierenland Hospital, Tiel, Netherlands; Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; St. Lucas Andreas Hospital, Amsterdam, Netherlands; Tergooi Hospitals, Blaricum, Netherlands; Gelre Hospitals, Apeldoorn, Netherlands; Kennemer Gasthuis, Haarlem, Netherlands; Zuwe Hofpoort Hospital, Woerden, Netherlands; Mount Sinai School of Medicine, New York.

P4-11-02 Novel *BRCA1* and *BRCA2* genomic rearrangements in Southern Chinese breast/ovarian cancer patients
Kwong A, Ng EKO, Law FBF, Wa A, Wong CLP, Wong CHN, Kurian AW, West DW, Ford JM, Ma ESK. University of Hong Kong, Pokfulam, Hong Kong; Hong Kong Sanitorium & Hospital, Happy Valley, Hong Kong; Hong Kong Hereditary Breast Cancer Family Registry, Happy Valley, Hong Kong; Stanford University School of Medicine, Stanford, CA.

P4-11-03 Single nucleotide polymorphism testing for breast cancer risk assessment: patient trust and willingness to pay
Howe R, Omer Z, Hanoch Y, Miron-Shatz T, Thorsen C, Ozanne EM. Universiy of California San Francisco, CA; Massachusetts General Hospital, Boston, MA; Plymouth University, United Kingdom; Ono Academic College, Israel.

P4-11-04 A Structured Genetic Risk Evaluation and Testing Program in the Community Oncology Practice Increases Identification of Individuals at Risk for BRCA Mutations
Langer L, Clark L, Gress J, Patt D, Denduluri N, Wang Y, Andersen J, Solti M, Wheeler A, Delamelena T, Smith, II JW, Sandbach J. Compass Oncology, Portland, OR; Texas Oncology, Austin, TX; Virginia Cancer Specialists, Arlington, VA; McKesson Specialty Health/The US Oncology Network, The Woodlands, TX.

P4-11-05 Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk
Tilanus-Linthorst MMA, Lingsma H, Evans GD, Kaas R, Manders P, Hooning MJ, van Asperen CJ, Thompson D, Eeles R, Oosterwijk JC, Leach MO, Steyerberg EJ. Erasmus University MC, Rotterdam, Netherlands; Erasmus University MC, Netherlands; University of Manchester, United Kingdom; NKI/AVL, Amsterdam, Netherlands; UMC St Radboud, Netherlands; Leiden University Medical Centre, Netherlands; Centre for Cancer Genetic Epidemiology, Cambridge, United Kingdom; Royal Marsden NHS Foundation, United Kingdom; University Medical Centre Groningen, Netherlands; Institute of Cancer Research, Royal Marsden, Sutton, United Kingdom.

P4-11-06 Automatic referral to genetic counseling for identification of *BRCA1/2* mutations: a pilot program at Norton Cancer Institute, Louisville, KY
Lewis AL, Alabek ML, Dreher C, Goldberg JM, Brooks SE. Norton Healthcare, Louisville, KY.

Epidemiology, Risk, and Prevention: Risk Factors and Modeling

P4-12-01 A nomogram based on clinical, imaging and histological data to predict the risk of upgrades to malignancy at surgery in biopsy-diagnosed premalignant lesions of the breast
Uzan C, Mazouni C, Balleyguier C, Mathieu M-C, Ferchiou M, Delaloge S. Institut Gustave Roussy, Villejuif, France.

P4-12-02 Serum 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer in whites: the Multiethnic Cohort Study
Kim Y, Franke AA, Shvetsov YB, Wilkens LR, Lurie G, Cooney RV, Maskarinec G, Hernandez BY, Le Marchand L, Henderson B, Kolonel LN, Goodman MT. University of Hawai'i Cancer Center; University of Hawaii; Keck School of Medicine, University of Southern California.

P4-12-03 Towards a risk prediction model for breast cancer that utilizes breast tissue risk features
Pankratz VS, Degnim AC, Visscher DW, Frank RD, Vierkant RA, Ghosh K, Aziza N, Vachon CM, Frost M, Radisky DC, Hartmann LC. Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL.

P4-12-04 Association of single-strand breaks (SSBs) in normal breast DNA with estimates of breast cancer risk
Chatterton RT, Sahadevan M, Heinz RE, Sukumar S, Stearns V, Fackler MJ, Lee O, Sivaraman I, Kenney K, Khan SA. Northwestern University Feinberg School of Medicine, Chicago, IL; Johns Hopkins School of Medicine, Baltimore, MD.

P4-12-05 Enrichment of aldosterone synthase (*CYP11B2*) gene C-allele carriers in women at high risk in the OncoVue® polyfactorial risk model
Jupe ER, Pugh TW, Knowlton NS, DeFreese DC. InterGenetics Incorporated, Oklahoma City, OK; NSK Statistical Solutions, Choctaw, OK.

P4-12-06 A mammographic density prediction model using environmental factors, endogenous hormones and growth factors in Japanese women
Yoshimoto N, Nishiyama T, Toyama T, Takahashi S, Shiraki N, Sugiura H, Endo Y, Iwasa M, Asano T, Fujii Y, Yamashita H. Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.

P4-12-07 Diabetes Increases the Risk of Breast Cancer
Hardefeldt PJ, Edirimanne S, Eslick GD. University of Sydney, NSW, Australia; Nepean Hospital, University of Sydney, Penrith, NSW, Australia.

Epidemiology, Risk, and Prevention: Epidemiology, Risk, and Prevention - Other

P4-13-01 Racial Disparities in the Incidence of Dose-limiting Chemotherapy Induced Peripheral Neuropathy
Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ, Stineman MG, DeMichele A. Perelman School of Medicine, University of Pennsylvania.

P4-13-02 Comparing data quality of client intake forms by interview mode: results of a pilot study on the use of audio computer-assisted self-interview (ACASI) in the Avon Breast Health Outreach Program
Hallum-Montes R, Senter L, D'Souza R, Hurlbert M, Gates-Ferris K, Anastario M. CAI Global, New York, NY; Avon Foundation for Women, New York, NY; New York University, New York, NY.

P4-13-03 Hormone replacement therapy, is there an increased risk of in situ breast cancer? Data from a French cohort
Coussy F, Giacchetti S, Hamy A-S, Porcher R, Cuvier C, Lalloum M, de Roquancourt A, Albiter M, Espié M. Hôpital St Louis, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital St Louis, Paris, France.

P4-13-04 **Estrogen and Avoidance of Invasive Breast Cancer, Coronary Heart Disease and All-cause Mortality. Public Health Impact of Estrogen Guidelines for Women entering Menopause**
Ragaz J, Wilson K, Shakeraneh S, Budlovsky J, Wong H. University of British Columbia, Vancouver, BC, Canada; British Columbia Cancer Agency, Victoria, BC, Canada.

P4-13-05 **The gap between perceptions of risk and actual risk for breast cancer**
Kaplan CP, Lopez M, Tice J, Pasick R, Kerlikowske K, Chen A, Karliner L. University of California, San Francisco, CA.

P4-13-06 **Association of Age, Obesity and Incident Breast Cancer Phenotypes**
Scheri R, Power S, Marks J, Seewaldt V, Marcom K, Hwang S. Duke University Medical Center, Durham, NC.

P4-13-07 **Meta-analysis of epidemiological studies of Insulin Glargine and Breast Cancer Risk**
Boyle P, Koechlin A, Boniol M, Bota M, Robertson C, Rosenstock J, Bolli GB. International Prevention Research Institute, Lyon, France; University of Strathclyde, Glasgow, United Kingdom; Dallas Diabetes and Endocrine Center, Dallas; University of Perugia, Italy.

P4-13-08 **Diabetes, Related Factors and Breast Cancer Risk**
Boyle P, Boniol M, Koechlin A, Bota M, Robertson C, Leroith D, Rosenstock J, Bolli GB, Autier P. International Prevention Research Institute, Lyon, France; University of Strathclyde, Glasgow, United Kingdom; Mt. Sinai, New York; Dallas Diabetes and Endocrine Center, Dallas; University of Perugia, Italy.

P4-13-09 **The effect of weight change on breast adipose and dense tissue**
Graffy HJ, Harvie MN, Warren RM, Boggis CR, Astley SM, Evans GD, Adams JE, Howell A. University Hospital of South Manchester, Manchester, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom; University of Manchester, United Kingdom; Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.

P4-13-10 **Do *BRCA1* and *BRCA2* mutation carriers have an earlier natural menopause than their non-carrier relatives: A study from the Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab)**
Collins IM, Milne RL, McLachlan SA, Friedlander M, Birch KE, Weideman PC, Hopper JL, Phillips K-A. Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Australia; St Vincent's Hospital, Melbourne, VIC, Australia; Prince of Wales Cancer Centre, Sydney, Australia

P4-13-11 **Prognostic factors in young breast cancer patients over time – a 40 year longitudinal analysis**
Hagenbeck C, Muschler B, Jaeger BAS, Jueckstock J, Andergassen U, Katzorke N, Hepp P, Melcher CA, Janni JW, Rack BK. Heinrich Heine University, Duesseldorf, Germany; Freising Hospital, Freising, Germany; Ludwig-Maximilians-University, Munich, Germany.

P4-13-12 **Identifying women at increased risk for breast cancer using the electronic health record in an integrated health system**
Leader JB, Bengier A, Darer J, Stark A, Vogel VG. Geisinger Health System, Danville, PA; Geisinger Health System, Lewisburg, PA.

P4-13-13 **Risk Assessment and Personalized Decision Support: The University of California Athena Breast Health Network**
Ozanne EM, Crawford B, Petruse A, Madlensky L, Weiss L, Hogarth M, Wenger N, Goodman D, Park H, Anton-Culver H, Yasmeen S, Howell L, Ojeda H, Parker BA, Kaplan C, van't Veer L, Esserman L, Naeim A. University of California, San Francisco, CA; University of California, Los Angeles, CA; University of California, San Diego, CA; Athena Program Management Office, San Francisco, CA; University of California, Davis, CA; University of California, Irvine, CA.

P4-13-14 **Lung cancer after treatment of breast cancer: retrospective study from Curie Institut**
Sebbagh S, Cosquer M, Kirova YM, Livartowski A. Institut Curie, Paris, France.

Treatment: Surgery

P4-14-01 **Incidence rate of nipple areolar complex ischemia after nipple sparing mastectomy. Analysis of the American Society of Breast Surgeons Nipple Sparing Mastectomy Registry**
Mitchell SD, Willey SC, Feldman SM, Beitsch PD, Unzeitig GW, Manasseh DME, Neumayer LA, Laidley AL, Grutman SB, Habal N, Busch-Devereaux E, Dupont EL, Ashikari AY. White Plains Hospital Medical Center, White Plains, NY; Georgetown, Washington, DC; Columbia University College of Physicians & Surgeons, New York, NY; Dallas Breast Center, Dallas, TX; Laredo Breast Care, Laredo, TX; Maimonides Medical Center, Brooklyn, NY; University of Utah, Salt Lake City, UT; Texas Breast Specialists, Texas Oncology, Dallas, TX; American Society of Breast Surgeons, Columbia, MD; Carolina Breast & Oncologic Surgery, Greenville, NC; Breast Surgery Associates, Greenlawn, NY; Watson Clinic, Lakeland, FL; Ashikari Breast Center, Dobbs Ferry, NY.

P4-14-02 **National Trends and Indications for Nipple-Sparing Mastectomy: An Analysis Using the Surveillance, Epidemiology, and End Results (SEER) Database**
Agarwal S, Agarwal S, Agarwal J. Wayne State University, Detroit, MI; University of Michigan, Ann Arbor, MI; University of Utah, Salt Lake City, UT.

P4-14-03 **Nipple-sparing mastectomy and intra-operative nipple biopsy: To freeze or not to freeze?**
Guth AA, Blechman K, Samra F, Shapiro R, Axelrod D, Choi M, Karp N, Alperovich M. NYU School of Medicine, New York, NY.

P4-14-04 **Total skin-sparing mastectomy in BRCA mutation carriers**
Warren Peled A, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. University of California, San Francisco; Duke University Medical Center.

P4-14-05 **Skin sparing mastectomy – thorough breast tissue removal leads to a low local recurrence rate of breast cancer**
Paily AJ, Drabble EH. Derriford Hopsital, Plymouth, Devon, United Kingdom.

P4-14-06 **Withdrawn**

P4-14-07 **Impact of preservation of the intercostobrachial nerve during axillary dissection on sensory change and health-related quality of life two years after breast cancer surgery**
Taira N, Shimozuma K, Ohsumi S, Kuroi K, Shiroiwa T, Watanabe T, Saito M. Okayama University Hospital, Okayama, Japan; Ritsumeikan University, Japan; National Shikoku Cancer Center, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan; Teikyo University, Japan; Sendai Medical Center, Japan; Juntendo University, Japan.

P4-14-08 **Intraoperative ultrasound guidance for excision of non-palpable breast cancer**
Barentsz MW, van Dalen T, Gobardhan PD, Bongers V, Perre CI, Pijnappel RM, van den Bosch MA, Verkooijen HM. University Medical Center Utrecht, Netherlands; Diakonessenhuis, Utrecht, Netherlands; Amphia Hospital, Breda, Netherlands.

P4-14-09 **Feasibility of liposuction for treatment of arm lymphedema from breast cancer**
Doren EL, Smith PD, Sun W, Lacevic M, Fulp W, Reid R, Laronga C. University of South Florida, Tampa, FL; Moffitt Cancer Center, Tampa, FL.

P4-14-10 **Atypical Ductal Hyperplasia diagnosed on directional vacuum-assisted biopsy: is surgical excision mandatory?**
Chauvet M-P, Rivaux G, Farre I, Houpeau J-L, Giard S, Ceugnart L. Centre Oscar Lambret, Lille, France.

P4-14-11 **Risk reducing mastectomy for women with high personal breast cancer risk**
Onyekwelu O, Shetty G, Baildam A. Nightingale & Genesis Breast Cancer Prevention Centre, University Hospital of South Manchester, Wythenshawe, Manchester, United Kingdom; St. Bartholomew's Hospital (Bart's), West Smithfield, London, United Kingdom.

P4-14-12 **Evaluation of the effect of pasireotide LAR administration in the lymphocele prevention after mastectomy with axillary lymph node dissection for breast cancer: results of a phase 2 randomized study**
Chereau E, Uzan C, Zohar S, Bezu C, Mazouni C, Ballester M, Gouy S, Rimareix F, Garbay J-R, Darai E, Uzan S, Rouzier R. Tenon, APHP, UPMC - Paris 6, Paris, France; Institut Gustave Roussy, Villejuif, France; Hopital Saint-Louis, APHP, U444-INSERM, Paris 7, Paris, France.

P4-14-13 **Therapeutic mammaplasty does not cause a delay in the delivery of chemotherapy in high risk breast cancer patients**
Khan J, Barrett S, Stallard S, Forte C, Weiler-Mithoff E, Reid I, Winter A, Doughty J, Romics L. Victoria Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Royal Infirmary, Glasgow, United Kingdom.

P4-14-14 **Phyllodes tumour of the breast: A retrospective analysis of 87 cases**
Walter HS, Esmail F, Krupa J, Ahmed SI. Leicester Royal Infirmary, Leicester, United Kingdom; Glenfield Hospital, Leicester, United Kingdom.

Treatment: Breast Conservation

P4-15-01 **Second conservative treatment for ipsilateral breast tumor recurrence: GEC-ESTRO Breast WG study**
Hannoun-Levi J-M, Resch A, Gal J, Niehoff P, Loessl K, Kovács G, Van Limbergen E, Polgar C. Antoine Lacassagne Cancer Center, University of Nice-Sophia, Nice, France; Medical University, General Hospital of Vienna, Austria; Antoine Lacassagne Cancer Center, Nice, France; University Erlangen-Nuremberg, Erlangen, Germany; University Hospital Bernes, Switzerland; University Hospital Schleswig-Holstein Campus Lübeck, Germany; University Hospital Gasthuisberg, Leuven, Belgium; National Institute of Oncology, Budapest, Hungary.

P4-15-02 **Timing of infectious complications following breast conserving therapy with catheter-based accelerated partial breast irradiation**
Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RF, Caudle AS, Hunt KK, Graviss L, Chemaly RF, Tereffe W, Shaitelman SF, Babiera GV. University of Texas MD Anderson Cancer Center, Houston, TX.

P4-15-03 **Patterns of relapse following re-irradiation of the breast using partial breast brachytherapy (PBB)**
Chadha M, Boachie-Adjei K, Boolbol SK, Kirstein L, Osborne MP, Tarter P, Harrison LB. Beth Israel Medical Center, New York, NY.

P4-15-04 **Impact of awake breast cancer surgery on postoperative lymphocyte responses**
Vanni G, De Felice V, Buonomo C, Esser A, Petrella G, Buonomo OC. Tor Vergata University, Rome, Italy.

P4-15-05 **Long-term outcome of breast cancer patients treated with radiofrequency ablation**
Earashi M, Noguchi M, Motoyoshi A, Komiya H, Fujii H. Yatsuo General Hospital, Toyama, Japan; Kanazawa Medical University Hospital, Uchinada-Daigaku, Ishikawa, Japan.

Treatment: Radiotherapy

P4-16-01 **Accelerated hypofractionated whole breast radiotherapy for localized breast cancer: the effect of a boost on patient reported long-term cosmetic outcome**
Chan EK, Tabarsi N, Tyldesley S, Khan M, Woods R, Speers C, Weir L. British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.

P4-16-02 **A survival benefit from locoregional radiotherapy for node-positive and CMF treated breast cancer is most significant in Luminal A tumors**
Voduc D, Cheang MCU, Tyldesley S, Chia S, Gelmon K, Speers C, Nielsen TO. BC Cancer Agency, Vancouver, BC, Canada; University of British Columbia, Vancouver, BC, Canada.

P4-16-03 **Patterns of failure after accelerated partial breast irradiation by consensus panel group: A pooled analysis of William Beaumont Hospital and the American Society of Breast Surgeons Trial data**
Wilkinson JB, Beitsch PD, Arthur D, Shah C, Haffty BG, Wazer D, Keisch M, Shaitelman SF, Lyden M, Chen PY, Vicini FA. Oakland University William Beaumont School of Medicine, Royal Oak, MI; Dallas Surgical Group, Dallas, TX; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; Washington University School of Medicine, St. Louis, MO; Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Camden, NJ; Tufts Medical Center and Rhode Island Hospital/Brown University, Boston, MA; Cancer Healthcare Associates, Miami, FL; University of Texas M.D. Anderson Cancer Center, Houston, TX; Biostat International, Inc., Tampa, FL; Michigan Healthcare Professionals/21st Century Oncology, Farmington Hills, MI.

P4-16-04 **Outcome of stage II/III breast cancer treated with neoadjuvant versus adjuvant radiotherapy in British Columbia**
Lohmann AE, Voduc D, Speers C, Chia S. British Columbia Cancer Agency, Vancouver, BC, Canada.

P4-16-05 **Benefit from Postoperative Radiotherapy for N1 Breast Cancer**
Tsai Y-CS, Cheng H-CS, Yu B-L, Horng C-F, Chen C-M, Jian J-MJ, Chu N-M, Tsou M-H, Liu M-C, Huang AT. Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan; Duke University Medical Center, Durham, NC.

P4-16-06 **Radiotherapy to the Primary Tumor Is Associated with Improved Survival in Stage IV Breast Cancer**
Morgan SC, Caudrelier J-M, Clemons MJ. University of Ottawa, ON, Canada; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.

P4-16-07 **Selective use of post-mastectomy radiation therapy in the neoadjuvant setting**
Warren Peled A, Wang F, Stover AC, Rugo HS, Melisko ME, Park JW, Alvarado M, Ewing CA, Esserman LJ, Fowble B, Hwang ES. University of California, San Francisco; Duke University Medical Center.

P4-16-08 **Intraoperative electron radiotherapy in early stage breast cancer. A single-institution experience**
Dall'Oglio S, Maluta S, Marciai N, Gabbani M, Franchini Z, Pietrarota P, Meliadò G, Guariglia S, Cavedon C. University Hospital, Verona, Italy.

P4-16-09 **Dosimetric feasibility and acute toxicity in a prospective trial of ultra-short course accelerated partial breast irradiation (APBI) using a multi-lumen balloon brachytherapy device**
Khan AJ, Vicini FA, Brown S, Haffty BG, Kearney T, Dale R, Arthur DW. Cancer Institute of New Jersey, New Brunswick, NJ; Michigan Healthcare Professionals, Farmington Hills, MI; Wellstar Kennestone Hospital, Marietta, GA; Imperial College London, United Kingdom; Virginia Commonwealth University, Massey Cancer Center, Richmond, VA

P4-16-10 **Positive sentinel lymph nodes (SLNs) without axillary dissection in breast cancer: the tangent fields of irradiation may not allow optimal coverage and dose distribution in level I and II of the axilla**
Qiong P, Khodari W, Bigorie V, Bosc R, Dao TH, Totobenazara J-L, Assaf E, Caillet P, Diana C, Lagrange J-L, Calitchi E, Belkacemi Y. APHP GH Henri Mondor et Université de Paris-Est, Créteil, France; APHP GH Henri Mondor, Créteil, France; Association of Radiotherapy and Oncology of the Mediterranean Area, France; French Breast Intergroup, France.

P4-16-11 **Impact of receptor status on prognosis among breast cancer patients with brain metastases treated with Cyberknife radiosurgery**
Fasola CE, Gibbs IC, Soltys SG, Horst KC. Stanford Cancer Center, Stanford, CA.

P4-16-12 **Outcomes of low-risk Ductal Carcinoma in situ in South East Asian women treated with breast conservation surgery**
Wong FY, Wang FQ, Chen JJ, Tan CH, Tan PH. National Cancer Centre Singapore; Singapore General Hospital, Singapore, Singapore.

P4-16-13 **Relationship between coverage of axillary lymph nodes, with tangential breast irradiation, and body mass index**
Inokuchi M, Furukawa H, Fujimura T, Ohta T, Ohashi S, Takanaka T. Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.

P4-16-14 **Salvage Radiotherapy and Cisplatin for Triple Negative Breast Cancer: A Multi-Centre Study**
Lee JW, Brackstone M, Gandhi S, Arce Salinas C, Dinniwell R. University of Toronto, ON, Canada; London Regional Cancer Program, London, ON, Canada; Princess Margaret Hospital, University of Toronto, ON, Canada.

P4-16-15 **Improvement of accuracy and consistency in delineating the breast lumpectomy cavity using surgical clips**
Atrchian S, Sadeghi P, Cwajna W, Helyer L, Rheaume D, Nolan M, Rutledge R, Calverley V, Bennett S, Ago T, Robar J. Dalhousie University, Halifax, NS, Canada.

Treatment: Reconstruction

P4-17-01 **The effect of body mass index on breast reconstruction outcomes**
Lopez JJ, Laronga C, Doren EL, Sun W, Fulp WJ, Smith PD. University of South Florida, Tampa, FL; H. Lee Moffitt Cancer Center, Tampa, FL.

P4-17-02 **Radiation therapy and expander-implant breast reconstruction: an analysis of timing and comparison of complications**
Lentz RB, Higgins SA, Matthew MK, Kwei SL. Yale University School of Medicine, New Haven, CT.

P4-17-03 **Towards the standardisation of outcome reporting in reconstructive breast surgery: Initial results of the BRAVO (Breast Reconstruction and Valid Outcome) Study–A multicentre consensus process to develop a core outcome set for reconstructive breast surgery**
Potter S, Ward J, Cawthorn S, Holcombe C, Warr R, Wilson S, Tillett R, Weiler-Mithoff E, Winters Z, Barker J, Oates C, Harcourt D, Brookes S, Blazeby J. University of Bristol, United Kingdom; North Bristol NHS Trust, Bristol, United Kingdom; Linda McCartney Breast Centre, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom; University of the West of England, Bristol, United Kingdom.

P4-17-04 ***BRECONDA*: Development and acceptability of an interactive decisional support tool for women considering breast reconstruction**
Sherman KA, Harcourt D, Lam T, Boyages J. Macquarie University, Sydney, NSW, Australia; Westmead Hospital, University of Sydney, Westmead, NSW, Australia; University of the West of England, Bristol, United Kingdom.

P4-17-05 **Withdrawn**

P4-17-06 **The use of specialist nurse-led clinics in preparation for reconstructive breast surgery**
Affan AM, Ali RA, Morton-Gittens JA, Perry A, Harry A, O'Donoghue JM, Rampaul R. St James Medical Complex, St James, POS, Trinidad and Tobago; Royal Victoria Infirmary, Newcastle-upon-Tyne, London, United Kingdom.

P4-17-07 **Reconstructive Outcomes of Nipple-Sparing Mastectomy: A Five Year Experience**
Guth AA, Blechman K, Samra F, Shapiro R, Axelrod D, Choi M, Karp N, Alperovich M. NYU School of Medicine, New York, NY.

P4-17-08 **Tissue Expander/Implant Breast Reconstruction with and without Postmastectomy Radiation: Predictive Factors for Complications**
Nguyen SKA, Oxley P, Rastegar R, Joffres M, Kwan W. British Columbia Cancer Agency, Fraser Valley Cancer Centre; University of British Columbia; Simon Fraser University.

P4-17-09 **Efficacy and safety of lipomodelling and adipose tissue derived degenerative stem cells(ADRC) for breast reconstruction – Medium term follow up**
Noor L, Bhaskar P, Hennessy C. University Hospital of North Tees, Cleveland, United Kingdom.

9:00 am–9:30 am
PLENARY LECTURE 3
Exhibit Hall D

Breast Radiotherapy: Fractionation and Other Fashions
John Yarnold, MD
Institute of Cancer Research
Sutton, UNITED KINGDOM

9:30 am–11:30 am
GENERAL SESSION 5
Exhibit Hall D

Moderator: George W. Sledge, Jr., MD
Indiana University Simon Cancer Center
Indianapolis, IN

9:30 **S5-1. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)**
Baselga J, Cortés J, Im S-A, Clark E, Kiermaier A, Ross G, Swain SM. Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Vall d'Hebron University Hospital, Barcelona, Spain; Seoul National University College of Medicine, Seoul, Korea; Roche Products Limited, Welwyn, United Kingdom; F. Hoffmann-La Roche Limited, Basel, Switzerland; MedStar Washington Hospital Center, Washington, DC.

9:45 **S5-2. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up**
Goldhirsch A, Piccart-Gebhart MJ, Procter M, de Azambuja E, Weber HA, Untch M, Smith I, Gianni L, Jackisch C, Cameron D, Bell R, Dowsett M, Gelber RD, Leyland-Jones B, Baselga J, on behalf of the HERA Study Team NA. European Institute of Oncology, Milan, Italy; BrEAST Data Centre, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium; Frontier Science (Scotland) Ltd, Kincraig, Kingussie, United Kingdom; F Hoffmann-La Roche, Basel, Switzerland; Helios Klinikum Berlin-Buch, Akademisches LK der Universität Charité, Berlin, Germany; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; San Raffaele Institute, Milan, Italy; Klinikum Offenbach, Offenbach, Germany; University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom; Geelong Hospital, Geelong, Australia; The Royal Marsden NHS Trust, London, United Kingdom; Dana-Farber Cancer Institute, Boston, MA; Sanford Research, Sioux Falls, SD; Massachusetts General Hospital Cancer Center, Boston, MA.

10:00 S5-3. PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer
Pivot X, Romieu G, Bonnefoi H, Pierga J-Y, Kerbrat P, Guastalla J-P, Lortholary A, Espié M, Fumoleau P, Khayat D, Pauporte I, Kramar A. University Hospital J. Minjoz, Besancon, France; Anti Cancer Center Val d'Aurelle, Montpellier, France; Anti Cancer Center Bergonie, Bordeaux, France; Curie Institute, Paris, France; Anti Cancer Center Eugene Marquis, Rennes, France; Anti Cancer Center Leon Berard, Lyon, France; Catherine de Sienne Center, Nantes, France; University Hospital St Louis, Paris, France; Anti Cancer Center Georges Francois Leclerc, Dijon, France; University Hospital Pitie Salpetriere, Paris, France; French National Cancer Institut (INCa), France; Centre Oscar Lambret, Lille, France.

10:15 S5-4. EGFR expression measured by quantitative immunofluorescense is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial
Rimm D, Ballman KV, Cheng H, Vassilakopoulou M, Chen B, Gralow J, Hudis C, Davidson NE, Psyrri A, Fountzilas G, Perez EA. Yale University School of Medicine, New Haven, CT; Mayo Clinic, Rochester, MN; Seattle Cancer Care Alliance, Seattle, WA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Pittsburgh Cancer Institute, Pittsburgh, PA; "Papageorgiou" Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Macedonia, Greece; Attikon University Hospital, Athens, Greece; Mayo Clinic, Jacksonville, FL.

10:30 S5-5. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831
Romond E, Suman VJ, Jeong J-H, Sledge, Jr. GW, Geyer Jr. CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer E, Colon-Otero G, Hudis C, Paik S, Davidson N, Mamounas EP, Zujewski JA, Wolmark N, Perez EA. National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers; University of Kentucky; Mayo Clinic; University of Pittsburgh Graduate School of Public Health; IU Simon Cancer Center; University of Texas Southwestern Medical Center; The Angeles Clinic and Research Institute; University of Pittsburgh Cancer Institute; University of Washington; Medstar Washington Hospital Center; Dana-Farber Cancer Institute; Memorial Sloan-Kettering Cancer Center; Aultman Hospital; Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, D.H.H.S; Allegheny Cancer Center Allegheny General Hospital.

10:45 S5-6. Activating HER2 mutations in HER2 gene amplification negative breast cancers
Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Li S, Ding L, Mardis ER, Ellis MJ. Washington University School of Medicine, St. Louis, MO.

11:00 S5-7. Combined blockade of PI3K/AKT and EGFR/HER3 enhances anti-tumor activity in triple negative breast cancer
Tao J, Ip P, Auricchio N, Juric D, Yu M, Shyamala M, Kim P, Singh S, Hazra S, Haber D, Scaltriti M, Baselga J. Massachusetts General Hospital; Prometheus Lab.

11:15 S5-8. Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib
Giuliano M, Wang YC, Gutierrez C, Rimawi MF, Chang JC, Wang T, Hilsenbeck SG, Trivedi MV, Chamness GC, Osborne CK, Schiff R. Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; University of Houston, Houston, TX.

11:30 am–12:00 pm
AACR DISTINGUISHED LECTURESHIP IN BREAST CANCER RESEARCH
Exhibit Hall D

Genes and the Microenvironment: The Twosome of Gene Expression and Breast Cancer
Mina J. Bissell, PhD
Lawrence Berkeley National Laboratory
Berkeley, CA

12:00 pm–1:35 pm
LUNCH

12:30 pm–1:35 pm
CASE DISCUSSION 2
Ballroom A

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists:

Dian Corneliussen-James
METAvivor Research and Support
Annapolis, MD

Jennifer De Los Santos, MD
University of Alabama at Birmingham
Birmingham, AL

Tari King, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Hope Rugo, MD
University of California San Francisco
San Francisco, CA

George W. Sledge, Jr., MD
Indiana University Simon Cancer Center
Indianapolis, IN

12:30 pm–1:35 pm
BASIC SCIENCE FORUM
Ballroom B

Molecular Imaging of Breast Cancer: Visualizing In Vivo Breast Cancer Biology
Moderator: David A. Mankoff, MD, PhD
University of Pennsylvania Health System – PENN Medicine
Philadelphia, PA

Molecular imaging to characterize breast cancer models
Lewis A. Chodosh, MD, PhD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Molecular imaging for breast cancer patients
David A. Mankoff, MD, PhD
University of Pennsylvania Health System - PENN Medicine
Philadelphia, PA

1:45 pm–3:15 pm

MINI-SYMPOSIUM 3
Exhibit Hall D

Snp's - Germline Polymorphisms in Breast Cancer Susceptibility and Treatment Toxicity
Moderator: Laura J. van 't Veer, PhD
University of California, San Francisco
San Francisco, CA

Germline polymorphisms and susceptibility to breast cancer
Douglas Easton, PhD
University of Cambridge
Cambridge, UNITED KINGDOM

Exploring germline variability as predictors for therapy-induced toxicity
Bryan P. Schneider, MD, PhD
Indiana University School of Medicine
Indianapolis, IN

Identifying the real promise of genomic medicine
James P. Evans, MD, PhD
University of North Carolina at Chapel Hill
Chapel Hill, NC

3:15 pm–5:00 pm

GENERAL SESSION 6
Exhibit Hall D

Moderator: Suzanne Fuqua, PhD
Baylor College of Medicine
Houston, TX

3:15 S6-1. Exploration of isoform switching and mutation expression in breast cancer by mRNA-sequencing analysis
Hoadley KA, Parker JS, Wilkerson MD, Mose LE, Jefferys SR, Soloway MG, Turman YJ, Auman JT, Hayes DN, Perou CM. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC; University of North Carolina at Chapel Hill, Chapel Hill, NC.

3:30 S6-2. Characterization of different foci of multifocal breast cancer using genomic, transcriptomic and epigenomic data
Desmedt C, Nik-Zainal S, Fumagalli D, Rothé F, Singhal S, Majjaj S, Brown D, Dedeurwaerder S, Defrance M, Maetens M, Adnet P-Y, Vincent D, Salgado R, Fuks F, Piccart M, Larsimont D, Campbell P, Sotiriou C. Institut Jules Bordet, Brussels, Belgium; Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Libre de Bruxelles, Brussels, Belgium.

3:45 S6-3. Neurocognitive impact in adjuvant chemotherapy for breast cancer linked to fatigue: A prospective functional MRI study
Cimprich B, Hayes DF, Askren MK, Jung MS, Berman MG, Ossher L, Therrien B, Reuter-Lorenz PA, Zhang M, Peltier S, Noll DC. University of Michigan, Ann Arbor, MI; University of Washington, Seattle, WA; Rotman Research Institute at Baycrest, University of Toronto, Canada.

4:00 S6-4. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: An AZURE translational study
Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D, Bell R. University of Leeds, United Kingdom; University of Sheffield, United Kingdom; University of Edinburgh, United Kingdom; Andrew Love Cancer Centre, Geelong, Australia.

4:15 S6-5. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger G, Suter T, Toi M, Parmar M, Bubuteishvili-Pacaud L, Henschel V, Laeufle R, Bell R. University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, United Kingdom; University of Leeds, United Kingdom; Sunnybrook Health Sciences Center and University of Toronto, Toronto, ON, Canada; Klinikum Offenbach, Offenbach, Germany; Cross Center Institute, Edmonton, Canada; University Hospital Jean Minjoz, Besançon, France; Medical University of Vienna, Austria; Bern University Hospital, Inselspital, Switzerland; Kyoto University, Kyoto, Japan; MRC Clinical Trials Unit, London, United Kingdom; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Andrew Love Cancer Centre, Geelong, Australia; National Cancer Center, Singapore, Singapore.

4:30 S6-6. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Wanders J, Olivo MS, He Y, Dutcus CE, Cortes. Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Jules Bordet Institute, Brussels, Belgium; Leeds Institute of Molecular Medicine and St James's Institute of Oncology, Leeds, United Kingdom; University of Montreal, Montreal, Canada; Mayo Medical Clinic, Jacksonville, FL; Eisai Ltd., Hatfield, United Kingdom; Eisai Inc., Woodcliff Lake, NJ; Vall D'Hebron University Hospital, Barcelona, Spain.

4:45 S6-7. Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study
Gianni L, Bianchini G, Valagussa P, Belousov A, Thomas M, Ross G, Pusztai L. San Raffaele Hospital - Scientific Institute, Milano, Italy; Fondazione Michelangelo, Milano, Italy; Roche Diagnostics GmbH, Penzberg, Germany; Roche Products Limited, Welwyn, United Kingdom; Yale School of Medicine, New Haven, CT.

5:00 pm–7:00 pm

POSTER DISCUSSION 9: DNA REPAIR
Ballroom A

Viewing 5:00 pm
Discussion 5:15 pm

Daniel Silver, MD, PhD, Chair and Discussant
Dana-Farber Cancer Institute
Boston, MA

Shridar Ganesan, MD, PhD, Discussant
The Cancer Institute of New Jersey
New Brunswick, NJ

PD09-01 BRCA1 inactivation induces NF-κB in human breast cancer cells and in murine and human mammary glands
Sau A, Arnaout A, Pratt C. University of Ottawa, ON, Canada; Ottawa Hospital, Ottawa, ON, Canada.

PD09-02 BRCA1 insufficiency is predictive of superior survival in patients with triple negative breast cancer treated with platinum based chemotherapy
Sharma P, Stecklein S, Kimler BF, Klemp JR, Khan QJ, Fabian CJ, Tawfik OW, Connor CS, McGinness MK, Mammen JMW, Jensen RA. University of Kansas Medical Center, Westwood, KS; University of Kansas Medical Center, Kansas City, KS.

PD09-03 **Impact of BRCA1/2 mutation status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer**
Isakoff SJ, Goss PE, Mayer EL, Traina T, Carey LA, Krag KJ, Liu MC, Rugo H, Stearns V, Come S, Finkelstein D, Hartman A-R, Garber JE, Ryan PD, Winer EP, Ellisen LW. Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Mass General/North Shore Cancer Ctr, Danvers, MA; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Beth Israel Deaconess Medical Center, Boston, MA; Myriad Genetics, Salt Lake City, UT; Fox Chase Cancer Center, Philadelphia, PA.

PD09-04 **Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)**
Telli ML, Jensen KC, Abkevich V, Hartman A-R, Vinayak S, Lanchbury J, Gutin A, Timms K, Ford JM. Stanford University School of Medicine, Stanford, CA; Myriad Genetics, Salt Lake City, UT.

PD09-05 **Single nucleotide polymorphism of XRCC1 which participates in DNA repair mechanism predicts clinical outcome in relapsed or metastatic breast cancer patients treated with S1 and oxaliplatin chemotherapy: Results from multicenter prospective study (TORCH_KCSG BR07-03)**
Im S-A, Oh D-Y, Keam B, Lee KS, Ahn J-H, Sohn J, Ahn JS, Kim JH, Lee MH, Lee KE, Kim HJ, Lee K-H, Han SW, Kim S-Y, Kim SB, Im Y-H, Ro J, Park H-S. Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea.

PD09-06 **Two phase I trials exploring different dosing schedules of carboplatin (C), paclitaxel (P), and the poly-ADP-ribose polymerase (PARP) inhibitor, veliparib (ABT-888) (V) with activity in triple negative breast cancer (TNBC)**
Puhalla SL, Appleman LJ, Beumer JH, Tawbi H, Stoller RG, Owonikoko TK, Ramalingam SS, Belani CP, Brufsky AM, Abraham J, Shepherd SP, Giranda V, Chen AP, Chu E. University of Pittsburgh Cancer Institute, Pittsburgh, PA; Winship Cancer Institute of Emory University, Atlanta, GA; West Virginia University Cancer Center, Morgantown, WV; Penn State Hershey Cancer Institute, Hershey, PA; National Cancer Institute, Bethesda, MD; Abbott Laboratories, Abbott Park, IL.

PD09-07 **Therapeutic potential of targeting ATM-PELP1-p53 axis in triple negative breast cancer**
Krishnan SR, Nair BC, Sareddy GR, Mann M, Roy SS, Vadlamudi RK. UTHSCSA, San Antonio, TX.

PD09-08 **The potential role of TLK2 as a therapeutic target in breast cancer**
Kim J-A, Cao X, Tan Y, Schiff R, Wang X. Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.

PD09-09 **The Akt inhibitor MK-2206 is an effective radio-sensitizer of p53 deficient triple negative breast cancer (TNBC) cells**
Connolly EP, Sun Y, Chao KC, Hei TK. Columbia University, New York, NY.

PD09-10 **DNA damage and repair in mammary gland development**
Kass EM, Helgadottir H, Moynahan ME, Jasin M. Memorial Sloan-Kettering Cancer Center, New York, NY.

5:00 pm–7:00 pm
POSTER DISCUSSION 10: PROGNOSTIC/PREDICTIVE
Ballroom B

Viewing 5:00 pm
Discussion 5:15 pm

Matthew Goetz, MD, Chair
Mayo Clinic College of Medicine
Rochester, MN

Dennis C. Sgroi, MD, Discussant
Massachusetts General Hospital
Charlestown, MA
and
Hiltrud Brauch, PhD, Discussant
Dr. Margarete Fischer-Bosch – Institute of Clinical Pharmacology
Stuttgart, GERMANY

PD10-01 **Rescheduled as S1-10**

PD10-02 **Metabolic syndrome and recurrence within the 21-gene recurrence score assay risk categories in lymph node negative breast cancer**
Lakhani A, Guo R, Duan X, Ersahin C, Gaynor ER, Godellas C, Kay C, Lo SS, Mai H, Perez C, Albain K, Robinson P. Loyola University Medical Center, Maywood, IL.

PD10-03 **Predictive value of a proliferation score (MS) in postmenopausal women with endocrine-responsive breast cancer: results from International Breast Cancer Study Group (IBCSG) Trial IX**
Sninsky J, Wang A, Gray K, Lagier R, Christopherson C, Rowland C, Chang M, Kammler R, Viale G, Kwok S, Regan M, Leyland-Jones B. Celera, Alameda, CA; Dana-Farber Cancer Institute, Boston, MA; IBCSG Coordinating Center, Berne, Switzerland; European Institute of Oncology, Milan, Italy; Sanford Research, Sioux Falls, SD.

PD10-04 **Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study**
Perez EA, Eckel-Passow JE, Ballman KV, Anderson SK, Thompson EA, Asmann YW, Jen J, Dueck AC, Lingle WL, Sledge GW, Winer EP, Gralow J, Jenkins RB, Reinholz MM. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Dana Farber Cancer Institute, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Ventana Medical Systems, Inc., Tuscon, AZ.

PD10-05 **HLA-DQA1*02:01/DRB1*07:01 as a biomarker for lapatinib-induced hepatotoxicity: prospective confirmation in a large randomised clinical trial (TEACH, EGF105485)**
Spraggs CF, Schaid DJ, Parham LR, McDonnell SK, Briley LP, King KS, Rappold E, Goss PE. GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom; GlaxoSmithKline, Raleigh, NC; Mayo Clinic, Rochester, MN; GlaxoSmithKline, Collegeville, PA; Massachussets General Hospital, Boston, MA.

PD10-06 **CXCL13 mRNA predicts docetaxel benefit in triple negative tumors**
Wirtz RM, Leinonen M, Bono P, Isola J, Kellokumpu-Lehtinen P-L, Kataja V, Turpeenniemi-Hujanen T, Jyrkkiö S, Eidt S, Schmidt M, Joensuu H. STRATIFYER Molecular Pathology GmbH, Cologne, Germany; Pharma, Turku, Finland; Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; University of Tampere and Tampere University Hospital, Finland; Tampere University Hospital, Tampere, Finland; Kuopio University Hospital, Kuopio, Finland; Oulu University Hospital, Oulu, Finland; Turku University Hospital, Turku, Finland; Institute of Pathology at the St-Elisabeth-Hospital, Cologne, Germany; University Hospital Mainz, Germany.

PD10-07 **Patients carrying CYP2C8*3 are at increased risk of paclitaxel-induced neuropathy**
Hertz DL, Dees EC, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA. University of North Carolina at Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC; North Carolina State University, Raleigh, NC; Gentris Corp., Morrisville, NC.

PD10-08 **Venlafaxine inhibits the CYP2D6 mediated metabolic activation of tamoxifen: Results of a prospective multicenter study: (NCT00667121)**
Goetz MP, Suman V, Henry NL, Reid J, Safgren S, Kosel M, Kuffel M, Sideras K, Flockhart D, Stearns V, Denduluri N, Irvin WJ, Ames M. Mayo Clinic, Rochester, MN; University of Michigan, Ann Arbor, MI; Indiana University, Indianapolis, IN; Johns Hopkins, Baltimore, MD; Fairfax-Northern Virginia Hematology-Oncology, Arlington, VA; University of North Carolina, Chapel Hill, NC.

PD10-09 **CYP2D6 and adjuvant tamoxifen: Impact on outcome in pre- but not postmenopausal breast cancer patients**
Margolin S, Lindh J, Thorén L, Xie H, Koukel L, Dahl M-L, Eliasson E. Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.

5:00 pm–7:00 pm
POSTER SESSION 5 & RECEPTION
Exhibit Halls A-B

Detection/Diagnosis: Diagnostic Pathology

P5-01-01 **Predicting OncoDX Recurrence Scores with Immunohistochemical Markers**
Bradshaw SH, Gravel DH, Song X, Marginean EC, Robertson SJ. The Ottawa Hospital, Ottawa, ON, Canada.

P5-01-02 **Inter-observer concordance of Ki-67 labeling index in breast cancer: Japan Breast Cancer Research Group (JBCRG) Ki-67 Ring Study**
Ueno T, Mikami Y, Yoshimura K, Tsuda H, Kurosumi M, Masuda S, Horii R, Toi M, Sasano H. Kyoto University Hospital, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Saitama Cancer Center, Saitama, Japan; Nihon University School of Medicine, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Tohoku University School of Medicine, Sendai, Japan.

P5-01-03 **Discordant Estrogen and Progesterone Receptor Status in Breast Cancer**
Hefti MM, Hu R, Knoblauch N, Collins L, Tamimi RM, Beck AH. Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA.

P5-01-04 **Clinico-pathological features of low-grade triple negative early breast cancers**
Nourieh M, Furhmann L, Feron J-G, Caly M, Diéras V, Sastre-Garau X, Chavrier P, Vincent-Salomon A. Institut Curie, Paris, France.

P5-01-05 **Could *C-myc* amplification replace Cahan's criteria to discriminate secondary from primary angiosarcoma of the breast?**
Laé M, Hamel F, Hadj-Hamou S, Malfoy B, Kirova YM. Institut Curie, Paris, France.

P5-01-06 **Differences in FGF1 and FGFR2 expression in BRCA1-associated, BRCA2-associated, and sporadic breast carcinomas**
Vos S, van der Wall E, van Diest PJ, van der Groep P. University Medical Center Utrecht, Netherlands.

P5-01-07 **Fibroadenomatoid changes are more prevalent in middle-aged women and have a positive association with invasive breast cancer**
Chen Y, Bekhash A, Kovatich AJ, Hooke JA, Kvecher L, Mitchell EP, Rui H, Mural RJ, Shriver CD, Hu H. Windber Research Institute, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; MDR, Global Systems LLC, Windber, PA; Thomas Jefferson University, Philadelphia, PA.

P5-01-08 **Complex fibroadenoma is not an independent risk marker for breast cancer**
Nassar A, Visscher DW, Degnim AC, Frank RD, Vierkant RA, Hartmann LC, Frost MH, Ghosh K. Mayo Clinic, Rochester, MN.

P5-01-09 **Identification of Molecular Apocrine Triple Negative Breast Cancer Using a Novel 2-Gene Assay and Comparison with Androgen Receptor Protein Expression and Gene Expression Profiling by DASL**
Alvarez J, Schaffer M, Karkera J, Martinez G, Gaffney D, Bell K, Sharp M, Wong J, Hertzog B, Ricci D, Platero S. Janssen Pharmaceuticals.

P5-01-10 **Clinical-pathological features and outcomes of Invasive lobular (ILC) vs Invasive ductal (IDC) breast cancer (BC): a mono-institutional series**
Ferro A, Eccher C, Triolo R, Caldara A, Di Pasquale MC, Russo LM, De Carli NL, Cuorvo LV, Barbareschi M, Gasperetti F, Berlanda G, Pellegrini M, Moroso S, Galligioni E. S Chiara Hospital, Trento, Italy; FBK, Trento, Italy.

P5-01-11 **Same-day diagnosis' of women suspected of breast cancer: success rate and impact on diagnostic quality and patients' anxiety levels**
Barentsz MW, Wessels H, van Diest PJ, Pijnappel RM, van der Pol CC, Witkamp AJ, van den Bosch MA, Verkooijen HM. University Medical Center Utrecht.

P5-01-12 **Over- and Undergrading of Breast Cancer on Core Biopsies in Comparison to Surgical Specimens**
Decker T, Focke CM, Gläser D, Finsterbusch K. Bonhoeffer Medical Center, Neubrandenburg, Germany.

P5-01-13 **Flat Epithelial Atypia: Management and outcome in three Dutch teaching hospitals**
Ghuijs PM, de Vries B, Strobbe LJA, van Deurzen CHM, Heuts EM, Keymeulen KBMI, Lobbes MBI, Wauters CAP, Van de Vijver KKBT, Smidt ML. Maastricht University Medical Centre, Maastricht, Netherlands; Canisius-Wilhelmina Hospital, Nijmegen, Netherlands; Erasmus Medical Centre, Rotterdam, Netherlands.

P5-01-14 **Discrepancy between routine and expert pathologists in histological assessment of early stage non palpable breast cancer and its impact on loco regional and systemic treatment**
Postma EL, Verkooijen HM, van Diest PJ, Willems SM, van den Bosch MA, van Hillegersberg R. UMC Utrecht.

P5-01-15 **Anti-ER monoclonal antibody SP1 seems more sensitive in the identification of ER alpha positive breast cancer cases than anti-ER monoclonal antibody 1D5**
Madeira KP, Daltoé RD, Sirtoli GM, Rezende LCD, Carvalho AA, Silva IV, Rangel LBA. Universidade Federal do Espírito Santo, Vitória, ES, Brazil.

P5-01-16 **Value of ultrasonography appearance of breast mass in prediction of histologic type**
Xu Z, Sun L, Yang H, Song Y, Sun G. JiLin Province Breast Dieases Institue, Changchun, JiLin, China.

Detection/Diagnosis: Detection/Diagnosis - Other

P5-02-01 **Discrepancy between CT and FDG-PET/CT in the staging of patients with inflammatory breast cancer: Implications for radiation therapy treatment planning**
Jacene H, DiPiro P, Bellon J, Nakhlis F, Hirshfield-Bartek J, Yeh E, Overmoyer B. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

P5-02-02 Factors influencing time to seeking medical advice and start of treatment in breast cancer (BC) patients – an International survey
Jassem J, Ozmen V, Bacanu F, Drobniene M, Eglitis J, Kahan Z, Lakshmaiah K, Mardiak J, Pienkowski T, Semiglazova T, Stamatovic L, Timcheva C, Vasovics S, Vrbanec D, Zaborek P. Medical University of Gdansk, Poland; University of Istanbul, Turkey; Sf Maria Hospital, Bucharest, Romania; Institute of Oncology, Vilnius University, Vilnus, Lithuania; Riga East University Hospital, Riga, Latvia; University of Szeged, Hungary; Kidwai Memorial Institute of Oncology, Bangaluru, India; National Cancer Institute and Medical School of Comenius University, Bratislava, Slovakia (Slovak Republic); Medical Center of Postgraduate Education, ECZ, Otwock, Poland; Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Institute of Oncology and Radiology, Belgrade, Serbia; Chemiotherapy Clinic, Sofia, Bulgaria; Zagreb University Hospital Center, Zagreb, Croatia; Warsaw School of Economics, Warsaw, Poland.

P5-02-03 Large-scale genomic instability consistently identifies BRCA1/2 inactivation in breast cancers
Stern M-H, Popova T, Manié E, Dubois T, Sigal-Zafrani B, Bollet M, Sastre-Garau X, Vincent-Salomon A, Houdayer C, Stoppa-Lyonnet D. Institut Curie, Paris, France.

Tumor Cell and Molecular Biology: Stem/Progenitor Cells

P5-03-01 Cancer stem cells predict engraftment and poor prognosis of primary breast tumors
Charaffe-Jauffret E, Ginestier C, Bertucci F, Cabaud O, Wicinski J, Finetti p, Josselin E, Adelaide J, Nguyen T-T, Monville F, Jacquemier J, Thomassin-Piana J, Pinna G, Jalaguier A, Lambaudie E, Houvenaeghel G, Xerri l, Harel-bellan A, Chaffanet M, Viens P, Birnbaum D. CRCM-IPC; CEA.

P5-03-02 Targeting mRNA Translation To Enhance the Radiosensitivity of Inflammatory Breast Cancer Stem Cells
Silvera D, Connolly EP, Volta V, Arju R, Venuto T, Schneider RJ. NYU School of Medicine, New York, NY; NYU Cancer Institute, NYU School of Medicine, New York, NY; Columbia University College of Physicians and Surgeons, New York, NY.

P5-03-03 Antitumor Activity and Cancer Stem Cells Effect of Cetuximab in Combination with Ixabepilone in Triple Negative Breast Cancers (TNBC)
Tanei T, Rodriguez AA, Dobrolecki L, Choi DS, Landis M, Chang JC. The Methodist Hospital Research Institute and Weill Cornell Medical School, Houston, TX.

P5-03-04 Effect of aging on the function and transformation of murine mammary stem cells
Bandyopadhyay A, Dong Q, Wang D, Gao H, Wu A, Yeh I-T, Sun L. University of Texas Health Science Center, San Antonio, TX; Virginia Hospital Center, Arlington, VA.

P5-03-05 Histone deacetylase (HDAC)-inhibitor mediated reprogramming drives cancer cells to the pentose phosphate metabolic pathway
Debeb BG, Larson RA, Lacerda L, Xu W, Smith DL, Ueno NT, Reuben JM, Gilcrease M, Krishnamurthy S, Buchholz TA, Woodward WA. MD Anderson Cancer Center, Houston, TX.

P5-03-06 Bisphenol A and mammary stem cells: implications in breast cancer susceptibility
Dong Q, Wang D, Gao H, Bandyopadhyay A, Wu A, Yeh I-T, Huang C, Sun L. University of Texas Health Science Center at San Antonio, TX; Wenzhou Medical College, Wenzhou, Zhejiang, China; Virginia Hospital Center, Arlington, VA.

P5-03-07 Targeting Hedgehog pathway to reverse chemoresistance in breast cancer stem cells
Mañu A, Fresquet V, Mena M, Sánchez S, Espinós J, Fernandez Hidalgo OA, Fernández-Zapico M, Knutson KL, Martínez-Climent JA, Santisteban M. Clinic University of Navarra, Pamplona, Navarra, Spain; Foundation for Applied Medical Research, Pamplona, Navarra, Spain; Mayo Clinic, Rochester, MN.

P5-03-08 A fluorescence STAT3 reporter preferentially expressed in human breast cancer tumor-initiating cells
Wei W, Tweardy D, Zhang M, Roarty K, Rosen J, Lewis M. Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.

P5-03-09 Receptor Activator of Nuclear Factor Kappa B (RANK) as a potential therapeutic target in triple-negative breast cancer
Reyes ME, Masuda H, Zhang D, Reuben JM, Woodward W, Darnay BG, Hortobagyi GN, Ueno NT. MD Anderson Cancer Center, Houston, TX.

P5-03-10 HIF-1alpha knockout radiosensitizes select Inflammatory Breast Cancer cells through reduction of stem-like cancer cells
Xu W, Debeb BG, Smith DL, Li JL, Ueno NT, Alvarez de Lacerda LC, Larson RA, Schwba LP, Seagroves TN, Woodward WA. MD Anderson Cancer Center, Houston, TX; U of Tennessee Health Science Center, Memphis, TN.

P5-03-11 Possible role for cancer stem cells: results from a pilot neoadjuvant trial of HER-2 positive breast cancer patients treated with a combination of (Nab)-paclitaxel and lapatinib
Siziopikou KP, Gradishar WJ, Kaklamani VG. Northwestern University Feinberg School of Medicine, Chicago, IL.

P5-03-12 Targeting breast cancer stem cells using the autophagy inhibitor N-Acetyl cysteine
Dave B, Granados S, Mitra S, Chang JC. Methodist Hostpital Research Institute, Houston, TX.

P5-03-13 Detection of tumor initiating cells (TIC) among the peripherally circulating epithelial tumor cells from patients with breast cancer
Pachmann K, Zimon D, Pizon M, Carl S, Rabenstein C, Camara O, Pachmann U. University Hospital Jena, Germany; Transfusion Center, Bayreuth, Germany.

P5-03-14 Expression of ALDH1 in metastasizing axillary lymphnodes in breast cancer
Shi A, Dong Y, Bi L, Xu N, Fan Z, Li S, Yang H, Li Y. First Hospital of Bethune Medical College, Jilin University, Changchun, Jilin, China; Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.

Tumor Cell and Molecular Biology: Epithelial-Mesenchymal Transition

P5-04-01 Expression of epithelial-mesenchymal transition (EMT)-related markers in primary tumors and matched lymph node metastases in breast cancer patients
Zaczek AJ, Ahrends T, Markiewicz A, Seroczynska B, Szade J, Welnicka-Jaskiewicz M, Jassem J. Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland; Medical University of Gdansk, Pomorskie, Poland.

P5-04-02 DYRK2 regulates breast cancer invasion via Snail/E-cadherin pathway
Mimoto R, Imawari Y, Kamio M, Kato K, Nogi H, Toriumi Y, Takeyama H, Yoshida K, Uchida K. The Jikei University School of Medicine, Tokyo, Japan.

P5-04-03 Epithelial-mesenchymal transition is associated with in situ to invasive transition of basal-like breast cancer
Park SY, Choi Y, Kim EJ, Lee HE, Lee HJ, Kang E, Kim S-W. Seoul National University College of Medicine, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

P5-04-04 Significance of PELP1/HDAC2/microRNA-200 regulatory network in EMT and metastasis of breast cancer
Roy SS, Gonugunta VK, Bandyopadhyay AM, Rao M, Goodall G, Sun L, Tekmal RR, Vadlamudi RK. UTHSCSA, San Antonio, TX; Centre for Cancer Biology, Adelaide, Australia.

P5-04-05 E-Cadherin Is Required for In Vivo Growth of Inflammatory Breast Cancer: Importance of Mesenchymal-Epithelial Transition (MET) and Role of HIF1α
Chu K, Boley KM, Cristofanilli M, Robertson FM. The University of Texas MD Anderson Cancer Center, Houston, TX; Fox Chase Cancer Center, Philadelphia, PA.

P5-04-06 Soluble factors from activated immune cells induce epithelial mesenchymal transition in inflammatory breast cancer cells
Cohen EN, Gao H, Anfossi S, Giordano A, Tin S, Wu Q, Lee B-N, Luthra R, Krishnamurthy S, Hortobagyi GN, Ueno NT, Woodward WA, Reuben JM. The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas at Houston Health Science Center, Houston, TX; The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX.

P5-04-07 Epithelial-mesenchymal transition phenotype in breast cancers is associated with clinicopathologic factors indicating aggressive biologic behavior and poor clinical outcome
Bae YK, Kim A, Choi JE, Kang SH, Lee SJ. Yeungnam University College of Medicine, Daegu, Korea.

P5-04-08 Identifying and characterizing human kinases for novel regulators of epithelial-mesenchymal transition in breast cancer cells
Li L, Azizian N, Li W. Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, TX.

P5-04-09 Squamous Cell Carcinoma Antigen 1 (SCCA1) Upregulation Causes Epithelial to Mesenchymal Transition (EMT) and Promotes Mammary Tumorigenesis
Sheshadri N, Ullman E, Catanzaro J, Chen E, Zong W-X. Stony Brook University, Stony Brook, NY.

Tumor Cell and Molecular Biology: Systems Biology of Breast Cancer

P5-05-01 Catalogued phospho-sensing peptides identifying active, oncogenic kinase signatures
Mori M, Chen Z, Boudreau A, van't Veer L, Coppé J-P. University of California, San Francisco, CA; Kinogea Inc., Shanghai, China; Lawrence Berkeley National Laboratory, Berkeley, CA.

P5-05-02 The role of cellular heterogeneity on the therapeutic response of breast cancer: Clinical insights from a hybrid multiscale computational model
Powathil GG, Thompson A, Chaplain MAJ. University of Dundee, Scotland, United Kingdom; Dundee Cancer Centre, University of Dundee, Scotland, United Kingdom.

P5-05-03 The 5p12 breast cancer susceptibility locus is associated with MRPS30 expression in estrogen receptor - positive tumors
Quigley DA, Van Loo P, Alnæs GG, Tost J, Zelenika D, Balmain A, Børresen-Dale A-L, Kristensen VN. Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA; CEA - Institut de Génomique, Evry, France.

P5-05-04 Intraductal delivery of RNAi-based therapeutics to gene targets identified through computational systems modeling
Brock A, Krause S, Li H, Kowalski M, Collins J, Ingber D. Wyss Institute, Harvard University, Boston, MA; Boston Children's Hospital, Boston, MA.

P5-05-05 Computational modeling of breast cancer growth and spread: the role of matrix degrading enzymes
Deakin NE, Thompson AM, Chaplain MAJ. University of Dundee, United Kingdom; Dundee Cancer Centre, University of Dundee, United Kingdom.

P5-05-06 Spatio-temporal computational modeling of the p53-Mdm2 pathway
Sturrock M, Thompson AM, Chaplain MAJ. University of Dundee, United Kingdom; Dundee Cancer Centre, University of Dundee, United Kingdom.

Tumor Cell and Molecular Biology: Cell Cycle Regulation

P5-06-01 Active pak6 induces aneuploidy in breast cancer cells
Paul BA, Lu ML. University of Miami Miller School of Medicine, Miami, FL; Florida Atlantic University, Boca Raton, FL.

P5-06-02 The Role of Breast Tumor Kinase (Brk) in Cell Cycle Control
Nimnual AS, Chan E. Stony Brook University, Stony Brook, NY.

Tumor Cell and Molecular Biology: Cellular Mechanisms

P5-07-01 Defining the mechanism of breast cancer growth by chemokine receptor CXCR7 and Epidermal Growth Factor Receptor coupling interaction
Salazar N, Muñoz D, Singh RK, Lokeshwar BL. University of Miami Miller School of Medicine, Miami, FL; Miami VA Medical Center, Miami, FL; Dow Corning Inc., Midland, MI.

P5-07-02 Analysis of a novel synergistic relationship between the FK506 binding protein FKBP52 and beta catenin in androgen receptor signaling pathways
Storer CL, Olivares K, Fletterick RJ, Webb P, Cox MB. The University of Texas at El Paso, El Paso, TX; The University of California, San Francisco, CA; The Methodist Hospital Research Institute, Houston, TX.

P5-07-03 Gallotannins and Gallic acid From Mango Fruit (Mangifera Indica L) Suppress Breast Cancer Tumor Growth by Targeting Phosphatidylinositol3-kinase (PI3K)-Akt-NF-kB Pathway and Associated microRNAs
Banerjee N, Kim H, Krenek K, Talcott S, Talcott SM. Texas A&M University, College Station, TX.

P5-07-04 Aurora kinase regulates PKC-mediated MMP-9 expression and invasion in MCF-7 breast cancer cells
Kim JS, Noh EM, Lee YR, Hwang B-M, Jung SH, Youn HJ, Lee SJ. Institute for Medical Sciences Chonbuk National University Medical School, Jeonju, Republic of Korea; Chonbuk National University Medical School, Jeonju, Republic of Korea; School of Dentistry, Wonkwang University, Iksan, Republic of Korea; College of Phamacy, Ewha Womans University, Seoul, Republic of Korea.

P5-07-05 Insulin-like growth factor binding protein-3 is a key component of the breast cancer cell response to DNA-damaging therapy
Baxter RC, Lin MZ, Marzec KA, Martin JL. University of Sydney, Sydney, NSW, Australia.

P5-07-06 Triple negative receptor status is associated with low DNA repair capacity in women with breast cancer
Matta J, Ortiz C, Vargas W, Echenique M, Sanchez F, Ramirez E, Torres A, Ortiz J, Bolaños G, Gonzalez J, Laboy J, Barnes R, Santiago S, Romero A, Martinez R, Alvarez-Garriga C, Bayona M. Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico; Auxilio Mutuo Hospital, San Juan, Puerto Rico; Ponce School of Medicine and Health Sciences and Damas Hospital, Ponce, Puerto Rico; Private Office, Ponce, Puerto Rico; Ponce School of Medicine and Health Sciences and Private Practice, Ponce, Puerto Rico; Ponce School of Medicine and Health Sciences and San Lucas Hospital, Ponce, Puerto Rico; Ponce School of Medicine and Health Sciences, Ponce, Puerto Rico; Dr. Pila Hospital, Ponce, Puerto Rico; Food and Drug Administration, Silver Spring, MD.

Tumor Cell and Molecular Biology: Telomeres/Telomerase

P5-08-01 Investigating the role of BRCA1 in sensitivity to GRN163L, a telomerase template antagonist
Phipps EA, Gryaznov SM, Herbert B-S. Indiana University School of Medicine, Indianapolis, IN; Geron Corporation, Menlo Park, CA.

Tumor Cell and Molecular Biology: Apoptosis and Senescence

P5-09-01 Evaluation of BCL2 sequence variant in Iranian women patients with Breast cancer
Motahari B, Ghaffarpour M, Javadi GH, Houshmand M. Science and Research branch, Islamic Azad University, Tehran, Islamic Republic of Iran; National Institute of Genetic Engineering and Biotechnology, Tehran, Islamic Republic of Iran; Iranian Research Organization for Science and Technology, Tehran, Islamic Republic of Iran; Special Medical Center, Tehran, Islamic Republic of Iran.

Tumor Cell and Molecular Biology: MicroRNAs

P5-10-01 MicroRNAs *-181* and *-135a* modulate tumour infiltrating immune cell programs in distinct molecular breast cancer subtypes
Paladini L, Truglia M, Arcangeli A, De Mattos Aruda L, Bianchini G, Iwamoto T, Bottai G, Pusztai L, Calin GA, Di Leo A, Santarpia L. Istituto Toscano Tumori, Prato, Italy; Istituto Toscano Tumori - Hospital of Prato, Prato, Italy; University of Florence, Italy; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy; Okayama University Hospital, Okayama, Japan; The University of Texas M.D. Anderson Cancer Center, Houston.

P5-10-02 High serum levels of miR-19a are associated with poor outcome in metastatic inflammatory breast cancer
Anfossi S, Giordano A, Cohen EN, Gao H, Woodward W, Ueno NT, Valero V, Alvarez RH, Hortobagyi GN, Lee B-N, Cristofanilli M, Reuben JM. The University of Texas MD Anderson Cancer Center; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center; Fox Chase Cancer Center.

P5-10-03 OncomiR-569 deregulates p53 pathway and initiate breast oncogenesis
Chaluvally-Raghavan P, Zhang F, Pradeep S, Hee-Dong H, Lu Y, Borresen-Dale A-L, Flores ER, Sood AK, Mills GB. MD Anderson Cancer Centre, Houston, TX; Institute for Cancer Research, Oslo University Hospital, Oslo, Oslo, Norway.

P5-10-04 Metformin mediated upregulation of microRNA-193 triggers apoptosis by decreasing fatty acid synthase
Cochrane DR, Wahdan-Alaswad RS, Edgerton SM, Terrell KL, Spoelstra NS, Thor AD, Anderson SM, Richer JK. University of Colorado Denver School of Medicine, Aurora, CO.

P5-10-05 Novel Mechanisms of Metformin Action in TN Breast Cancer: Upregulation of miRNA 141 and 192, Are Associated with a Decrease in Targets *GRB2* and *MSN* Involved in Signaling and Motility Respectively
Edgerton SM, Richer JK, Fan Z, Spoelstra NS, Wahdan-Alsawad RS, Arnadottir SS, Thor AD. University of Colorado Denver School of Medicine, Aurora, CO; Aarhus University, Aarhus, Denmark.

P5-10-06 A functional role for miR-150 in breast cancer
D'Amato NC, Gu H, Lee M, Heinz R, Spoelstra NS, Jean A, Cochrane DR, Richer JK. University of Colorado Anschutz Medical Campus, Aurora, CO.

P5-10-07 Luminal A breast cancer: identification of novel circulating miRNA biomarkers
McDermott AM, Miller N, Ball G, Sweeney KJ, Kerin MJ. National University of Ireland, Galway, Galway, Ireland; Nottingham Trent University, Nottingham, United Kingdom.

P5-10-08 Hyperactive MAPK signaling alters expression of miR-221/222 and miR-30 families, which impacts multiple pathways and contributes to breast cancer aggressiveness and progression
Miller P, El-Ashry D. University of Miami, FL.

P5-10-09 Prediction of Trastuzumab treatment response for HER2-positive breast cancer by microRNA profiling
Sato F, Wang Z, Ueno T, Myomoto A, Takizawa S, Masuda N, Mikami Y, Shimizu K, Tsujimoto G, Toi M. Graduate School of Medicine, Kyoto University, Kyoto, Japan; Toray Industry, Kamakura, Kanagawa, Japan; Kyoto University Hospital, Kyoto, Japan; Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.

P5-10-10 The miR-34a is down-regulated in breast cancer and breast stem cells and a potential to eradicating breast cancer via a systemic delivery of a VISA –miR-34a nanoparticle system
Xie X, Li L, Xie X, Wei W, Kong Y, Wu M, Yang L, Gao J, Xiao X, Tang J, Xie Z, Wang X, Liu P, Li X, Guo J. Sun Yat-Sen University Cancer Center, Guangzhou, China.

P5-10-11 Clinical significance of microRNA expression as a prognostic factor in early N+ breast cancer (BC)
Ciruelos EM, de Velasco GA, Castañeda C, Rodriguez-Peralto JL, Gamez A, Sepúlveda JM, Cortés-Funes H, Castellano DE, Fresno JA. Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Enfermedades Neoplásicas, Lima, Peru; Hospital Universitario La Paz, Madrid, Spain.

P5-10-12 Differences in microRNA expression patterns in breast cancer and triple negative tumors
Romero-Cordoba SL, Rebollar-Vega RG, Quintanar-Jurado V, Rodriguez-Cuevas S, Bautista-Pina V, Maffuz-Aziz A, Hidalgo-Miranda A. National Institute of Genomic Medicine, Mexico; Instituto de Enfermedades de la Mama FUCAM, Mexico.

P5-10-13 Pre-surgical plasma microRNA pattern defines a biologically distinct triple negative breast cancer (TNBC) occuring in black (B) compared to white (W) women
Shapira I, Lee A, Oswald M, Taioli E, Bradley T, Barginear M, Mason C, Keogh M, Budman D. Monter Cancer Center, Hofstra North Shore LIJ School of Medicine, Lake Success, NY; Hofstra North Shore LIJ School of Medicine, Manhasset, NY.

P5-10-14 MicroRNAs as biomarkers and therapeutic adjuvants for the prognosis and treatment of drug-resistant breast cancers
Chang Y-F, Panneerdoss S, Zoghi B, Pertsemlidis A, Rao M. Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, TX; UT Health Science Center at San Antonio, TX.

P5-10-15 Genetic variants located in beta2 adrenergic receptor gene (ADRB2) and miRNA let-7 binding site alter breast cancer susceptibility: a case control analysis
Du Y, Lu J. Shanghai Cancer Center, Fudan University, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.

P5-10-16 miRNAs as novel therapeutic adjuvants for the prognosis and treatment of triple negative breast cancers
Zoghi B, Chang Y-F, Subbarayalu P, Plyler JR, Rao M. University of Texas Health Science Center at San Antonio, TX; Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio.

P5-10-17 Radiotherapy-induced miR expression influences the formation of local recurrence in breast cancer
Fabris L, Berton S, Massarut S, D'Andrea S, Roncadin M, Perin T, Calin G, Belletti B, Baldassarre G. CRO, National Cancer Institute; MD Anderson Cancer Center.

Psychosocial, Quality of Life, and Educational Aspects: Advocacy

P5-11-01 Extending breast conservation choices for women with breast cancer
Egbeare DM, Chan HY. Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom.

P5-11-02 **Breast Cancer Radiation Therapy and the Risk of Developing Bronchiolitis Obliterans Organizing Pneumonia (BOOP): Communication of BOOP Risk by Breast Cancer Information Websites and General Medical Information Websites**
Kelly EM. Kelly Consulting, Smithtown, NY.

Psychosocial, Quality of Life, and Educational Aspects: Education

P5-12-01 **Are web-based resources the breast? An evaluation of the quality of online resources for breast cancer patients**
Nguyen S, Regehr G, Brar B, Lin J, Ingledew P. British Columbia Cancer Centre, Fraser Valley Cancer Centre, Surrey, BC, Canada; Centre for Health Education Scholarship, Vancouver, BC, Canada; UBC, Vancouver, BC, Canada.

P5-12-02 **Tangled in the Breast Cancer Web: An Evaluation of the Usage of Web-based Information Resources by Breast Cancer Patients**
Nguyen SKA, Ingledew P. British Columbia Cancer Agency, FVCC, Surrey, BC, Canada.

P5-12-03 **Developing the ePromotora: Increasing Promotora's Access to Breast Cancer Electronic Resources**
Lopez AM, Ryan J, Valencia A, El-Khayat Y, Nunez A. University of Arizona, Tucson, AZ.

Psychosocial, Quality of Life, and Educational Aspects: Doctor-Patient Communication

P5-13-01 **Does empowering patients improve accrual to breast cancer trials?**
Arnaout A, Kuchuk I, Bouganim N, Verma S, Clemons M. Ottawa Hospital, Ottawa, ON, Canada; Mcgill University and Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada.

P5-13-02 **Decision making from multidisciplinary team meetings to bedside: factors predicting for physicians' and breast cancer patients' acceptance of clinical trials proposed by MTMs**
Deneuve J, Mazouni C, Arnedos M, Prenois F, Saghatchian M, André F, Bourrgier C, Delaloge S. Institut Gustave Roussy, Villejuif, France.

P5-13-03 **Breast cancer risk assessment for underserved minority women in primary care: patient and provider perspectives**
Hoskins KF, Anderson EE, Tejedo S, Stolley M, VandeWydeven K, Korah V, Moreno L, Rojas M, Carillo A, Caseras M, Awolala Y, Calhoun E, Campbell R, Warnecke R. The University of Illinois Hospital and Health Sciences System, Chicago, IL; The University of Illinois at Chicago School of Public Health, Chicago, IL; OSF Saint Anthony Medical Center, Rockford, IL; Loyola University Medical Center, Maywood, IL; Chicago Family Health Center, Chicago, IL.

Psychosocial, Quality of Life, and Educational Aspects: Disparities and Barriers to Care

P5-14-01 **Withdrawn**

P5-14-02 **Women's responses to changes in US Preventive Services Task Force mammography screening guidelines: results from focus groups among ethnically diverse women**
Bluethmann SM, Allen JD, Hernandez C, Opdyke KM, Gates-Ferris K, Hurlbert M, Harden E. University of Texas School of Public Health; Dana Farber Cancer Institute; Avon Foundation for Breast Cancer Crusade; Cicatelli and Associates.

P5-14-03 **Breast cancer screening and follow-up of abnormal mammogram results: A population-based study comparing results from an urban university cancer center to a national database**
Mitchell EP, Avery TP, Jaslow RC, Berger AC, Lee SY, Vaughan-Briggs C, Bonat J. Thomas Jefferson University, Philadelphia, PA.

P5-14-04 **Alleviate the pain in the system: Using process improvement and systems design tools to strive for a high quality breast healthcare system in the District of Columbia metro area**
Brousseau MK, Graham L, Kaye P, Nolan T, Moraras N. Primary Care Coalition of Montgomery County, Maryland, Silver Spring, MD; Regional Primary Care Coalition, Washington, DC; Associates in Process Improvement, Silver Spring, MD.

P5-14-05 **Compliance with radiation therapy in breast cancer patients in Southeastern Kentucky**
Elsoueidi R, Adane E, Dignan M. Appalachian Regional Healthcare, Hazard, KY; University of Kentucky, Lexington, KY.

P5-14-06 **Analysis of test-therapy concordance for biomarkers uPA and PAI-1 in primary breast cancer in clinical hospital routine: Results of a prospective multi-center study at Certified Breast Cancers in Germany**
Jacobs VR, Augustin D, Wischnik A, Kiechle M, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P. Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top-Expertise, Germering/Munich, Germany; AOK Bayern, Munich.

Psychosocial, Quality of Life, and Educational Aspects: Cost-Effectiveness

P5-15-01 **Cost-effectiveness of gene expression profiling for ductal carcinoma in-situ (Oncotype DCIS Score)**
Alvarado MD, Harrison BL, Solin LJ, Ozanne EM. University of California, San Francisco, CA; Albert Einstein Medical Center, Philadelphia, PA.

P5-15-02 **The benefit of targeted therapeutics in medical oncology since the development of trastuzumab**
Conter HJ, Conter D, Wolff RA, Valero V, Zwelling L. University of Texas M.D. Anderson Cancer Center, Houston, TX; Huron College, London, ON, Canada.

P5-15-03 **Cost-effectiveness of 'radioguided occult lesion localization' (ROLL) versus 'wire-guided localization' (WGL) in breast conserving surgery for non-palpable breast cancer: results from a randomized controlled multicentre trial**
Postma EL, Koffijberg E, Verkooijen HM, Witkamp AJ, van den Bosch MA, van Hillegersberg R. UMC Utrecht; Julius Center Utrecht.

P5-15-04 **CTX and CTX-related direct medication costs saved by testing biomarkers uPA and PAI-1 in primary breast cancer: Results of a prospective multi-center study at Certified Breast Centers in Germany**
Jacobs VR, Augustin D, Wischnik A, Kiechle M, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P. Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany.

P5-15-05 **Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States**
Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M. Analysis Group, Inc., New York, NY; Analysis Group, Inc., Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

P5-15-06 **Societal economics of the 21-gene Recurrence Score® in estrogen-receptor-positive early-stage breast cancer in Japan**
Yamauchi H, Nakagawa C, Yamashige S, Takei H, Yagata H, Yoshida A, Hayashi N, Hornberger J, Yu T, Chien R, Chao C, Yoshizawa C, Nakamura S. St. Luke's International Hospital, Chu-o-ku, Tokyo, Japan; Hitotsubashi University, Tokyo, Japan; Saitama Cancer Center, Saitama, Japan; Cedar Associates LLC, Menlo Park, CA; Stanford University School of Medicine, Stanford, CA; Mailman School of Public Health, Columbia University, New York, NY; Genomic Health, Inc., Redwood City, CA; Showa University, Tokyo, Japan.

P5-15-07 **Time savings with trastuzumab subcutaneous (SC) injection vs. trastuzumab intravenous (IV) infusion: First results from a Time-and-Motion study (T&M)**
de Cock E, Tao S, Alexa U, Pivot X, Knoop A. United Biosource Corporation, Barcelona, Spain; United Biosource Corporation, Montreal, Canada; F Hoffmann-La Roche Ltd, Basel, Switzerland; CHU Jean Minjoz, Besancon, France; Odense University Hospital, Odense, Denmark.

Treatment: Immunotherapy

P5-16-01 **Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial**
Ibrahim NK, Murray JL, Zhou D, Mittendorf EA, Sample D, Tautchin M, Miles D. University of Texas MD Anderson Cancer Center, Houston, TX; Biomira, Inc., AB, Canada; Mount Vernon Cancer Center, Northwood, Middlesex, United Kingdom.

P5-16-02 **Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine**
Vreeland TJ, Clifton GT, Hale DF, Sears AK, Patil R, Holmes JP, Ponniah S, Mittendorf EA, Peoples GE. San Antonio Military Medical Center, San Antonio, TX; Joyce Murtha Breast Care Center, Windber, PA; Redwood Regional Medical Group, Santa Rosa Memorial Hospital, Santa Rosa, CA; Uniformed Services University of Health Sciences, Bethesda, MD; MD Anderson Cancer Center, Houston, TX.

P5-16-03 **Phase II study of autologous dendritic cell vaccination in patients with HER2 negative breast cancer combined with neoadjuvant chemotherapy**
Castillo A, Salgado E, Inoges S, Arevalo E, Castañon E, López Díaz de Cerio A, Sola JJ, Pina L, Nuñez J, Rodriguez-Spiteri N, Espinós J, Aramendia JM, Fernandez Hidalgo OA, Santisteban M. Clínica Universidad de Navarra, Pamplona, Navarra, Spain; Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain; Universidad de Navarra, Pamplona, Navarra, Spain; Clínica Universidad de Navarra.

P5-16-04 **A phase I study of a DNA plasmid based vaccine encoding the HER-2/neu intracellular domain in subjects with HER2+ breast cancer**
Salazar LG, Slota M, Higgens D, Coveler A, Dang Y, Childs J, Bates N, Guthrie K, Waisman J, Disis ML. University of Washington, Seattle, WA; BREASTLINK, Hawthorne, CA.

P5-16-05 **The combination of trastuzumab and HER2-directed peptide vaccines is safe in HER2-expressing breast cancer patients**
Hale DF, Vreeland TJ, Perez SA, Berry JS, Ardavanis A, Trappey AF, Tzonis P, Sears AK, Clifton GT, Shumway NM, Papamichail M, Ponniah S, Peoples GE, Mittendorf EA. Brooke Army Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Athens, Greece; MD Anderson Cancer Center, Houston, TX; Uniformed Services University of the Health Sciences, Bethesda, MD.

P5-16-06 **A phase 2 randomized trial of docetaxel (DOC) alone or in combination with therapeutic cancer vaccine, CEA-, MUC-1-TRICOM (PANVAC)**
Heery CR, Ibrahim NK, Mohebtash M, Madan RA, Arlen PM, Bilusic M, Kim JW, Singh NK, Hodge S, McMahon S, Steinberg SM, Hodge JW, Schlom J, Gulley JL. National Cancer Institute.

Treatment: Antiangiogenic Therapy

P5-17-01 **Bevacizumab (B) in the adjuvant treatment of breast cancer - first toxicity results from Eastern Cooperative Oncology Group trial E5103**
Miller KD, O'Neill A, Dang C, Northfelt D, Gradishar W, Sledge GW. Indiana University Melvin and Bren Simon Cancer Center; Dana Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Mayo Clinic; Northwestern University.

P5-17-02 **Withdrawn**

P5-17-03 **Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC)**
Láng I, Inbar MJ, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Ahlers S, Brodowicz T, Zielinski C. National Institute of Oncology, Budapest, Hungary; Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; University of Szeged, Hungary; Paracelsus Medical University, Salzburg, Austria; Institute of Oncology, Sarajevo, Bosnia and Herzegowina; Rabin Medical Center, Petah-Tikva, Israel; Sheba Medical Center, Ramat Gan, Israel; IST GmbH Mannheim, Mannheim, Germany; Medical University of Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria.

P5-17-04 **Management of Antiangiogenics' Renovascular Safety in breast cancer. Subgroup and intermediate results of the MARS Study**
Launay-Vacher V, Janus N, Daniel C, Rey J-B, Ray-Coquard I, Gligorov J, Spano J-P, Thery J-C, Jouannaud C, Goldwasser F, Mir O, Morere J-F, Oudard S, Azizi M, Dorent R, Deray G, Beuzeboc P. Institut Curie, Paris, France; Hôpital de la Pitié-Salpêtrière, Paris, France; Institut Jean Godinot, Reims, France; Centre Léon Bérard, Lyon, France; Hôpital Tenon, Paris, France; Hôpital Cochin, Paris, France; Hôpital Avicenne, Bobigny, France; Hôpital Européen Georges Pompidou, Paris, France.

P5-17-05 **Sorafenib plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer: Preliminary Results of the Phase II Trial of the Sarah Cannon Research Institute**
Yardley DA, Barton, Jr. J, Dickson N, Shipley D, Drosick DR, Hendricks C, Inhorn RC, Shastry M, Finney L, Burris HA. Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN; National Capital Clinical Research Consortium, Bethesda, MD; Oncology Hematology Care, Cincinnati, OH; Mercy Hospital, Portland, ME.

P5-17-06 **The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab**
Del Re M, Ferrarini I, Fontana A, Santoro M, Bona E, Del Re I, Stasi I, Bertolini I, Laurà F, Landucci E, Salvadori B, Falcone A, Danesi R. University Hospital, Pisa, Italy.

P5-17-07 **Influence of bevacizumab on local-regional recurrence in triple negative breast cancer**
Prendergast BM, De Los Santos JF, Barrett OC, Forero A, Falkson CI, Urist MM, Krontiras H, Bland KI, Meredith RF, Keene KS, You Z, Carpenter JT. University of Alabama Birmingham, AL.

Treatment: HER2-Targeted Therapy

P5-18-01 Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study
Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. Mount Vernon Cancer Centre, Middlesex, United Kingdom; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy; Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand; NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation; Roche Products Limited, Welwyn, United Kingdom; MedStar Washington Hospital Center, Washington, DC.

P5-18-02 Selective Crossover in Randomized Trials of Adjuvant Trastuzumab for Breast Cancer: Coping with Success
Regan MM, Dafni U, Karlis D, Goldhirsch A, Untch M, Smith I, Gianni L, Jackisch C, de Azambuja E, Heinzmann D, Cameron D, Bell R, Dowsett M, Baselga J, Leyland-Jones B, Piccart-Gebhart MJ, Gelber RD, On behalf of the HERA Study Team. Dana-Farber Cancer Institute, Boston, MA; University of Athens and Frontier Science Foundation-Hellas, Athens, Greece; Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium; Helios Klinikum Berlin Buch, Berlin, Germany; Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; San Raffaele Institute, Milan, Italy; Western General Hospital and University of Edinburgh, United Kingdom; The Royal Marsden NHS Trust, London, United Kingdom; European Institute of Oncology, Milan, Italy; Athens University of Economics, Athens, Greece; Massachusetts General Hospital, Boston, MA; F. Hoffmann-La Roche, Basel, Switzerland; Sanford Research, Sioux Falls, SD; The Andrew Love Cancer Centre, The Geelong Hospital, Geelong, Australia; Klinikum Offenbach, Offenbach, Germany.

P5-18-03 Clinicopathological features among patients with HER2-positive breast cancer with prolonged response to trastuzumab based therapy
Vaz-Luis I, Seah D, Olson E, Metzger O, Wagle N, Sohl J, Litsas G, Burstein H, Krop I, Winer E, Lin NU. Dana Farber Cancer Institute, Boston, MA; Ohio State University.

P5-18-04 Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
Gajria D, King T, Pannu H, Sakr R, Modi S, Drullinsky P, Syldor A, Patil S, Seidman A, Norton L, Rosen N, Hudis C, Chandarlapaty S. Memorial Sloan-Kettering Cancer Center, New York, NY.

P5-18-05 Interim Results from a Phase 1b/2a Study of Trastuzumab Emtansine and Docetaxel, With and Without Pertuzumab, in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
Martin M, García-Sáenz JÁ, Dewar JA, Albanell J, Limentani SA, Strasak A, Patre M, Branle F, Fumoleau P. Hospital General Universitario Gregorio Marañón; Hospital San Carlos; Ninewells Hospital; Hospital del Mar; Levine Cancer Institute; F. Hoffmann-La Roche Limited; Centre Georges François Leclerc.

P5-18-06 Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies
Diéras V, Harbeck N, Budd GT, Greenson JK, Guardino E, Samant M, Chernyukhin N, Smitt M, Krop IE. Institut Curie; Breast Center, University of Munich; Cleveland Clinic, Lerner College of Medicine; University of Michigan; Genentech, Inc.; Dana-Farber Cancer Institute.

P5-18-07 Completed SN33 Trial: 60 month follow-up of Early Stage Node Positive HER2 Negative patients with NeuVax ™(E75) and sargramostim
Mazanet R, Schwartz MW, Ramadan D, Lavin PT. Galena Biopharma, Lake Oswego, OR; Aptiv Solutions, Southborough, MA.

P5-18-08 Identification of ErbB2 function in the heart: implication for anti-ErbB2 therapy in breast cancer
Perry M-C, Eichner LJ, Dufour CR, Muller WJ, Giguère V. Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, QC, Canada; McGill University, Montréal, QC, Canada.

P5-18-09 A Phase I Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2- Positive Breast Cancer
Wickham T, Futch K. Merrimack Pharmaceuticals.

P5-18-10 Chemotherapy can enhance trastuzumab-mediated ADCC
Tagliabue E, Sfondrini L, Regondi V, Casalini P, Pupa SM, Sommariva M, Balsari A, Triulzi T. Fondazione IRCCS Istituto Nazionale dei Tumori; Università degli Studi di Milano.

P5-18-11 Pharmacokinetics and exposure-efficacy relationship of trastuzumab emtansine in EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer
Wang B, Jin J, Wada R, Fang L, Saad O, Olsen S, Althaus B, Swain S, Untch M, Girish S. Genentech, Inc.; Quantitative Solutions; Washington Hospital Center; HELIOS Hospital Berlin-Buch.

P5-18-12 Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; a retrospective analysis
Gauthier G, Guérin A, Styles AL, Wu EQ, Masaquel A, Brammer MG, Lalla D. Analysis Group Inc., Boston, MA; Genentech, Inc., South San Francisco, CA.

P5-18-13 Inhibiting telomerase to reverse trastuzumab (T) resistance in HER2+ breast cancer
Miller KD, Steding CE, Prasad N, Rojas LA, Herbert B-S. Indiana University Melvin and Bren Simon Cancer Center.

P5-18-14 Cardiac monitoring during adjuvant trastuzumab therapy for breast cancer
Ng D, Ferrusi I, Khong H, Earle C, Trudeau M, Marshall D, Leighl N. University of Toronto, ON, Canada; McMaster University, Hamilton, ON, Canada; University of Calgary, AB, Canada; Ontario Institute for Cancer Research, Toronto, ON, Canada.

P5-18-15 Molecular effects of lapatinib in HER2 positive ductal carcinoma in situ (DCIS)
Estevez LG, Suarez A, Calvo I, Garcia E, Miro C, Durán H, Quijano Y, Perea S, Herrero M, Lopez-Rios F, Hidalgo M. Centro Integral Oncologico Clara Campal, Madrid, Spain.

P5-18-16 A Multicenter Phase 2 Study (JO22997) Evaluating the Efficacy and Safety of Trastuzumab Emtansine in Japanese Patients With Heavily Pretreated HER2-Positive Metastatic Breast Cancer
Masuda N, Ito Y, Takao S, Doihara H, Rai Y, Horiguchi J, Kohno N, Fujiwara Y, Tokuda Y, Watanabe J, Iwata H, Ishiguro H, Miyoshi Y, Matsubara M, Kashiwaba M. NHO Osaka National Hospital, Osaka, Japan; The Cancer Institute Hospital of JFCR, Tokyo, Japan; Hyogo Cancer Center, Akashi, Japan; Okayama University Hospital, Okayama, Japan; Sagara Hospital, Kagoshima, Japan; Gunma University, Maebashi, Japan; Tokyo Medical University, Tokyo, Japan; National Cancer Center Central Hospital, Tokyo, Japan; Tokai University, Isehara, Japan; Shizuoka Cancer Center, Sunto-gun, Japan; Aichi Cancer Center, Nagoya, Japan; Kyoto University, Kyoto, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Chugai Pharmaceutical Co.,Ltd., Tokyo, Japan; Iwate Medical University, Morioka, Japan.

P5-18-17 **Impact of compliance with National Comprehensive Cancer Network guidelines on adjuvant trastuzumab administration for patients with HER2-positive breast cancer**
Mullins DN, Maly J, Abdel-Rasoul M, Shapiro CL, Olson EM. Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH; The Ohio State University Wexner Medical Center, Columbus, OH; The Ohio State University, Columbus, OH.

P5-18-18 **Lapatinib versus trastuzumab, or both, added to preoperative chemotherapy for breast cancer: A meta-analysis of randomized evidence**
Valachis A, Nearchou A, Lind P. University of Uppsala, Sweden; Mälarsjukhuset, Eskilstuna, Sweden; Karolinska Institute, Stockholm, Sweden.

P5-18-19 **The 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later**
Vanderhaegen J, Paridaens R, Piccart M, Lalami Y, Machiels J-P, Louis E, Borms M, Mebis J, Dirix L, Lintermans A, Brouckaert O, Neven P. University Hospital Leuven, Belgium; University Hospital Leuven/ Catholic University Leuven, Belgium; Institut Jules Bordet, Brussels, Belgium; Cliniques Universitaires St-Luc, Brussels, Belgium; CHU de Liège, Liege, Belgium; AZ Groeninge, Kortrijk, Belgium; Limburgs Oncologisch Centrum, Limburg, Belgium; St Augustinus Hospital, Wilrijk, Belgium.

P5-18-20 **Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer**
Datko F, D'Andrea G, Dickler M, Theodoulou M, Goldfarb S, Lake D, Fornier M, Modi S, Sklarin N, Comen E, Fasano J, Gajria D, Drullinsky P, Gilewski T, Murphy C, Syldor A, Lau A, Hamilton N, Patil S, Liu J, Chandarlapaty S, Hudis C, Dang C. Memorial Sloan-Kettering Cancer Center, New York, NY; Bon Secours Hospital, Cork, Ireland.

P5-18-21 **A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)**
Janni W, Sarosiek T, Pikiel J, Karaszewska B, Staroslawska E, Salat C, Caglevic C, Potemski P, Brain E, Briggs K, de Silvio M, Sapunar F, Papadimitriou C. Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ "KOMED", Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece.

P5-18-22 **Long-term survival of patients with HER2 metastatic breast cancer treated by targeted therapies**
Fiteni F, Villanueva C, Bazan F, Chaigneau L, Cals L, Dobi E, Montcuquet P, Nerich V, Limat S, Pivot X. Besançon University Hospital, Besançon, Doubs, France.

P5-18-23 **The prognosis of T1a, T1b N0 M0, HER2+ patients in Korea**
Lee JW, Moon H-G, Han W, Noh D-Y. Seoul National University Hospital, Seoul, Korea.

P5-18-24 **Population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of various covariates**
Lu D, Girish S, Gao Y, Wang B, Yi J-H, Guardino E, Samant M, Cobleigh M, Rimawi M, Conte P, Jin J. Genentech, Inc.; Quantitative Solutions; Rush University Medical Center; Baylor College of Medicine; University of Modena and Reggio Emilia.

P5-18-25 **Bispecific Fynomer-antibody fusion proteins targeting two epitopes on HER2**
Grabulovski D, Brack S, Toller I, Mourlane F, Bertschinger J. Covagen AG, Zurich-Schlieren, Switzerland.

P5-18-26 **Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)**
Swain SM, Kim S-B, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. MedStar Washington Hospital Center, Washington; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Vall d'Hebron University Hospital, Barcelona, Spain; National Cancer Center, Goyang, Korea; NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation; Centre René Gauducheau, Saint-Herblain (Nantes), France; Hospital 12 De Octubre, Madrid, Spain; Centre Antoine Lacassagne, Nice, France; University Hospital Heidelberg, Heidelberg, Germany; Roche Products Limited, Welwyn, United Kingdom; Genentech, South San Francisco; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston.

Treatment: Signal Transduction Inhibitors

P5-19-01 **Targeting the HER3-phosphatidyl inositol-3 kinase pathway in breast cancers**
Cook RS, Morrison MM, Arteaga CL, Perou CM. Vanderbilt University, Nashville, TN; University of North Carolina.

P5-19-02 **Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models**
Friedman L, Ross LB, Wallin J, Guan J, Prior WW, Wu E, Nannini M, Sampath D. Genentech, Inc., South San Francisco, CA.

P5-19-03 **Olaparib plus carboplatin in combination with vandetanib inhibited the growth of *BRCA-wt* triple negative breast tumors in mice: Outside *BRCA*-box**
Dey N, Sun Y, De P, Leyland-Jones B. Sanford Research/USD, Sioux Falls, SD.

Treatment: Targeted Therapy - Advanced Disease

P5-20-01 **A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER2- negative metastatic breast cancer (MBC)**
Goldstein LJ, Oliveria CT, Heinrich B, Stemmer SM, Mala C, Selder S, Bevan P, Harbeck N. Fox Chase Cancer Center, Philadelphia, PA; Instituto Brasilerio Controle Cancer, Sao Paulo, Brazil; Hamatologisch-Onkologische-Praxis Augsburg, Augsburg, Germany; Rabin Medical Center, Petah Tikva, Israel; Wilex, Munich, Germany; Univeristy of Munich, Munich, Germany.

P5-20-02 **Predictors of long-term survival in a large cohort of patients with HER2-positive (HER2+) metastatic breast cancer (MBC)**
Chavez Mac Gregor M, Lei X, Giordano SH, Valero V, Esteva F, Mittendorf EA, Gonzalez-Angulo AM, Hortobagyi GN. University of Texas MD Anderson Cancer Center, Houston, TX.

P5-20-03 **A phase 2, double-blind, randomized, placebo-controlled, dose-finding study of sotatercept for the treatment of patients with chemotherapy-induced anemia and metastatic breast cancer**
Auerbach M, Osborne CRC, Klesczewski K, Laadem A, Sherman ML, Bianca R. Auerbach Hematology/Oncology, Baltimore, MD; Texas Oncology, P.A., Sammons Cancer Center, Dallas, TX; Celgene Corporation, Summit, NJ; Acceleron Pharma, Cambridge, MA.

P5-20-04 **Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study**
Vahdat L, Schwartzberg L, Wilks S, Rege J, Liao J, Cox D, O'Shaughnessy J. Weill Cornell Medical College, New York, NY; The West Clinic, Memphis, TN; Cancer Care Centers of South Texas, San Antonio, TX; Eisai Inc, Woodcliff Lake, NJ; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX.

P5-20-05 **A Phase 2 trial of RAD 001 and Carboplatin in patients with triple negative metastatic breast cancer**
Singh JC, Volm M, Novik Y, Speyer J, Adams S, Omene CO, Meyers M, Smith JA, Schneider R, Formenti S, Goldberg JD, Li X, Davis S, Beardslee B, Tiersten A. New York University, New York, NY.

P5-20-06 **RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study**
Safra T, Kaufman B, Ben Baruch N, Kadouri-Sonenfeld L, Nisenbaum B, Greenberg J, Ryvo L, Yerushalmi R, Evron E. Tel Aviv Sourasky MC, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Sheba Medical Center, Ramat Gan, Israel; Kaplan Medical Center, Rehovot, Israel; Hadassah Ein Karem Medical Center, Jerusalem, Israel; Meir Kfar Saba Medical Center, Kfar Saba, Israel; Rabin Medical Center Belinson Campus, Petach Tikva, Israel; Assaf Harofeh Medical Center, Assaf Harofeh, Israel.

P5-20-07 **Phase II Trial of Dasatinib in Combination With Weekly Paclitaxel for Patients with Metastatic Breast Carcinoma**
Morris PG, Lake D, McArthur HL, Gilewski T, Dang C, Chaim J, Patl S, Lim K, Norton L, Hudis CA, Fornier MN. Memorial Sloan-Kettering Cancer Center, New York.

P5-20-08 **Phase II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC)**
Schwartzberg LS, Tauer KW, Schnell FM, Hermann R, Rubin P, Christianson D, Weinstein P, Epperson A, Walker M. The West Clinic, Memphis, TN; Central Georgia Cancer Care, Macon, GA; Northwest Georgia Oncology Centers, Marietta, GA; Cone Health Cancer Center, Greensboro, NC; Hematology Oncology Centers of the Northern Rockies, Billings, MT; Hematology Oncology PC, Stamford, CT; ACORN Research, LLC, Memphis, TN.

P5-20-09 **Tumor mutational analysis and therapy outcomes for patients (pts) with metastatic/unresectable locally advanced myoepithelial/metaplastic breast cancer treated with PI3K targeted therapy**
Moulder S, Wheler J, Albarracin C, Gilcrease M, Falchook G, Naing A, Hong D, Fu S, Piha-Paul S, Tsimberidou A, Janku F, Kurzrock R. University of Texas, MD Anderson Cancer Center.

P5-20-10 **Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer: Preliminary Results of a Phase II Trial of the Sarah Cannon Research Institute**
Yardley DA, Ward P, Handricks C, Daniel B, Harwin W, Kannarkat G, Saez R, Shastry M, Chirwa T, Peacock N. Sarah Cannon Research Institute, Nashville, TN; Oncology Hematology Care, Cincinnati, OH; National Capital Clinical Research Consortium, Bethesda, MD; Chattanooga Oncology and Hematology Associates, Chattanooga, TN; Florida Cancer Specialists, Ft. Myers, FL; Peninsula Cancer Institute, Newport News, VA; Texas Health Physician Group, Arlington, TX; Tennessee Oncolcogy, PLLC, Nashville, TN.

P5-20-11 **Bevacizumab in metastatic breast cancer: a retrospective matched-pair analysis**
Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, Greil R. Paracelsus Medical University, Salzburg, Austria; Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria; Hospital of Vöcklabruck, Vöcklabruck, Austria.

P5-20-12 **Aromatase inhibitor failure: predictors and time to first failure among women with metastatic ER+/HER2- breast cancer in the US**
Thomson E, Namjoshi M, Landsman-Blumberg P, Chu BC. Thomson Reuters, Washington, DC; Novartis Pharmaceuticals Corporation, East Hanover, NJ.

P5-20-13 **Preliminary report of a phase I/II study of entinostat (IND#NSC 706995, /M275) and lapatinib (IND#NSC 727989) in patients with HER2-positive metastatic breast cancer in whom trastuzumab has failed**
Ueno NT, Jackson SA, Alvarez RH, Willey JS, Hortobagyi GN, Angulo-Gonzalez AM, Giordano SH, Booser DJ, Valero V. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX; University of Texas, MD Anderson Cancer Center, Houston, TX.

Treatment: Targeted Therapy - Adjuvant

P5-21-01 **pT1a,bpN0M0 breast cancer: clinicopathological characteristics and their impact on treatment decision. Central review of the prospective ODISSEE cohort**
Lacroix-Triki M, Radosevic-Robin N, Louis B, Roche-Comet I, Soubeyrand M-S, Bourgeois H, Chauvet M-P, Fourrier-Réglat A, Gligorov J, Peyrat J-P, Dalenc F, Belkacemi Y, Penault-Llorca F. Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Laboratoire d'Anatomie et Cytologie Pathologiques, Strasbourg, France; Institut Histo-Cyto-Pathologie, Le Bouscat, France; Cabinet CY-PATH, Villeurbanne, France; Clinique Victor Hugo, Le Mans, France; Centre Oscar Lambret, Lyon, France; Université Victor Segalen, Bordeaux, France; Hôpital Tenon, Paris, France; CHU Henri Mondor-UPEC, Créteil, France.

P5-21-02 **Hormone receptor status and endocrine therapy in a prospective observation study on trastuzumab (Herceptin®) in the adjuvant treatment of breast cancer**
Dall P, Friedrichs K, Petersen V, Hinke A, Brucker C, Schmidt P, von der Assen A, Jungberg P, Bohnsteen B. Städtisches Klinikum, Lüneburg, Germany; Krankenhaus Jerusalem, Mammazentrum, Hamburg, Germany; Praxis, Heidenheim, Germany; WiSP, Biostatistik, Langenfeld, Germany; Klinikum Nürnberg, Brustzentrum, Nürnberg, Germany; Praxis, Neunkirchen, Germany; Franziskus-Hospital Harderberg, Georgsmarienhütte, Germany; Praxis, Chemnitz, Germany; Praxis, Dessau-Rosslau, Germany.

P5-21-03 **Concurrent loco-regional radiotherapy and trastuzumab in early-stage breast cancer: Long term results of prospective single-institution study**
Jacob J, Belin L, Pierga J-Y, Vincent-Salomon A, Dendale R, Beuzeboc P, Cottu P-H, Campana F, Fourquet A, Kirova YM. Institut Curie, Paris, France.

P5-21-04 **Real-world use and effectiveness of adjuvant trastuzumab in 2665 consecutive breast cancer patients**
Tjan-Heijnen VCG, Seferina SC, Lobbezoo DJA, Voogd AC, Dercksen MW, van den Berkmortel F, van Kampen RJW, van de Wouw AJ, Joore MA, Borm GF. Maastricht University Medical Centre, Maastricht, Limburg, Netherlands; GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, Limburg, Netherlands; Máxima Medical Centre, Veldhoven, Brabant, Netherlands; Atrium Medical Centre Parkstad, Heerlen, Limburg, Netherlands; Orbis Medical Center, Sittard-Geleen, Limburg, Netherlands; VieCuri Medical Centre, Venlo, Limburg, Netherlands; Radboud University Medical Center, Nijmegen, Gelderland, Netherlands.

Ongoing Trials 3: Immunotherapy

OT3-1-01 A pilot study of single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer scheduled for mastectomy
Diab A, McArthur HL, Solomon S, Comstock C, Maybody M, Sacchini V, Durack J, Gucalp A, Yuan J, Patil S, Thorne A, Sung J, Kotin A, Morris E, Brogi E, Morrow M, Wolchok J, Allison J, Hudis C, Norton L. Memorial Sloan-Kettering Cancer Center, New York, NY.

OT3-1-02 Phase II randomized study of combination immunotherapy with or without Polysaccharide Krestin (PSK®) concurrently with a HER2 ICD peptide-based vaccine and trastuzumab in patients with stage IV breast cancer
Childs JS, Higgins DM, Parker S, Reichow J, Lu H, Standish L, Disis ML, Salazar LG. University of Washington, Seattle, WA; Bastyr University, Kenmore, WA.

Ongoing Trials 3: Survivorship

OT3-2-01 Influence of strength and endurance training on selected physical and psychological parameters and on immune system, metabolism and circulating tumor cells during adjuvant chemotherapy
Mundhenke C, Weisser B, Keller L, Sanders L, Summa B, Duerkop J, Schmidt T, Jonat W. University of Kiel, SH, Germany; Institute of Sport Science, University of Kiel, SH, Germany; Comprehensive Cancer Center North, Kiel, SH, Germany.

OT3-2-02 The PREDICT Study (Prospective, Randomized Early Detection and Intervention after Breast Cancer-Treatment, for women at risk of lymphedema)
Taghian AG, Skolny MN, O'Toole J, Miller CL, Jammallo LS, Specht MC. Massachusetts General Hospital, Boston, MA.

Ongoing Trials 3: Chemotherapy

OT3-3-01 Eniluracil + 5-fluorouracil + leucovorin (EFL) vs. capecitabine phase 2 trial for metastatic breast cancer
Rivera E, Chang JC, Semiglazov V, Gorbunova V, Manikhas A, Krasnozhon D, Kirby G, Spector T. Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s.Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC.

OT3-3-02 ADAPT - Adjuvant Dynamic marker-Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
Gluz O, Hofmann D, Kates RE, Harbeck N, Nitz U. West German Study Group, Moenchengladbach, NRW, Germany; Ev. Bethesda Hospital, Moenchengladbach, NRW, Germany; University Clinic Großhadern, Munich, Bavaria, Germany.

OT3-3-03 Withdrawn

OT3-3-04 ALOPREV : first cooling scalp trial for prevention of persisting alopecia after docetaxel for early breast cancer patients
Bourgeois H, Soulié P, Lucas B, Mercier Blas A, Zannetti A, Delecroix V, L'haridon T, Blot E, Delaloge S, Grudé F. Clinique Victor Hugo, Le Mans, France; Observatoire dédié au Cancer Bretagne Pays de Loire, Angers, France; Institut de Cancérologie de l'Ouest, Angers Nantes, France; CHRU Morvan, Brest, France; CHP, Saint Grégoire, France; CHD, Cholet, France; Pôle Hospitalier Mutualiste, Saint Nazaire, France; CHD, La Roche sur Yon, France; Centre Hospitalier Bretagne Atlantique, Vannes, France; Clinique Océane, Centre Saint Yves, Vannes, France; Institut Gustave Roussy, Villejuif, France.

OT3-3-05 Neurotoxicity characterization phase II randomized study of nab-paclitaxel versus conventional paclitaxel as first-line therapy of metastatic HER2-negative breast cancer. An ONSOCUR Study Group
Ciruelos E, Bueno C, Cantos B, Carrión R, Echarri M, Enrech S, García Saenz JA, Guerra JA, Lara MA, Martínez N, Rodríguez-Antona C, Domínguez-González C, Sanz JL, Baquero J, Cortés-Funes H, Sepúlveda JM. Hospital 12 de Octubre, Madrid, Spain; Hospital Universitario Ramón y Cajal, Madrid, Spain; Hospital Universitario del Sureste, Arganda del Rey (Madrid), Spain; Hospital Universitario Clínico San Carlos, Madrid, Spain; Hospital Universitario Severo Ochoa, Leganés (Madrid), Spain; Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain; Hospital Universitario Infanta Cristina, Parla (Madrid), Spain; Hospital Universitario Infanta Leonor, Madrid, Spain; Hospital Universitario de Getafe, Getafe (Madrid), Spain; Hospital Universitario de Fuenlabrada, Fuenlabrada (Madrid), Spain; APICES, Madrid, Spain; Celgene, Madrid, Spain; Centro Nacional de Investigaciones Oncologicas, Madrid, Spain.

OT3-3-06 NeoEribulin: A Phase II, non-randomized, open-label, single-arm, multicenter, exploratory pharmacogenomic study of single agent eribulin as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer
Prat A, Llombart A, de la Peña L, Di Cosimo S, Ortega V, Rubio I, Muñoz E, Harbeck N, Cortés J. Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Arnau de Vilanova, Valencia, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Istituto Nazionale dei Tumori, Milan, Italy; Brustzentrum am Klinikum der Universität München, Munich, Germany.

OT3-3-07 Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer
Snider JN, Allen JW, Young R, Schwartzberg L, Javed Y, Jahanzeb M, Sachdev JC. University of Tennessee, Memphis, TN; The West Clinic, Memphis, TN; The Center for Cancer and Blood Disorders, Fort Worth, TX.

OT3-3-08 Eribulin/Cyclophosphamide versus Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer: A Randomized Phase II Trial of the Sarah Cannon Research Institute
Yardley DA, Hainsworth JD, Shastry M, Finney L, Burris HA. Tennessee Oncology, PLLC, Nashville, TN; Sarah Cannon Research Institute, Nashville, TN.

OT3-3-09 ARTemis trial - randomised trial with neo-adjuvant chemotherapy for patients with early breast cancer
Earl HM, Blenkinsop C, Grybowicz L, Vallier A-L, Cameron DA, Bartlett JMS, Murray N, Caldas C, Thomas J, Dunn JA, Higgins HB, Hiller L, Hayward L. University of Cambridge, United Kingdom; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom; University of Warwick, Coventry, United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Edinburgh University, Edinburgh, United Kingdom; University of Edinburgh, United Kingdom; Royal Adelaide Hospital, Adelaide, SA, Australia; Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom; Western General Hospital, Edinburgh, United Kingdom.

OT3-3-10 **ASTER 70s: Benefit of adjuvant chemotherapy for oestrogen receptor-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade. A French UNICANCER Geriatric Oncology Group (GERICO) and Breast Group (UCBG) multicentre phase III trial**
Brain E, Baffert S, Bonnefoi HR, Cottu P, Girre V, Lacroix-Triki M, Latouche A, Leger-Falandry C, Peyro Saint Paul HP, Rollot F, Romieux G, Servent V, Orsini C, Bonnetain F. Institut Curie, Saint-Cloud, France; Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; Centre Hospitalier La Roche sur Yon, La Roche sur Yon, France; Institut Claudius Regaud, Toulouse, France; CNAM, Paris, France; Centre Hospitalier Lyon Sud, Lyon, France; Ipsogen SA, Marseille, France; Centre Val d'Aurelle, Montpellier, France; Centre Oscar Lambret, Lille, France; R&D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France.

OT3-3-11 **A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto) GBG 69**
Untch M, Jackisch C, Blohmer J-U, Costa S-D, Denkert C, Eidtmann H, Gerber B, Hanusch C, Hilfrich J, Huober J, Kuemmel S, Schneeweiss A, Paepke S, Loibl S, Nekljudova V, von Minckwitz G. Helios Kliniken Berlin; Klinikum Offenbach; Sankt-Gertrauden Berlin; University Magdeburg; Charite Berlin; University Kiel; University Rostock; Rotkreuzklinikum Muenchen; Eilenriedeklinik Dueseldorf; University Duesseldorf; Kliniken Essen Mitte; Frauenklinik Muenchen; German Breast Group, Neu-Isenburg.

Ongoing Trials 3: Response Prediction

OT3-4-01 **PROMIS: Prospective Registry Of MammaPrint in breast cancer patients with an Intermediate recurrence Score**
Soliman H, Untch S, Stork-Sloots L. Moffitt Cancer Center; Agendia Inc; Agendia NV.

OT3-4-02 **MINT I: Multi-Institutional Neo-adjuvant Therapy, MammaPrint Project I**
Cox C, Blumencranz P, Reintgen D, Saez R, Howard N, Gibson J, Stork-Sloots L, Glück S. University of South Florida; Morton Plant Hospital; Florida Hospital North Pinellas; Plano Cancer Institute; Agendia Inc; Agendia NV; Miller School of Medicine, University of Miami.

OT3-4-03 **Prospective neo-adjuvant registry trial linking MammaPrint, subtyping and treatment response: Neo-adjuvant Breast Registry – Symphony Trial (NBRST)**
Whitworth P, Gittleman M, Akbari S, Nguyen B, Baron P, Rotkiss M, Beatty J, Gibson J, Stork-Sloots L, de Snoo F, Beitsch P. Nashville Breast Center; Breast Care Specialists; Virginia Hospital Center; Todd Cancer Institute, Long Beach Memorial Medical Center; Cancer Specialists of Charleston; Northern Indiana Cancer Research Consortium; The Breast Place Charleston; Agendia Inc; Agendia NV; Dallas Surgical Group.

OT3-4-04 **InVite: an observational pilot study evaluating the feasibility of genome-wide association studies using self-reported data from patients with metastatic breast cancer treated with bevacizumab**
Leyland-Jones B, Faoro L, Barnholt K, Kiefer A, Yager S, Yi J, Turner B, Keane A, Wang L, Eriksson N, Milián ML, O'Neill V. Genentech, Inc.; 23andMe; Sanford Research/USD.

OT3-4-05 **Use of early CIRculating tumor CElls count changes to guide the use of chemotherapy in advanced metastatic breast cancer patients: the CirCe01 randomized trial**
Bidard F-C, Asselain B, Baffert S, Brain E, Campone M, Delaloge S, Bachelot T, Tubiana-Mathieu N, Pelissier S, Pierga J-Y. Institut Curie; Institut de Cancérologie de l'Ouest; Institut Gustave Roussy, Villejuif; Centre Léon Bérard, Lyon; CHU Limoges.

OT3-4-06 **Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial**
Bidard F-C, Baffert S, Hajage D, Brain E, Armanet S, Simondi C, Mignot L, Asselain B, Tresca P, Pierga J-Y. Institut Curie, France.

SATURDAY, DECEMBER 8, 2012

6:45 am–9:00 am
REGISTRATION
Bridge Hall

7:00 am–8:30 am
POSTER SESSION 6 & CONTINENTAL BREAKFAST
Exhibit Hall C

Tumor Cell and Molecular Biology: Metabolism and Breast Cancer

P6-01-01 **Metastatic and non-metastatic isogenic breast cancer cells lines show different metabolic signatures in response to intermittent hypoxia and transient glutamine/glucose deprivation**
Simoes RV, Ackerstaff E, Serganova I, Kruchevsky N, Sukenick G, Blasberg R, Koutcher JA. Memorial Sloan-Kettering Cancer Center, New York, NY; Cornell University, New York, NY.

P6-01-02 **Adipose tissue from breast cancer patients with the metabolic syndrome promotes proliferation and invasion of tumor cells and influences expression of genes involved in carcinogenesis**
McGarrigle SA, Carroll PA, Healy LA, Boyle T, Pidgeon GP, Kennedy MJ, Connolly EM. Trinity College Dublin and St. James's Hospital, Dublin, Ireland.

P6-01-03 **Decreasing the metastatic potential in Triple Negative Breast Cancer through the miR-17 cluster**
Jin L, Simone B, Sano Y, Lim M, Zhao S, Savage JE, Baserga R, Camphausen K, Simone NL. Thomas Jefferson University, Philadelphia, PA; National Cancer Institute, Bethesda, MD.

P6-01-04 **DDB2 a new regulator of metabolism and cell death in human breast tumor cells**
Klotz R, Besancenot V, Brunner E, Becuwe P, Grandemange S. Université de Lorraine, Vandoeuvre les Nancy, France.

P6-01-05 **Enhancement of ^{18}F-FDG uptake and glycolysis by epidermal growth factor via PI3K activation in T47D breast cancer cells**
Lee EJ, Park JW, Cung Q, Jung K-H, Lee JH, Paik J-Y, Lee K-H. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Tumor Cell and Molecular Biology: Microenvironment - Stromal-Epithelial Interactions

P6-02-01 **Apoptotic cell clearance lies at the interface of post-lactational involution and breast cancer**
Cook RS, Stanford JC, Earp S. Vanderbilt University; University of North Carolina.

P6-02-02 **Altered matrix homeostasis regulates estrogen biosynthesis in adipose tissue**
Ghosh S, Ashcraft K, Li R. UT Health Science Center at San Antonio, TX.

P6-02-03 **Mouse Models Of Breast Cancer Identify Oncogene-Specific Stroma Associated With Human Breast Cancer Molecular Subtypes**
Saleh SM, Laferriere J, Cory S, Souleimanova M, Zacksenhaus E, Muller W, Hallett M, Park M. McGill University, Montreal, QC, Canada; Toronto General Hospital, Toronto, ON, Canada.

P6-02-04 **TMEM (Tumor MicroEnvironment of Metastasis) in human breast cancer is a blood vessel associated intravasation microenvironment unrelated to lymphatics**
Ginter PS, Robinson BD, D'Alfonso TM, Oktay MH, Gertler FB, Rohan TE, Condeelis JS, Jones JG. Weill Cornell Medical College, New York, NY; Albert Einstein College of Medicine, Bronx, NY; Massachusetts Institute of Technology, Cambridge, MA.

P6-02-05 **A novel culturing 3-D model to evaluate the role of tumor microenvironment in IBC**
Dong X, Franco-Barraza J, Mu Z, Alpaugh RK, Cristofanilli M, Cukierman E. Fox Chase Cancer Center, Philadelphia, PA.

P6-02-06 **A 3D tri-culture model of normal mammary gland. A tool for breast cancer initiation studies**
Nash CE, Holliday DL, Mavria G, Tomlinson DC, Hanby AM, Speirs V. Leeds Institute of Molecular Medicine, The University of Leeds, Leeds, West Yorkshire, United Kingdom.

P6-02-07 **In vitro 3D Model of Breast Tumor Stroma**
Jaganathan H, Mitra S, Dave B, Godin B. The Methodist Hospital Research Institute, Houston, TX.

P6-02-08 **Molecular drivers of adipogenotoxicosis in breast tumor-associated adipose**
Ellsworth RE, Field LA, van Laar R, Deyarmin B, Hooke JA, Shriver CD. Windber Research Institute, Windber, PA; Signal Genetics, New York, NY; Walter Reed National Military Medical Center, Bethesda, MD; Henry M. Jackson Foundation, Windber, PA.

P6-02-09 **Role of HGF in obesity-associated tumorigenesis: C3(1)-Tag mice as a model for human basal-like breast cancer**
Sundaram S, Freemerman AJ, Hamilton J, McNaughton K, Galanko JA, Darr DB, Perou CM, Troester MA, Makowski L. University of North Carolina at Chapel Hill, Chapel Hill, NC.

Tumor Cell and Molecular Biology: Mammary Development and Differentiation

P6-03-01 **Molecular Dissection of Breast Luminal Cell Transcription Factor Networks**
Bargiacchi FG, Earp HS, Perou CM. University of North Carolina Chapel Hill, NC.

Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance

P6-04-01 **Global analysis of breast cancer metastasis suggests cellular reprogramming is central to the endocrine resistant phenotype**
Bolger JC, McCartan D, Walsh CA, Hao Y, Hughes E, Byrne C, Hill ADK, O'Gaora P, Young LS. Royal College of Surgeons in Ireland, Dublin 2, Ireland; University College Dublin, Ireland.

P6-04-02 **Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer**
Piccart M, Baselga J, Noguchi S, Burris H, Gnant M, Hortobagyi G, Mukhopadhyay P, Taran T, Sahmoud T, Rugo H. Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Osaka University, Osaka, Japan; Sarah Cannon Research Institute, Nashville, TN; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; The University of Texas MD Anderson Cancer Center, Houston, TX; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA.

P6-04-03 **Changes in breast tumor metabolism and estradiol binding as measured by FES PET in patients treated with the histone deacetylace inhibitor vorinostat and aromatase inhibitor therapy**
Linden HM, Kurland BF, Specht JM, Vijayakrishn GK, Gralow JR, Peterson LM, Schubert EK, Link JM, David MA, Eary JF, Krohn KA. University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Pennsylvania, Philadelphia, PA.

P6-04-04 **Upregulation of the androgen agonist prosaposin in aromatase inhibitor resistant breast cancer; mediation by the developmental protein HOXC11**
McIlroy M, Hao Y, Bane FT, Young L, O'Gaora P. Royal College of Surgeons in Ireland, Dublin, Ireland; University College Dublin, Ireland.

P6-04-05 **Tamoxifen dose escalation based on endoxifen level: a prospective trial with genotyping, phenotyping and pharmacokinetics over 4 months**
Zaman K, Dahmane E, Perey L, Bodmer A, Anchisi S, Wolfer A, Galmiche M, Stravodimou A, Buclin T, Eap C, Decosterd L, Csajka C, Leyvraz S. University Hospital CHUV, Lausanne, Switzerland; Ensemble Hospitalier de la Côte, Morges, Switzerland; University Hospital CHUV, University of Geneva, Lausanne, Switzerland; University Hospital, Geneva, Switzerland; Hôpital Cantonal, Sion, Switzerland.

P6-04-06 **Inverse regulation of Neuregulin1 and HER-3 during treatment with aromatase inhibitors of estrogen receptor-positive breast cancer**
Flågeng MH, Larionov A, Geisler J, Dixon JM, Lønning PE, Mellgren G. Haukeland University Hospital, Bergen, Norway; University of Edinburgh, United Kingdom; Akershus University Hospital, Lørenskog, Norway; University of Bergen, Norway.

P6-04-07 **Significance and therapeutic potential of PELP1-mTOR axis in breast cancer progression and therapy resistance**
Gonugunta VK, Cortez V, Sareddy GR, Roy SS, Zhang H, Tekmal RR, Vadlamudi RK. UTHSCSA, San Antonio, TX; Shantou University Medical College, Shantou, China.

P6-04-08 **FOXA1 expression: regulated by EZH2 and associated with favorable outcome to tamoxifen in advanced breast cancer**
Reijm EA, Helmijr JCA, Soler CMJ, Beekman R, Gerritse FL, Prager-van der Smissen WJC, Ruigrok-Ritstier K, van IJcken WFJ, Stevens MG, Smid M, Look MP, Meijer ME, Sieuwerts AM, Sleijfer S, Foekens JA, Berns EMJJ, Jansen MPHM. Erasmus MC - Daniel den Hoed, Rotterdam, Netherlands; Erasmus MC, Rotterdam, Netherlands.

P6-04-09 **Lack of response to aromatase inhibitors involves distinct mechanisms**
Turnbull AK, Larionov AA, Renshaw L, Kay C, Sims AH, Dixon JM. University of Edinburgh, United Kingdom.

P6-04-10 **Comprehensive gene and protein assessment of the role of Her2 in the response to neoadjuvant Letrozole suggests patients without amplification may also benefit from anti-Her2 treatment**
Webber V, Turnbull AK, Larionov AA, Sims AH, Harrison D, Renshaw L, Dixon JM. Melville Trust for Care and Cure of Cancer, Edinburgh; Western General Hospital, Edinburgh.

P6-04-11 **Combination of PI3K-AKT-mTOR and MEK-ERK pathway inhibitors overcome acquired resistance to letrozole in ER+ breast cancer models**
De P, Sun Y, Friedman LS, Chen S, Dey N, Leyland-Jones B. Sanford Research/USD, Sioux Falls, SD; Genentech, Inc., South San Francisco, CA; Beckman Research Institute of the City of Hope, Duarte, CA.

P6-04-12 **Novel selective estrogen receptors degraders regress tumors in pre-clinical models of endocrine-resistant breast cancer**
Hager JH, Darimont B, Joseph J, Govek S, Grillot K, Aparicio A, Bischoff E, Kahraman M, Kaufman J, Lai A, Lee K-J, Lu N, Nagasawa J, Prudente R, Qian J, Sensintaffar J, Shao G, Heyman R, Rix P, Smith ND. Aragon Pharmaceuticals, San Diego, CA.

P6-04-13 **HOXB7 functions as a co-activator of estrogen receptor in the development of tamoxifen resistance**
Jin K, Teo WW, Yoshida T, Park S, Sukumar S. Johns Hopkins University School of Medicine, Baltimore, MD.

P6-04-14 **Targeting the PI3K/mTOR pathway in patient-derived xenograft models of endocrine resistant luminal breast cancer**
Cottu PH, Bagarre T, Assayag F, Bièche I, Chateau-Joubert S, Fontaine J-J, Decaudin D, Slimane K, Vincent-Salomon A, Marangoni E. Institut Curie, Paris, France; Institut Curie, Saint-Cloud, France; Ecole Veterinaire d'Alfort, Maisons-Alfort, France; Novartis Pharma, Rueil Malmaison, France.

P6-04-15 **The involvement of LMTK3 in endocrine resistance is mediated via multiple signaling pathways**
Giamas G, Xu Y, Filipovic A, Grothey A, Coombes CR, Stebbing J. Imperial College, London, United Kingdom.

P6-04-16 **The role of RIP140 and FOXA1 in breast cancer endocrine sensitivity and resistance**
Harada-Shoji N, Coombes RC, Lam EW-F. Imperial College London, United Kingdom.

P6-04-17 **The androgen metabolite-dependent growth in hormone receptor positive breast cancer as a novel aromatase inhibitor-resistance mechanism**
Hanamura T, Niwa T, Nishikawa S, Konno H, Ghono T, Kobayashi Y, Kurosumi M, Takei H, Yamaguchi Y, Ito K-I, Hayashi S-I. Graduate School of Medicine, Tohoku University, Sendai, Japan; Shinshu University School of Medicine, Matsumoto, Japan; Saitama Cancer Center, Saitama, Japan.

P6-04-18 **Evaluation of the molecular mechanisms behind fulvestrant resistant breast cancer**
Kirkegaard T, Hansen SK, Reiter BE, Sorensen BS, Lykkesfeldt AE. Danish Cancer Society Research Center, Copenhagen, Denmark; Aarhus University Hospital, Aarhus, Denmark.

P6-04-19 **Neutralizing antibody to human GP88 (progranulin) restores sensitivity to tamoxifen and inhibits breast tumor growth in mouse xenografts**
Serrero G, Dong J, Hayashi J. A&G Pharmaceutical Inc, Columbia, MD.

P6-04-20 **Endocrine resistance in invasive lobular carcinoma cells parallels unique estrogen-mediated gene expression**
Sikora MJ, Luthra S, Chandran UR, Dabbs DJ, Welm AL, Oesterreich S. University of Pittsburgh Cancer Institute, Pittsburgh, PA; University of Pittsburgh, PA; Magee-Womens Hospital, Pittsburgh, PA; University of Utah Huntsman Cancer Institute, Salt Lake City, UT.

P6-04-21 **AIB1 expression specifically predicts breast cancer patient response to aromatase inhibitor therapy**
Vareslija D, O'Hara J, Tibbitts P, McBryan J, Hao Y, Hill A, Young L. Royal College of Surgeons Ireland, Dublin, Ireland.

P6-04-22 **Regulation of Notch localization by endocrine therapy in Estrogen Receptor positive breast cancer cells: Clinical implications for endocrine resistance**
Espinoza I, Caskey M, Baker RC, Miele L. University of Mississippi, Jackson, MS.

P6-04-23 **Targeting of endocrine therapy resistance through combined mTOR and histone deacetylase inhibition**
Ordentlich P, Flechsig S, Hoffmann J. Syndax Pharmaceuticals, Waltham, MA; EPO-GmbH Berlin, Berlin, Germany.

P6-04-24 **Overexpression of protein kinase C alpha differentially activates transcription factors in T47D breast cancer cells in the presence of 17β-estradiol both in the 2D and 3D environments**
Pham TND, Asztalos S, Weiss MS, Shea LD, Tonetti DA. University of Illinois at Chicago, IL; Northwestern University, Evanston, IL.

P6-04-25 **Genomic Deregulation and Therapeutic Role of Nemo-like Kinase in Luminal B Breast Cancer**
Cao X, Qin L, Kim J-A, Tan Y, Wang X, Schiff R. Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX.

P6-04-26 **Tamoxifen may block estrogen induced secretion of certain cytokines to interrupt tumor associated macrophage infiltration in breast cancer**
Ding J, Chen CM, Jin W, Shao Z, Wu J. Breast Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China.

P6-04-27 **EBAG9 immunoreactivity is a potential prognostic factor for poor outcome of breast cancer patients with adjuvant tamoxifen therapy**
Shigekawa T, Ijichi N, Ikeda K, Miyazaki T, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S. Research Center for Genomic Medicine, Saitama Medical University; International Medical Center, Saitama Medical University; Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital; National Cancer Center Hospital; Graduate School of Medicine, Kyoto University; National Shikoku Cancer Center; Graduate School of Medicine, The University of Tokyo.

P6-04-28 **Changes in BAG-1 expression level affect the Tamoxifen-induced apoptosis and Gefitinib-induced apoptosis in breast cancer cells**
Lu S, Zhuang X, Liu H. Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Tianjin Medical University, Minstry of Education, Tianjin, China.

P6-04-29 **Vitamin D induces expression of estrogen receptor and restores endocrine therapy response in estrogen receptor-negative breast cancer**
Santos N, Diaz L, Ordaz D, Garcia J, Barrera D, Avila E, Halhali A, Medina H, Camacho J, Larrea F, Garcia R. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF, Mexico; Centro de Investigación y de Estudios Avanzados del I.P.N., México, DF, Mexico.

P6-04-30 **COUP-TFII suppresses NFκB activation in endocrine-resistant breast cancer cells**
Litchfield LM, Klinge CM. University of Louisville School of Medicine, Louisville, KY.

Tumor Cell and Molecular Biology: Hormonal Factors and Receptors

P6-05-01 **Evaluation of the prognostic significance of androgen receptor (AR) expression in relation to ER expression in breast cancer (BC)**
Gucalp A, Datko FM, Patil S, Hedvat CV, Kalinsky K, Hudis CA, Traina TA, Moynahan ME. Memorial Sloan-Kettering Cancer Center; Columbia University Medical Center.

P6-05-02 **Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(-) metastatic breast cancer (MBC) (TBCRC011)**
Gucalp A, Tolaney S, Isakoff SJ, Ingle J, Liu MC, Carey L, Blackwell KL, Rugo H, Nabell L, Forero A, Stearns V, Momen L, Gonzalez J, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA. Memorial Sloan-Kettering Cancer Center; Dana Farber/Harvard Cancer Center; Mayo Clinic Cancer Center; Lombardi Comprehensive Cancer Center at Georgetown University; University of North Carolina Lineberger Cancer Center; University of California San Francisco Comprehensive Cancer Center; Duke University Medical Cancer Center; University of Alabama Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.

P6-05-03 **Targeted inhibition of recurrent PIK3CA mutations synergizes with bicalutamide in AR-expressing triple negative breast cancer**
Lehmann BD, Bauer JA, Schafer JM, Tang L, Pendleton CS, Sanders ME, Pietenpol JA. Vanderbilt, Nashville, TN.

P6-05-04 **Expression of the Androgen Receptor in triple negative tumors and its modulation by receptor tyrosine kinases and downstream pathways**
Cuenca D, Montero JC, Morales JC, Prat A, Pandiella A, Ocana A. Albacete University Hospital, Albacete, Spain; Cancer Research Center, CIC-CSIC, Salamanca, Spain; Lineberger Cancer Center, University of North Carolina.

P6-05-05 **Triple receptor comparison between primary breast cancer and metachronous or synchronous liver metastasis**
Tuyls S, Brouckaert O, Vanderstichele A, Vanderhaegen J, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Weltens C, Peeters S, Vanbeckevoort D, Floris G, Moerman P, Paridaens R, Wildiers H, Vergote I, Christiaens M-R, Neven P. University Hospitals Leuven, Belgium.

P6-05-06 **Serum estradiol levels in postmenopausal ER+/PR- breast cancer are lower than those in postmenopausal ER+/PR+**
Yamamoto Y, Ibusuki M, Goto H, Murakami K, Iwase H. Kumamoto University Hospital, Kumamoto, Japan.

P6-05-07 **Amplified in breast cancer 1 and ankyrin repeat containing cofactor 1 mediate estrogen induced repression of the ErbB2 oncogene**
Garee JP, Riegel AT. Georgetown University, Washington, DC.

P6-05-08 **Significant heterogeneity in ERalpha and PR receptor status in different distant breast cancer metastases of the same patient**
Hoefnagel LDC, van der Groep P, Broers JE, van der Wall E, van Diest PJ. UMC Utrecht, Utrecht, Netherlands.

P6-05-09 **Unravelling the global effect of estrogen on breast cancer cell proteome using quantitative proteomics**
Pavlou MP, Drabovich AP, Dimitromanolakis A, Diamandis EP. University of Toronto, ON, Canada; Mount Sinai Hospital, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.

P6-05-10 **Progestins exert divergent growth effects and regulate tumor-unique gene cohorts in patient derived breast cancer xenografts**
Sartorius CA, Finlay-Schultz J, Li C, Rosen RB, Hendricks P, Wisell J, Finlayson C, Elias A, Kabos P. University of Colorado Denver Anschutz Medical Campus, Aurora, CO.

P6-05-11 **Leptin and Leptin receptor expression in human breast cancer**
Wazir U, Al Sarakbi W, Jiang WG, Mokbel K. The London Breast Institute, The Princess Grace Hospital, London, United Kingdom; Cardiff University-Peking University Oncology Joint Institute, Cardiff, United Kingdom.

P6-05-12 **Lack of Frequent Estrogen Receptor Mutation in Primary Breast Tumors**
Oesterreich S, Kitchens C, Gavin P, Wu C-C, Riehle K, Coarfa C, Edwards D, Schiff R, Milosavljevic A, Lee A. University of Pittsburgh Cancer Institute, Pittsburgh, PA; Baylor College of Medicine, Houston, TX; NSABP, Pittsburgh, PA.

P6-05-13 **ESR1 gene amplification in breast cancer: influence of RNAse treatment on FISH results**
Moelans CB, Holst F, Hellwinkel O, Simon R, van Diest PJ. University Medical Center Utrecht, Netherlands; University Medical Center Hamburg Eppendorf, Hamburg, Germany.

P6-05-14 **Estrogen-induced genes in ductal carcinoma in situ(DCIS): their comparison with invasive ductal carcinoma**
Ebata A, Suzuki T, Takagi K, Miki Y, Onodera Y, Nakamura Y, Fujishima F, Ishida K, Watanabe M, Tamaki K, Ishida T, Ohuchi N, Sasano H. Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Tohoku University Hospital, Sendai, Miyagi, Japan.

P6-05-15 **Glucocorticoids has diverse effect on the tumorigenicity in estrogen receptor positive and estrogen receptor negative cancer cells**
Gao M, Yeh L-C, Chang C-P, Cheng A-L, Lu Y-S. National Taiwan University Hospital, Taipei, Taiwan.

Tumor Cell and Molecular Biology: Tumor Cell and Molecular Biology - Other

P6-06-01 **Lobular involution reduces breast cancer risk through downregulation of invasive and proliferative cellular processes**
Radisky DC, Visscher DW, Stallings-Mann ML, Frost MH, Allers TM, Degnim AC, Hartmann LC. Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN.

P6-06-02 **Characterization of an exosome-associated apoptosis-inducing activity produced by triple negative breast cancer cells**
Georgoulia NE, Iliopoulos D, Mitchison TJ. Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Boston, MA.

P6-06-03 **Caveolin-1: A potential mediator of RhoC GTPase driven Inflammatory breast cancer cell invasion**
Joglekar M, van Golen K. University of Delaware, Newark, Delaware.

P6-06-04 **Withdrawn**

P6-06-05 **Down-regulation of the circadian factor Period 2 by the oncogenic E3 ligase Mdm2: Relevance of circadian components for cell cycle progression**
Liu J, Gotoh T, Vila-Caballer M, Santos CS, Yang J, Finkielstein CV. Virginia Tech, Blacksburg, VA.

P6-06-06 **The therapeutic potential and hazard of exposure to *Cerbera odollam* leaf extracts**
Chung F, Chan K, Lim YY, Li B. Monash University Sunway Campus, Subang Jaya, Selangor, Malaysia; Taylor's University, Subang Jaya, Selangor, Malaysia.

Prognostic and Predictive Factors: Prognostic and Predictive Factors - Other

P6-07-01 **Withdrawn**

P6-07-02 **Prediction of onco*type* DX® recurrence score using pathology generated equations**
Bhargava R, Klein ME, Shuai Y, Brufsky AM, Puhalla SL, Jankowitz R, Dabbs DJ. Magee-Womens Hospital of UPMC, Pittsburgh, PA; University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI; University of Pittsburgh Cancer Institute, Pittsburgh, PA.

P6-07-03 **Risk classification of Early Stage Breast Cancer as Assessed by MammaPrint and Onco*type* DX Genomic Assays**
Clough KB, Poulet B, Jamshidian F, Butler S, Svedman C, Levy E. L'Institut du Sein-Paris Breast Centre, Paris, Ile de France, France; Genomic Health, Inc., Redwood City, CA.

P6-07-04 **Evaluation of Adjuvant! Online for primary operable grade 2 breast cancers with 10-year follow-up**
Van Calster B, Brouckaert O, Wildiers H, Christiaens M-R, Weltens C, Paridaens R, Van Limbergen E, Neven P. On behalf of Multidisciplinary Breast Centre, UZ Leuven.

P6-07-05 **Prognosis of 368 women with primary breast cancer during pregnancy: results from an international collaborative trial**
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring A, Giermek J, Fehm T, Wildiers H, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Lenhard M, Witteveen PO, Kaufmann M, Van Calster B, Loibl S. Leuven Cancer Institute, University Hospitals Leuven, KU Leuven, Belgium; German Breast Group, Neu-Isenburg, Germany; BOOG Study Center, Amsterdam, Netherlands; Royal Sussex County Hospital, Brighton, United Kingdom; Institute in Warsaw Breast Cancer and Reconstructive Surgery Clinic, Warsaw, Poland; University Women Hospital, Tübingen, Germany; University Women Hospital Heidelberg, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; University Hospitals Leuven, KU Leuven, Belgium; Ludwigs Maximilian University, Frauenklinik Innenstadt, München, Germany; University Women Hospital Cologne, Germany; Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe Klinikum der Universität München, Grosshadern, Germany; University Medical Center Utrecht, Netherlands; J.W. Goethe University, Frankfurt, Germany.

P6-07-06 **Patterns of locoregional failure in the CALOR (Chemotheraphy as Adjuvant for Locally Recurrent Breast Cancer) Trial**
Wapnir IL, Gelber S, Lang I, Anderson SJ, Robidoux A, Martin M, Nortier JWR, Mamounas EP, Geyer CE, Maibach R, Gelber RD, Wolmark N, Aebi S. National Surgical Adjuvant Breast and Bowel Project (NSABP) Operations and Biostatistical Centers; Stanford University Medical School of Medicine; International Breast Cancer Study Group; National Institute of Oncology; University of Pittsburgh Graduate School of Public Health; Centre Hospitalier de l'Université de Montréal; Hospital General Universitario Gregorio Marañón; Leiden University Medical Center, Leiden, Netherlands; Aultman Hospital; University of Texas Southwestern Medical Center; Allegheny Cancer Center at Allegheny General Hospital.

P6-07-07 **Withdrawn**

P6-07-08 **Associations between lifestyle parameters and prognostic factors used for stratifying for adjuvant treatment in breast cancer**
Guldberg TL, Christensen S, Ravnsbaek A, Zachariae B, Jensen AB. Aarhus University Hospital, Aarhus, Denmark.

P6-07-09 **Identification of Trophinin associated protein (TROAP) as a novel biological marker in breast cancer (BC): Co-expression of TROAP and TOPO2A predicts response of anthracycline based chemotherapy (ATC-CT)**
Abdel-Fatah TMA, Balls G, Miles AK, Moseley P, Green A, Rees R, Ellis IO, Chan SYT. Nottinigham City Hospital NHS Trust; The Van Geest Cancer Research Center, Nottingham Trent University; University of Nottingham.

P6-07-10 **Luminal A vs. Basal-like Breast Cancer: time dependent changes in the risk of relapse in the absence of treatment**
Cheang MCU, Parker J, DeSchryver K, Snider J, Walsh T, Davies S, Prat A, Vickery T, Reed J, Zehnbauer B, Leung S, Voduc D, Nielsen T, Mardis E, Bernard P, Perou C, Ellis M. University of North Carolina at Chapel Hill, NC; University of British Columbia, Vancouver, BC, Canada; Washington University School of Medicine; University of Utah.

P6-07-11 **Is the prognosis of lymphotropic invasive micropapillary carcinoma worse than invasive ductal carcinoma?: A population-based study of 645 patients**
Chen AC, Paulino AC, Schwartz MR, Rodriguez AA, Bass BL, Chang JC, Teh BS. Baylor College of Medicine, Houston, TX; The Methodist Hospital, Houston, TX.

P6-07-12 **Akt2 expression is associated with good long-term prognosis in estrogen receptor positive breast cancer**
Fohlin H, Pérez-Tenorio G, Fornander T, Skoog L, Nordenskjöld B, Carstensen J, Stål O. Regional Cancer Center, Southeast Sweden, Linköping, Sweden; Faculty of Health Sciences, Linköping University, Linköping, Sweden; Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden; Linköping University, Linköping, Sweden.

P6-07-13 **Local relapse and survival**
Harland R, Prathap P, Lionaki A, Mahmood N. Royal Albert Edward Infirmary, Wigan, United Kingdom; Euxton Hall Hospital, Chorley, United Kingdom.

P6-07-14 **Mutational and transcriptomic characterization of breast cancer (BC) arising in young patients (pts) and during pregnancy and their associations with long-term outcome**
Azim Jr HA, Peccatori FA, Loi S, Lambrechts D, Majjaj S, Renne G, Desmedt C, Rotmensz N, Michiels S, Dell'Orto P, Ignatiadis M, Goldhirsch A, Piccart M, Viale G, Sotiriou C. Universite Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; European Institute of Oncology, Milan, Italy; University of Leuven, Belgium.

P6-07-15 **The effect of taxanes in ER+ early breast cancer is likely to be mitigated by chromosomal instability**
A'Hern RP, Bliss JM, Szallasi Z, Johnston S, Roylance R, Swanton C. The Institute of Cancer Research, Sutton, United Kingdom; Technical University of Denmark, Lyngby, Denmark; Barts and The Royal London Hospital, London, United Kingdom; Cancer Research UK London Research Institute, London, United Kingdom; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom.

P6-07-16 **Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study**
Masuda N, Yamamoto D, Sato N, Sagara Y, Yamamoto Y, Saito M, Iwata H, Oura S, Watanabe J, Kuroi K. National Hospital Organization Osaka National Hospital, Osaka, Japan; Kansai Medical University Hirakata Hospital, Hirakata, Osaka, Japan; Niigata Cancer Center Hospital, Niigata, Japan; Sagara Hospital, Kagoshima, Japan; Kumamoto University Hospital, Kumamoto, Japan; Juntendo University Hospital, Bunkyo, Tokyo, Japan; Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Wakayama Medical University, Wakayama, Wakayama, Japan; Shizuoka Cancer Center, Nagaizumi-cho, Suntou-gun, Shizuoka, Japan; Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo, Tokyo, Japan.

P6-07-17 **Proteomic screening of FFPE tissue identifies FKBP4 as an independent prognostic factor in hormone receptor positive breast cancers**
Hu J, Pohorelic B, Konno M, Price JT, Morris D, Krizman D, Magliocco AM, Klimowicz AC. Alberta Health Services, Calgary, AB, Canada; University of Calgary, AB, Canada; Monash University, Clayton, VIC, Australia; OncoPlex Diagnostics, Rockville, MD; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

P6-07-18 **Identification of Sperm Associated Antigen 5 (SPAG5) as a novel biological and predictive biomarker in Breast cancer**
Abdel-Fatah TMA, Ball G, Miles AK, Moseley P, Green A, Rees B, Ellis IO, Chan SYT. Nottingham City Hospital NHS Trust, Nottingham; The John van Geest Cancer Research Centre, Nottingham Trent University; University of Nottingham.

P6-07-19 **Prognostic relevance of PR and detection mode in Luminal Her-2 negative breast cancer**
Brouckaert O, Van Calster B, Paridaens R, Wildiers H, Van Limbergen E, Weltens C, Christiaens M-R, Neven P. On behalf of Multidisciplinary Breast Centre.

P6-07-20 **Variables measured at Central Nervous System (CNS) relapse, but not Immunophenotype, identify groups of breast cancer patients with shorter post CNS-relapse survival**
Gómez HL, Pinto JA, Schwarz JL, Vigil CE, Vallejos CS. Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Oncosalud, Lima, Peru.

P6-07-21 **Signs and symptoms at central nervous system (CNS) relapse in breast cancer patients with Leptomeningeal carcinomatosis related with shorter survival after recurrence**
Gomez HL, Schwarz LJ, Vásquez J, Neciosup SP, Pinto JA, Vidaurre T, Ferreyros G, Vallejos CS. Instituto Nacional de Enfermedades Neoplásicas, Peru; Oncosalud, Peru.

P6-07-22 **Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer (BC): a pooled *in-silico* analysis**
Azim Jr HA, Singhal S, Michiels S, Ignatiadis M, Djazouli K, Fumagalli D, Desmedt C, Piccart M, Sotiriou C. Universite Libre de Bruxelles, Brussels, Belgium; Institut Jules Bordet, Brussels, Belgium; Celgene International.

P6-07-23 **Proportion of invasive micropapillary carcinoma lesion and primary breast cancer prognosis**
Takei J, Nakayama K, Yagata H, Hayashi N, Yoshida A, Ohde S, Suzuki K, Nakamura S, Yamauchi H. St. Luke's International Hospital, Tokyo, Japan; Showa University School of Medicine, Tokyo, Japan.

P6-07-24 **Prognostic Tools in Early Breast Cancer: Predicting benefit of adjuvant chemotherapy**
Parkes EE, Davidson C, James CR, Hanna GG. Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, United Kingdom; Queen's University of Belfast, United Kingdom.

P6-07-25 **Annexin expression and survival outcomes in women with breast cancer**
Dawood S, Gonzalez-Angulo AM, Liu S, Chen H, Li Y, Albarracin CT. MD Anderson Cancer Center, Houston, TX; Dubai Hospital, United Arab Emirates.

P6-07-26 **Prognostic significance of the maximal value of the baseline standardized uptake value on fluorine 18 fluorodeoxyglucose positron emission tomography /computed tomography for predicting pathologic malignancy of operable breast cancer with neoadjuvant chemotherapy**
Kadoya T, Akimoto E, Emi A, Shigematsu H, Masumoto N, Okada M. Hiroshima University, Hiroshima, Japan.

P6-07-27 **Body mass index and survival after breast cancer diagnosis in Japanese women**
Kawai M, Minami Y, Nishino Y, Ohuchi N, Kakugawa Y. Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Miyagi Cancer Center Research Institute, Natori, Miyagi, Japan; Miyagi Cancer Center Hospital, Natori, Miyagi, Japan.

P6-07-28 **Assessment of T stage in the multiple breast carcinomas**
Gong G, Jo J-H, Lee HJ, Kang J. University of Ulsan College of Medicine, Asan Medical Center, Republic of Korea; University of Ulsan College of Medicine, Gangneung Asan Hospital, Republic of Korea; Seoul National University Bundang Hospital, Republic of Korea; Haeundae Paik Hospital, Inje University College of Medicine, Republic of Korea.

P6-07-29 **Independent prognostic value of age depends on breast cancer subtype**
Brouckaert O, Salihi R, Laenen A, Vanderhaegen J, Amant F, Leunen K, Smeets A, Berteloot P, Van Limbergen E, Weltens C, Moerman P, Peeters S, Paridaens R, Floris G, Wildiers H, Vergote I, Christiaens M-R, Neven P. UZ Leuven; Interuniversity Centre for Biostatistics and Statistical Bioinformatics.

P6-07-30 **The clinical significance of pathologic complete response using different definitions after neoadjuvant chemotherapy in HER2 positive breast cancer patients according to hormonal receptor status**
Tanioka M, Hirokaga K, Kitao A, Matsumoto K, Yoshida S, Miki M, Maekawa Y, Takao S, Negoro S. Hyogo Cancer Center, Akashi, Japan.

P6-07-31 **Moved to Poster Session 2, Thursday, December 6 7:00 AM - 9:00 AM**

P6-07-32 **Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2 positive subtype is associated with the most favorable outcome**
Tjan-Heijnen VCG, Lobbezoo DJA, van Kampen RJW, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FPJ, van Riel JMGH, Peters NAJB, Borm GF. Maastricht University Medical Center, Maastricht, Netherlands; Maxima Medical Center, Eindhoven, Netherlands; Atrium Medical Center Parkstad, Heerlen, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Viecuri Medical Center, Venlo, Netherlands; Orbis Medical Center, Sittard, Netherlands; St Elisabeth Hospital, Tilburg, Netherlands; St Jans Hospital, Weert, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands.

P6-07-33 **A clinicopathologic analysis of 45 patients with metaplastic breast cancer**
Verma S, Cimino-Mathews A, Figueroa Magalhaes MC, Zhang Z, Stearns V, Connolly RM. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; St. Agnes Hospital, Baltimore, MD; Johns Hopkins Hospital, Baltimore, MD.

P6-07-34 **Disease-related outcomes with adjuvant chemotherapy in HER2 positive or triple negative T1a/bN0 breast cancers**
Shao T, Olszewski AJ, Boolbol SK, Migdady Y, Boachie-Adjei K, Sakr BJ, Klein P, Sikov W. Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; The Warren Alpert Medical School of Brown University, Providence, RI.

P6-07-35 **Dragonfly Effect or Ironic Paradox: Prognostic Implication of Postsurgical Drain in Breast Cancer Patients**
Yin W, Lin Y, Shen Z, Shao Z-M, Lu J. Fudan University Shanghai Cancer Center, Shanghai, China.

P6-07-36 **A Prognostic Model For Triple-Negative Breast Cancer Patients Based On Node Status, Cathpesin-D And Ki-67**
Huang L, Liu Yb, Chen S, Zhou Rj, Liu Y, Shao Z-M. Fudan University Shanghai Cancer Hospital, Shanghai, China.

P6-07-37 **Impact of body mass index on recurrence risk in patients with ductal carcinoma in situ**
Klepczyk LC, Meredith RF, De Los Santos JF, Li Y, Keene KS. University of Alabama at Birmingham, AL.

P6-07-38 **The Value of Progesterone Receptor in Predicting the Recurrence Score for Hormone-Receptor–Positive Invasive Breast Cancer Patients**
Onoda T, Yamauchi H, Yagata H, Hayashi N, Yoshida A, Nakamura S. St Luke's International Hospital, Tokyo, Japan; Showa University, Tokyo, Japan; Yokohama Asahi Central General Hospital, Kanagawa, Japan.

P6-07-39 **Prognostic Value of Body Mass Index in Japanese Breast Cancer Patients: A Collaborative Study by the Kobe Breast Cancer Oncology Group and Hokkaido Cancer Center**
Shigeoka Y, Watanabe K, Takahashi M, Hirokaga K, Takao S, Miyashita M, Wakita K, Miyoshi Y, Okuno T, Kohno S, Kishimoto M, Kokufu I. Yodogawa Christian Hospital, Osaka, Japan; Hokkaido Cancer Center, Sapporo, Japan; Hyogo Cancer Center, Akashi, Japan; Konan Hospital, Kobe, Japan; Chayamachi Breast Clinic, Osaka, Japan; Hyogo College of Medicine, Nishinomiya, Japan; Kobe Urban Breast Clinic, Kobe, Japan; Kobe University, Kobe, Japan; Meiwa Hospital, Nishinomiya, Japan; Kokufu Breast Clinic, Takarazuka, Japan.

P6-07-40 **Initial Neutrophil-to-Lymphocyte ratio in primary breast cancer patients: a simple and useful biomarker as prognostic factor**
Han A, Noh H, Lee J. Yonsei University Wonju Medical School, Wonju, Gangwon, Republic of Korea.

P6-07-41 **Sub classification of early stage hormone positive (HP) Her-2 negative breast cancer (BC) by immunohistochemistry (IHC) into intrinsic subtypes (IS) and their correlation with Oncotype Recurrence Score (RS)**
Mahesh S, Lane J, Ravichandran P. Summa Health Systems, Akron, OH.

P6-07-42 **Patients with Nipple-areola Paget's Disease and Underlying Invasive Breast Carcinoma had a Very Poor Survival: a Matched Cohort Study**
Ling H, Xu X-L, Liu Z-B, Shao Z-M. Fudan University Shanghai Cancer Center, Shanghai, China.

P6-07-43 **The Maximum Standardized Uptake Value of ^{18}F-FDG to Prognosticate Prognosis of Hormone-Receptor Positive Metastatic Breast Cancer**
Hu X-C, Zhang (co-first author) J, Jia Z, Ragaz J, Zhang Y-J, Zhou M, Zhang Y-P. Fudan University Shanghai Cancer Center, Shanghai, China; School of Population and Public Health; University of British Columbia, Vancouver, Canada.

P6-07-44 **Overall survival and the prognostic factors among women with infiltrating lobular carcinoma of the breast in National Cancer Institute of Brazil**
Bello MA, Monteiro SO, Lima DT, Gomes DO, Thuler LCS, Carmo PAO, Carvalho RM, Pinto RR, Bergmann A. Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.

P6-07-45 **Molecular Morphology Based Genomic Signatures of Moderate Complexity Predict Pathologic Complete Response in *HER2* Molecular Breast Carcinoma Class Patients Treated with Trastuzumab-based Preoperative Therapy**
Tubbs RR, Portier BP, Morrison L, Wang Z, Minca E, Lanigan C, Budd T. Cleveland Clinic, Cleveland, OH; Ventana Medical Systems, Tucson, AZ; Cleveland Clinic Tausig Cancer Center, Cleveland, OH.

Psychosocial, Quality of Life, and Educational Aspects: Psychosocial Aspects

P6-08-01 **Perceptions of breast cancer risk, psychological adjustment and behaviors in adolescent girls at high-risk and population-risk for breast cancer**
Bradbury AR, Patrick-Miller L, Egleston B, Schwartz L, Tuchman L, Moore C, Rauch P, Sands C, Shorter R, Rowan B, Malhotra S, van Decker S, Schmidheiser H, Sicilia P, Bealin L, Daly M. University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA.

P6-08-02 **Do personal, familial or counseling factors influence the choice for prophylactic mastectomy and/or bilateral salpingo-oöphorectomy of female BRCA mutation carriers?**
Caanen BA, Gielen M, GomezGarcia EB, Kruitwagen RF, Keymeulen KB, Ter Haar-van Eck SA, Schenk K, Helderman-van den Enden A. Maastricht University Medical Centre, GROW School for Oncology and Developmental Biology, Maastricht Medical Centre, Maastricht, Netherlands; NUTRIM School for Nutrition, Toxicology and Metaboloism, University of Birmingham, Birmingham, United Kingdom; Maxima Medical Centre, Eindhoven, Netherlands.

P6-08-03 **Informational needs and psychosocial assessment of patients in their first year after metastatic breast cancer diagnosis**
Seah DS, Lin NU, Curley C, Winer E, Partridge A. Dana-Farber Cancer Institution, Boston, MA.

P6-08-04 **The Impact of a Breast Cancer Diagnosis in Young Women on their Relationship with their Mothers**
Ali A, Fergus K, Wright F, Pritchard K, Kiss A, Warner E. Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto.

P6-08-05 **Changes in Cognitive Function in Older Women With Breast Cancer Treated with Standard Chemotherapy and Capecitabine within CALGB 49907**
Freedman RA, Pitcher B, Keating NL, Barry WT, Ballman KV, Kornblith A, Mandelblatt J, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB. Dana-Farber Cancer Institute, Boston, MA; Duke University Medical Center, Durham, NC; Harvard Medical School, Boston, MA; Mayo Clinic, Rochester, MN; Georgetown University, Washington, DC; City of Hope, Duarte, CA; Memorial Sloan-Kettering, New York, NY; University of North Carolina, Chapel Hill, NC.

P6-08-06 **Use of an NIH PROMIS® instrument to identify predictors of fatigue in breast cancer patients receiving adjuvant chemotherapy**
Cohen J, Junghaenel DU, Schneider S, Mahler L, Stone A, Broderick J. Stony Brook University, Stony Brook, NY.

P6-08-07 **Quality of life of women with breast cancer: A Middle East perspective**
Jassim GA, Whitford DL. Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen, Bahrain.

P6-08-08 **Three months of adjuvant hormone therapy does not increase fatigue or cognitive failure: results of a prospective early stage breast cancer trial**
Kennedy D, Lower EE. Oncology Hematology Consultants, Cincinnati, OH.

P6-08-09 **Overcoming Breast Cancer: The Importance of Connecting with Fellow Survivors**
Geoghegan C, Whitman B. Y-ME National Breast Cancer Organization, Chicago, IL; Whitman Insight Strategies, New York, NY.

P6-08-10 **Cancer as self: a novel assessment of patient identity as it relates to a cancer diagnosis**
Horst KC, Fero KE, Haimovitz K, Dweck CS. Stanford University, Stanford, CA.

Psychosocial, Quality of Life and Educational Aspects: Psychosocial, QOL and Educational Aspects-Other

P6-09-01 **Investigating the effectiveness of a psycho-educational behavioral intervention for cancer-related cognitive dysfunction in women with breast and gynecological cancer: Knowledge, self-efficacy, and behavioral change**
Bernstein LJ, Dissanayake D, Tirona KM, Nyhof-Young JM, Catton PA. Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto, ON, Canada.

P6-09-02 **Pre-treatment cognitive function (CF) in women with locally advanced breast cancer (LABC) and in healthy controls**
Bernstein LJ, Seruga B, Pond G, Tirona KM, Dodd A, Tannock IF. Princess Margaret Hospital, Toronto, ON, Canada; University of Toronto; Institute of Oncology Ljubljana, Slovenia; McMaster University, Hamilton, ON, Canada.

P6-09-03 **Fatigue after breast cancer may be related to conditions other than the cancer. The impact of comorbidity is essential**
Reidunsdatter RJ, Hjermstad M, Oldervoll L, Lundgren S. HiST/NTNU, Trondheim, Norway; HIST, Trondheim, Norway; NTNU, Trondheim, Norway; Oslo University Hospital, Oslo, Norway; Røros Rehabilitation, Røros, Norway; St. Olav University Hospital, Trondheim, Norway.

P6-09-04 **The Association of Low Level Arm Volume Increases with Lymphedema Symptoms Following Treatment for Breast Cancer**
Skolny MN, Miller CL, Shenouda M, Jammallo LS, O'Toole J, Niemierko A, Taghian AG. Massachusetts General Hospital, Boston, MA.

P6-09-05 **Women's perceptions of lymphedema risk management: Psychological factors do matter**
Sherman KA, Roussi P, Miller SM. Macquarie University, Sydney, NSW, Australia; Aristotle University, Thessaloniki, Greece; Fox Chase Cancer Center, Philadelphia, PA.

P6-09-06 **Family Members' Burden in Patients with Metastatic and Early Stage Breast Cancer**
Wan Y, Gao X, Mehta S, Zhang Z, Faria C, Schwartzberg L. Pharmerit North America; Eisai, Inc.; The West Clinic.

P6-09-07 **Impact of comprehensive geriatric assessment on treatment decision and follow-up in older breast cancer patients**
Kenis C, Decoster L, Bode H, Bastin J, Lobelle J-P, Milisen K, van Puyvelde K, Paridaens R, Neven P, Fontaine C, de Grève J, Flamaing J, Wildiers H. University Hospitals Leuven; University Hospitals Brussels; Consult in Statistics, Beernem; Catholic University Leuven.

P6-09-08 **COMPliance and Arthralgia in Clinical Therapy: The COMPACT trial, assessing the incidence of arthralgia, therapy costs and compliance within the first year of adjuvant anastrozole therapy**
Harbeck N, Blettner M, Bolten WW, Hindenburg H-J, Jackisch C, Klein P, König K, Kreienberg R, Rief W, Wallwiener D, Zaun S, Hadji P. University of Munich, Germany; University of Mainz, Germany; Klaus-Miehlke-Hospital for Rheumatology, Wiesbaden, Germany; Head of BNGO e.V., Germany; Hospital for Gynecology and Obstetrics, Offenbach, Germany; d.s.h. Statistical Services, Rohrbach, Germany; Gynecological Society Germany e.V., Germany; University Women's Hospital, Ulm, Germany; Outpatient Clinic for Psychotherapy, Philipps-University, Marburg, Germany; University Women's Hospital, Tübingen, Germany; AstraZeneca GmbH, Wedel, Germany; Women's Hospital Phillips-University, Marburg, Germany.

P6-09-09 **Perceptions of marginalization in those affected by advanced breast cancer**
Ahmed I, Harvey A, Amsellem M. Cancer Support Community, Washington, DC.

P6-09-10 **Informational needs among women considering breast reconstruction post-mastectomy**
Ahmed I, Harvey A, Amsellem M. Cancer Support Community, Washington, DC.

P6-09-11 **Examining patient treatment choices involving efficacy, toxicity, and cost tradeoffs in the metastatic breast cancer setting**
White CB, Smith ML, Abidoye O, Lalla D. Carol B. White & Associates; Research Advocacy Network; Genentech, Inc.

Treatment: Novel Targets and Targeted Agents

P6-10-01 **A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study**
Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citron D, Oliff I, Bechhold R, Loutfi R, Garcia A, Crowley E, Green J, Yellin MJ, Davis TA, Vahdat LT. Florida Cancer Specialists, Tampa, FL; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Georgia Cancer Specialists PC, Sandy Springs, GA; Arena Onc Assoc PC, Lake Success, NY; Bium Inc, Birmingham, AL; Weill Cornell Medical College, New York, NY; Celldex Therapeutics, Inc., Needham, MA; Arizona Cancer Center at the University of Arizona, Tucson, AZ; Cancer Treatment Centers of America/Midwestern Regional Medical Center, Zion, IL; Orchard Healthcare Research Inc., Skokie, IL; Oncology Hematology Care, Cincinnati, OH; Henry Ford Health System, Detroit, MI; USC/Norris Comprehensive Cancer Center, Los Angeles, CA.

P6-10-02 **MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results**
Alvarez RH, DeMichele A, Mailliez A, Benaim E, Fingert H, Schusterbauer C, Zhang B, Melichar B. The University of Texas MD Anderson Cancer Center, Houston, TX; Abramson Cancer Center, Philadelphia, PA; Centre Oscar Lambret, Lille, Cedex 59, France; Millennium Pharmaceuticals, Inc., Cambridge, MA; Fakultní nemocnice Olomouc - Onkologická klinika, Olomouc, Czech Republic.

p6-10-03 **The PKC inhibitor PKC412 antagonizes breast cancer cell growth and enhances tamoxifen sensitivity**
Shou J, Chew SA, Mitsiades N, Kumar V, Fu X, Chamness G, Osborne K, Schiff R. Lester & Sue Smith Breast Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX.

P6-10-04 **The Presence of Anaplastic Lymphoma Kinase Recapitulates Formation of Breast Tumor Emboli with Encircling Lymphovasculogenesis**
Liu H, Chu K, Ochoa AE, Ye Z, Zhang X, Jin J, Wright MC, Barsky SH, Cristofanilli M, Robertson FM. The University of Texas MD Anderson Cancer Center, Houston, TX; University of Nevada School of Medicine, Reno, NV; Fox Chase Cancer Center, Philadelphia, PA.

P6-10-05 **SU2C Phase 1b Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2- Metastatic Breast Cancer (MBC)**
Mayer IA, Abramson VG, Balko JM, Isakoff SJ, Forero A, Kuba MG, Sanders ME, Li Y, Winer E, Arteaga CL. Vanderbilt-Ingram Cancer Center, Nashville, TN; Massachussets General Hospital, Boston, MD; University of Alabama at Birmingham, AL; MD Anderson Cancer Center, Houston, TX; Dana-Farber Cancer Institute, Boston, MD.

P6-10-06 **Rational combination therapy against triple-negative breast cancer**
Al-Ejeh F, Miranda M, Simpson PT, Chenevix-Trench G, Lakhani SR, Khanna KK. Queensland Institute of Medical Research, Brisbane, QLD, Australia; The University of Queensland, Brisbane, QLD, Australia.

P6-10-07 **Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with *PIK3CA* mutant advanced solid tumors: preliminary efficacy and safety in patients with *PIK3CA* mutant ER-positive (ER+) metastatic breast cancer (MBC)**
Juric D, Argiles G, Burris HA, Gonzalez-Angulo AM, Saura C, Quadt C, Douglas M, Demanse D, De Buck S, Baselga J. M.assachussetts General Hospital Cancer Center, Boston, MA; Vall d'Hebron University Hospital, Barcelona, Spain; Sarah Cannon Research Institute, Nashville, TN; M.D. Anderson Cancer Center, Houston, TX; Novartis Pharma Corporation, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland.

P4-06-07 **Isoform specific antibodies against the fibroblast growth factor receptor 2 have predictive and therapeutic implications in the treatment of human breast cancers**
Ettyreddy AR, Somarelli J, Bitting R, Armstrong A, Garcia Blanco MA. Duke University, Durham, NC.

Treatment: New Drugs and Treatment Strategies

P6-11-01 **Intermittent High Dose Proton Pump Inhibitor Improves Progression Free Survival as Compared to Standard Chemotherapy in the First Line Treatment of Patients with Metastatic Breast Cancer**
Hu X, Wang B, Sun S, Chiesi A, Wang J, Zhang J, Fais S. Fudan University Shanghai Cancer Center, Shanghai, China; National Institute of Health, Roma, Italy.

P6-11-02 **Inhibition of mTOR and Fatty Acid Synthase (FASN) overcome acquired resistance to Trastuzumab, Lapatinib and both in HER2+ breast cancer**
Puig T, Blancafort A, Giro A, Viqueira A, Viñas G, Massaguer A, Carrion-Salip D, Bolos MV, Urruticoechea A, Oliveras G. University of Girona and Girona Biomedical Research Institute (IDIBGi), Girona, Spain; Catalan Institute of Oncology (ICO) and Girona Biomedical Research Institute (IDIBGi), Girona, Spain; Pfizer, Madrid, Spain; University of Girona, Spain; Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.

P6-11-03 **Site-Specific, Concomitant Delivery of Rapamycin and Paclitaxel in Breast Cancer: Consequent Synergistic Efficacy Enhancement**
Blanco E, Sangai T, Hsiao A, Ruiz-Esparza GU, Ferrari M, Meric-Bernstam F. The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX.

P6-11-04 **Targeting the tumor microenvironment: tetrathiomolybdate decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse**
Jain S, Kornhauser N, Lam C, Ward MM, Chuang E, Cigler T, Moore A, Donovan D, Cobham MV, Schneider S, Hurtado Rua SM, Lane ME, Mittal V, Vahdat LT. Weill Cornell Medical College.

P6-11-05 **Novel sorafenib-derivatives induce apoptosis in breast cancer cells through STAT3 inhibition**
Liu C-Y, Tseng L-M, Chang K-C, Chu P-Y, Su J-C, Shiau C-W, Chen K-F. Taipei Veterans General Hospital, Taipei, Taiwan; National Yang-Ming University, Taipei, Taiwan; St. Martin De Porres Hospital, Chia-Yi, Taiwan; National Taiwan University Hospital, Taipei, Taiwan.

P6-11-06 **A phase Ib study of LCL161, an oral inhibitor of apoptosis (IAP) antagonist, in combination with weekly paclitaxel in patients with advanced solid tumors**
Dienstmann R, Vidal L, Dees EC, Chia S, Mayer EL, Porter D, Baney T, Dhuria S, Sen SK, Firestone B, Papoutsakis D, Cameron S, Infante JR. Vall d'Hebron University Hospital, Barcelona, Spain; Hospital Clinic i Provincial, Barcelona, Spain; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corporation, Cambridge, MA; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Sarah Canon Research Institute, Nashville, TN.

P6-11-07 **The Cancer Stem Cell-Targeting Wnt Inhibitor VS-507 Reduces Breast Cancer Growth and Metastasis**
Ring JE, Kolev VN, Padval MV, Keegan M, Vidal CM, Neill AA, Shapiro IM, Pachter JA, Xu Q. Verastem, Inc., Cambridge, MA.

P6-11-08 **A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer**
Campone M, Fumoleau P, Gil-Martin M, Isambert N, Beck JT, Becerra C, Shtivelband M, Duval V, di Tomaso E, Roussou P, Urban P, Urruticoechea A. Centre René Gauducheau, Nantes, France; Centre Georges François Leclerc, Dijon, France; Institut Català d'Oncologia, Barcelona, Spain; Highlands Oncology Group, Fayetteville, AR; Baylor University Medical Center, Dallas, TX; Ironwood Cancer and Research Centers, Chandler, AZ; Novartis Pharma AG, Basel, Switzerland; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA.

P6-11-09 **FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function In Vitro and In Vivo**
Kolev VN, Vidal CM, Shapiro IM, Pavdal M, Keegan M, Xu Q, Pachter JA. Verastem, Cambridge, MA.

P6-11-10 **IBL2001: Phase I/II study of a novel dose-dense schedule of oral indibulin for the treatment of metastastic breast cancer**
Traina TA, Hudis C, Seidman A, Gajria D, Gonzalez J, Anthony SP, Smith DA, Chandler JC, Jac J, Youssoufian H, Korth CC, Barrett JA, Sun L, Norton L. Memorial Sloan-Kettering Cancer Center, New York, NY; Evergreen Hematology and Oncology, Spokane, WA; Compass Oncology, Vancouver, WA; The West Clinic, Memphis, TN; US Oncology Research, Woodlands, TX; ZIOPHARM Oncology, Inc., Boston, MA; Harmon Hill Consulting, New York, NY.

P6-11-11 **Multistage Delivery of Paclitaxel: Increased Drug Stability and Sustained Release Results in Enhanced Efficacy in Breast Cancer**
Blanco E, Sangai T, Hsiao A, Ferrati S, Bai L, Liu X, Meric-Bernstam F, Ferrari M. The Methodist Hospital Research Institute, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX.

P6-11-12 **Nanoparticle-enhanced chemotherapeutics delivery in drug-resistant triple-negative breast cancer**
van de Ven AL, Landis MD, Paskett LA, Meyn A, Frieboes HB, Chang JC, Ferrari M. The Methodist Hospital Research Institute, Houston, TX; University of Louisville, KY.

P6-11-13 ***In vitro* antineoplastic evaluation of rationally designed naphthoquinone-derived drugs in triple-negative breast cancer cell line**
Madeira KP, Daltoé RD, Herlinger AL, Guimarães IS, Allochio Filho JF, Teixeira SF, Valadão IC, Greco S, Rangel LBA. Federal University of Espirito Santo, Brazil.

P6-11-14 **Post-hoc safety and tolerability assessment in patients receiving palliative radiation during treatment with eribulin mesylate for metastatic breast cancer**
Yardley DA, Vahdat L, Rege J, Cortés J, Wanders J, Twelves C. Sarah Cannon Research Institute, Nashville, TN; Weill Cornell Medical College, New York, NY; Eisai Inc, Woodcliff Lake, NJ; Vall d'Hebron University Hospital, Barcelona, Spain; European Knowledge Center, Eisai Ltd., Hatfield, Hertfordshire, United Kingdom; St James University Hospital, Leeds, United Kingdom.

Treatment: Adjuvant Therapy - Other

P6-12-01 **Adjuvant treatment in breast cancer patients aged 70 years or older during three years. A systematic review of patients charts**
Nätterdal T, Klint L, Holmberg E, Gunnarsdottír KA, Linderholm BK. Institution of Medical Sciences, Sahlgrenska University Hospital, Gothenburg, Sweden; Sahlgrenska University Hospital, Gothenburg, Sweden; Karolinska Institute Science Park, Stockholm, Sweden.

P6-12-02 **Use of cytochrome P450 interacting medications in the setting of adjuvant therapy for breast cancer**
Njiaju UO, Kolesar JM, Johnston SA, Eickhoff JC, Osterby KR, Poggi LE, Tevaarwerk AJ, Millholland RJ, Oliver KA, Heideman JL, Wisinski KB. University of Wisconsin-Madison, WI; University of Wisconsin-Madison; University of Wisconsin Hospitals and Clinics.

P6-12-03 **Effects of high dose of bisphosphonate therapy on bone microarchitecture of the peripheral skeleton in women with early stage breast cancer**
Shao T, Shane ES, McMahon D, Crew KD, Kalinsky K, Maurer M, Brown M, Gralow JR, Hershman DL. Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY; Columbia University Medical Center, New York, NY; University of Washington/ Seattle Cancer Care Alliance, Seattle, WA.

Treatment: Therapy for Advanced Disease - Other

P6-13-01 **Lyso-thermosensitive liposomal doxorubicin + local hyperthermia for radiation-pretreated chest wall recurrence**
Formenti S, Rugo H, Myerson R, Diederich C, Straube W, O'Conner B, Matzkowitz AJ, Goodman RL, Muggia F. New York University Cancer Institute, New York, NY; UC San Francisco, San Francisco, CA; Siteman Cancer Center, Saint Louis, MO; Rhode Island Hospital, Providence, RI; New Hope Cancer Center, Hudson, FL; Saint Barnabas Medical Center, Livingston, NJ.

P6-13-02 **Overcoming therapy resistance of metastatic breast cancer by enhanced tumor delivery of polymeric doxorubicin**
Shen H, Xu R, Mai J, Huang Y, Ferrari M. The Methodist Hospital Research Institute, Houston, TX.

P6-13-03 **Symptomatic bone marrow involvement (BMinv) in breast cancer (BC): Clinical presentation, treatment and prognosis according to BC subtype and Zoledronic acid (ZA) use. A single institution review**
Torrejon-Castro D, Zamora E, Sanchez-Olle G, Balmaña J, Gomez P, Saura C, Perez-Garcia J, Muñoz-Cousuelo E, Vidal M, Ortega V, Oliveira M, De Mattos L, Cortes J, Bellet M. Vall d´Hebron University Hospital, Barcelona, Spain.

Treatment: Treatment - Other

P6-14-01 **Estrogen/progestogen use after Breast Cancer – a long-term follow-up of the Stockholm randomized trial**
Fahlén MC, Fornander T, Johansson H, Rutqvist L-E, Wilking N, von Schoultz E. Capio St Görans Hospital, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden.

P6-14-02 **Withdrawn**

P6-14-03 **Statin and aspirin use is not associated with a reduced risk of VTE's in breast cancer patients**
Shai A, Rennert HS, Ballan Haj M, Lavie O, Steiner M, Rennert G. Lin Medical Center, Haifa, Israel; Carmel Lady Davis Medical Center, Haifa, Israel.

P6-14-04 **Rosehip extracts prevent triple negative breast cancer cell proliferation by regulating the phosphorylation of p70S6 Kinase**
Coburn TL, Cagle PD, Shofoluwe AI, Martin PM. North Carolina Agricultural and Technical State University, Greensboro, NC.

P6-14-05 **Impact of breast cancer CME: Physician practice pattern, knowledge, and competence assessments**
Haas M, Heintz A, Stacy T. Educational Concepts Group, LLC, Atlanta, GA.

8:30 am–9:00 am
PLENARY LECTURE 4
Exhibit Hall D

1st International Consensus Guidelines Conference for Advanced Breast Cancer – ABC1
Fatima Cardoso, MD
Champalimaud Cancer Centre
Lisbon, PORTUGAL

9:00 am–11:00 am
THE YEAR IN REVIEW
Exhibit Hall D

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Advances in basic breast cancer research
Jeffrey M. Rosen, PhD
Baylor College of Medicine
Houston, TX

Discoveries in translational breast cancer research in 2012
Douglas Yee, MD
University of Minnesota
Minneapolis, MN

Adjuvant and neoadjuvant
Kathy D. Miller, MD
Indiana University School of Medicine
Indianapolis, IN

New therapies in 2012 for advanced disease – where do they all fit in
Stephen Johnston, MA, PhD, FRCP
Royal Marsden Hospital
London, UNITED KINGDOM

11:00 am
ADJOURNMENT